
<html lang="en"     class="pb-page"  data-request-id="0237d40d-e48b-4a2e-833e-30516aaf5dab"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/jm400336x;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2013.56.issue-11;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Dual Targeting of Adenosine A2A Receptors and Monoamine Oxidase B by 4H-3,1-Benzothiazin-4-ones" /></meta><meta name="dc.Creator" content="Anne  Stößel" /></meta><meta name="dc.Creator" content="Miriam  Schlenk" /></meta><meta name="dc.Creator" content="Sonja  Hinz" /></meta><meta name="dc.Creator" content="Petra  Küppers" /></meta><meta name="dc.Creator" content="Jag  Heer" /></meta><meta name="dc.Creator" content="Michael  Gütschow" /></meta><meta name="dc.Creator" content="Christa E.  Müller" /></meta><meta name="dc.Description" content="Blockade of A2A adenosine receptors (A2AARs) and inhibition of monoamine oxidase B (MAO-B) in the brain are considered attractive strategies for the treatment of neurodegenerative diseases such as ..." /></meta><meta name="Description" content="Blockade of A2A adenosine receptors (A2AARs) and inhibition of monoamine oxidase B (MAO-B) in the brain are considered attractive strategies for the treatment of neurodegenerative diseases such as ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="May 30, 2013" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm400336x" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2013 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm400336x" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm400336x" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm400336x" /></link>
        
    
    

<title>Dual Targeting of Adenosine A2A Receptors and Monoamine Oxidase B by 4H-3,1-Benzothiazin-4-ones | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm400336x" /></meta><meta property="og:title" content="Dual Targeting of Adenosine A2A Receptors and Monoamine Oxidase B by 4H-3,1-Benzothiazin-4-ones" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400336x/production/images/large/jm-2013-00336x_0014.jpeg" /></meta><meta property="og:description" content="Blockade of A2A adenosine receptors (A2AARs) and inhibition of monoamine oxidase B (MAO-B) in the brain are considered attractive strategies for the treatment of neurodegenerative diseases such as Parkinson’s disease (PD). In the present study, benzothiazinones, e.g., 2-(3-chlorophenoxy)-N-(4-oxo-4H-3,1-benzothiazin-2-yl)acetamide (13), were identified as a novel class of potent MAO-B inhibitors (IC50 human MAO-B: 1.63 nM). Benzothiazinones with large substituents in the 2-position, e.g., methoxycinnamoylamino, phenylbutyrylamino, or chlorobenzylpiperazinylbenzamido residues (14, 17, 27, and 28), showed high affinity and selectivity for A2AARs (Ki human A2AAR: 39.5–69.5 nM). By optimizing benzothiazinones for both targets, the first potent, dual-acting A2AAR/MAO-B inhibitors with a nonxanthine structure were developed. The best derivative was N-(4-oxo-4H-3,1-benzothiazin-2-yl)-4-phenylbutanamide (17, Ki human A2A, 39.5 nM; IC50 human MAO-B, 34.9 nM; selective versus other AR subtypes and MAO-A), which inhibited A2AAR-induced cAMP accumulation and showed competitive, reversible MAO-B inhibition. The new compounds may be useful tools for validating the A2AAR/MAO-B dual target approach in PD." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm400336x"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm400336x">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm400336x&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm400336x&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm400336x&amp;href=/doi/10.1021/jm400336x" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2013</span><span class="cit-fg-volume">, 56</span><span class="cit-fg-issue">, 11</span><span class="cit-fg-pageRange">, 4580-4596</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/56/11" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm400312y" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm4003632" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Dual Targeting of Adenosine A<sub>2A</sub> Receptors and Monoamine Oxidase B by 4<i>H</i>-3,1-Benzothiazin-4-ones</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Anne++St%C3%B6%C3%9Fel">Anne Stößel</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Miriam++Schlenk">Miriam Schlenk</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sonja++Hinz">Sonja Hinz</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Petra++K%C3%BCppers">Petra Küppers</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jag++Heer">Jag Heer</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michael++G%C3%BCtschow">Michael Gütschow</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Christa+E.++M%C3%BCller">Christa E. Müller</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">PharmaCenter Bonn, University of Bonn, Pharmaceutical Institute, Pharmaceutical Chemistry I, Bonn, Germany</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Medicinal Chemistry & Lead Generation, CNS Research, UCB S.A., Chemin du Foriest, B-1420 Braine l’Alleud, Belgium</span></div><div class="corresp-info"><strong>*</strong>PharmaCenter Bonn, Pharmaceutical Institute, Pharmaceutical Chemistry I, An der Immenburg 4, D-53121 Bonn, Germany. Phone: +49-228-732317 (M.G.); +49-228-73-2301 (C.E.M.). Fax: +49-228-73-2567. E-mail: <a href="/cdn-cgi/l/email-protection#61061404151202090e1621140f084c030e0f0f4f0504"><span class="__cf_email__" data-cfemail="9ef9ebfbeaedfdf6f1e9deebf0f7b3fcf1f0f0b0fafb">[email protected]</span></a> (M.G.); <a href="/cdn-cgi/l/email-protection#dab9b2a8b3a9aebbf4b7afbfb6b6bfa89aafb4b3f7b8b5b4b4f4bebf"><span class="__cf_email__" data-cfemail="37545f455e444356195a42525b5b52457742595e1a55585959195352">[email protected]</span></a> (C.E.M.).</div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm400336x&amp;href=/doi/10.1021%2Fjm400336x" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2013</span></span><span class="cit-volume">, 56</span><span class="cit-issue">, 11</span><span class="cit-pageRange">, 4580–4596</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">April 30, 2013</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>5 March 2013</li><li><span class="item_label"><b>Published</b> online</span>30 May 2013</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 13 June 2013</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm400336x" title="DOI URL">https://doi.org/10.1021/jm400336x</a></div><div class="article_header-article-copyright"><strong>Copyright © 2013 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D4580%26pageCount%3D17%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DAnne%2BSt%25C3%25B6%25C3%259Fel%252C%2BMiriam%2BSchlenk%252C%2BSonja%2BHinz%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D56%26issueNum%3D11%26contentID%3Djm400336x%26title%3DDual%2BTargeting%2Bof%2BAdenosine%2BA2A%2BReceptors%2Band%2BMonoamine%2BOxidase%2BB%2Bby%2B4H-3%252C1-Benzothiazin-4-ones%26numPages%3D17%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D4596%26publicationDate%3DJune%2B2013">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm400336x"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2462</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">55</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm400336x" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Dual Targeting of Adenosine A2A Receptors and Monoamine Oxidase B by 4H-3,1-Benzothiazin-4-ones&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Anne&quot;,&quot;last_name&quot;:&quot;Stößel&quot;},{&quot;first_name&quot;:&quot;Miriam&quot;,&quot;last_name&quot;:&quot;Schlenk&quot;},{&quot;first_name&quot;:&quot;Sonja&quot;,&quot;last_name&quot;:&quot;Hinz&quot;},{&quot;first_name&quot;:&quot;Petra&quot;,&quot;last_name&quot;:&quot;Küppers&quot;},{&quot;first_name&quot;:&quot;Jag&quot;,&quot;last_name&quot;:&quot;Heer&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;Gütschow&quot;},{&quot;first_name&quot;:&quot;Christa&quot;,&quot;last_name&quot;:&quot;E. Müller&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2013&quot;,&quot;month&quot;:&quot;05&quot;,&quot;day&quot;:&quot;30&quot;,&quot;issue&quot;:&quot;11&quot;,&quot;volume&quot;:&quot;56&quot;,&quot;pages&quot;:&quot;4580-4596&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm400336x&quot;},&quot;abstract&quot;:&quot;Blockade of A2A adenosine receptors (A2AARs) and inhibition of monoamine oxidase B (MAO-B) in the brain are considered attractive strategies for the treatment of neurodegenerative diseases such as Parkinson’s disease (PD). In the present study, benzothiazinones, e.g., 2-(3-chlorophenoxy)-N-(4-oxo-4H-3,1-benzothiazin-2-yl)acetamide (13), were identified as a novel class of potent MAO-B inhibitors (IC50 human MAO-B: 1.63 nM). Benzothiazinones with large substituents in the 2-position, e.g., methoxycinnamoylamino, phenylbutyrylamino, or chlorobenzylpiperazinylbenzamido residues (14, 17, 27, and 28), showed high affinity and selectivity for A2AARs (Ki human A2AAR: 39.5–69.5 nM). By optimizing benzothiazinones for both targets, the first potent, dual-acting A2AAR/MAO-B inhibitors with a nonxanthine structure were developed. The best derivative was N-(4-oxo-4H-3,1-benzothiazin-2-yl)-4-phenylbutanamide (17, Ki human A2A, 39.5 nM; IC50 human MAO-B, 34.9 nM; selective versus other AR subtypes and MAO-A), which inhibit&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm400336x&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm400336x" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm400336x&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm400336x" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm400336x&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm400336x" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm400336x&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm400336x&amp;href=/doi/10.1021/jm400336x" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm400336x" /></input><a href="/doi/pdf/10.1021/jm400336x" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (1 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm400336x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm400336x%26sid%3Dliteratum%253Aachs%26pmid%3D23631427%26genre%3Darticle%26aulast%3DSt%25C3%25B6%25C3%259Fel%26date%3D2013%26atitle%3DDual%2BTargeting%2Bof%2BAdenosine%2BA2A%2BReceptors%2Band%2BMonoamine%2BOxidase%2BB%2Bby%2B4H-3%252C1-Benzothiazin-4-ones%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D56%26issue%3D11%26spage%3D4580%26epage%3D4596%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291788" title="Reaction products">Reaction products</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/56/11" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jmcmar.2013.56.issue-11/production/jmcmar.2013.56.issue-11.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400336x/production/images/medium/jm-2013-00336x_0014.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400336x/production/images/large/jm-2013-00336x_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400336x&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Blockade of A<sub>2A</sub> adenosine receptors (A<sub>2A</sub>ARs) and inhibition of monoamine oxidase B (MAO-B) in the brain are considered attractive strategies for the treatment of neurodegenerative diseases such as Parkinson’s disease (PD). In the present study, benzothiazinones, e.g., 2-(3-chlorophenoxy)-<i>N</i>-(4-oxo-4<i>H</i>-3,1-benzothiazin-2-yl)acetamide (<b>13</b>), were identified as a novel class of potent MAO-B inhibitors (IC<sub>50</sub> human MAO-B: 1.63 nM). Benzothiazinones with large substituents in the 2-position, e.g., methoxycinnamoylamino, phenylbutyrylamino, or chlorobenzylpiperazinylbenzamido residues (<b>14</b>, <b>17</b>, <b>27</b>, and <b>28</b>), showed high affinity and selectivity for A<sub>2A</sub>ARs (<i>K</i><sub>i</sub> human A<sub>2A</sub>AR: 39.5–69.5 nM). By optimizing benzothiazinones for both targets, the first potent, dual-acting A<sub>2A</sub>AR/MAO-B inhibitors with a nonxanthine structure were developed. The best derivative was <i>N</i>-(4-oxo-4<i>H</i>-3,1-benzothiazin-2-yl)-4-phenylbutanamide (<b>17</b>, <i>K</i><sub>i</sub> human A<sub>2A</sub>, 39.5 nM; IC<sub>50</sub> human MAO-B, 34.9 nM; selective versus other AR subtypes and MAO-A), which inhibited A<sub>2A</sub>AR-induced cAMP accumulation and showed competitive, reversible MAO-B inhibition. The new compounds may be useful tools for validating the A<sub>2A</sub>AR/MAO-B dual target approach in PD.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_44303" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_44303" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Parkinson’s disease (PD) is a chronic neurodegenerative disorder of the central nervous system, characterized by the loss of dopaminergic neurons in the substantia nigra and the subsequent depletion of dopamine stores.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> The consequence is a progressive impairment in motor functions characterized by rigidity, resting tremor, and bradykinesia as major symptoms.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> The current treatment for PD includes the administration of levodopa, a metabolic precursor of dopamine (DA) to increase the DA level, as well as dopamine agonists to mimic the dopamine-mediated neurotransmission. This DA-replacing therapy alleviates most of the symptoms especially in the early stage of the disease but cannot stop the neurodegenerative processes. In particular, a long-term levodopa treatment leads to the development of adverse effects, such as dyskinesia, a disorder characterized by involuntary motor movements. Furthermore, increasing doses are required to maintain the therapeutic effect, and after several years, the drug often loses its effect.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> For these reasons, the development of novel disease-modifying drugs that stop or at least retard disease progression, delay the onset of levodopa therapy, and/or reduce levodopa doses is urgently needed in PD therapy.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a></div><div class="NLM_p">The A<sub>2A</sub> adenosine receptor (A<sub>2A</sub>AR), which is activated by the nucleoside adenosine, represents one promising target for anti-Parkinsonian drugs.<a onclick="showRef(event, 'ref1 ref4'); return false;" href="javascript:void(0);" class="ref ref1 ref4">(1, 4)</a> Four subtypes of adenosine receptors (ARs) exist, referred to as A<sub>1</sub>, A<sub>2A</sub>, A<sub>2B</sub>, and A<sub>3</sub>. They belong to the superfamily of G protein-coupled receptors (GPCRs) and differ in their affinity for adenosine, in the type of G proteins that they recruit, and in the subsequent downstream signaling pathways that are activated in the target cells.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> While A<sub>1</sub> and A<sub>3</sub> receptors preferentially inhibit adenylate cyclase (AC) activity and thereby reduce intracellular cAMP production, A<sub>2A</sub> and A<sub>2B</sub>ARs stimulate AC and consequently increase cAMP levels. The A<sub>2A</sub>AR shows a restricted expression in the central nervous system being mainly localized in dopamine-innervated areas, such as the nucleus accumbens, the caudate-putamen, and the olfactory tubercle.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> The A<sub>2A</sub>AR is colocalized and physically associated with the dopamine D<sub>2</sub> receptor, forming heteromeric A<sub>2A</sub>/D<sub>2</sub> receptor complexes.<a onclick="showRef(event, 'ref4 ref7'); return false;" href="javascript:void(0);" class="ref ref4 ref7">(4, 7)</a> Both receptors have an opposing effect on AC and the cellular production of cAMP. Inhibition of A<sub>2A</sub>ARs leads to enhanced D<sub>2</sub> receptor function and therefore a potentiated dopamine neurotransmission, while an activation of A<sub>2A</sub>ARs inhibits D<sub>2</sub> receptor signaling.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Thus, binding of agonists to A<sub>2A</sub>ARs reduces the affinity of DA and other DA agonists for their binding site at the heteromeric DA receptor.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a></div><div class="NLM_p">The blockade of the A<sub>2A</sub>AR is considered as an attractive nondopaminergic treatment for PD.<a onclick="showRef(event, 'ref1 ref9'); return false;" href="javascript:void(0);" class="ref ref1 ref9">(1, 9)</a> A large number of structurally diverse A<sub>2A</sub>AR antagonists has been identified to date (for examples, see Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>).<a onclick="showRef(event, 'ref4 ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref4 ref10 ref11">(4, 10, 11)</a> These include xanthine-like structures, e.g., istradefylline (<b>1</b>), (<i>E</i>)-8-(3-chlorostyryl)caffeine (<b>2</b>), and adenine-like compounds, e.g., preladenant (<b>3</b>). While <b>1</b> is expected to be marketed for the treatment of PD in Japan in the near future, <b>3</b> is currently being evaluated in phase III clinical trials, and both drugs have demonstrated beneficial anti-Parkinsonian effects.<a onclick="showRef(event, 'ref4 ref11'); return false;" href="javascript:void(0);" class="ref ref4 ref11">(4, 11)</a> Experimental models of PD indicated that A<sub>2A</sub> antagonists might be less prone to induce dyskinesias than treatment with levodopa.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Furthermore, several animal studies indicated neuroprotective effects induced by a blockade of A<sub>2A</sub>ARs.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Novel A<sub>2A</sub> antagonists, such as the benzothiazole derivative tozadenant (SYN-115, <b>4</b>)<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> and the benzothiazinone <b>5</b>,<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> that are structurally neither related to xanthines nor to adenine have been identified by high-throughput screening. Recently, virtual screening approaches have provided further novel scaffolds.<a onclick="showRef(event, 'ref10 ref14'); return false;" href="javascript:void(0);" class="ref ref10 ref14">(10, 14)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400336x/production/images/medium/jm-2013-00336x_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400336x/production/images/large/jm-2013-00336x_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of selected A<sub>2A</sub> adenosine receptor antagonists (<b>1</b>–<b>5</b>) and MAO-B inhibitors (<b>6</b>,<b>7</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400336x/production/images/large/jm-2013-00336x_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400336x&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Another therapeutic approach in the treatment of PD is provided by the blocking of monoamine oxidase B (MAO-B).<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> This flavin adenine dinucleotide (FAD) containing enzyme is one of the two existing isoforms A and B, which catalyze the oxidative deamination of amine neurotransmitters. Both isoforms are present in the human brain and involved in the catabolic pathway of dopamine in the striatum.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> MAO-A is the prevalent isoform in catecholaminergic neurons, whereas MAO-B is predominantly located in glial cells and serotonergic neurons. The activity as well as the expression levels of MAO-B in the human brain increase with age, while MAO-A activity remains constant.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Moreover, the increased MAO-B activity, e.g., under levodopa treatment, is associated with a higher production of hydrogen peroxide. The occurrence of reactive oxygen species (ROS) may contribute to apoptotic signaling causing the death of neuronal cells.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Inhibition of the enzyme MAO-B improves symptoms of PD. Selegiline (<b>6</b>) and the related drug rasagiline are successfully used as irreversible inhibitors in PD monotherapy or in combination with levodopa.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> For safety reasons and to prevent undesired side effects, reversible inhibitors (e.g., <b>7</b>) might be advantageous. Safinamide (<b>7</b>) is currently under development in phase III clinical trials as an adjuvant therapy for PD.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></div><div class="NLM_p">Considering these two promising approaches, a compound that antagonizes A<sub>2A</sub>ARs on the one hand and inhibits MAO-B on the other hand may have enhanced therapeutic and neuroprotective potential in the treatment of PD. Such drugs would possess the combined benefits of addressing two pharmacological targets with a reduced risk for side effects compared to a combination of two separate drugs.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Examples for such an approach include dual-acting drug candidates for neurodegenerative diseases addressing both MAO-B and acetylcholinesterase.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Moreover, it has been discovered that the well-known A<sub>2A</sub> antagonist <b>2</b> is also a potent and reversible MAO-B inhibitor.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> A series of analogues of <b>2</b> has been developed in the course of the continued exploration of the dual targeting concept.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> One major drawback of xanthines, such as compound <b>2</b>, is their low water solubility.<a onclick="showRef(event, 'ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref25 ref26">(25, 26)</a> Furthermore, all recently published dual compounds blocking A<sub>2A</sub>ARs and MAO-B are styryl- or phenylbutadienyl-substituted xanthine derivatives, which are not only highly lipophilic but also sensitive to light, undergoing light-induced isomerization in solution or light-induced dimerization in the solid state, respectively.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></div><div class="NLM_p last">In the present study, we focused on the development of nonxanthine-derived, dual-acting compounds, which exhibit an antagonistic effect at A<sub>2A</sub>ARs and at the same time inhibit MAO-B. Previously reported 4<i>H</i>-3,1-benzothiazin-4-ones, such as derivative <b>5</b>, are potent A<sub>2A</sub>AR antagonists but lack selectivity versus the other AR subtypes.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> As a continuation of our research, further 4<i>H</i>-3,1-benzothiazin-4-one derivatives have been synthesized and evaluated at all four AR subtypes as well as MAO-B and optimized for dual A<sub>2A</sub>/MAO-B blockade.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_32713" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_32713" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Chemistry</h3><div class="NLM_p">Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a> outlines the synthetic route toward 4<i>H</i>-3,1-benzothiazin-4-ones <b>8</b>–<b>24</b>. Starting with compound <b>8</b>, it was intended to systematically vary and extend the spacer between the heterobicyclic core and the phenyl group and to introduce substituents at the latter. Thioureide <b>38</b>, obtained by the reaction of anthranilic acid (<b>37</b>) and benzoyl isothiocyanate, gave the benzothiazinone skeleton of <b>39</b> in a sulfuric acid-promoted cyclization with a concomitant loss of the benzoyl residue.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Structural diversity of <b>8</b>–<b>24</b> was introduced in the last step of this route by an acylation reaction according to a previously described procedure.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Because of the low nucleophilicity of the amino group of <b>39</b>, several carboxylic acids (<b>40</b> and <b>41</b>) were activated as mixed anhydrides using the Yamaguchi reagent (2,4,6-trichlorobenzoyl chloride).<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a></div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400336x/production/images/medium/jm-2013-00336x_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400336x/production/images/large/jm-2013-00336x_0006.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of 2-Acylaminobenzothiazinones <b>8</b>–<b>24</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400336x/production/images/large/jm-2013-00336x_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400336x&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) benzoyl isothiocyanate, acetone, RT, 20 min; (ii) 1. concd H<sub>2</sub>SO<sub>4</sub>, 100 °C, 4 h; 2. NaHCO<sub>3</sub>; (iii) 1. carboxylic acids <b>40</b> or <b>41</b> (residues R correspond to those of compounds <b>8</b>–<b>24</b>), <i>N</i>-methylmorpholine, 2,4,6-trichlorobenzoyl chloride, THF, RT, 1 h; 2. <b>39</b>, pyridine, toluene, reflux, 2 h.</p></p></figure><div class="NLM_p">Some of the required carboxylic acids <b>40</b> and <b>41</b> are expensive or not commercially available and were prepared as follows. The phenylbutenoic acid derivatives <b>40</b> were obtained via a Wittig reaction (Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>), and for this purpose, the phosphonium salt of 3-bromopropionic acid (<b>42</b>) was generated and reacted with the appropriate aldehydes <b>43</b> to form the alkenes <b>40</b>.</div><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400336x/production/images/medium/jm-2013-00336x_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400336x/production/images/large/jm-2013-00336x_0007.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Phenylbutenoic Acids <b>40</b> and Phenylbutyric Acids <b>41</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400336x/production/images/large/jm-2013-00336x_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400336x&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) PPh<sub>3</sub>, acetonitrile, reflux, 5 h; (ii) 1. aldehyde <b>43</b>, <i>tert</i>-BuOK, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C → RT, 12 h; (iii) Pd/C, H<sub>2</sub>, EtOH or THF, RT, 1–2 h.</p></p></figure><div class="NLM_p">A subsequent Pd-catalyzed hydrogenation step provided the saturated phenylbutyric acids <b>41</b>. 3-(2-Fluorophenyl)propanoic acid (see Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>) was similarly obtained via hydrogenation of the corresponding cinnamic acid. 3-(3-Methoxyphenyl)propiolic acid was synthesized according to a literature procedure.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a></div><div class="NLM_p">In order to increase the compounds’ polarity and water solubility, we planned to attach a basic moiety. Previous studies indicated an <i>N</i>-benzylpiperazine residue connected via an amide bond to the benzoylaminobenzothiazinone as in compound <b>25</b><a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> (Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a>) to be an advantageous substitution pattern with respect to bioactivity and solubility.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a></div><figure id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400336x/production/images/medium/jm-2013-00336x_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400336x/production/images/large/jm-2013-00336x_0008.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of 2-Acylaminobenzothiazinones <b>26</b>–<b>28</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400336x/production/images/large/jm-2013-00336x_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400336x&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) 1. 4-formylbenzoic acid, (COCl)<sub>2</sub>, DMF (cat), CH<sub>2</sub>Cl<sub>2</sub>, RT, 2 h; 2. pyridine, CH<sub>2</sub>Cl<sub>2</sub>, reflux, 2 h; (ii) oxone, DMF, RT, 12 h; (iii) 1. 1,1′-carbonyldiimidazole, DMF, RT, 1 h; 2. piperazine <b>45</b> (1.25 equiv), imidazole (1.0 equiv), HCl (2.0 equiv), DMF, RT, 2 h.</p></p></figure><div class="NLM_p">To synthesize further analogues, 4-formylbenzoic acid was activated by the conversion to the acyl chloride and reacted with 2-aminobenzothiazinone <b>39</b>. According to a reported method,<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> oxone was successfully utilized to oxidize the intermediate aldehyde to the corresponding carboxylic acid <b>44</b>. In order to prevent a Dimroth rearrangement of the benzothiazinone system,<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> an imidazole buffer was applied for the carbonyldiimidazole-promoted coupling of <b>44</b> with different <i>N</i>-benzylpiperazines <b>45</b> to give the basic carboxamides <b>26</b>–<b>28</b>. The following syntheses were performed in order to achieve minor structural modifications of compound <b>17</b> (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>) as this benzothiazinone turned out to be a particularly promising candidate (vide infra).</div><figure id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400336x/production/images/medium/jm-2013-00336x_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400336x/production/images/large/jm-2013-00336x_0009.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of <i>N</i>-Methylated 2-Acylaminobenzothiazinone <b>29</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400336x/production/images/large/jm-2013-00336x_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400336x&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) 1. CH<sub>3</sub>I, THF, 0 °C; 2. NaH, RT, 24 h.</p></p></figure><div class="NLM_p">To identify the potential role of the amide proton as a hydrogen bond donor for protein binding, the <i>N</i>-methylated compound <b>29</b> was prepared (Scheme <a class="ref internalNav" href="#sch4" aria-label="4">4</a>).</div><figure id="sch5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400336x/production/images/medium/jm-2013-00336x_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400336x/production/images/large/jm-2013-00336x_0010.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Substituted 2-Acylaminobenzothiazinones <b>30</b>–<b>33</b> and 2-Acylaminothienothiazinone <b>34</b>–<b>36</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400336x/production/images/large/jm-2013-00336x_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400336x&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) benzoyl isothiocyanate, acetone, RT, 20 min; (ii) 1. concd H<sub>2</sub>SO<sub>4</sub>, 100 °C, 4 h; 2. NaHCO<sub>3</sub>; (iii) 1. 4-phenylbutyric acid, <i>N</i>-methylmorpholine, 2,4,6-trichlorobenzoyl chloride, THF, RT; 2. amine <b>48</b> or <b>49</b>, pyridine, toluene, reflux, 2 h.</p></p></figure><div class="NLM_p last">Substituted 2-amino-4<i>H</i>-3,1-benzothiazin-4-ones <b>30</b>–<b>33</b> were synthesized (Scheme <a class="ref internalNav" href="#sch5" aria-label="5">5</a>) in order to implement diversity at the fused benzene ring. Additionally, a bioisosteric replacement by a non- or dimethyl-substituted thiophene moiety (compounds <b>34</b>–<b>36</b>) increases the electron density of the thiazinone ring, which may have an impact on its interaction with the target proteins. In all derivatives, the acyl residue of compound <b>17</b> was kept constant. The starting reaction was carried out under the conditions specified in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a> to yield derivatives <b>48</b> and <b>49</b>, whose acylation with 4-phenylbutyric acid resulted in the target compounds <b>30</b>–<b>36</b>.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Radioligand Binding Studies at Adenosine Receptors</h3><div class="NLM_p">The newly synthesized derivatives (<b>8</b>–<b>36</b>) were investigated in radioligand binding studies, in most cases initially at rat brain A<sub>1</sub> and A<sub>2A</sub>ARs and in the case of measurable affinities subsequently at human recombinant A<sub>1</sub>, A<sub>2A</sub>, A<sub>2B</sub>, and A<sub>3</sub>ARs expressed in Chinese hamster ovary (CHO) cells.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> For binding assays at A<sub>1</sub>ARs, [<sup>3</sup><i>H</i>]2-chloro-<i>N</i><sup>6</sup>-cyclopentyladenosine (CCPA), and at A<sub>2A</sub> receptors, [<sup>3</sup><i>H</i>]3-(3-hydroxypropyl)-7-methyl-8-(<i>m</i>-methoxystyryl)-1-propargylxanthine (MSX-2), were used as selective radioligands in both species. For A<sub>2B</sub>AR binding studies, the selective radioligand [<sup>3</sup><i>H</i>]8-(4-(4-(4-chlorophenyl)piperazine-1-sulfonyl)phenyl)-1-propylxanthine (PSB-603) and for A<sub>3</sub>AR binding studies the A<sub>3</sub>-selective radioligand [<sup>3</sup><i>H</i>]2-phenyl-8-ethyl-4-methyl-(8<i>R</i>)-4,5,7,8-tetrahydro-1<i>H</i>-imidazo[2,1-<i>i</i>]purin-5-one (PSB-11) were employed. Initial screening was usually performed at two concentrations, 10 μM and 1 μM. In A<sub>2B</sub> and A<sub>3</sub> radioligand binding studies, the highest concentration of test compound was 1 μM because higher concentrations often led to precipitation of the radioligands [<sup>3</sup>H]PSB-603 and [<sup>3</sup>H]PSB-11. The results of the AR binding assays are presented in Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a> together with data for standard ligands for comparison.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Adenosine Receptor Affinities of <b>1</b>–<b>36</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400336x/production/images/medium/jm-2013-00336x_0011.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400336x/production/images/medium/jm-2013-00336x_0012.gif" alt="" id="GRAPHIC-d247e1011-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last"><i>n</i> = 3, unless otherwise noted.</p></div><div class="footnote" id="t1fn2"><sup>Table b</sup><p class="last">Data are from ref <a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">33</a>.</p></div><div class="footnote" id="t1fn3"><sup>Table c</sup><p class="last">Data are from ref <a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">34</a>.</p></div><div class="footnote" id="t1fn4"><sup>Table d</sup><p class="last">Data are from ref <a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">35</a>.</p></div><div class="footnote" id="t1fn5"><sup>Table e</sup><p class="last">Data are from ref <a onclick="showRef(event, 'cit24b'); return false;" href="javascript:void(0);" class="ref cit24b">24b</a>.</p></div><div class="footnote" id="t1fn6"><sup>Table f</sup><p class="last">Data are from ref <a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">13</a>.</p></div><div class="footnote" id="t1fn7"><sup>Table g</sup><p class="last">n.d., not determined.</p></div><div class="footnote" id="t1fn8"><sup>Table h</sup><p class="last"><i>n</i> = 2.</p></div></div><div></div></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Structure–Activity Relationships at Adenosine Receptors</h3><div class="NLM_p">The phenylpropionyl derivative <b>8</b> was potent at the human A<sub>2A</sub>AR (<i>K</i><sub>i</sub> = 80.9 nM) and showed a higher selectivity over the human A<sub>1</sub> and A<sub>3</sub>AR subtypes than the previously described homologue, the benzoyl derivative compound <b>5</b>. For the purpose of further optimization, a first set of related derivatives (<b>9</b>–<b>24</b>), characterized by different acyl residues at the exocyclic 2-amino group, was synthesized. The introduction of a methoxy group in the 3-position of the phenyl ring (compound <b>9</b>) was well tolerated by the A<sub>2A</sub>AR. In contrast to <b>8</b>, the affinity for the human subtype (<i>K</i><sub>i</sub> = 64.9 nM) was more than 4-fold higher compared to that of the rat A<sub>2A</sub>AR (<i>K</i><sub>i</sub> = 294 nM). The additional 3-methoxy substituent did not improve AR subtype selectivity. A 3,4-dichloro- (compound <b>10</b>) as well as a fluoro- or a bromo-substitution in the <i>ortho</i>-position (compounds <b>11</b> and <b>12</b>) greatly reduced or abolished A<sub>2A</sub> affinity. These halogen-substituted derivatives showed also no or only weak affinity for the other AR subtypes. Only derivative <b>11</b> was moderately potent at the A<sub>2B</sub>AR (<i>K</i><sub>i</sub> = 801 nM). For compound <b>13</b>, which contains an aryl ether linkage, no significant affinity for the ARs was observed. Replacement of the 3-(3-methoxyphenyl)propionyl residue of compound <b>9</b> by a corresponding cinnamoyl moiety (compound <b>14</b>) led to a similarly high A<sub>2A</sub> affinity (<i>K</i><sub>i</sub> = 62.4 nM). Moreover, the double bond was beneficial concerning selectivity for the human A<sub>2A</sub>AR, which was 10-fold over the human A<sub>2B</sub>AR and more than 16-fold versus the A<sub>3</sub>AR. While compound <b>14</b> was inactive at human A<sub>1</sub>AR, it showed good affinity for the rat A<sub>1</sub>AR (<i>K</i><sub>i</sub> = 205 nM). An exchange of the methoxy group of <b>14</b> for a chloro substituent (compound <b>15</b>) or the alkenyl for an alkynyl spacer (compound <b>16</b>) resulted in a loss of affinity.</div><div class="NLM_p">The extension of the 3-phenylpropionyl (compound <b>8</b>) to a 4-phenylbutyryl-substituent (compound <b>17</b>) increased the affinity for the human A<sub>2A</sub>AR (<i>K</i><sub>i</sub> = 39.5 nM) and provided the best A<sub>2A</sub> antagonist of the present series. In addition, this spacer elongation had a positive effect on selectivity, which was more than 60-fold over the human A<sub>1</sub> and more than 25-fold over the human A<sub>2B</sub> and A<sub>3</sub>ARs. In contrast, an unsaturated spacer, as in derivative <b>21</b>, decreased the A<sub>2A</sub> affinity 3-fold at human and 2-fold at rat A<sub>2A</sub>ARs while increasing affinity for the other three AR subtypes. Introduction of a 3-methoxy substituent at the phenyl ring of <b>17</b> leading to compound <b>18</b> also reduced the affinity for A<sub>2A</sub>ARs (hA<sub>2A</sub>: <i>K</i><sub>i</sub> = 115 nM) and increased A<sub>1</sub>, A<sub>2B</sub>, and A<sub>3</sub>AR affinities. Similar receptor affinities were obtained for the corresponding 3-methoxy-substituted unsaturated derivative <b>22</b> in which both modifications were combined. In the set of compounds containing one or two chloro substituents at the phenyl ring (<b>19</b>, <b>20</b>, <b>23</b>, and <b>24</b>), a complete loss of A<sub>2A</sub> affinity was observed. These derivatives were also inactive at the other AR subtypes, except for compound <b>23</b>, which showed high affinity for the rat A<sub>1</sub>AR (<i>K</i><sub>i</sub> = 11.4 nM) and moderate affinity for the human A<sub>1</sub>AR (<i>K</i><sub>i</sub> = 562 nM). Among the benzothiazinones bearing a spacer-connected phenyl ring attached to the 2-position of the benzothiazinone core structure (i.e., <b>8</b>–<b>24</b>), only 3-methoxy-substituted or unsubstituted derivatives possessed good A<sub>2A</sub> affinity, whereas halogen-substituted compounds proved to be inactive.</div><div class="NLM_p">As mentioned above, benzylpiperazine-substituted derivatives <b>26</b>–<b>28</b> were synthesized to enhance water solubility. Their structure was designed based on the previously reported benzothiazinone derivative <b>25</b>.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Compound <b>25</b> with an unsubstituted benzyl residue was found to be a potent A<sub>2A</sub> and A<sub>2B</sub> receptor antagonist (hA<sub>2A</sub>, <i>K</i><sub>i</sub> = 69.5 nM; A<sub>2B</sub>, <i>K</i><sub>i</sub> = 178 nM) and exhibited high A<sub>2A</sub>-selectivity versus A<sub>1</sub>ARs. Apparently, a chloro substituent (compound <b>26</b>) in the <i>ortho</i>-position was not tolerated by any of the AR subtypes. In contrast, the A<sub>2A</sub> affinity of the <i>meta</i>- and the <i>para</i>-chloro-substituted compounds (hA<sub>2A</sub>, <b>27</b>, <i>K</i><sub>i</sub> = 58.3 nM; <b>28</b>, <i>K</i><sub>i</sub> = 44.3 nM) was at least as high as that of the unsubstituted derivative <b>25</b>. Moreover, <b>28</b> was more than 22-fold selective for A<sub>2A</sub> versus the A<sub>2B</sub> and the A<sub>3</sub>ARs and nearly 100-fold versus the A<sub>1</sub>ARs (human species). These results indicated that the binding pocket for the A<sub>2A</sub>AR is able to accommodate large and basic substituents and requires a correct orientation of the chloro substituent. Thus, <i>N</i>-(chlorobenzyl)piperazine-substituted benzothiazinone derivatives like <b>27</b> and <b>28</b> are interesting new starting points for the development of selective A<sub>2A</sub>AR antagonists with an expected improved water solubility, at least in slightly acidic media.</div><div class="NLM_p">Because of the high A<sub>2A</sub>AR affinity and selectivity of compound <b>17</b>, we used the phenylbutyryl residue as a fixed motif for further modification of the benzothiazinone core and the amide linker (compound <b>29</b>–<b>36</b>). Compound <b>29</b>, an <i>N</i>-methylated derivative of <b>17</b>, was completely inactive at all adenosine receptor subtypes. This indicates that the amide proton may be required as a hydrogen bond donor for receptor binding.</div><div class="NLM_p">Next, we considered the modification of the benzothiazinone core (<b>30</b>–<b>36</b>). Neither methyl-, chloro-, or bromo-substitution in the 6-postition nor a chloro-substituent in the 7-position was tolerated by the rat A<sub>2A</sub>AR. Finally, the fused benzene ring of <b>17</b> was bioisosterically replaced by thiophene (compounds <b>34</b>–<b>36</b>). Thieno[3,2-<i>d</i>][1,3]thiazin-4-one <b>34</b> was inactive at A<sub>1</sub>, A<sub>2A</sub>, and A<sub>3</sub>ARs and had only a moderate potency at the A<sub>2B</sub>AR subtype (<i>K</i><sub>i</sub> = 547 nM). In contrast, the isomeric thieno[2,3-<i>d</i>][1,3]thiazin-4-one <b>35</b> exhibited high affinities for most of the AR subtypes, except for the A<sub>3</sub>AR, comparable to those of the corresponding benzothiazinone analogue <b>17</b>. Surprisingly, the dimethylated thienothiazinone <b>36</b> did not bind to any of the four AR subtypes.</div><div class="NLM_p">In summary, the benzothiazinones with a methoxy-substituted cinnamoyl or a phenylbutyryl residue (<b>14</b>,<b>17</b>), as well as representatives with an <i>N</i>-(chlorobenzyl)piperazine moiety (<b>27</b>,<b>28</b>) exhibited the most favorable properties with regard to A<sub>2A</sub> affinity and selectivity, being comparable to the standard ligands <b>1</b> and <b>2</b>.</div><div class="NLM_p">With respect to bioactivity, the benzothiazinone scaffold turned out to be versatile. We did not only obtain potent A<sub>2A</sub>AR antagonists, as intended in this study, but also discovered benzothiazinones with high affinity for A<sub>1</sub>, A<sub>2B</sub>, and A<sub>3</sub>ARs, e.g., <b>33</b>, a relatively potent and selective A<sub>3</sub> antagonist for human A<sub>3</sub>ARs (<i>K</i><sub>i</sub> = 91.6 nM).</div><div class="NLM_p last">With the exception of <b>8</b>, which was equipotent at human and rat A<sub>2A</sub>ARs, the affinity for the human A<sub>2A</sub>AR was consistently higher (2–10-fold) than that for the rat orthologue (plot of 12 rat p<i>K</i><sub>i</sub> values versus human p<i>K</i><sub>i</sub> values; linear regression, gave the following results, slope = 0.60, <i>y</i>-intercept = 2.16, <i>r</i><sup>2</sup> = 0.08; for details see <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>). In contrast, all investigated benzothiazinones exhibited lower affinity for the human than that for the rat A<sub>1</sub>AR (plot of 10 rat p<i>K</i><sub>i</sub> values versus human p<i>K</i><sub>i</sub> values yielded the following results: slope = 1.39, <i>y</i>-intercept = −1.32, <i>r</i><sup>2</sup> = 0.58; for details see <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>). At that receptor subtype, some derivatives (e.g., <b>22</b> and <b>23</b>) had a preference for the rat species of up to 45-fold. Such extreme species differences have to be taken into account prior to preclinical in vivo studies, which are typically performed in rodents. In view of the low <i>r</i><sup>2</sup> values of our analysis, cross-species extrapolations for benzothiazinones are very limited.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Functional Studies at Adenosine Receptors</h3><div class="NLM_p">Cyclic AMP (cAMP) accumulation studies at human A<sub>2A</sub>ARs were performed with the most potent A<sub>2A</sub>AR antagonist of the present series, compound <b>17</b>, as a representative of the benzothiazinone scaffold (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>).</div><figure id="fig2" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400336x/production/images/medium/jm-2013-00336x_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400336x/production/images/large/jm-2013-00336x_0003.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. cAMP accumulation experiments in CHO cells stably transfected with the human A<sub>2A</sub>AR. The nonselective AR agonist NECA (0.1 and 1 μM) showed a concentration-dependent stimulation of cAMP formation. Benzothiazinone <b>17</b> did not show an effect by itself but inhibited NECA-induced cAMP accumulation. Graph bars represent results from three independent experiments ± SEM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400336x/production/images/large/jm-2013-00336x_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400336x&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Benzothiazinone <b>17</b> did not show any agonistic activity at CHO cells transfected with the human A<sub>2A</sub>AR, even at high concentrations up to 20 μM. However, the increase in intracellular cAMP production induced by the agonist NECA was significantly blocked in the presence of compound <b>17</b>. We used relatively high concentrations of the agonist NECA and therefore also had to add high concentrations of antagonist <b>17</b> to prove significant inhibitory effects (see Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>). These results clearly confirm previous findings that the class of benzothiazinones acts as antagonists at ARs.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a></div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Monoamine Oxidase Inhibition Studies</h3><div class="NLM_p">All compounds were investigated for inhibition of rat and human MAO-B using mitochondria-enriched rat liver fractions and human recombinant MAO-B enzyme, respectively. The Amplex Red monoamine oxidase assay was utilized. MAO-A (human) inhibition assays were performed analogously for selected compounds. The inhibitors clorgyline for MAO-A and selegiline for MAO-B were used to block the respective enzyme in rat liver fractions for determining selective inhibition of one of the isoenzymes. The inhibitory potencies for the benzothiazinones and for standard inhibitors are collected in Tables <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a> and <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. MAO-B Inhibitory Potencies of Benzothiazinones and Standard Compounds</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">IC<sub>50</sub>  ± SEM (nM)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">IC<sub>50</sub>  ± SEM (nM)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">rat MAO-B</th><th class="colsep0 rowsep0" align="center">human MAO-B</th><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">rat MAO-B</th><th class="colsep0 rowsep0" align="center">human MAO-B</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left"><b>2</b></td><td class="colsep0 rowsep0" rowspan="2" align="left">38.5 ± 5.1</td><td class="colsep0 rowsep0" align="left">18.1 ± 3.3</td><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" align="left">3300 ± 280</td><td class="colsep0 rowsep0" align="left">3440 ± 1400</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">96 (baboon enzyme)<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left"><b>21</b></td><td class="colsep0 rowsep0" align="left">361 ± 38</td><td class="colsep0 rowsep0" align="left">39.8 ± 6.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="left">6.74 ± 0.81, 7<a class="ref internalNav" href="#t2fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">6.13 ± 0.85, 20<a class="ref internalNav" href="#t2fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left"><b>22</b></td><td class="colsep0 rowsep0" align="left">2020 ± 580</td><td class="colsep0 rowsep0" align="left">238 ± 12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="left">25.8 ± 3.0</td><td class="colsep0 rowsep0" align="left">7.67 ± 1.81</td><td class="colsep0 rowsep0" align="left"><b>23</b></td><td class="colsep0 rowsep0" align="left">840 ± 135</td><td class="colsep0 rowsep0" align="left">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="left">>10000</td><td class="colsep0 rowsep0" align="left">n.d.<a class="ref internalNav" href="#t2fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left"><b>24</b></td><td class="colsep0 rowsep0" align="left">4640 ± 436</td><td class="colsep0 rowsep0" align="left">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="left">42.7 ± 19.8</td><td class="colsep0 rowsep0" align="left">17.6 ± 3.7</td><td class="colsep0 rowsep0" align="left"><b>25</b></td><td class="colsep0 rowsep0" align="left">n.d.</td><td class="colsep0 rowsep0" align="left">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9</b></td><td class="colsep0 rowsep0" align="left">621 ± 39</td><td class="colsep0 rowsep0" align="left">95.3 ± 8.8</td><td class="colsep0 rowsep0" align="left"><b>26</b></td><td class="colsep0 rowsep0" align="left">n.d.</td><td class="colsep0 rowsep0" align="left">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10</b></td><td class="colsep0 rowsep0" align="left">>10000</td><td class="colsep0 rowsep0" align="left">>10000</td><td class="colsep0 rowsep0" align="left"><b>27</b></td><td class="colsep0 rowsep0" align="left">n.d.</td><td class="colsep0 rowsep0" align="left">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="left">725 ± 183</td><td class="colsep0 rowsep0" align="left">11.2 ± 2.4</td><td class="colsep0 rowsep0" align="left"><b>28</b></td><td class="colsep0 rowsep0" align="left">n.d.</td><td class="colsep0 rowsep0" align="left">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12</b></td><td class="colsep0 rowsep0" align="left">64.0 ± 18.4</td><td class="colsep0 rowsep0" align="left">2.09 ± 0.17</td><td class="colsep0 rowsep0" align="left"><b>29</b></td><td class="colsep0 rowsep0" align="left">n.d.</td><td class="colsep0 rowsep0" align="left">53.1 ± 16.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13</b></td><td class="colsep0 rowsep0" align="left">661 ± 126</td><td class="colsep0 rowsep0" align="left">1.63 ± 0.18</td><td class="colsep0 rowsep0" align="left"><b>30</b></td><td class="colsep0 rowsep0" align="left">325 ± 28<a class="ref internalNav" href="#t2fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="left">94.0 ± 8.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14</b></td><td class="colsep0 rowsep0" align="left">281 ± 178<a class="ref internalNav" href="#t2fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="left">470 ± 112</td><td class="colsep0 rowsep0" align="left"><b>31</b></td><td class="colsep0 rowsep0" align="left">>10000</td><td class="colsep0 rowsep0" align="left">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15</b></td><td class="colsep0 rowsep0" align="left">815 ± 436</td><td class="colsep0 rowsep0" align="left">93.3 ± 9.2</td><td class="colsep0 rowsep0" align="left"><b>32</b></td><td class="colsep0 rowsep0" align="left">>10000</td><td class="colsep0 rowsep0" align="left">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16</b></td><td class="colsep0 rowsep0" align="left">73.9 ± 16.1</td><td class="colsep0 rowsep0" align="left">43.7 ± 4.2</td><td class="colsep0 rowsep0" align="left"><b>33</b></td><td class="colsep0 rowsep0" align="left">1220 ± 452</td><td class="colsep0 rowsep0" align="left">76.4 ± 14.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17</b></td><td class="colsep0 rowsep0" align="left">186 ± 37</td><td class="colsep0 rowsep0" align="left">34.9 ± 2.5</td><td class="colsep0 rowsep0" align="left"><b>34</b></td><td class="colsep0 rowsep0" align="left">298 ± 8<a class="ref internalNav" href="#t2fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="left">206 ± 42</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18</b></td><td class="colsep0 rowsep0" align="left">1300 ± 80</td><td class="colsep0 rowsep0" align="left">389 ± 122</td><td class="colsep0 rowsep0" align="left"><b>35</b></td><td class="colsep0 rowsep0" align="left">291 ± 107<a class="ref internalNav" href="#t2fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="left">69.7 ± 6.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19</b></td><td class="colsep0 rowsep0" align="left">6880 ± 310</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left"><b>36</b></td><td class="colsep0 rowsep0" align="left">26.6 ± 10.1<a class="ref internalNav" href="#t2fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="left">9.80 ± 1.97</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last"><i>n</i> = 3, unless otherwise noted.</p></div><div class="footnote" id="t2fn2"><sup>b</sup><p class="last">Data are from ref <a onclick="showRef(event, 'cit24b'); return false;" href="javascript:void(0);" class="ref cit24b">24b</a>.</p></div><div class="footnote" id="t2fn3"><sup>c</sup><p class="last">Data are from ref <a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">36</a>.</p></div><div class="footnote" id="t2fn4"><sup>d</sup><p class="last">Data are from ref <a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">37</a>.</p></div><div class="footnote" id="t2fn5"><sup>e</sup><p class="last">n.d., not determined.</p></div><div class="footnote" id="t2fn6"><sup>f</sup><p class="last"><i>n</i> = 2.</p></div></div></div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Structure–Activity Relationships at Monoamine Oxidase B</h3><div class="NLM_p">The previously reported benzoyl-substituted 2-aminobenzothiazinone <b>5</b><a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> did not show noticeable activity at rat MAO-B. However, extension of the linker to obtain the phenylpropionyl derivative <b>8</b> provided the first potent MAO-B inhibitor. Compound <b>8</b> exhibited a slight preference for the human versus the rat isoenzyme (human, IC<sub>50</sub> = 17.6 nM; rat, IC<sub>50</sub> = 42.7 nM). We therefore considered <b>8</b> as a starting point and focused on structural variations to explore the potency of this type of inhibitor more precisely. The introduction of a 3-methoxy group at the phenyl ring (compound <b>9</b>) led to decreased inhibition (human, IC<sub>50</sub> = 95.3 nM; rat, IC<sub>50</sub> = 621 nM). While a 3,4-dichloro substitution pattern (compound <b>10</b>) produced no activity at all, an <i>ortho</i>-fluoro or <i>ortho</i>-bromo substitution resulted in potent MAO-B inhibitors at the human enzyme (<b>11</b>, IC<sub>50</sub> = 11.2 nM; <b>12</b>, IC<sub>50</sub> = 2.09 nM). The number and position of halogen substituents on the phenyl ring appeared to be crucial for inhibitory activity toward MAO-B. At the rat enzyme, both compounds were considerably weaker (<b>11</b>, IC<sub>50</sub> = 725 nM, 65-fold; <b>12</b>, IC<sub>50</sub> = 64.0 nM, 31-fold). An incorporation of oxygen into the spacer and the introduction of a 3-chloro substituent (compound <b>13</b>) provided the most potent inhibitor of the entire series (human, IC<sub>50</sub> = 1.63 nM) and exhibited a nearly 4-fold higher inhibitory activity toward human MAO-B than the irreversible standard inhibitor <b>6</b>. Again, <b>13</b> was much less potent at the rat MAO-B enzyme (IC<sub>50</sub> = 661 nM, 400-fold) than at the human orthologue. The high potency of compounds <b>11</b>–<b>13</b> shows that benzothiazinones represent a new class of potent MAO-B inhibitors. However, all three compounds were inactive at the A<sub>2A</sub>AR (see above) and therefore not suitable for a dual target approach.</div><div class="NLM_p">Among the derivatives with an unsaturated spacer (<b>14</b>–<b>16</b>), 3-methoxy-cinnamoyl derivative <b>14</b> showed only a moderate effect and was about equipotent at both species (human, IC<sub>50</sub> = 470 nM; rat, IC<sub>50</sub> = 281 nM). The corresponding 3-chlorinated compound <b>15</b> was 5-times more potent than the related methoxy derivative <b>14</b> only at the human enzyme (human, IC<sub>50</sub> = 93.3 nM; rat, IC<sub>50</sub> = 815 nM). Introduction of a (3-methoxyphenyl)propioloyl residue (compound <b>16</b>) resulted in a good MAO-B inhibitory potency (human, IC<sub>50</sub> = 43.7 nM; rat, IC<sub>50</sub> = 73.9 nM) without species preference.</div><div class="NLM_p">In the group with an extended spacer (<b>17</b>–<b>20</b>), the phenylbutyryl-substituted compound <b>17</b> exhibited a remarkable MAO-B inhibitory activity (human, IC<sub>50</sub> = 34.9 nM; rat, IC<sub>50</sub> = 186 nM). As noted above, <b>17</b> was identified as a potent and selective A<sub>2A</sub> antagonist and can thus be considered to be a promising dual-acting candidate. The activity of compound <b>18</b> with an additional <i>meta</i>-methoxy group was about 10-fold lower (human, IC<sub>50</sub> = 389 nM) compared to that of the unsubstituted analogue <b>17</b>. One or two chloro substituents (<b>19</b>,<b>20</b>) dramatically decreased the affinity. The same trend was observed for the unsaturated analogues (<b>21</b>–<b>24</b>), where only the unsubstituted derivative <b>21</b> showed notable MAO-B inhibitory potency (human, IC<sub>50</sub> = 39.8 nM; rat, IC<sub>50</sub> = 361 nM). The introduction of different <i>N</i>-benzylpiperazine moieties (<b>25</b>–<b>28</b>) was not tolerated by MAO-B and resulted in completely inactive compounds. The activity of the <i>N</i>-methylated compound <b>29</b> for human MAO-B was only slightly decreased (IC<sub>50</sub> = 53.1 nM) compared to the corresponding <i>N</i>-unsubstituted derivative <b>17</b>. This indicates that the amide proton, in contrast to the situation at the A<sub>2A</sub>AR, is not essential for MAO-B binding.</div><div class="NLM_p">Next, modified 6- or 7-substituted benzothiazinones (<b>30</b>–<b>33</b>) and thiophene analogues (<b>34</b>–<b>36</b>) were considered. In position 6, only a methyl group (compound <b>30</b>) was tolerated by MAO-B (human, IC<sub>50</sub> = 94.0 nM), whereas the derivatives with a 6-chloro or a 6-bromo substituent (<b>31</b> and <b>32</b>) were inactive. In contrast, the 7-chlorinated compound <b>33</b> was potent toward MAO-B (human, IC<sub>50</sub> = 76.4 nM). Thieno[3,2-<i>d</i>][1,3]thiazin-4-one <b>34</b> had a moderate inhibitory effect (human, IC<sub>50</sub> = 206 nM; rat, IC<sub>50</sub> = 298 nM) and showed, as one of only a few examples in this series, no major species differences. The isomeric thieno[2,3-<i>d</i>][1,3]thiazin-4-one <b>35</b> exhibited slightly better MAO-B inhibition (human, IC<sub>50</sub> = 69.7 nM; rat, IC<sub>50</sub> = 291 nM) but was still weaker than the benzothiazinone lead structure <b>17</b>. Dimethylation of <b>35</b> to compound <b>36</b> increased potency at both human and rat MAO-B, leading to a potent MAO-B inhibitor (human, IC<sub>50</sub> = 9.80 nM; rat, IC<sub>50</sub> = 26.6 nM) that had a 3-fold higher potency than that of the lead compound <b>17</b>.</div><div class="NLM_p">Considering the whole series (<b>8</b>–<b>36</b>), more than half of the compounds were found to be active at MAO-B. The highest inhibition potencies were achieved with dimethylated thienothiazinone derivative <b>36</b> and benzothiazinones bearing an <i>ortho</i>-halogen-substituted phenylpropionyl residue (compound <b>11</b> and <b>12</b>) or a <i>meta</i>-chloro-substituted phenoxyethyl moiety (compound <b>13</b>). All of these compounds inhibited MAO-B in the low nanomolar range, comparable or even superior to the standard inhibitors (<b>6</b> and <b>7</b>). For the established inhibitor <b>2</b> as well as related xanthine derivatives and analogues, the styryl moiety had been identified as an essential unit to achieve MAO-B inhibition.<a onclick="showRef(event, 'ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref23 ref24">(23, 24)</a> However, in the present study we could not observe a marked difference between benzothiazinones with a saturated and those with an unsaturated spacer.</div><div class="NLM_p last">A comparison of the IC<sub>50</sub> values determined at the human and the rat MAO-B enzyme revealed significant species differences. For the present benzothiazinone series (except for <b>14</b>, <b>20</b>, and <b>24</b>), the inhibitory potency at the human MAO-B was always higher (1.4–400-fold) than that at the rat enzyme (plot of 18 rat pIC<sub>50</sub> values versus human pIC<sub>50</sub> values; linear regression gave the following results: slope = 0.40, <i>y</i>-intercept = 3.54, <i>r</i><sup>2</sup> = 0.33; for details, see <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>). As these differences did not follow a clear trend with respect to the benzothiazinones’ structures, it will always be required to determine both human and rat enzyme inhibition constants prior to planning preclinical and clinical in vivo studies. Similar findings of moderate correlations between human and rat IC<sub>50</sub> values were previously reported for other classes of MAO-B inhibitors.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a></div></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Mechanism of Monoamine Oxidase B Inhibition</h3><div class="NLM_p">It has already been mentioned that from a therapeutic point of view, reversible inhibition of MAO-B may have significant advantages over the irreversible inactivation of the enzyme. Therefore, it was investigated whether four selected compounds, <b>8</b>, <b>9</b>, <b>17</b>, and <b>35</b>, act as reversible or irreversible inhibitors of MAO-B. For this purpose, human MAO-B was treated with a test compound, with the irreversible inhibitor <b>6</b>, or the reversible inhibitor <b>7</b> as reference compounds (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>).</div><figure id="fig3" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400336x/production/images/medium/jm-2013-00336x_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400336x/production/images/large/jm-2013-00336x_0004.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Reactivation of MAO-B. Human MAO-B was treated under assay conditions with several inhibitors (each at the concentration that represents its IC<sub>80</sub> value) in the presence of the substrate <i>p</i>-tyramine. After 22 min, the substrate concentration was increased from 150 μM to 1 mM, and fluorescence was measured over a period of 5 h.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400336x/production/images/large/jm-2013-00336x_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400336x&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">After preincubation, the substrate concentration was increased, and the course of the reaction was observed to assess reactivation of MAO-B. In the case of reversible inhibition, the inhibitor will be replaced by the competing excess substrate. The measurements with the reference compound <b>7</b> and the inhibitors <b>8</b>, <b>9</b>, <b>17</b>, and <b>35</b>, clearly indicated the expected reversible mode of interaction because an elevated fluorescence could be detected after increasing the substrate concentration. In contrast, in the experiment with irreversible inhibitor <b>6</b>, the residual activity was not enhanced, as expected. These results clearly showed that the benzothiazinones are reversible inhibitors of MAO-B.</div><div class="NLM_p">To further characterize the interaction of the benzothiazinones with MAO-B, the type of enzyme inhibition was determined by Michaelis–Menten kinetics. Thus, the initial rates of the MAO-B-catalyzed oxidation of the substrate <i>p</i>-tyramine, applied at six different concentrations, were measured in the presence of different concentrations of inhibitor <b>17</b>. The results are depicted as double reciprocal Lineweaver–Burk plots in Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>.</div><figure id="fig4" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400336x/production/images/medium/jm-2013-00336x_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400336x/production/images/large/jm-2013-00336x_0005.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Lineweaver–Burk plot of the inhibition of human MAO-B in the presence of different concentrations of benzothiazinone <b>17</b> (0, 50, 100, and 300 nM) with <i>p</i>-tyramine (0.05, 0.1, 0.5, 1.0, 1.5, and 3.0 mM) as substrate. The reciprocal MAO-B activity was plotted against the reciprocal substrate concentration (<i>n</i> = 2).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400336x/production/images/large/jm-2013-00336x_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400336x&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The plots for compound <b>17</b> were linear and intersected at the <i>y</i>-axis with the plot for the uninhibited enzyme. These results led us to conclude that the benzothiazinones are competitive inhibitors, which occupy the substrate binding site of MAO-B, in agreement with their reversible mode of interaction.</div></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Identification of Dual-Acting Drugs</h3><div class="NLM_p">With regard to the dual target approach to develop candidates that simultaneously antagonize A<sub>2A</sub>ARs and inhibit the activity of MAO-B, four derivatives have to be highlighted (<b>8</b>, <b>9</b>, <b>17</b>, and <b>35</b>). The corresponding data are summarized in Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>. We have additionally determined the inhibitory potency of theses compounds toward the human MAO-A. They did not inhibit MAO-A even at high concentrations and could therefore be characterized as selective inhibitors for the isoenzyme MAO-B.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Selected Dual-Acting 2-Acylaminobenzothiazinones and 2-Acylaminothienothiazinones</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400336x/production/images/medium/jm-2013-00336x_0013.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>Table a</sup><p class="last"><i>n</i> = 3.</p></div><div class="footnote" id="t3fn2"><sup>Table b</sup><p class="last">(h): human enzyme.</p></div><div class="footnote" id="t3fn3"><sup>Table c</sup><p class="last">(r): rat enzyme.</p></div></div><div></div></div><div class="NLM_p">The most potent dual-acting compounds <b>8</b>, <b>9</b>, <b>17</b>, and <b>35</b> are characterized by a high shape similarity. Considering the benzothiazinone core, an unsubstituted fused benzene ring provided the best activities toward both targets. While the introduction of halogen atoms or methyl groups was not tolerated, the benzene moiety could be replaced by a thiophene isostere retaining the duality of action. An unsubstituted phenylpropionyl or phenylbutyryl moiety turned out to be the most beneficial acyl substituent at the exocyclic 2-amino group. Only for the shorter phenylpropionyl side chain, the attachment of an additional methoxy substituent was allowed without losing dual activity. Compound <b>17</b> was the most potent human A<sub>2A</sub> antagonist (<i>K</i><sub>i</sub> = 39.5 nM) of the whole series and showed high selectivity over the other adenosine receptor subtypes. Furthermore, <b>17</b> had the capability to selectively inhibit human MAO-B in the same nanomolar range (IC<sub>50</sub> = 34.9 nM). A reduced spacer length in the phenylpropionyl derivative <b>8</b> resulted in a better human MAO-B inhibition but a slightly reduced human A<sub>2A</sub> affinity and selectivity.</div><div class="NLM_p">We investigated the stability of compound <b>17</b> dissolved in DMSO by LCMS and <sup>1</sup>H NMR spectroscopy and compared it to that of standard compound <b>2</b> (for details, see Figures S2, S3, S4, and S5 and Table S1, <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>). In accordance with previously published observations for styrylxanthine derivatives,<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> compound <b>2</b> was unstable when exposed to daylight at room temperature, which was already seen after 24 h of incubation. In contrast, <b>17</b> was found to be completely stable even after 7 days of incubation under the same conditions.</div><div class="NLM_p last">Our findings indicate the restricted opportunities for scaffold modifications, when addressing two diverse and unrelated protein targets. In general, the development of a dual-acting compound requires a complex design and optimization process to adjust the ratio of activities at the two diverse targets. However, it may be well worth while developing such dual or multiple target-directed drugs. A multiple ligand might be able to enhance efficacy and improve safety compared to a mixture of two compounds each of which addresses only a single target. There is an increasing interest in modulating multiple targets, especially in complex diseases such as PD.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_03253" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_03253" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In conclusion, we discovered 4<i>H</i>-3,1-benzothiazin-4-ones and thienothiazinone analogues as a structurally novel class of nonxanthine- and nonadenine-related compounds with a dual mode of action targeting A<sub>2A</sub>ARs and MAO-B at the same time. Twenty-eight new compounds were synthesized and investigated in radioligand binding studies at all four adenosine receptor subtypes and in enzyme inhibition studies at MAO-B and MAO-A. Structural optimization and SAR analyses led to the development of potent and selective A<sub>2A</sub>AR antagonists and the discovery of the first MAO-B inhibitors within the class of benzothiazinones. We were able to identify several ligands potently addressing both targets at similar concentrations. Species differences were determined between the human and the rat ARs. All derivatives showed a preference for the human over the rat A<sub>2A</sub>AR, while the opposite trend was observed for the A<sub>1</sub>AR. A similar observation was made for MAO-B, where in most cases a strong preference for the human enzyme was found. 4<i>H</i>-3,1-Benzothiazin-4-one <b>17</b> was characterized as a potent and selective A<sub>2A</sub>AR antagonist and a reversible, competitive MAO-B inhibitor. This compound is a promising new lead structure for dual-acting drugs and may serve as a pharmacological tool for proof-of-concept in vivo studies to validate this dual target approach as a novel strategy for the treatment of PD.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_43324" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_43324" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Chemistry</h3><div class="NLM_p">All reagents were obtained from various producers (Acros, Sigma Aldrich, Alfa Aesar, and Fluorochem) and used without further purification. Solvents were used without additional purification or drying unless otherwise noted. Reactions were monitored by thin layer chromatography (TLC) using aluminum sheets coated with silica gel 60 F<sub>254</sub> (Merck). Compounds were visualized under UV light (254 nm). Preparative column chromatography was performed on silica gel 60 (Acros Organics) 0.060–0.200 mm. Mass spectra were recorded on an API 2000 mass spectrometer (electron spray ion source, Applied Biosystems, Darmstadt, Germany) coupled with an Agilent 1100 HPLC system using a Phenomenex Luna HPLC C18 column (50 × 2.00 mm, particle size 3 μm). The purity of the tested compounds was determined by HPLC-UV obtained on an LC-MS instrument (Applied Biosystems API 2000 LC-MS/MS, HPLC Agilent 1100) using the procedure as follows: dissolving of the compounds at a concentration of 1.0 mg/mL in methanol and if necessary sonicated to complete dissolving. Then, 10 μL of the substance solution was injected into a Phenomenex Luna C18 HPLC column (50 × 2.00 mm, particle size 3 μm) and elution performed with a gradient of water/methanol either containing 2 mM ammonium acetate and 0.1% formic acid (chrom. system A) or 2 mM ammonium acetate (chrom. system B) from 90:10 up to 0:100 for 30 min at a flow rate of 250 μL/min, starting the gradient after 10 min. UV absorption was detected from 220 to 400 nm using a diode array detector. All tested compounds possessed a purity of not less than 95%. <sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded on a Bruker Avance 500 MHz NMR spectrometer. DMSO-<i>d</i><sub>6</sub>, CDCl<sub>3</sub>, and acetone-<i>d</i><sub>6</sub> were used as solvents as indicated below. NMR spectra were recorded at room temperature. Chemical shifts are given in parts per million (ppm) relative to the remaining protons of the deuterated solvent used as internal standard. Coupling constants <i>J</i> are given in Hertz, and spin multiplicities are given as s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), and br (broad).</div><div class="NLM_p">Melting points were determined on a Büchi B-545 melting point apparatus and were uncorrected. The benzothiazinones <b>25</b> and <b>44</b>,<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a><b>39</b> and <b>48</b> (R′ = CH<sub>3</sub> and R″ = H, and R′ = Cl, R″ = H),<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> and the thienothiazinones <b>49</b><a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> were prepared as described.</div><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> (2-Carboxyethyl)triphenylphosphonium Bromide</h4><div class="NLM_p last">3-Bromopropanoic acid <b>42</b> (25.4 g, 165.5 mmol) and triphenylphosphine (45.7 g, 174 mmol) were suspended in acetonitrile (125 mL) and refluxed for 5 h. After stirring for an additional 12 h at room temperature, diethylether (200 mL) was added, and the mixture was kept at −18 °C for 2 h. The formed precipitate was collected by suction filtration, washed with diethylether, and dried in vacuo to obtain the product (54.1 g, 79%) as a colorless powder. The crude product was used in the next step without further purification.</div></div><div id="sec4_1_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> General Procedure for the Synthesis of Phenylbutenoic Acids <b>40</b></h4><div class="NLM_p">(2-Carboxyethyl)triphenylphosphonium bromide (1.2 equiv) was suspended in CH<sub>2</sub>Cl<sub>2</sub> (1 mL/mmol) and cooled to 0 °C, and the appropriate aldehyde <b>43</b> (1.0 equiv) was added. After the addition of <i>tert</i>-BuOK (2.5 equiv) in portions, the reaction mixture was stirred for 12 h at room temperature. The reaction was quenched with water (2 mL/mmol), washed two times with CH<sub>2</sub>Cl<sub>2</sub>, and adjusted to pH 1. After extraction with diethylether, the combined organic layers were washed with brine and dried (MgSO<sub>4</sub>), and the solvent was rotary evaporated. The crude material was purified by silica gel chromatography as indicated below.</div><div id="sec4_1_1_1_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i24" class="anchor-spacer"></div><h5 class="article-section__title" id="_i24"> (<i>E</i>)-4-Phenylbut-3-enoic Acid (<b>40</b>, R‴ = H)</h5><div class="NLM_p last">Purification by silica gel chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH, 15:1 v/v) to obtain a colorless solid (790 mg, 53%); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ = 3.18 (dd, <i>J</i> = 1.5, 7.1 Hz, 2H), 6.32 (dt, <i>J</i> = 7.1, 15.9 Hz, 1H), 6.48 (d, <i>J</i> = 16.0 Hz, 1H), 7.20–7.24 (m, 1H), 7.28–7.33 (m, 2H), 7.42–7.38 (m, 2H), 12.35 (br, 1H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ = 38.0, 123.3, 126.1 (2C), 127.5, 128.7 (2C), 132.4, 136.9, 172.7.</div></div><div id="sec4_1_1_1_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i25" class="anchor-spacer"></div><h5 class="article-section__title" id="_i25"> (<i>E</i>)-4-(3-Methoxyphenyl)but-3-enoic Acid (<b>40</b>, R‴ = 3-OMe)</h5><div class="NLM_p last">Purification by silica gel chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH, 10:1 v/v) to obtain a colorless solid (2.12 g, 75%); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ = 3.17 (dd, <i>J</i> = 1.3, 7.1 Hz, 2H), 3.75 (s, 3H), 6.31 (dt, <i>J</i> = 7.1, 15.9 Hz, 1H), 6.45 (d, <i>J</i> = 16.0 Hz, 1H), 6.80 (dd, <i>J</i> = 2.6, 8.2 Hz, 1H), 6.94–6.96 (m, 1H), 7.22 (t, <i>J</i> = 7.9 Hz, 1H), 6.97 (d, <i>J</i> = 7.7 Hz, 1H), 12.32 (br, 1H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ = 38.0, 55.2, 111.3, 113.4, 118.7, 123.7, 129.8, 132.4, 138.4, 159.7, 172.7.</div></div><div id="sec4_1_1_1_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i26" class="anchor-spacer"></div><h5 class="article-section__title" id="_i26"> (<i>E</i>)-4-(3-Chlorophenyl)but-3-enoic Acid (<b>40</b>, R‴ = 3-Cl)</h5><div class="NLM_p last">Purification by silica gel chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH, 15:1 v/v) to obtain a colorless solid (12.6 g, 41%); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ = 3.19 (dd, <i>J</i> = 1.2, 6.9 Hz, 2H), 6.38 (dt, <i>J</i> = 6.9, 16.0 Hz, 1H), 6.48 (d, <i>J</i> = 16.0 Hz, 1H), 7.27 (ddd, <i>J</i> = 1.4, 2.0, 7.7 Hz, 1H), 7.33 (t, <i>J</i> = 7.7 Hz, 1H), 7.37 (dt, <i>J</i> = 1.4, 7.7 Hz, 1H), 7.46 (t, <i>J</i> = 1.8 Hz, 1H), 12.45 (br, 1H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ = 38.0, 124.8, 125.4, 125.9, 127.2, 130.6, 131.0, 133.6, 139.2, 172.5.</div></div><div id="sec4_1_1_1_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i27" class="anchor-spacer"></div><h5 class="article-section__title" id="_i27"> (<i>E</i>)-4-(3,4-Dichlorophenyl)but-3-enoic Acid (<b>40</b>, R‴ = 3,4-Cl)</h5><div class="NLM_p last">Purification by silica gel chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH, 10:1 v/v) to obtain a colorless solid (1.61 g, 61%); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ = 3.18 (d, <i>J</i> = 6.0 Hz, 2H), 6.42 (dt, <i>J</i> = 6.3, 16.0 Hz, 1H), 6.47 (d, <i>J</i> = 16.1 Hz, 1H), 7.41 (dd, <i>J</i> = 2.1, 8.4 Hz, 1H), 7.54 (d, <i>J</i> = 8.4 Hz, 1H), 7.66 (d, <i>J</i> = 2.0 Hz, 1H), 12.28 (br, 1H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ = 38.0, 123.0, 126.2, 126.3, 128.0, 129.7, 130.8, 131.6, 137.8, 172.4.</div></div></div><div id="sec4_1_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> General Procedure for the Synthesis of Phenylbutyric Acids <b>41</b></h4><div class="NLM_p">Ten percent Pd/C (10 wt %) was added to a solution of the corresponding olefins (<b>40</b> or commercially available reagent) in EtOH or THF (3 mL/mmol) and stirred under H<sub>2</sub> atmosphere for 1 h. After filtration through a pad of Celite, the filter cake was rinsed with EtOH or THF, and the solvent of the filtrate was removed to obtain the desired product. In some cases, purification by silica gel chromatography was necessary as indicated below.</div><div id="sec4_1_1_2_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i29" class="anchor-spacer"></div><h5 class="article-section__title" id="_i29"> 4-(3-Methoxyphenyl)butanoic Acid (<b>41</b>, R‴ = 3-OMe)</h5><div class="NLM_p last">Light beige solid (587 mg, 97%); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ = 1.83–1.73 (m, 2H), 2.19 (t, <i>J</i> = 7.4 Hz, 2H), 2.55 (t, <i>J</i> = 7.5 Hz, 2H), 3.72 (s, 3H), 6.71–6.78 (m, 3H), 7.01–7.27 (m, 1H), 12.13 (br, 1H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ = 26.3, 33.2, 34.6, 55.0, 111.4, 114.1, 120.7, 129.4, 143.3, 159.5, 174.4.</div></div><div id="sec4_1_1_2_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i30" class="anchor-spacer"></div><h5 class="article-section__title" id="_i30"> 4-(3-Chlorophenyl)butanoic Acid (<b>41</b>, R‴ = 3-Cl)</h5><div class="NLM_p last">Purification by silica gel chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH, 15:1 → 10:1 v/v) to obtain a colorless oil (345 mg, 38%); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ = 1.94 (m, 2H), 2.36 (t, <i>J</i> = 7.4 Hz, 2H), 2.64 (t, <i>J</i> = 7.4 Hz, 2H), 7.04 (d, <i>J</i> = 7.4 Hz, 1H), 7.14–7.19 (m, 3H), 12.10 (br, 1H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ = 26.0, 33.6, 33.8, 126.0, 127.2, 128.4, 130.2, 133.0, 144.6, 174.3.</div></div><div id="sec4_1_1_2_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i31" class="anchor-spacer"></div><h5 class="article-section__title" id="_i31"> 4-(3,4-Dichlorophenyl)butanoic Acid (<b>41</b>, R‴ = 3,4-Cl)</h5><div class="NLM_p last">Purification by silica gel chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH, 15:1 → 10:1 v/v) to obtain a colorless oil (513 mg, 57%); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ = 1.73–1.83 (m, 2H), 2.20 (t, <i>J</i> = 7.4 Hz, 2H), 2.58 (t, <i>J</i> = 7.5 Hz, 2H), 7.19 (dd, <i>J</i> = 2.1, 8.2 Hz, 1H), 7.46 (d, <i>J</i> = 2.0 Hz, 1H), 7.52 (d, <i>J</i> = 8.2 Hz, 1H), 12.10 (br, 1H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ = 26.0, 33.1, 33.5, 128.5, 128.9, 130.48, 130.50, 130.9, 143.1, 174.2.</div></div><div id="sec4_1_1_2_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i32" class="anchor-spacer"></div><h5 class="article-section__title" id="_i32"> 3-(2-Fluorophenyl)propanoic Acid (<b>41</b>, R‴ = 2-F)</h5><div class="NLM_p last">Colorless solid (506 mg, quantitative); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ = 2.68 (t, <i>J</i> = 7.8 Hz, 2H), 2.97 (t, <i>J</i> = 7.7 Hz, 2H), 6.98–7.03 (m, 1H), 7.03–7.07 (m, 1H), 7.15–7.23 (m, 2H), 10.09 (br, 1H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ = 24.3, 34.1, 115.4 (d, <i>J</i>(C,F) = 21.8 Hz), 124.1. (d, <i>J</i>(C,F) = 16.0 Hz), 127.0 (d, <i>J</i>(C,F) = 15.5 Hz), 128.2 (d, <i>J</i>(C,F) = 8.1 Hz), 130.6 (d, <i>J</i>(C,F) = 4.6 Hz), 161.2 (d, <i>J</i>(C,F) = 256 Hz), 178.8.</div></div><div id="sec4_1_1_2_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i33" class="anchor-spacer"></div><h5 class="article-section__title" id="_i33"> 2-Amino-6-bromo-4<i>H</i>-3,1-benzothiazin-4-one (<b>48</b>, R′ = Br, R″ = H)</h5><div class="NLM_p last">Benzoyl isothiocyanate (2.00 mL, 15.0 mmol) was added dropwise to a solution of methyl 2-amino-5-bromobenzoate (3.00 g, 13.0 mmol) in acetone (10 mL). After stirring for 20 min at room temperature, the formed precipitate was filtered by suction filtration and recrystallized from toluene to obtain the thioureide as a light yellow solid (4.48 g, 87%). The intermediate (1.00 g, 2.54 mmol) was treated with 10 drops of water and concentrated H<sub>2</sub>SO<sub>4</sub> (7 mL) and stirred for 4 h at 100 °C. After cooling to room temperature, the reaction mixture was put carefully into ice water and neutralized by the addition of solid NaHCO<sub>3</sub>. The formed precipitate was filtered by suction filtration and dried in vacuo. After recrystallization from toluene, the product <b>48</b> (R′ = Br, R″ = H) was obtained as a light yellow solid (510 mg, 78%); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ = 7.22 (d, <i>J</i> = 8.8 Hz, 1H), 7.77 (dd, <i>J</i> = 2.5, 8.8 Hz, 1H), 7.93 (d, <i>J</i> = 2.5 Hz, 1H), 8.04 (br, 2H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ = 115.0, 117.8, 126.3, 129.9, 138.6, 150.4, 157.5, 183.1. LC/ESI-MS (<i>m</i>/<i>z</i>): negative mode 257 [M – H]<sup>−</sup>, positive mode 259 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_1_2_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i34" class="anchor-spacer"></div><h5 class="article-section__title" id="_i34"> 2-Amino-7-chloro-4<i>H</i>-3,1-benzothiazin-4-one (<b>48</b>, R′ = H, R″ = Cl)</h5><div class="NLM_p last">Benzoyl isothiocyanate (0.90 mL, 6.70 mmol) was added dropwise to a solution of 6-chloroanthranilic acid (1.00 g, 5.80 mmol) in acetone (34 mL). After stirring for 20 min at room temperature, the formed precipitate was filtered by suction filtration and recrystallized from MeOH to obtain the thioureide as a light yellow solid (1.55 g, 79%). The intermediate (1.00 g, 2.99 mmol) was treated with 10 drops water and concentrated H<sub>2</sub>SO<sub>4</sub> (20 mL) and stirred for 4 h at 100 °C. After cooling to room temperature, the reaction mixture was placed carefully in ice water and neutralized by the addition of solid NaHCO<sub>3</sub>. The formed precipitate was filtered by suction filtration and dried in vacuo. After recrystallization from toluene, product <b>48</b> (R′ = H, R″ = Cl) was obtained as a light yellow solid (526 mg, 83%); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ = 7.19 (dd, <i>J</i> = 2.1, 8.6 Hz, 1H), 7.27 (d, <i>J</i> = 2.1 Hz, 1H), 7.87 (d, <i>J</i> = 8.6 Hz, 1H), 8.09 (br, 2H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ = 115.4, 123.4, 126.3, 126.5, 140.7, 152.6, 158.4, 183.2. LC/ESI-MS (<i>m</i>/<i>z</i>): negative mode 211 [M – H]<sup>−</sup>, positive mode 213 [M + H]<sup>+</sup>.</div></div></div><div id="sec4_1_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> General Procedure for Acylation of 2-Amino-4<i>H</i>-3,1-benzothiazin-4-one with Acids <b>40</b> and <b>41</b> to Produce 2-Acylamino-4<i>H</i>-3,1-benzothiazin-4-ones (<b>8</b>–<b>24</b>)</h4><div class="NLM_p"><i>N</i>-Methylmorpholine (1.1 equiv) was added to a solution of the appropriate carboxylic acid <b>40</b> or <b>41</b> (1.0 equiv) in THF (4 mL/mmol). After the addition of 2,4,6-trichlorobenzoyl chloride (1.1 equiv), the reaction mixture was stirred for 2 h at room temperature. The solvent was removed under reduced pressure, and the residue was taken up in toluene (12 mL/mmol). After the addition of pyridine (2.4 equiv) and amine <b>39</b> (1 equiv), the mixture was refluxed for 2 h. Then, the hot mixture was filtered, and the filtrate was cooled. The formed precipitate was collected by suction filtration, washed with petroleum ether, and purified as indicated below.</div><div id="sec4_1_1_3_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i36" class="anchor-spacer"></div><h5 class="article-section__title" id="_i36"> <i>N</i>-(4-Oxo-4<i>H</i>-3,1-benzothiazin-2-yl)-3-phenylpropanamide (<b>8</b>)</h5><div class="NLM_p last">Recrystallization two times from toluene afforded <b>8</b> as a colorless solid (130 mg, 50%); mp, 186–188 °C (toluene); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 2.75 (t, <i>J =</i> 7.5 Hz, 2H), 2.88 (t, <i>J =</i> 7.7 Hz, 2H), 7.18 (tt, <i>J =</i> 1.3, 7.2 Hz, 1H), 7.25–7.21 (m, 2H), 7.25–7.31 (m, 2H), 7.49 (ddd, <i>J =</i> 1.2, 7.3, 8.2 Hz, 1H), 7.57 (dd, <i>J =</i> 0.7, 8.2 Hz, 1H), 7.85 (ddd, <i>J =</i> 1.6, 7.2, 8.7 Hz, 1H), 8.02 (dd, <i>J =</i> 1.4, 8.0 Hz, 1H), 11.89 (br, 1H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 30.1, 37.2, 119.5, 124.4, 126.2, 127.1, 128.4 (2C), 128.5 (2C), 128.9, 136.4, 140.7, 147.7, 153.0, 172.9, 184.5. LC/ESI-MS (<i>m</i>/<i>z</i>): negative mode 309 [M – H]<sup>−</sup>, positive mode 311 [M + H]<sup>+</sup>; purity, 99% (A), 99% (B).</div></div><div id="sec4_1_1_3_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i37" class="anchor-spacer"></div><h5 class="article-section__title" id="_i37"> 3-(3-Methoxyphenyl)-<i>N</i>-(4-oxo-4<i>H</i>-3,1-benzothiazin-2-yl)propanamide (<b>9</b>)</h5><div class="NLM_p last">Recrystallization two times from toluene afforded <b>9</b> as colorless crystals (128 mg, 45%); mp, 168–170 °C (toluene); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 2.75 (t, <i>J</i> = 8.1 Hz, 2H), 2.86 (t, <i>J</i> = 7.6 Hz, 2H), 3.72 (s, 3H), 6.75 (ddd, <i>J</i> = 1.2, 2.4, 8.2 Hz, 1H), 6.78–6.81 (m, 2H), 7.19 (t, <i>J</i> = 8.0 Hz, 1H), 7.50 (ddd, <i>J</i> = 1.2, 7.4, 15.1 Hz, 1H), 7.57 (ddd, <i>J =</i> 0.5, 1.2, 8.2 Hz, 1H), 7.85 (ddd, <i>J =</i> 1.7, 7.2, 8.2 Hz, 1H), 8.03 (ddd, <i>J =</i> 8.0, 1.6, 0.4 Hz, 1H), 11.89 (br, 1H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 30.2, 37.1, 55.0, 111.6, 114.1, 119.5, 120.6, 124.5, 127.1, 129.0, 136.4, 142.3, 147.7, 153.0, 159.4, 173.0, 177.7, 184.6. LC/ESI-MS (<i>m</i>/<i>z</i>): negative mode 339 [M – H]<sup>−</sup>, positive mode 341 [M + H]<sup>+</sup>; purity, 95% (A), 95% (B).</div></div><div id="sec4_1_1_3_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i38" class="anchor-spacer"></div><h5 class="article-section__title" id="_i38"> 3-(3,4-Dichlorophenyl)-<i>N</i>-(4-oxo-4<i>H</i>-3,1-benzothiazin-2-yl)propanamide (<b>10</b>)</h5><div class="NLM_p last">Recrystallization from EtOH afforded <b>10</b> as a colorless solid (188 mg, 36%); mp, 230 °C (EtOH); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 2.77 (t, <i>J</i> = 7.5 Hz, 2H), 2.89 (t, <i>J</i> = 7.5 Hz, 2H), 7.24 (dd, <i>J</i> = 2.0, 8.3 Hz, 1H), 7.48–7.56 (m, 3H), 7.57 (dd, <i>J =</i>0.7, 8.2 Hz, 1H), 7.86 (ddd, <i>J =</i> 1.6, 7.2, 8.7 Hz, 1H), 8.03 (dd, <i>J</i> = 1.6, 7.9 Hz, 1H), 11.90 (br, 1H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 29.2, 36.7, 119.5, 124.5, 127.2, 128.8, 128.97, 129.00, 130.6 (2C), 131.0, 136.5, 142.1, 147.7, 153.0, 172.7, 184.5. LC/ESI-MS (<i>m</i>/<i>z</i>): negative mode 377 [M – H]<sup>−</sup>, positive mode 379 [M + H]<sup>+</sup>; purity, 100% (A), 100% (B).</div></div><div id="sec4_1_1_3_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i39" class="anchor-spacer"></div><h5 class="article-section__title" id="_i39"> 3-(2-Fluorophenyl)-<i>N</i>-(4-oxo-4<i>H</i>-3,1-benzothiazin-2-yl)propanamide (<b>11</b>)</h5><div class="NLM_p last">Recrystallization from EtOH afforded <b>11</b> as colorless crystals (140 mg, 48%); mp, 190–192 °C (EtOH); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 2.76 (t, <i>J</i> = 7.6 Hz, 2H), 2.91 (t, <i>J</i> = 7.6 Hz, 2H), 7.10–7.17 (m, 2H), 7.22–7.28 (m, 1H), 7.31 (td, <i>J</i> = 1.5, 7.7 Hz, 1H), 7.50 (ddd, <i>J</i> = 1.2, 7.2, 8.2 Hz, 1H), 7.57 (dd, <i>J</i> = 0.8, 8.2 Hz, 1H), 7.83–7.88 (m, 1H), 7.83 (dd, <i>J =</i> 1.4, 8.0 Hz, 1H), 11.91 (br, 1H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 23.4 (d, <i>J</i> (C,F) = 2.5 Hz), 35.7, 115.2 (d, <i>J</i> (C,F) = 21.3 Hz), 119.5, 124.48, 124.55 (d, <i>J</i> (C,F) = 2.5 Hz), 127.2, 127.3 (d, <i>J</i> (C,F) = 16.3 Hz), 128.4 (d, <i>J</i> (C,F) = 7.5 Hz), 129.0, 130.8 (d, <i>J</i> (C,F) = 5.0 Hz), 136.5, 147.7, 153.0, 160.6 (d, <i>J</i> (C,F) = 242 Hz), 172.7, 184.6. LC/ESI-MS (<i>m</i>/<i>z</i>): negative mode 327 [M – H]<sup>−</sup>, positive mode 329 [M + H]<sup>+</sup>; purity, 96% (A), 100% (B).</div></div><div id="sec4_1_1_3_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i40" class="anchor-spacer"></div><h5 class="article-section__title" id="_i40"> 3-(2-Bromophenyl)-<i>N</i>-(4-oxo-4<i>H</i>-3,1-benzothiazin-2-yl)propanamide (<b>12</b>)</h5><div class="NLM_p last">Recrystallization from EtOH afforded <b>12</b> as colorless crystals (253 mg, 52%); mp, 195 °C (EtOH); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 2.77 (t, <i>J</i> = 7.7 Hz, 2H), 2.99 (t, <i>J</i> = 7.7 Hz, 2H), 7.16 (ddd, <i>J =</i> 2.0, 7.2, 8.0 Hz, 1H), 7.35 (td, <i>J</i> = 2.0, 7.2, 8.0 Hz, 1H), 7.36 (dd, <i>J</i> = 1.9, 7.7 Hz, 1H), 7.51 (ddd, <i>J =</i> 1.0, 7.0, 8.0 Hz, 1H), 7.51–7.56 (m, 2H), 7.86 (ddd, <i>J =</i> 1.6, 7.2, 8.2 Hz, 1H), 8.03 (ddd, <i>J =</i> 0.4, 1.5, 8.0 Hz, 1H), 11.94 (br, 1H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 30.5, 35.4, 119.5, 123.9, 124.5, 127.2, 128.1, 128.6, 129.0, 130.7, 132.7, 136.5, 139.7, 147.7, 153.0, 172.5, 184.6. LC/ESI-MS (<i>m</i>/<i>z</i>): negative mode 387 [M – H]<sup>−</sup>, positive mode 389 [M + H]<sup>+</sup>; purity, 100% (A), 100% (B).</div></div><div id="sec4_1_1_3_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i41" class="anchor-spacer"></div><h5 class="article-section__title" id="_i41"> 2-(3-Chlorophenoxy)-<i>N</i>-(4-oxo-4<i>H</i>-3,1-benzothiazin-2-yl)acetamide (<b>13</b>)</h5><div class="NLM_p last">Recrystallization from EtOH afforded <b>13</b> as a colorless solid (142 mg, 57%); mp, 188–189 °C (EtOH); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 4.99 (s, 2H), 6.98 (td, <i>J</i> = 1.3, 7.7 Hz, 1H), 7.06 (dd, <i>J</i> = 1.2, 8.3 Hz, 1H), 7.28 (ddd, <i>J</i> = 1.6, 7.5, 8.4 Hz, 1H), 7.44 (dd, <i>J</i> = 1.6, 7.9 Hz, 1H), 7.53 (td, <i>J</i> = 1.1, 8.1 Hz, 1H), 7.62 (dd, <i>J</i> = 0.8, 8.2 Hz, 1H), 7.88 (ddd, <i>J</i> = 1.6, 7.2, 8.7 Hz, 1H), 8.05 (dd, <i>J</i> = 1.4, 8.0 Hz, 1H), 12.09 (br, 1H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 66.8, 114.0, 119.4, 121.5, 122.4, 124.6, 127.5, 128.4, 129.2, 130.3, 136.6, 147.5, 152.4, 153.3, 168.5, 184.1. LC/ESI-MS (<i>m</i>/<i>z</i>): negative mode 345 [M – H]<sup>−</sup>, positive mode 347 [M + H]<sup>+</sup>; purity, 97% (A), 96% (B).</div></div><div id="sec4_1_1_3_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i42" class="anchor-spacer"></div><h5 class="article-section__title" id="_i42"> (<i>E</i>)-3-(3-Methoxyphenyl)-<i>N</i>-(4-oxo-4<i>H</i>-3,1-benzothiazin-2-yl)acrylamide (<b>14</b>)</h5><div class="NLM_p last">The crude material was recrystallized from toluene and purified by silica gel chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH, 50:1 v/v) to obtain <b>14</b> as colorless crystals (61.0 mg, 16%); mp, 182–184 °C; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 3.79 (s, 3H), 6.96 (d, <i>J</i> = 15.8 Hz, 1H), 7.01 (dd, <i>J</i> = 2.2, 7.9 Hz, 1H), 7.15–7.18 (m, 1H), 7.20 (d, <i>J</i> = 7.6 Hz, 1H), 7.36 (t, <i>J</i> = 7.9 Hz, 1H), 7.50 (ddd, <i>J</i> = 1.2, 7.2, 8.2 Hz, 1H), 7.60 (dd, <i>J</i> = 0.8, 8.2 Hz, 1H), 7.68 (d, <i>J</i> = 15.8 Hz, 1H), 7.86 (ddd, <i>J</i> = 1.5, 7.0, 8.8 Hz, 1H), 8.03 (dd, <i>J</i> = 1.5, 8.0 Hz, 1H), 12.02 (br, 1H), <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 55.3, 113.6, 116.4, 119.5, 120.1, 120.4, 124.5, 127.2, 129.1, 130.3, 135.6, 136.4, 143.5, 147.7, 153.4, 159.7, 165.2, 184.6. LC/ESI-MS (<i>m</i>/<i>z</i>): negative mode 337 [M – H]<sup>−</sup>, positive mode 339 [M + H]<sup>+</sup>; purity, 97% (A), 98% (B).</div></div><div id="sec4_1_1_3_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i43" class="anchor-spacer"></div><h5 class="article-section__title" id="_i43"> (<i>E</i>)-3-(3-Chlorophenyl)-<i>N</i>-(4-oxo-4<i>H</i>-3,1-benzothiazin-2-yl)acrylamide (<b>15</b>)</h5><div class="NLM_p last">The crude material was recrystallized from toluene and purified by silica gel chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH, 100:1 v/v) to obtain <b>15</b> as a colorless solid (72 mg, 19%); mp, 246–247 °C; <sup>1</sup>H NMR (500 MHz,) δ 7.00 (d, <i>J</i> = 15.8 Hz, 1H), 7.47–7.56 (m, 3H), 7.58–7.61 (m, 1H), 7.63 (dd, <i>J</i> = 0.8, 8.2 Hz, 1H), 7.68–7.71 (m, 1H), 7.72 (d, <i>J</i> = 15.8 Hz, 1H), 7.88 (ddd, <i>J</i> = 1.6, 7.2, 8.2 Hz, 1H), 8.06 (dd, <i>J</i> = 1.4, 8.0 Hz, 1H), 12.10 (br, 1H), <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 119.5, 121.4, 124.5, 126.5, 127.2, 128.0, 129.0, 130.2, 131.0, 134.0, 136.46, 136.50, 141.9, 147.7, 153.3, 164.9, 184.6. LC/ESI-MS (<i>m</i>/<i>z</i>): negative mode 341 [M – H]<sup>−</sup>, positive mode 343 [M + H]<sup>+</sup>; purity, 97% (A), 95% (B).</div></div><div id="sec4_1_1_3_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i44" class="anchor-spacer"></div><h5 class="article-section__title" id="_i44"> 3-(3-Methoxyphenyl)-<i>N</i>-(4-oxo-4<i>H</i>-3,1-benzothiazin-2-yl)propiolamide (<b>16</b>)</h5><div class="NLM_p last">The crude material was recrystallized from toluene and purified by silica gel chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH, 100:1 v/v) to obtain <b>16</b> as a colorless solid (104 mg, 27%); mp, 172–174 °C; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 3.80 (s, 3H), 7.14 (dd, <i>J =</i> 2.1, 8.3 Hz, 1H), 7.22 (s, 1H), 7.25 (d, <i>J =</i> 7.5 Hz, 1H), 7.41 (t, <i>J =</i> 7.9 Hz, 1H), 7.54 (t, <i>J</i> = 7.5 Hz, 1H), 7.63 (d, <i>J =</i> 8.1 Hz, 1H), 7.89 (t, <i>J =</i> 7.6 Hz, 1H), 8.05 (d, <i>J =</i> 7.9 Hz, 1H), 12.76 (br, 1H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 55.5, 82.5, 88.7, 117.4, 118.0, 119.4, 120.1, 124.6, 125.2, 127.6, 129.1, 130.4, 136.6, 147.2, 152.2, 152.8, 159.3, 184.0. LC/ESI-MS (<i>m</i>/<i>z</i>): negative mode 335 [M – H]<sup>−</sup>, positive mode 337 [M + H]<sup>+</sup>; purity, 95% (A), 95% (B).</div></div><div id="sec4_1_1_3_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i45" class="anchor-spacer"></div><h5 class="article-section__title" id="_i45"> <i>N</i>-(4-Oxo-4<i>H</i>-3,1-benzothiazin-2-yl)-4-phenylbutanamide (<b>17</b>)</h5><div class="NLM_p last">Recrystallization from EtOH afforded <b>17</b> as colorless crystals (340 mg, 47%); mp, 185 °C (EtOH); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ = 1.83–1.90 (m, 2H), 2.46 (t, <i>J</i> = 7.4 Hz, 2H), 2.60 (t, <i>J</i> = 7.7 Hz, 2H), 7.14–7.21 (m, 3H), 7.25–7.29 (m, 2H), 7.49 (ddd, <i>J</i> = 1.3, 7.3, 8.0 Hz, 1H), 7.57 (dd, <i>J</i> = 0.6, 8.2 Hz, 1H), 7.85 (ddd, <i>J</i> = 1.6, 7.3, 8.2 Hz, 1H), 8.02 (dd, <i>J</i> = 1.3, 8.2 Hz, 1H), 11.84 (br, 1H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ = 26.1, 34.5, 35.0, 119.5, 124.4, 126.0, 127.1, 128.4 (2C), 128.5 (2C), 129.0, 136.4, 141.5, 147.8, 153.1, 173.6, 184.7. LC/ESI-MS (<i>m</i>/<i>z</i>): negative mode 323 [M – H]<sup>−</sup>, positive mode 325 [M + H]<sup>+</sup>; purity, 97% (A), 99% (B).</div></div><div id="sec4_1_1_3_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i46" class="anchor-spacer"></div><h5 class="article-section__title" id="_i46"> 4-(3-Methoxyphenyl)-<i>N</i>-(4-oxo-4<i>H</i>-3,1-benzothiazin-2-yl)butanamide (<b>18</b>)</h5><div class="NLM_p last">Recrystallization two times from EtOH afforded <b>18</b> as colorless crystals (604 mg, 65%); mp, 130–132 °C (EtOH); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ = 1.86 (q, <i>J</i> = 7.0 Hz, 2H), 2.45 (t, <i>J</i> = 7.4 Hz, 2H), 2.57 (t, <i>J</i> = 7.5 Hz, 2H), 3.72 (s, 3H), 6.71–6.79 (m, 3H), 7.18 (t, <i>J</i> = 8.0 Hz, 1H), 7.49 (ddd, <i>J =</i> 1.2, 7.2, 8.2 Hz, 1H), 7.57 (dd, <i>J</i> = 0.8, 8.2 Hz, 1H), 7.85 (ddd, <i>J =</i> 1.7, 7.2, 8.3 Hz, 1H), 8.02 (dd, <i>J</i> = 1.4, 8.2 Hz, 1H), 11.84 (br, 1H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ = 25.9, 34.6, 35.0, 55.0, 111.5, 114.1, 119.5, 120.7, 124.5, 127.1, 129.0, 129.4, 136.4, 143.1, 147.8, 153.1, 159.4, 173.6, 184.7. LC/ESI-MS (<i>m</i>/<i>z</i>): negative mode 353 [M – H]<sup>−</sup>, positive mode 355 [M + H]<sup>+</sup>; purity, 99% (A), 100% (B).</div></div><div id="sec4_1_1_3_12" class="NLM_sec NLM_sec_level_4"><div id="ac_i47" class="anchor-spacer"></div><h5 class="article-section__title" id="_i47"> 4-(3-Chlorophenyl)-<i>N</i>-(4-oxo-4<i>H</i>-3,1-benzothiazin-2-yl)butanamide (<b>19</b>)</h5><div class="NLM_p last">Recrystallization from EtOH afforded <b>19</b> as colorless crystals (112 mg, 37%); mp, 177 °C (EtOH); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 1.87 (q, <i>J</i> = 7.5 Hz, 2H), 2.45 (t, <i>J</i> = 7.4 Hz, 2H), 2.62 (t, <i>J</i> = 7.5 Hz, 2H), 7.15–7.25 (m, 2H), 7.25–7.33 (m, 2H), 7.50 (ddd, <i>J =</i> 1.0, 7.0, 8.0 Hz, 1H), 7.57 (dd, <i>J</i> = 0.7, 8.2 Hz, 1H), 7.86 (ddd, <i>J =</i> 1.6, 7.2, 8.7 Hz, 1H), 8.03 (dd, <i>J</i> = 1.4, 8.0 Hz, 1H), 11.84 (br, 1H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 25.7, 34.1, 34.9, 119.5, 124.5, 126.0, 127.1, 127.3, 128.4, 129.0, 130.3, 133.1, 136.4, 144.2, 148.0, 153.1, 173.5, 184.7. LC/ESI-MS (<i>m</i>/<i>z</i>): negative mode 359 [M – H]<sup>−</sup>, positive mode 357 [M + H]<sup>+</sup>; purity, 96% (A), 96% (B).</div></div><div id="sec4_1_1_3_13" class="NLM_sec NLM_sec_level_4"><div id="ac_i48" class="anchor-spacer"></div><h5 class="article-section__title" id="_i48"> 4-(3,4-Dichlorophenyl)-<i>N</i>-(4-oxo-4<i>H</i>-3,1-benzothiazin-2-yl)butanamide (<b>20</b>)</h5><div class="NLM_p last">Recrystallization from EtOH afforded <b>20</b> as a light beige solid (233 mg, 41%); mp, 200–201 °C (EtOH); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 1.87 (q, <i>J</i> = 7.5 Hz, 2H), 2.44 (t, <i>J</i> = 7.3 Hz, 2H), 2.62 (t, <i>J</i> = 7.5 Hz, 2H), 7.21 (dd, <i>J</i> = 2.0, 8.2 Hz, 1H), 7.46–7.54 (m, 3H), 7.57 (dd, <i>J =</i> 0.6, 8.2 Hz, 1H), 7.86 (ddd, <i>J =</i> 1.6, 7.2, 8.7 Hz, 1H), 8.03 (dd, <i>J</i> = 1.3, 8.0 Hz, 1H), 11.82 (br, 1H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 25.5, 33.4, 34.8, 119.5, 124.4, 127.1, 128.6, 128.97, 129.03, 130.5, 130.6, 130.9, 136.4, 142.8, 147.8, 153.0, 173.4, 184.6. LC/ESI-MS (<i>m</i>/<i>z</i>): negative mode [M – H]<sup>−</sup>, 391 positive mode 393 [M + H]<sup>+</sup>; purity, 100% (A), 98% (B).</div></div><div id="sec4_1_1_3_14" class="NLM_sec NLM_sec_level_4"><div id="ac_i49" class="anchor-spacer"></div><h5 class="article-section__title" id="_i49"> (<i>E</i>)-<i>N</i>-(4-Oxo-4<i>H</i>-3,1-benzothiazin-2-yl)-4-phenylbut-3-enamide (<b>21</b>)</h5><div class="NLM_p last">Recrystallization from EtOH afforded <b>21</b> as colorless crystals (91.0 mg, 30%); mp, 180–181 °C (EtOH); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 3.41 (dd, <i>J</i> = 1.2, 7.1 Hz, 2H), 6.35 (dt, <i>J</i> = 7.1, 16.0 Hz, 1H), 6.55 (d, <i>J</i> = 16.0 Hz, 1H), 7.23 (dd, <i>J</i> = 4.2, 10.4 Hz, 1H), 7.32 (dd, <i>J</i> = 4.8, 10.4 Hz, 1H), 7.39–7.44 (m, 2H), 7.48–7.54 (m, 2H), 7.59 (dd, <i>J</i> = 0.7, 8.2 Hz, 1H), 7.84–7.89 (m, 1H), 8.03 (dd, <i>J</i> = 1.4, 8.0 Hz, 1H), 11.98 (br, 1H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 25.7, 34.1, 34.9, 119.5, 124.5, 126.0, 127.1, 127.3, 128.4, 129.0, 130.3, 133.1, 136.4, 144.2, 184.7, 147.8, 153.1, 173.5. LC/ESI-MS (<i>m</i>/<i>z</i>): positive mode 323 [M + H]<sup>+</sup>; purity, 98% (A), 97% (B).</div></div><div id="sec4_1_1_3_15" class="NLM_sec NLM_sec_level_4"><div id="ac_i50" class="anchor-spacer"></div><h5 class="article-section__title" id="_i50"> (<i>E</i>)-4-(3-Methoxyphenyl)-<i>N</i>-(4-oxo-4<i>H</i>-3,1-benzothiazin-2-yl)but-3-enamide (<b>22</b>)</h5><div class="NLM_p last">The crude material was recrystallized from toluene and purified by silica gel chromatography using CH<sub>2</sub>Cl<sub>2</sub> as eluent to obtain <b>22</b> as colorless crystals (126 mg, 28%); mp, 167 °C; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 3.40 (dd, <i>J</i> = 1.3, 7.0 Hz, 2H), 3.75 (s, 3H), 6.36 (dt, <i>J</i> = 7.0, 15.9 Hz, 1H), 6.52 (d, <i>J</i> = 15.9 Hz, 1H), 6.80 (ddd, <i>J</i> = 0.8, 2.5, 8.2 Hz, 1H), 6.95–7.02 (m, 2H), 7.23 (t, <i>J</i> = 7.9 Hz, 1H), 7.50 (ddd, <i>J</i> = 1.0, 7.0, 8.0 Hz, 1H), 7.59 (dd, <i>J</i> = 0.8, 8.2 Hz, 1H), 7.86 (ddd, <i>J =</i> 1.6, 7.2, 8.2 Hz, 1H), 8.03 (dd, <i>J =</i> 1.3, 8.0 Hz, 1H), 11.97 (br, 1H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 40.0, 55.2, 111.4, 113.5, 118.8, 119.5, 122.8, 124.5, 127.2, 129.0, 129.8, 133.3, 136.5, 138.2, 147.7, 153.1, 159.7, 171.6, 184.5. LC/ESI-MS (<i>m</i>/<i>z</i>): negative mode 351 [M – H]<sup>−</sup>, positive mode 353 [M + H]<sup>+</sup>; purity, 96% (A),97% (B).</div></div><div id="sec4_1_1_3_16" class="NLM_sec NLM_sec_level_4"><div id="ac_i51" class="anchor-spacer"></div><h5 class="article-section__title" id="_i51"> (<i>E</i>)-4-(3-Chlorophenyl)-<i>N</i>-(4-oxo-4<i>H</i>-3,1-benzothiazin-2-yl)but-3-enamide (<b>23</b>)</h5><div class="NLM_p last">The crude material was purified by silica gel chromatography (petroleum ether/ethyl acetate, 1:1 v/v) and recrystallized from EtOH to obtain <b>23</b> as a colorless solid (178 mg, 20%); mp, 197 °C (EtOH); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ = 3.42 (dd, <i>J</i> = 1.1, 6.9 Hz, 2H), 6.45 (dt, <i>J</i> = 6.9, 16.0 Hz, 1H), 6.55 (d, <i>J</i> = 16.0 Hz, 1H), 7.29 (ddd, <i>J =</i> 1.2, 2.1, 7.9 Hz, 1H), 7.35 (t, <i>J</i> = 7.8 Hz, 1H), 7.40 (dt, <i>J</i> = 1.3, 7.7 Hz, 1H), 7.46–7.54 (m, 2H), 7.61 (dd, <i>J</i> = 0.8, 8.2 Hz, 1H), 7.88 (ddd, <i>J =</i> 1.7, 7.2, 8.2 Hz, 1H), 8.04 (dd, <i>J =</i> 1.3, 8.0 Hz, 1H), 12.00 (br, 1H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ = 39.6, 119.5, 124.50, 124.54, 124.9 125.9, 127.3, 127.4, 129.1, 130.6, 131.9, 133.6, 136.5, 139.0, 147.7, 153.0, 171.4, 184.5. LC/ESI-MS (<i>m</i>/<i>z</i>): negative mode 355 [M – H]<sup>−</sup>, positive mode 357 [M + H]<sup>+</sup>; purity, 99% (A), 99% (B).</div></div><div id="sec4_1_1_3_17" class="NLM_sec NLM_sec_level_4"><div id="ac_i52" class="anchor-spacer"></div><h5 class="article-section__title" id="_i52"> (<i>E</i>)-4-(3,4-Dichlorophenyl)-<i>N</i>-(4-oxo-4<i>H</i>-3,1-benzothiazin-2-yl)but-3-enamide (<b>24</b>)</h5><div class="NLM_p last">The crude material was purified by silica gel chromatography using CH<sub>2</sub>Cl<sub>2</sub> as eluent and recrystallized from toluene to obtain <b>24</b> as a light beige solid (116 mg, 18%); mp, 215 °C (toluene); <sup>1</sup>H NMR (500 MHz, aceton-<i>d</i><sub><i>6</i></sub>) δ 3.57 (d, <i>J</i> = 6.1 Hz, 2H), 6.57 (dt, <i>J</i> = 6.6, 16.0 Hz, 1H), 6.64 (d, <i>J</i> = 16.0 Hz, 1H), 7.44–7.56 (m, 4H), 7.66 (d, <i>J</i> = 2.0 Hz, 1H), 7.82 (ddd, <i>J</i> = 1.6, 7.2, 8.3 Hz, 1H), 8.08 (dd, <i>J =</i> 8.0, 1.6 Hz, 1H), 10.71 (br, 1H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 40.0, 119.5, 124.5, 125.4, 126.3, 127.3, 128.1, 129.1, 129.8, 130.85, 130.88, 131.6, 136.5, 137.6, 147.7, 153.0, 171.3, 184.5. LC/ESI-MS (<i>m</i>/<i>z</i>): positive mode 391 [M + H]<sup>+</sup>; purity, 98% (A), 97% (B).</div></div></div><div id="sec4_1_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> General Procedure for the Amide Coupling of Compound <b>44</b> with Piperazines <b>45</b> (<b>26</b>–<b>28</b>)</h4><div class="NLM_p">1,1′-Carbonyldiimidazole (1.1 equiv) was added to 4-(4-oxo-4<i>H</i>-3,1-benzothiazin-2-ylcarbamoyl)benzoic acid <b>44</b> (1 equiv) dissolved in DMF (6 mL/mmol) and stirred at room temperature for 1 h. To a solution of the piperazine derivative <b>45</b> (1.25 equiv) in DMF/1,4-dioxane (1:1, 2 mL/mmol), imidazole (1.0 equiv) and HCl (2.0 equiv, 4 N in 1,4-dioxane) were added dropwise. The two mixtures were combined, stirred at room temperature for 2 h, and poured into saturated aqueous NaHCO<sub>3</sub> solution (∼100 mL/mmol). The precipitate was collected by suction filtration, dried, and recrystallized from EtOH.</div><div id="sec4_1_1_4_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i54" class="anchor-spacer"></div><h5 class="article-section__title" id="_i54"> 4-(4-(2-Chlorobenzyl)piperazine-1-carbonyl)-<i>N</i>-(4-oxo-4<i>H</i>-3,1-benzothiazin-2-yl)benzamide (<b>26</b>)</h5><div class="NLM_p last">Colorless solid (109 mg, 23%); mp, 230–232 °C (EtOH); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 2.42 (br, 2H), 3.29 (br, 4H), 3.61 (s, 2H), 3.67 (br, 2H), 7.28 (td, <i>J</i> = 1.9, 7.6 Hz, 1H), 7.32 (td, <i>J</i> = 1.5, 7.4 Hz, 1H), 7.39–7.46 (m, 2H), 7.46–7.52 (m, 3H), 7.57–7.63 (m, 1H), 7.77–7.85 (m, 1H), 7.99–8.04 (m, 1H), 8.09–8.13 (m, 2H), 12.41 (br, 1H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 41.8, 47.3, 52.4, 53.0, 58.6, 119.5, 124.4, 126.2, 126.9, 127.2, 128.5, 128.9 (2C), 129.4, 131.1, 133.5, 135.4, 136.1, 139.5, 148.3, 168.3, 176.9, 185.9. LC/ESI-MS (<i>m</i>/<i>z</i>): negative mode 517 [M – H]<sup>−</sup>, positive mode 519 [M + H]<sup>+</sup>; purity, 99% (B).</div></div><div id="sec4_1_1_4_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i55" class="anchor-spacer"></div><h5 class="article-section__title" id="_i55"> 4-(4-(3-Chlorobenzyl)piperazine-1-carbonyl)-<i>N</i>-(4-oxo-4<i>H</i>-3,1-benzothiazin-2-yl)benzamide (<b>27</b>)</h5><div class="NLM_p last">Colorless solid (163 mg, 34%); mp, 243–244 °C (EtOH); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 2.36 (br, 2H), 2.43 (br, 2H), 3.29 (br, 2H), 3.52 (s, 2H), 3.65 (br, 2H), 7.25–7.29 (m, 1H), 7.29–7.32 (m, 1H), 7.34 (d, <i>J</i> = 7.4 Hz, 1H), 7.36–7.38 (m, 1H), 7.50–7.56 (m, 3H), 7.66–7.69 (m, 1H), 7.89 (ddd, <i>J</i> = 1.6, 7.2, 8.3 Hz, 1H), 8.06 (dd, <i>J</i> = 1.5, 8.0 Hz, 1H), 8.08–8.12 (m, 2H), 12.39 (br, 1H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 41.7, 47.2, 52.2, 52.7, 61.1, 119.6, 124.6, 127.1, 127.2, 127.6, 128.6, 128.9 (2C), 130.2, 132.5, 133.1, 136.5, 140.2, 140.8, 148.9, 167.5, 168.1, 184.7. LC/ESI-MS (<i>m</i>/<i>z</i>): negative mode 517 [M – H]<sup>−</sup>, positive mode 519 [M + H]<sup>+</sup>; purity, 100% (B).</div></div><div id="sec4_1_1_4_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i56" class="anchor-spacer"></div><h5 class="article-section__title" id="_i56"> 4-(4-(4-Chlorobenzyl)piperazine-1-carbonyl)-<i>N</i>-(4-oxo-4<i>H</i>-3,1-benzothiazin-2-yl)benzamide (<b>28</b>)</h5><div class="NLM_p last">Colorless solid (83.0 mg, 17%); mp, 240–243 °C (EtOH); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 2.35 (br, 2H), 2.43 (br, 2H), 3.29 (br, 2H), 3.50 (s, 2H), 3.63 (br, 2H), 7.31–7.35 (m, <i>J</i> = 8.6, 2H), 7.35–7.39 (m, 2H), 7.49–7.56 (m, 3H), 7.65–7.69 (m, 1H), 7.87–7.92 (m, 1H), 8.06 (dd, <i>J</i> = 1.5, 8.0 Hz, 1H), 8.08–8.12 (m, 2H), 12.47 (br, 1H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 41.7, 47.2, 52.2, 52.7, 61.0, 119.5, 124.6, 127.0, 127.2, 128.3 (2C), 128.9, 130.8 (2C), 131.7, 133.2, 136.5, 137.0, 140.2, 147.1, 168.1, 168.3, 184.7. LC/ESI-MS (<i>m</i>/<i>z</i>): negative mode 517 [M – H]<sup>−</sup>, positive mode 519 [M + H]<sup>+</sup>; purity, 95% (B).</div></div><div id="sec4_1_1_4_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i57" class="anchor-spacer"></div><h5 class="article-section__title" id="_i57"> <i>N</i>-Methyl-<i>N</i>-(4-oxo-4<i>H</i>-3,1-benzothiazin-2-yl)-4-phenylbutanamide (<b>29</b>)</h5><div class="NLM_p last">Iodomethane (19 μL, 0.31 mmol) was added dropwise to an ice cooled solution of <b>17</b> (100 mg, 0.31 mmol) in THF (5 mL). After the addition of sodium hydride (12.0 mg, 0.31 mmol), the reaction mixture was stirred for 24 h at room temperature. The solvent was removed under reduced pressure, and the obtained residue was treated with water (5 mL) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 4 mL). The combined organic layers were washed with brine and dried (MgSO<sub>4</sub>), and the solvents were rotary evaporated. The crude material was absorbed on silica gel and purified by silica gel chromatography (petroleum ether/ethyl acetate, 5:1 v/v) to obtain <b>29</b> as a colorless solid (40 mg, 38%); mp, 150 °C; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 1.89 (dt, <i>J</i> = 7.5, 15.0 Hz, 2H), 2.64 (t, <i>J</i> = 7.5 Hz, 2H), 2.74 (t, <i>J</i> = 7.3 Hz, 2H), 3.52 (s, 3H), 7.15–7.19 (m, 1H), 7.19–7.23 (m, 2H), 7.25–7.30 (m, 2H), 7.56 (ddd, <i>J</i> = 1.2, 7.3, 8.3 Hz, 1H), 7.69 (dd, <i>J</i> = 0.9, 8.2 Hz, 1H), 7.90 (ddd, <i>J</i> = 1.5, 7.0, 8.0 Hz, 1H), 8.05 (dd, <i>J</i> = 1.6, 7.9 Hz, 1H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 25.9, 34.4 (2C), 35.1, 119.1, 124.3, 126.0, 127.8, 128.4 (2C), 128.5 (2C), 129.9, 136.4, 141.7, 146.9, 154.3, 175.3, 185.7. LC/ESI-MS (<i>m</i>/<i>z</i>): positive mode 339 [M + H]<sup>+</sup>; purity, 96% (B).</div></div></div><div id="sec4_1_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> General Procedure for Acylation of Compounds <b>48</b> and <b>49</b> with 4-Phenylbutyric Acid (<b>30</b>–<b>36</b>)</h4><div class="NLM_p"><i>N</i>-Methylmorpholine (1.1 equiv) was added to a solution of 4-phenylbutyric acid (1.0 equiv) in THF (4 mL/mmol). After the addition of 2,4,6-trichlorobenzoyl chloride (1.1 equiv), the reaction mixture was stirred for 2 h at room temperature. The solvent was removed under reduced pressure, and the residue was taken up in toluene (12 mL/mmol). After the addition of pyridine (2.4 equiv) and amine <b>48</b> or <b>49</b> (1 equiv), the mixture was refluxed for 2 h. Then the hot mixture was filtered, and the filtrate was cooled. The formed precipitate was collected by suction filtration, washed with petroleum ether, and recrystallized from EtOH.</div><div id="sec4_1_1_5_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i59" class="anchor-spacer"></div><h5 class="article-section__title" id="_i59"> <i>N</i>-(6-Methyl-4-oxo-4<i>H</i>-3,1-benzothiazin-2-yl)-4-phenylbutanamide (<b>30</b>)</h5><div class="NLM_p last">Colorless crystals (144 mg, 43%); mp, 175–176 °C (EtOH); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 1.86 (dt, <i>J</i> = 7.5, 15.0 Hz, 2H), 2.41 (s, 3H), 2.45 (t, <i>J</i> = 7.5 Hz, 2H), 2.60 (t, <i>J</i> = 7.5 Hz, 2H), 7.14–7.22 (m, 3H), 7.24–7.30 (m, 2H), 7.48 (d, <i>J</i> = 8.3 Hz, 1H), 7.68 (dd, <i>J =</i> 2.0, 8.5 Hz, 1H), 7.83 (d, <i>J =</i> 0.9 Hz, 1H), 11.78 (br, 1H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 20.7, 26.1, 34.5, 35.0, 119.2, 123.9, 126.0, 128.41 (2C), 128.44 (2C), 128.9, 137.0, 141.5, 137.5, 145.7, 152.1, 173.4, 184.6. LC/ESI-MS (<i>m</i>/<i>z</i>): negative mode 337 [M – H]<sup>−</sup>, positive mode 339 [M + H]<sup>+</sup>; purity, 100% (A), 100% (B).</div></div><div id="sec4_1_1_5_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i60" class="anchor-spacer"></div><h5 class="article-section__title" id="_i60"> <i>N</i>-(6-Chloro-4-oxo-4<i>H</i>-3,1-benzothiazin-2-yl)-4-phenylbutanamide (<b>31</b>)</h5><div class="NLM_p last">Colorless crystals (147 mg, 44%); mp, 208–209 °C (EtOH); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 1.86 (dt, <i>J</i> = 7.5, 15.0 Hz, 2H), 2.46 (t, <i>J</i> = 7.5 Hz, 2H), 2.59 (t, <i>J</i> = 7.5 Hz, 2H), 7.14–7.22 (m, 3H), 7.24–7.30 (m, 2H), 7.56 (d, <i>J</i> = 8.8 Hz, 1H), 7.86 (dd, <i>J =</i> 2.6, 8.7 Hz, 1H), 7.93 (d, <i>J =</i> 2.4 Hz, 1H), 11.94 (br, 1H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 26.0, 34.5, 35.1, 120.3, 123.5, 126.0, 128.4 (2C), 128.5 (2C), 131.1, 131.2, 136.1, 141.5, 146.6, 153.7, 173.7, 183.9. LC/ESI-MS (<i>m</i>/<i>z</i>): negative mode 357 [M – H]<sup>−</sup>, positive mode 359 [M + H]<sup>+</sup>; purity, 99% (A), 99% (B).</div></div><div id="sec4_1_1_5_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i61" class="anchor-spacer"></div><h5 class="article-section__title" id="_i61"> <i>N</i>-(6-Bromo-4-oxo-4<i>H</i>-3,1-benzothiazin-2-yl)-4-phenylbutanamide (<b>32</b>)</h5><div class="NLM_p last">Colorless crystals (121 mg, 39%); mp, 219–220 °C (EtOH); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 1.86 (dt, <i>J</i> = 7.5, 15.0 Hz, 2H), 2.46 (t, <i>J</i> = 7.4 Hz, 2H), 2.60 (t, <i>J</i> = 7.5 Hz, 2H), 7.14–7.22 (m, 3H), 7.24–7.30 (m, 2H), 7.50 (d, <i>J</i> = 8.7 Hz, 1H), 7.99 (dd, <i>J =</i> 2.5, 8.7 Hz, 1H), 8.07 (d, <i>J =</i> 2.4 Hz, 1H), 11.95 (br, 1H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 26.0, 34.5, 35.1, 119.3, 120.7, 126.0, 126.5, 128.42 (2C), 128.44 (2C), 131.2, 138.9, 141.5, 146.9, 153.8, 173.7, 183.8. LC/ESI-MS (<i>m</i>/<i>z</i>): negative mode 403 [M – H]<sup>−</sup>, positive mode 405 [M + H]<sup>+</sup>; purity, 99% (A), 99% (B).</div></div><div id="sec4_1_1_5_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i62" class="anchor-spacer"></div><h5 class="article-section__title" id="_i62"> <i>N</i>-(7-Chloro-4-oxo-4<i>H</i>-3,1-benzothiazin-2-yl)-4-phenylbutanamide (<b>33</b>)</h5><div class="NLM_p last">Colorless crystals (163 mg, 48%); mp, 176 °C (EtOH); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 1.86 (dt, <i>J</i> = 7.5, 15.0 Hz, 2H), 2.46 (t, <i>J</i> = 7.5 Hz, 2H), 2.59 (t, <i>J</i> = 7.5 Hz, 2H), 7.14–7.22 (m, 3H), 7.24–7.31 (m, 2H), 7.49–7.54 (m, 2H), 8.00 (dd, <i>J</i> = 0.8, 8.1 Hz, 1H), 11.97 (br, 1H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 26.0, 34.5, 35.1, 118.3, 126.0, 126.6, 127.1, 127.9, 128.4 (2C), 128.5 (2C), 140.9, 141.5, 149.1, 155.0, 173.8, 183.9. LC/ESI-MS (<i>m</i>/<i>z</i>): negative mode 357 [M – H]<sup>−</sup>, positive mode 359 [M + H]<sup>+</sup>; purity, 98% (A), 99% (B).</div></div><div id="sec4_1_1_5_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i63" class="anchor-spacer"></div><h5 class="article-section__title" id="_i63"> <i>N</i>-(4-Oxo-4<i>H</i>-thieno[3,2-<i>d</i>][1,3]thiazin-2-yl)-4-phenylbutanamide (<b>34</b>)</h5><div class="NLM_p last">Colorless crystals (166 mg, 66%); mp, 194 °C (EtOH); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 1.87 (dt, <i>J</i> = 7.5, 14.9 Hz, 2H), 2.47 (t, <i>J</i> = 7.5 Hz, 2H), 2.60 (t, <i>J</i> = 7.5 Hz, 2H), 7.13–7.21 (m, 3H), 7.23–7.30 (m, 2H), 7.36 (d, <i>J</i> = 5.3 Hz, 1H), 8.34 (d, <i>J</i> = 5.3 Hz, 1H), 12.05 (br, 1H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 26.0, 34.5, 35.0, 118.4, 125.9, 127.4, 128.40 (2C), 128.42 (2C), 136.8, 141.5, 156.8, 158.7, 173.3, 176.0. LC/ESI-MS (<i>m</i>/<i>z</i>): negative mode 329 [M – H]<sup>−</sup>, positive mode 331 [M + H]<sup>+</sup>; purity, 99% (A), 99% (B).</div></div><div id="sec4_1_1_5_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i64" class="anchor-spacer"></div><h5 class="article-section__title" id="_i64"> <i>N</i>-(4-Oxo-4<i>H</i>-thieno[2,3-<i>d</i>][1,3]thiazin-2-yl)-4-phenylbutanamide (<b>35</b>)</h5><div class="NLM_p last">Light beige crystals (119 mg, 43%); mp, 174–175 °C (EtOH); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 1.87 (dt, <i>J</i> = 7.5, 15.0 Hz, 2H), 2.46 (t, <i>J</i> = 7.4 Hz, 2H), 2.60 (t, <i>J</i> = 7.5 Hz, 2H), 7.14–7.22 (m, 3H), 7.24–7.30 (m, 2H), 7.36 (d, <i>J =</i> 5.9 Hz, 1H), 7.54 (d, <i>J</i> = 5.9 Hz, 1H), 12.09 (br, 1H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 26.0, 34.5, 35.1, 119.9, 121.0, 122.7, 126.0, 128.4 (2C), 128.5 (2C), 141.5, 157.9, 165.6, 173.2, 176.9. LC/ESI-MS (<i>m</i>/<i>z</i>): negative mode 329 [M – H]<sup>−</sup>, positive mode 331 [M + H]<sup>+</sup>; purity, 99% (A), 99% (B).</div></div><div id="sec4_1_1_5_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i65" class="anchor-spacer"></div><h5 class="article-section__title" id="_i65"> <i>N</i>-(5,6-Dimethyl-4-oxo-4<i>H</i>-thieno[2,3-<i>d</i>][1,3]thiazin-2-yl)-4-phenylbutanamide (<b>36</b>)</h5><div class="NLM_p last">Light beige powder (109 mg, 39%); mp, 235–237 °C (EtOH); <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 1.85 (dt, <i>J</i> = 7.5, 15.0 Hz, 2H), 2.31 (d, <i>J</i> = 0.7 Hz, 3H), 2.32 (d, <i>J</i> = 0.7 Hz, 3H), 2.43 (t, <i>J</i> = 7.4 Hz, 2H), 2.59 (t, <i>J</i> = 7.4 Hz, 2H), 7.10–7.21 (m, 3H), 7.23–7.32 (m, 2H), 11.98 (br, 1H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 12.4, 13.7, 26.0, 34.5, 35.0, 119.1, 126.0, 128.2, 128.42 (2C), 128.44 (2C), 128.7, 141.5, 157.0, 163.3, 173.3, 177.3. LC/ESI-MS (<i>m</i>/<i>z</i>): negative mode 357 [M – H]<sup>−</sup>, positive mode 359 [M + H]<sup>+</sup>; purity, 98% (A), 100% (B).</div></div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> Biological Experiments</h3><div class="NLM_p">Stock solutions of the compounds were prepared in DMSO; the final concentration of DMSO was not more than 2.5% for radioligand binding assays, 2.4% for cAMP assays, and 1% for the MAO assays. At least three independent experiments were performed, each in duplicate or triplicate.</div><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> Radioligand Binding Assays</h4><div class="NLM_p last">Radioligands were obtained from the following sources: [<sup>3</sup>H]CCPA from GE Healthcare (58 Ci/mmol), [<sup>3</sup>H]MSX-2 from Quotient Bioresearch (84 Ci/mmol), [<sup>3</sup>H]PSB-603 from GE Healthcare (73 Ci/mmol), and [<sup>3</sup>H]PSB-11 (53 Ci/mmol) from Quotient Bioresearch. The nonradioactive precursors of [<sup>3</sup>H]MSX-2,<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> [<sup>3</sup>H]PSB-603,<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> and [<sup>3</sup>H]PSB-11<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> were synthesized in our laboratory. Membranes from Chinese hamster ovary (CHO) cells stably transfected with the human A<sub>1</sub>, human A<sub>2A</sub>, human A<sub>2B</sub>, and human A<sub>3</sub> AR were prepared as described.<a onclick="showRef(event, 'ref40 ref41 ref42'); return false;" href="javascript:void(0);" class="ref ref40 ref41 ref42">(40-42)</a> Frozen rat brains obtained from Pel Freez, Rogers, Arkansas, USA, were dissected to obtain cortical membrane preparations for A<sub>1</sub> assays and striatal membrane preparations for A<sub>2A</sub> assays as described.<a onclick="showRef(event, 'ref39 ref43'); return false;" href="javascript:void(0);" class="ref ref39 ref43">(39, 43)</a> The radioligand concentrations were [<sup>3</sup>H]CCPA,<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> 1.0 nM (rat and human A<sub>1</sub>); [<sup>3</sup>H]MSX-2,<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> 1.0 nM (rat and human A<sub>2A</sub>); [<sup>3</sup>H]PSB-603,<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> 0.3 nM (human A<sub>2B</sub>); nd [<sup>3</sup>H]PSB-11,<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> 1.0 nM (human A<sub>3</sub>). Binding assays were performed as described.<a onclick="showRef(event, 'ref44 ref45 ref39 ref41 ref43'); return false;" href="javascript:void(0);" class="ref ref44 ref45 ref39 ref41 ref43">(44, 45, 39, 41, 43)</a> About 30–70 μg/mL of protein were used in the assays. Data were analyzed using Graph Pad Prism, version 4 (San Diego, CA, USA). For the calculation of <i>K</i><sub>i</sub> values by nonlinear regression analysis, the Cheng–Prusoff equation and <i>K</i><sub>D</sub> values of 0.2 nM (rat A<sub>1</sub>) and 0.61 nM (human A<sub>1</sub>) for [<sup>3</sup>H]CCPA, 8 nM for [<sup>3</sup>H]MSX-2 (rat A<sub>2A</sub>), 7.3 nM (human A<sub>2A</sub>) and 0.41 nM for [<sup>3</sup>H]PSB-603 (human A<sub>2B</sub>), and 4.9 nM for [<sup>3</sup>H]PSB-11 (human A<sub>3</sub>) were used.</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> cAMP Accumulation Assays</h4><div class="NLM_p last">Stably transfected CHO cells expressing human A<sub>2A</sub>ARs were transferred into 24-well plates at a density of 200000 cells/well. After 24 h, the medium was removed, and the cells were washed with 1 mL of 37 °C warm Hank’s Balanced Salt Solution {HBSS [20 mM HEPES, 13 mM NaCl, 5.5 mM glucose, 5.4 mM KCl, 4.2 mM NaHCO<sub>3</sub>, 1.25 mM CaCl<sub>2</sub>, 1 mM MgCl<sub>2</sub>, 0.8 mM MgSO<sub>4</sub>, 0.44 mM KH<sub>2</sub>PO<sub>4</sub>, and 0.34 mM Na<sub>2</sub>HPO<sub>4</sub> (pH adjusted to 7.3)]}. Then, the cells were incubated in 300 μL of HBSS with adenosine deaminase (ADA, Sigma, 1 unit/mL) at 37 °C and 5% CO<sub>2</sub> for 2 h. Then, 100 μL of the phosphodiesterase inhibitor Ro20-1724 (Hoffmann La Roche; final concentration of 40 μM) was added to each well, and the cells were incubated for 10 min at 37 °C. Subsequently, 50 μL of antagonist solution and after another 10 min of preincubation 50 μL of agonist dissolved in HBSS-buffer containing 10% DMSO were added. For assays with NECA in the absence of test compound, 50 μL of NECA solution and 50 μL of 10% DMSO/90% HBSS-buffer were added. The cells were stimulated with NECA for 15 min at 37 °C. After incubation, the supernatant was removed, and 500 μL of 90 °C hot lysis buffer consisting of 4 mM EDTA and 0.01% Triton X-100 (pH adjusted to 7.3) was added. To quantify the cAMP concentration, competition experiments were performed<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> in a final volume of 120 μL containing 50 μL of cell lysate, 30 μL of [<sup>3</sup>H]cAMP solution in lysis buffer (final concentration of 3 nM), and 40 μL of cAMP binding protein diluted in the same buffer (50 μg of protein/vial). For determining cAMP concentrations, 50 μL of various cAMP dilutions were added instead of cell lysate to obtain a standard curve. Total binding was determined in the absence of cAMP, and nonspecific binding to the filters was determined without the addition of binding protein. The mixture was incubated for 60 min on ice and filtered through GF/B glass fiber filters using a cell harvester (Brandel). The filters were washed three times with 2–3 mL of ice-cold 50 mM Tris-HCl buffer (pH 7.4) and subsequently transferred into scintillation vials. The liquid scintillation counting of the filters started after incubation for 9 h in 2.5 mL of scintillation cocktail (Lumac). Three separate experiments were performed. The amount of cAMP was determined by comparison to a standard curve generated for each experiment.</div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> Monoamine Oxidase Assays</h4><div class="NLM_p last">To obtain the rat MAO-B enzyme, mitochondrial-enriched fractions were isolated from male SD rat livers and stored in sodium phosphate buffer (50 mM, pH 7.4) at −80 °C until used. The recombinant human MAO-B and MAO-A enzymes were expressed in baculovirus-infected insect cells purchased from Sigma Aldrich (M7441 and M7316). The assays were carried out at rt in 96-well plates in a final volume of 200 μL. The rat liver mitochondria were pretreated for 15 min at rt with an aqueous solution (final concentration 30 nM) of clorgyline (Sigma Aldrich M3778) to irreversibly inhibit MAO-A activity. A volume of 2 μL of test compound dissolved in DMSO was added to 90 μL of enzyme solution in sodium phosphate buffer (50 mM, pH 7.4) and incubated for 30 min at rt. In each assay, 12 μg of rat liver mitochondria or 0.9 μg of recombinant human MAO-B, respectively, were used. The reaction had to be kept protected from light and was started by adding 90 μL of freshly prepared Amplex Red reagent (Invitrogen A12214). The reagent was prepared following the manufacturer’s recommendation. For each plate, 1 mg of Amplex Red, dissolved in 200 μL of DMSO and 100 μL of reconstituted horseradish peroxidase (HRP 200 U/mL, Sigma Aldrich P6782), was added to 9700 μL of sodium phosphate buffer (250 mM, pH 7.4). To each well, 20 μL of an aqueous solution (final concentration 300 μM for rat and 150 μM for human enzyme) of <i>p</i>-tyramine (Alfa Aesar A12220) was added to start the enzymatic reaction. The production of hydrogen peroxide and consequently of resorufin was quantified in a microplate fluorescence reader (Polarstar BMG Labtech, excitation 544 nm, emission 590 nm) over 45 min. Non-MAO-B enzyme activity was determined in the presence of standard inhibitor <b>6</b> (final concentration 1 μM) and subtracted from the total activity measured. Concentration–response curves of <b>6</b> served as a positive control. The human MAO-A assays were performed following the protocol for human MAO-B. Non-MAO-A enzyme activity was determined in the presence of clorgyline (final concentration 1 μM) and subtracted from the total activity measured. Concentration–response curves of clorgyline served as a positive control. All data were analyzed using Graph Pad Prism, version 4 (San Diego, CA, USA).</div></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> Monoamine Oxidase Reactivation Experiment</h4><div class="NLM_p last">The time-dependent activity measurements were performed using human MAO-B under assay conditions. The test compounds <b>8</b>, <b>9</b>, <b>17</b>, and <b>35</b> as well as <b>6</b> and <b>7</b> as reference compounds were examined at their corresponding IC<sub>80</sub> value. The enzyme/inhibitor mixture was not preincubated. The enzyme reaction was started by the addition of 10 μM <i>p</i>-tyramine. After 22 min, the substrate concentration was increased to a final concentration of 1 mM of <i>p</i>-tyramine. The reactivation of the enzyme was monitored by fluorescence measurements over a period of 5 h.</div></div><div id="sec4_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> Substrate-Dependent Inhibition Kinetics</h4><div class="NLM_p last">To evaluate the mode of MAO-B inhibition, sets of Lineweaver–Burk plots were generated. By applying six different concentrations of the substrate <i>p</i>-tyramine (0.05, 0.1, 0.5, 1.0, 1.5, and 3.0 mM), the initial catalytic rates of human MAO-B were measured in the absence and in the presence of three different concentrations (50, 100, and 300 nM) of inhibitor <b>17</b>. The assay conditions and measurements were carried out as described above for the IC<sub>50</sub> determination. Linear regression analysis was performed using Graph Pad Prism, version 4 (San Diego, CA, USA).</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i72"><a href="/doi/suppl/10.1021/jm400336x">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_66247" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_66247" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Plots of rat versus human p<i>K</i><sub>i</sub> (A<sub>1</sub> and A<sub>2A</sub>ARs) and rat versus human pIC<sub>50</sub> values (MAO-B), HPLC chromatograms, and <sup>1</sup>H NMR spectra of compounds <b>2</b> and <b>17</b>. This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm400336x/suppl_file/jm400336x_si_001.pdf">jm400336x_si_001.pdf (414.74 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/jm400336x" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76017" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76017" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael Gütschow</span> - <span class="hlFld-Affiliation affiliation">PharmaCenter Bonn, University of Bonn,
Pharmaceutical Institute, Pharmaceutical
Chemistry I, Bonn, Germany</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#b9deccdccdcadad1d6cef9ccd7d094dbd6d7d797dddc99dad1cbd0cacdd897d4ccdcd5d5dccbf9ccd7d094dbd6d7d797dddc"><span class="__cf_email__" data-cfemail="b7d0c2d2c3c4d4dfd8c0f7c2d9de9ad5d8d9d999d3d2">[email protected]</span> <span class="__cf_email__" data-cfemail="72111a001b0106135c1f07171e1e170032071c1b5f101d1c1c5c1617">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christa E. Müller</span> - <span class="hlFld-Affiliation affiliation">PharmaCenter Bonn, University of Bonn,
Pharmaceutical Institute, Pharmaceutical
Chemistry I, Bonn, Germany</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#93f4e6f6e7e0f0fbfce4d3e6fdfabef1fcfdfdbdf7f6b3f0fbe1fae0e7f2bdfee6f6fffff6e1d3e6fdfabef1fcfdfdbdf7f6"><span class="__cf_email__" data-cfemail="afc8dacadbdcccc7c0d8efdac1c682cdc0c1c181cbca">[email protected]</span> <span class="__cf_email__" data-cfemail="bbd8d3c9d2c8cfda95d6ceded7d7dec9fbced5d296d9d4d5d595dfde">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anne Stößel</span> - <span class="hlFld-Affiliation affiliation">PharmaCenter Bonn, University of Bonn,
Pharmaceutical Institute, Pharmaceutical
Chemistry I, Bonn, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Miriam Schlenk</span> - <span class="hlFld-Affiliation affiliation">PharmaCenter Bonn, University of Bonn,
Pharmaceutical Institute, Pharmaceutical
Chemistry I, Bonn, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sonja Hinz</span> - <span class="hlFld-Affiliation affiliation">PharmaCenter Bonn, University of Bonn,
Pharmaceutical Institute, Pharmaceutical
Chemistry I, Bonn, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Petra Küppers</span> - <span class="hlFld-Affiliation affiliation">PharmaCenter Bonn, University of Bonn,
Pharmaceutical Institute, Pharmaceutical
Chemistry I, Bonn, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jag Heer</span> - <span class="hlFld-Affiliation affiliation">Medicinal Chemistry & Lead
Generation, CNS Research, UCB S.A., Chemin
du Foriest, B-1420 Braine l’Alleud, Belgium</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d247e5612-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i73">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_73814" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_73814" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank Dr. Jörg Hockemeyer for helpful discussions, Dr. Jürgen Gäb for preparing compound <b>25</b>, Norbert Furtmann for some calculations, Angelika Fischer and Anika Püsche for skillful technical assistance in compound testing, Marion Schneider for LC-MS analyses, and Sabine Terhart-Krabbe and Annette Reiner for NMR measurements. This study was supported by the BMBF (German Federal Ministry for Education and Research) within the BioPharma initiative “Neuroallianz”.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i74" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i74"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i75" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i75"> Abbreviations Used</h2><tr><td class="NLM_term">AC</td><td class="NLM_def"><p class="first last">adenylate cyclase</p></td></tr><tr><td class="NLM_term">AR</td><td class="NLM_def"><p class="first last">adenosine receptor</p></td></tr><tr><td class="NLM_term">cAMP</td><td class="NLM_def"><p class="first last">cyclic adenosine monophosphate</p></td></tr><tr><td class="NLM_term">CCPA</td><td class="NLM_def"><p class="first last">[<sup>3</sup><i>H</i>]2-chloro-<i>N</i><sup>6</sup>-cyclopentyladenosine</p></td></tr><tr><td class="NLM_term">CHO</td><td class="NLM_def"><p class="first last">Chinese hamster ovary</p></td></tr><tr><td class="NLM_term">CPA</td><td class="NLM_def"><p class="first last"><i>N</i><sup>6</sup>-cyclopentyladenosine</p></td></tr><tr><td class="NLM_term">DA</td><td class="NLM_def"><p class="first last">dopamine</p></td></tr><tr><td class="NLM_term">FAD</td><td class="NLM_def"><p class="first last">flavin adenine dinucleotide</p></td></tr><tr><td class="NLM_term">h</td><td class="NLM_def"><p class="first last">human</p></td></tr><tr><td class="NLM_term">HRP</td><td class="NLM_def"><p class="first last">horseradish peroxidase</p></td></tr><tr><td class="NLM_term">MAO</td><td class="NLM_def"><p class="first last">monoamine oxidase</p></td></tr><tr><td class="NLM_term">MSX-2</td><td class="NLM_def"><p class="first last">[<sup>3</sup><i>H</i>]3-(3-hydroxypropyl)-7-methyl-8-(<i>m</i>-methoxystyryl)-1-propargylxanthine</p></td></tr><tr><td class="NLM_term">NECA</td><td class="NLM_def"><p class="first last">5′-<i>N</i>-ethylcarboxamidoadenosine</p></td></tr><tr><td class="NLM_term">PD</td><td class="NLM_def"><p class="first last">Parkinson’s disease</p></td></tr><tr><td class="NLM_term">r</td><td class="NLM_def"><p class="first last">rat</p></td></tr><tr><td class="NLM_term">ROS</td><td class="NLM_def"><p class="first last">reactive oxygen species</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i76">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_05500" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_05500" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 46 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Samii, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nutt, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ransom, B. R.</span><span> </span><span class="NLM_article-title">Parkinson’s disease</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">363</span><span class="NLM_x">, </span> <span class="NLM_fpage">1783</span><span class="NLM_x">–</span> <span class="NLM_lpage">1793</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2004&pages=1783-1793&author=A.+Samiiauthor=J.+G.+Nuttauthor=B.+R.+Ransom&title=Parkinson%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSamii%26aufirst%3DA.%26aulast%3DNutt%26aufirst%3DJ.%2BG.%26aulast%3DRansom%26aufirst%3DB.%2BR.%26atitle%3DParkinson%25E2%2580%2599s%2520disease%26jtitle%3DLancet%26date%3D2004%26volume%3D363%26spage%3D1783%26epage%3D1793" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit1b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Schwarzschild, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agnati, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuxe, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morelli, M.</span><span> </span><span class="NLM_article-title">Targeting adenosine A<sub>2A</sub> receptors in Parkinson’s disease</span> <span class="citation_source-journal">Trends Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">647</span><span class="NLM_x">–</span> <span class="NLM_lpage">654</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2006&pages=647-654&author=M.+A.+Schwarzschildauthor=L.+Agnatiauthor=K.+Fuxeauthor=J.+F.+Chenauthor=M.+Morelli&title=Targeting+adenosine+A2A+receptors+in+Parkinson%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchwarzschild%26aufirst%3DM.%2BA.%26aulast%3DAgnati%26aufirst%3DL.%26aulast%3DFuxe%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DJ.%2BF.%26aulast%3DMorelli%26aufirst%3DM.%26atitle%3DTargeting%2520adenosine%2520A2A%2520receptors%2520in%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DTrends%2520Neurosci.%26date%3D2006%26volume%3D29%26spage%3D647%26epage%3D654" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Allain, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bentué-Ferre, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akwa, Y.</span><span> </span><span class="NLM_article-title">Disease-modifying drugs and Parkinson’s disease</span> <span class="citation_source-journal">Prog. Neurobiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">84</span><span class="NLM_x">, </span> <span class="NLM_fpage">25</span><span class="NLM_x">–</span> <span class="NLM_lpage">39</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm400336x&amp;key=10.1016%2Fj.pneurobio.2007.10.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm400336x&amp;key=18037225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm400336x&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVOrtb7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2008&pages=25-39&author=H.+Allainauthor=D.+Bentu%C3%A9-Ferreauthor=Y.+Akwa&title=Disease-modifying+drugs+and+Parkinson%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Disease-modifying drugs and Parkinson's disease</span></div><div class="casAuthors">Allain, Herve; Bentue-Ferrer, Daniele; Akwa, Yvette</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Neurobiology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25-39</span>CODEN:
                <span class="NLM_cas:coden">PGNBA5</span>;
        ISSN:<span class="NLM_cas:issn">0301-0082</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Symptomatic medications, L-Dopa and dopaminergic agents, remain the only clin. pertinent pharmacol. treatment proven effective and available for the large population of patients with Parkinson's disease.  The challenge for the pharmaceutical industry is to develop disease-modifying drugs which could arrest, delay or at least oppose the progression of the specific pathogenic processes underlying Parkinson's disease.  The purpose of this review, based on recent biol. and genetic data to be validated with appropriate animal models, was to re-examine the putative neuroprotective agents in Parkinson's disease and discuss the development of new strategies with the ultimate goal of demonstrating neurocytoprotective activity in this neurodegenerative disease.  Since guidelines for research on neurocytoprotective drugs remain to be written, innovation will be the key to success of future clin. trials.  It is reasonable to expect that future advances in our understanding of the pathogenic processes of Parkinson's disease will open the way to new perspectives for the treatment of other neurodegenerative diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOGvoX1QKb87Vg90H21EOLACvtfcHk0lii7gpnlSAmIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVOrtb7J&md5=1a67583b9cc70135c2d988c45e205d65</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.pneurobio.2007.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pneurobio.2007.10.003%26sid%3Dliteratum%253Aachs%26aulast%3DAllain%26aufirst%3DH.%26aulast%3DBentu%25C3%25A9-Ferre%26aufirst%3DD.%26aulast%3DAkwa%26aufirst%3DY.%26atitle%3DDisease-modifying%2520drugs%2520and%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DProg.%2520Neurobiol.%26date%3D2008%26volume%3D84%26spage%3D25%26epage%3D39" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Rezak, M.</span><span> </span><span class="NLM_article-title">Current pharmacotherapeutic treatment options in Parkinson’s disease</span> <span class="citation_source-journal">Dis. Mon.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">214</span><span class="NLM_x">–</span> <span class="NLM_lpage">222</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=16&amp;doi=10.1021%2Fjm400336x&amp;key=10.1016%2Fj.disamonth.2007.05.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=8&amp;doi=10.1021%2Fjm400336x&amp;key=17586328" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=32&amp;doi=10.1021%2Fjm400336x&amp;key=1%3ACAS%3A280%3ADC%252BD2szntFCltg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2007&pages=214-222&author=M.+Rezak&title=Current+pharmacotherapeutic+treatment+options+in+Parkinson%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3aR"><div class="casContent"><span class="casTitleNuber">3a</span><div class="casTitle"><span class="NLM_cas:atitle">Current pharmacotherapeutic treatment options in Parkinson's disease</span></div><div class="casAuthors">Rezak Michael</div><div class="citationInfo"><span class="NLM_cas:title">Disease-a-month : DM</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">214-22</span>
        ISSN:<span class="NLM_cas:issn">0011-5029</span>.
    </div><div class="casAbstract">Treatment options for Parkinson's disease have greatly expanded in recent years.  Pharmacological treatments, such as levodopa, dopamine receptor agonists, anticholinergic medications, monoamine oxidase B inhibitors, and the catechol-O-methyl transferase inhibitors, remain the mainstay of therapeutic intervention and are reviewed.  Additionally, the traditional and new roles for amantadine are explained.  Despite the great efficacy of levodopa, "levodopa-sparing strategies" in early Parkinson's disease are emphasized in order to delay the development of difficult-to-manage motor fluctuations and dyskinesias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTqbhJIOrJpJaNc3HjJRoFAfW6udTcc2ebwinl6Sv36Wrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2szntFCltg%253D%253D&md5=ce5582e06be45302518167dfb257829b</span></div><a href="/servlet/linkout?suffix=cit3a&amp;dbid=16384&amp;doi=10.1016%2Fj.disamonth.2007.05.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.disamonth.2007.05.002%26sid%3Dliteratum%253Aachs%26aulast%3DRezak%26aufirst%3DM.%26atitle%3DCurrent%2520pharmacotherapeutic%2520treatment%2520options%2520in%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DDis.%2520Mon.%26date%3D2007%26volume%3D53%26spage%3D214%26epage%3D222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit3b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Lees, A.</span><span> </span><span class="NLM_article-title">Alternatives to levodopa in the initial treatment of early Parkinson’s disease</span> <span class="citation_source-journal">Drugs Aging</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">731</span><span class="NLM_x">–</span> <span class="NLM_lpage">740</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=16&amp;doi=10.1021%2Fjm400336x&amp;key=10.2165%2F00002512-200522090-00002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=8&amp;doi=10.1021%2Fjm400336x&amp;key=16156677" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=32&amp;doi=10.1021%2Fjm400336x&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFyhtbrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2005&pages=731-740&author=A.+Lees&title=Alternatives+to+levodopa+in+the+initial+treatment+of+early+Parkinson%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3bR"><div class="casContent"><span class="casTitleNuber">3b</span><div class="casTitle"><span class="NLM_cas:atitle">Alternatives to levodopa in the initial treatment of early parkinson's disease</span></div><div class="casAuthors">Lees, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Drugs & Aging</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">731-740</span>CODEN:
                <span class="NLM_cas:coden">DRAGE6</span>;
        ISSN:<span class="NLM_cas:issn">1170-229X</span>.
    
            (<span class="NLM_cas:orgname">Adis International Ltd.</span>)
        </div><div class="casAbstract">A review.  Parkinson's disease (PD) is primarily a disease of elderly patients.  This article reviews current knowledge and recent developments relating to drugs that can be used as alternatives to levodopa as initial treatment of PD.  Synthetic orally acting dopamine agonists have found increasing favor as an option for early PD in relatively young patients.  This strategy is based on evidence that this approach may delay the onset of motor fluctuations, at least during the first 5 years of treatment.  S.c. apomorphine infusions may attenuate motor fluctuations in late-stage disease, and transdermal rotigotine, a dopamine agonist in development, has also been shown to be efficacious.  The greater proclivity for dopamine agonists to cause psychotoxicity has, however, limited their routine use in the elderly.  Selective monoamine oxidase type B (MAO-B) inhibitors, used as monotherapy, delay the need for the introduction of levodopa by about 9 mo.  These agents appear to be less efficacious than dopamine agonists but are better tolerated.  Concern has been expressed about the potential of the MAO-B inhibitor selegiline (deprenyl) to induce cardiovascular adverse effects (orthostatic hypotension), either directly or through its amphetamine catabolites.  Rasagiline is a new MAO-B inhibitor that is not broken down to amphetamine derivs. and is indicated as both monotherapy in early PD and as adjunctive therapy in PD patients with motor fluctuations.  Two older classes of agents have undergone a resurgence of interest in recent years.  Amantadine, which enhances dopaminergic transmission and has antiglutamate activity, is occasionally used as monotherapy but has recently been widely used as an antidyskinetic agent in late-stage PD.  Anticholinergic drugs, such as benztropine (benzatropine) and orphenadrine also provide control of symptoms when used as monotherapy, but their psychotoxic, cognitive and autonomic adverse events make them inappropriate for the treatment of the elderly.  Effective therapy in PD should prevent disease progression and abolish motor and cognitive handicap.  Currently, none of the existing drugs meets all these needs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZoKtxp2djj7Vg90H21EOLACvtfcHk0ljKoDZEMLyyFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFyhtbrN&md5=df3ab7c50632db266f027b420323c413</span></div><a href="/servlet/linkout?suffix=cit3b&amp;dbid=16384&amp;doi=10.2165%2F00002512-200522090-00002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00002512-200522090-00002%26sid%3Dliteratum%253Aachs%26aulast%3DLees%26aufirst%3DA.%26atitle%3DAlternatives%2520to%2520levodopa%2520in%2520the%2520initial%2520treatment%2520of%2520early%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DDrugs%2520Aging%26date%3D2005%26volume%3D22%26spage%3D731%26epage%3D740" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit3c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Dunkel, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chai, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sperlágh, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huleatt, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mátyus, P.</span><span> </span><span class="NLM_article-title">Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer’s, Parkinson’s and Huntington’s diseases, and amyotrophic lateral sclerosis</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">1267</span><span class="NLM_x">–</span> <span class="NLM_lpage">1308</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2012&pages=1267-1308&author=P.+Dunkelauthor=C.+L.+Chaiauthor=B.+Sperl%C3%A1ghauthor=P.+B.+Huleattauthor=P.+M%C3%A1tyus&title=Clinical+utility+of+neuroprotective+agents+in+neurodegenerative+diseases%3A+current+status+of+drug+development+for+Alzheimer%E2%80%99s%2C+Parkinson%E2%80%99s+and+Huntington%E2%80%99s+diseases%2C+and+amyotrophic+lateral+sclerosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDunkel%26aufirst%3DP.%26aulast%3DChai%26aufirst%3DC.%2BL.%26aulast%3DSperl%25C3%25A1gh%26aufirst%3DB.%26aulast%3DHuleatt%26aufirst%3DP.%2BB.%26aulast%3DM%25C3%25A1tyus%26aufirst%3DP.%26atitle%3DClinical%2520utility%2520of%2520neuroprotective%2520agents%2520in%2520neurodegenerative%2520diseases%253A%2520current%2520status%2520of%2520drug%2520development%2520for%2520Alzheimer%25E2%2580%2599s%252C%2520Parkinson%25E2%2580%2599s%2520and%2520Huntington%25E2%2580%2599s%2520diseases%252C%2520and%2520amyotrophic%2520lateral%2520sclerosis%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2012%26volume%3D21%26spage%3D1267%26epage%3D1308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Armentero, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinna, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferré, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lanciego, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franco., R.</span><span> </span><span class="NLM_article-title">Past, present and future of A<sub>2A</sub> adenosine receptor antagonists in the therapy of Parkinson’s disease</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">132</span><span class="NLM_x">, </span> <span class="NLM_fpage">280</span><span class="NLM_x">–</span> <span class="NLM_lpage">299</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm400336x&amp;key=10.1016%2Fj.pharmthera.2011.07.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm400336x&amp;key=21810444" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm400336x&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtl2ntrzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2011&pages=280-299&author=M.+T.+Armenteroauthor=A.+Pinnaauthor=S.+Ferr%C3%A9author=J.+L.+Lanciegoauthor=C.+E.+M%C3%BCllerauthor=R.+Franco.&title=Past%2C+present+and+future+of+A2A+adenosine+receptor+antagonists+in+the+therapy+of+Parkinson%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Past, present and future of A2A adenosine receptor antagonists in the therapy of Parkinson's disease</span></div><div class="casAuthors">Armentero, Marie Therese; Pinna, Annalisa; Ferre, Sergi; Lanciego, Jose Luis; Mueller, Christa E.; Franco, Rafael</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">280-299</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Several selective antagonists for adenosine A2A receptors (A2AR) are currently under evaluation in clin. trials (phases I to III) to treat Parkinson's disease, and they will probably soon reach the market.  The usefulness of these antagonists has been deduced from studies demonstrating functional interactions between dopamine D2 and adenosine A2A receptors in the basal ganglia.  At present it is believed that A2AR antagonists can be used in combination with the dopamine precursor L-DOPA to minimize the motor symptoms of Parkinson's patients.  However, a considerable body of data indicates that in addn. to ameliorating motor symptoms, adenosine A2AR antagonists may also prevent neurodegeneration.  Despite these promising indications, one further issue must be considered in order to develop fully optimized antiparkinsonian drug therapy, namely the existence of (hetero)dimers/oligomers of G protein-coupled receptors, a topic that is currently the focus of intense debate within the scientific community.  Dopamine D2 receptors (D2Rs) expressed in the striatum are known to form heteromers with A2A adenosine receptors.  Thus, the development of heteromer-specific A2A receptor antagonists represents a promising strategy for the identification of more selective and safer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2pOYdmdfQMLVg90H21EOLACvtfcHk0ljKoDZEMLyyFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtl2ntrzP&md5=39fa871338516f7574deb7845029e624</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2011.07.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2011.07.004%26sid%3Dliteratum%253Aachs%26aulast%3DArmentero%26aufirst%3DM.%2BT.%26aulast%3DPinna%26aufirst%3DA.%26aulast%3DFerr%25C3%25A9%26aufirst%3DS.%26aulast%3DLanciego%26aufirst%3DJ.%2BL.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26aulast%3DFranco.%26aufirst%3DR.%26atitle%3DPast%252C%2520present%2520and%2520future%2520of%2520A2A%2520adenosine%2520receptor%2520antagonists%2520in%2520the%2520therapy%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DPharmacol.%2520Ther.%26date%3D2011%26volume%3D132%26spage%3D280%26epage%3D299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Fredholm, B. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">IJzerman, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linden, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, C. E.</span><span> </span><span class="NLM_article-title">International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors–an update</span> <span class="citation_source-journal">Pharmacol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">34</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2011&pages=1-34&author=B.+B.+Fredholmauthor=A.+P.+IJzermanauthor=K.+A.+Jacobsonauthor=J.+Lindenauthor=C.+E.+M%C3%BCller&title=International+Union+of+Basic+and+Clinical+Pharmacology.+LXXXI.+Nomenclature+and+classification+of+adenosine+receptors%E2%80%93an+update"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFredholm%26aufirst%3DB.%2BB.%26aulast%3DIJzerman%26aufirst%3DA.%2BP.%26aulast%3DJacobson%26aufirst%3DK.%2BA.%26aulast%3DLinden%26aufirst%3DJ.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26atitle%3DInternational%2520Union%2520of%2520Basic%2520and%2520Clinical%2520Pharmacology.%2520LXXXI.%2520Nomenclature%2520and%2520classification%2520of%2520adenosine%2520receptors%25E2%2580%2593an%2520update%26jtitle%3DPharmacol.%2520Rev.%26date%3D2011%26volume%3D63%26spage%3D1%26epage%3D34" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Svenningsson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Moine, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisone, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fredholm, B. B.</span><span> </span><span class="NLM_article-title">Distribution, biochemistry and function of striatal adenosine A<sub>2A</sub> receptors</span> <span class="citation_source-journal">Prog. Neurobiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">355</span><span class="NLM_x">–</span> <span class="NLM_lpage">396</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm400336x&amp;key=10.1016%2FS0301-0082%2899%2900011-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm400336x&amp;key=10501634" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm400336x&amp;key=1%3ACAS%3A528%3ADyaK1MXmtlCgsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=1999&pages=355-396&author=P.+Svenningssonauthor=C.+Le+Moineauthor=G.+Fisoneauthor=B.+B.+Fredholm&title=Distribution%2C+biochemistry+and+function+of+striatal+adenosine+A2A+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Distribution, biochemistry and function of striatal adenosine A2A receptors</span></div><div class="casAuthors">Svenningsson, Per; Le Moine, Catherine; Fisone, Gilberto; Fredholm, Bertil B.</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Neurobiology (Oxford)</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">355-396</span>CODEN:
                <span class="NLM_cas:coden">PGNBA5</span>;
        ISSN:<span class="NLM_cas:issn">0301-0082</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review with >400 refs.  It is well known that the nucleoside adenosine exerts a modulatory influence in the central nervous system by activating G protein coupled receptors.  Adenosine A2A receptors, the subject of the present review, are predominantly expressed in striatum, the major area of the basal ganglia.  Activation of A2A receptors interferes with effects mediated by most of the principal neurotransmitters in striatum.  In particular, the inhibitory interactions between adenosine acting on A2A receptors and dopamine acting on D2 receptors have been well examd. and there is much evidence that A2A receptors may be a possible target for future development of drugs for treatment of Parkinson's disease, schizophrenia and affective disorders.  The authors' understanding of the role of striatal A2A receptors has increased dramatically over the last few years.  New selective antibodies, antagonist radioligands and optimized in situ hybridization protocols have provided detailed information on the distribution of A2A receptors in rodent as well as primate striatum.  Studies on the involvement of A2A receptors in the regulation of DARPP-32 and the expression of immediate early genes, such as nerve growth factor-induced clone A and c-fos, have pointed out an important role for these receptors in regulating striatopallidal neurotransmission.  Moreover, by using novel selective antagonists for A2A receptors and transgenic mice lacking functional A2A receptors, crucial information on the behavioral role of striatal A2A receptors has been provided, esp. concerning their involvement in the stimulatory action of caffeine and the anti-Parkinsonian properties of A2A receptor antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqANBDJTs7Mn7Vg90H21EOLACvtfcHk0lhvJZsqPrVWWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmtlCgsbo%253D&md5=84888e21d742a721f43e0332a4d86be8</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2FS0301-0082%2899%2900011-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0301-0082%252899%252900011-8%26sid%3Dliteratum%253Aachs%26aulast%3DSvenningsson%26aufirst%3DP.%26aulast%3DLe%2BMoine%26aufirst%3DC.%26aulast%3DFisone%26aufirst%3DG.%26aulast%3DFredholm%26aufirst%3DB.%2BB.%26atitle%3DDistribution%252C%2520biochemistry%2520and%2520function%2520of%2520striatal%2520adenosine%2520A2A%2520receptors%26jtitle%3DProg.%2520Neurobiol.%26date%3D1999%26volume%3D59%26spage%3D355%26epage%3D396" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Ferré, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quiroz, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woods, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cunha, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Popoli, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciruela, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lluis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franco, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azdad, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiffmann, S. N.</span><span> </span><span class="NLM_article-title">An update on adenosine A<sub>2A</sub>-dopamine D<sub>2</sub> receptor interactions. Implications for the function of G-protein coupled receptors</span> <span class="citation_source-journal">Curr. Pharm. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">1468</span><span class="NLM_x">–</span> <span class="NLM_lpage">1474</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Fjm400336x&amp;key=10.2174%2F138161208784480108" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2009&pages=1468-1474&author=S.+Ferr%C3%A9author=C.+Quirozauthor=A.+S.+Woodsauthor=R.+Cunhaauthor=P.+Popoliauthor=F.+Ciruelaauthor=C.+Lluisauthor=R.+Francoauthor=K.+Azdadauthor=S.+N.+Schiffmann&title=An+update+on+adenosine+A2A-dopamine+D2+receptor+interactions.+Implications+for+the+function+of+G-protein+coupled+receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.2174%2F138161208784480108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161208784480108%26sid%3Dliteratum%253Aachs%26aulast%3DFerr%25C3%25A9%26aufirst%3DS.%26aulast%3DQuiroz%26aufirst%3DC.%26aulast%3DWoods%26aufirst%3DA.%2BS.%26aulast%3DCunha%26aufirst%3DR.%26aulast%3DPopoli%26aufirst%3DP.%26aulast%3DCiruela%26aufirst%3DF.%26aulast%3DLluis%26aufirst%3DC.%26aulast%3DFranco%26aufirst%3DR.%26aulast%3DAzdad%26aufirst%3DK.%26aulast%3DSchiffmann%26aufirst%3DS.%2BN.%26atitle%3DAn%2520update%2520on%2520adenosine%2520A2A-dopamine%2520D2%2520receptor%2520interactions.%2520Implications%2520for%2520the%2520function%2520of%2520G-protein%2520coupled%2520receptors%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2009%26volume%3D14%26spage%3D1468%26epage%3D1474" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit7b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ferré, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fredholm, B. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morelli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Popoli, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuxe, K.</span><span> </span><span class="NLM_article-title">Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia</span> <span class="citation_source-journal">Trends Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">482</span><span class="NLM_x">–</span> <span class="NLM_lpage">487</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=1997&pages=482-487&author=S.+Ferr%C3%A9author=B.+B.+Fredholmauthor=M.+Morelliauthor=P.+Popoliauthor=K.+Fuxe&title=Adenosine-dopamine+receptor-receptor+interactions+as+an+integrative+mechanism+in+the+basal+ganglia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFerr%25C3%25A9%26aufirst%3DS.%26aulast%3DFredholm%26aufirst%3DB.%2BB.%26aulast%3DMorelli%26aufirst%3DM.%26aulast%3DPopoli%26aufirst%3DP.%26aulast%3DFuxe%26aufirst%3DK.%26atitle%3DAdenosine-dopamine%2520receptor-receptor%2520interactions%2520as%2520an%2520integrative%2520mechanism%2520in%2520the%2520basal%2520ganglia%26jtitle%3DTrends%2520Neurosci.%26date%3D1997%26volume%3D20%26spage%3D482%26epage%3D487" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Ferré, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Navarro, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casadó, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortés, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mallol, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Canela, E. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lluís, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franco, R.</span><span> </span><span class="NLM_article-title">G protein-coupled receptor heteromers as new targets for drug development</span> <span class="citation_source-journal">Prog. Mol. Biol. Transl. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">91</span><span class="NLM_x">, </span> <span class="NLM_fpage">41</span><span class="NLM_x">–</span> <span class="NLM_lpage">52</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=16&amp;doi=10.1021%2Fjm400336x&amp;key=10.1016%2FS1877-1173%2810%2991002-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=32&amp;doi=10.1021%2Fjm400336x&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1Ols7nO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2010&pages=41-52&author=S.+Ferr%C3%A9author=G.+Navarroauthor=V.+Casad%C3%B3author=A.+Cort%C3%A9sauthor=J.+Mallolauthor=E.+I.+Canelaauthor=C.+Llu%C3%ADsauthor=R.+Franco&title=G+protein-coupled+receptor+heteromers+as+new+targets+for+drug+development"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8aR"><div class="casContent"><span class="casTitleNuber">8a</span><div class="casTitle"><span class="NLM_cas:atitle">G protein-coupled receptor heteromers as new targets for drug development</span></div><div class="casAuthors">Ferre, Sergi; Navarro, Gemma; Casado, Vicent; Cortes, Antoni; Mallol, Josefa; Canela, Enric I.; Lluis, Carme; Franco, Rafael</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Molecular Biology and Translational Science</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">Membrane Proteins as Drug Targets</span>),
    <span class="NLM_cas:pages">41-52</span>CODEN:
                <span class="NLM_cas:coden">PNARC5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review on G protein-coupled receptor (GPCR) heteromers as new targets for drug development.  Exptl. evidence shows that GPCR oligomerization, including homo- and heteromerization, is a general phenomenon.  The discovery of GPCR oligomers have been related to the parallel discovery and application of a variety of resonance energy transfer (RET) techniques, such as bioluminescence, fluorescence and sequential RET, time-resolved fluorescence RET, and fluorescence recovery after photobleaching microscopy.  However, RET techniques are difficult to implement in native tissues.  For receptor heteromers, indirect approaches, such as the detn. of a unique biochem. characteristic ('biochem. fingerprint'), permit their identification in native tissues and their use as targets for drug development.  Dopamine and opioid receptor heteromers are the focus of intense research which is related to the possible multiple applications of their putative ligands in pathol. conditions, including basal ganglia disorders, schizophrenia and drug addiction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZbglJJr6xMLVg90H21EOLACvtfcHk0li7dBcyMsuIUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1Ols7nO&md5=22f6b343826798aac91e23d4620cd97b</span></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=10.1016%2FS1877-1173%2810%2991002-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1877-1173%252810%252991002-8%26sid%3Dliteratum%253Aachs%26aulast%3DFerr%25C3%25A9%26aufirst%3DS.%26aulast%3DNavarro%26aufirst%3DG.%26aulast%3DCasad%25C3%25B3%26aufirst%3DV.%26aulast%3DCort%25C3%25A9s%26aufirst%3DA.%26aulast%3DMallol%26aufirst%3DJ.%26aulast%3DCanela%26aufirst%3DE.%2BI.%26aulast%3DLlu%25C3%25ADs%26aufirst%3DC.%26aulast%3DFranco%26aufirst%3DR.%26atitle%3DG%2520protein-coupled%2520receptor%2520heteromers%2520as%2520new%2520targets%2520for%2520drug%2520development%26jtitle%3DProg.%2520Mol.%2520Biol.%2520Transl.%2520Sci.%26date%3D2010%26volume%3D91%26spage%3D41%26epage%3D52" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit8b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Pollack, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fink, J. S.</span><span> </span><span class="NLM_article-title">Adenosine antagonists potentiate D<sub>2</sub> dopamine dependent activation of Fos in the striatopallidal pathway</span> <span class="citation_source-journal">Neuroscience</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">721</span><span class="NLM_x">–</span> <span class="NLM_lpage">728</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=1995&pages=721-728&author=A.+E.+Pollackauthor=J.+S.+Fink&title=Adenosine+antagonists+potentiate+D2+dopamine+dependent+activation+of+Fos+in+the+striatopallidal+pathway"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPollack%26aufirst%3DA.%2BE.%26aulast%3DFink%26aufirst%3DJ.%2BS.%26atitle%3DAdenosine%2520antagonists%2520potentiate%2520D2%2520dopamine%2520dependent%2520activation%2520of%2520Fos%2520in%2520the%2520striatopallidal%2520pathway%26jtitle%3DNeuroscience%26date%3D1995%26volume%3D68%26spage%3D721%26epage%3D728" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Lozano, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lang, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutchison, W. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dostrovsky, J. O.</span><span> </span><span class="NLM_article-title">New developments in understanding the etiology of Parkinson’s disease and in its treatment</span> <span class="citation_source-journal">Curr. Opin. Neurobiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">783</span><span class="NLM_x">–</span> <span class="NLM_lpage">790</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1998&pages=783-790&author=A.+M.+Lozanoauthor=A.+E.+Langauthor=W.+D.+Hutchisonauthor=J.+O.+Dostrovsky&title=New+developments+in+understanding+the+etiology+of+Parkinson%E2%80%99s+disease+and+in+its+treatment"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLozano%26aufirst%3DA.%2BM.%26aulast%3DLang%26aufirst%3DA.%2BE.%26aulast%3DHutchison%26aufirst%3DW.%2BD.%26aulast%3DDostrovsky%26aufirst%3DJ.%2BO.%26atitle%3DNew%2520developments%2520in%2520understanding%2520the%2520etiology%2520of%2520Parkinson%25E2%2580%2599s%2520disease%2520and%2520in%2520its%2520treatment%26jtitle%3DCurr.%2520Opin.%2520Neurobiol.%26date%3D1998%26volume%3D8%26spage%3D783%26epage%3D790" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Müller, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferré, S.</span><span> </span><span class="NLM_article-title">Blocking striatal adenosine A<sub>2A</sub> receptors: a new strategy for basal ganglia disorders</span> <span class="citation_source-journal">Recent Pat. CNS Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">21</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=1-21&author=C.+E.+M%C3%BCllerauthor=S.+Ferr%C3%A9&title=Blocking+striatal+adenosine+A2A+receptors%3A+a+new+strategy+for+basal+ganglia+disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26aulast%3DFerr%25C3%25A9%26aufirst%3DS.%26atitle%3DBlocking%2520striatal%2520adenosine%2520A2A%2520receptors%253A%2520a%2520new%2520strategy%2520for%2520basal%2520ganglia%2520disorders%26jtitle%3DRecent%2520Pat.%2520CNS%2520Drug%2520Discovery%26date%3D2007%26volume%3D2%26spage%3D1%26epage%3D21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Müller, C. E.</span><span> </span><span class="NLM_article-title">A<sub>2A</sub> Adenosine receptor antagonists – future drugs for Parkinson’s disease?</span> <span class="citation_source-journal">Drugs Future</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">1043</span><span class="NLM_x">–</span> <span class="NLM_lpage">1052</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=16&amp;doi=10.1021%2Fjm400336x&amp;key=10.1358%2Fdof.2000.025.10.858696" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=32&amp;doi=10.1021%2Fjm400336x&amp;key=1%3ACAS%3A528%3ADC%252BD3MXoslyq" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2000&pages=1043-1052&author=C.+E.+M%C3%BCller&title=A2A+Adenosine+receptor+antagonists+%E2%80%93+future+drugs+for+Parkinson%E2%80%99s+disease%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10aR"><div class="casContent"><span class="casTitleNuber">10a</span><div class="casTitle"><span class="NLM_cas:atitle">A2A adenosine receptor antagonists - future drugs for Parkinson's disease?</span></div><div class="casAuthors">Muller, Christa E.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of the Future</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1043-1052</span>CODEN:
                <span class="NLM_cas:coden">DRFUD4</span>;
        ISSN:<span class="NLM_cas:issn">0377-8282</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review with 101 refs.  Topics discussed include the adenosine receptors; A2A adenosine receptor antagonists; A2A antagonists as antiparkinsonian agents; and PET ligands for A2A receptors as diagnostics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1gOWi5c8MDLVg90H21EOLACvtfcHk0li7dBcyMsuIUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXoslyq&md5=34c056a05c8a5dbd152c0d895684ca9f</span></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=10.1358%2Fdof.2000.025.10.858696&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdof.2000.025.10.858696%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26atitle%3DA2A%2520Adenosine%2520receptor%2520antagonists%2520%25E2%2580%2593%2520future%2520drugs%2520for%2520Parkinson%25E2%2580%2599s%2520disease%253F%26jtitle%3DDrugs%2520Future%26date%3D2000%26volume%3D25%26spage%3D1043%26epage%3D1052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit10b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Müller, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, K. A.</span><span> </span><span class="NLM_article-title">Recent developments in adenosine receptor ligands and their potential as novel drugs</span> <span class="citation_source-journal">Biochim. Biophys. Acta, Biomembr,</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_fpage">1290</span><span class="NLM_x">–</span> <span class="NLM_lpage">1308</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=16&amp;doi=10.1021%2Fjm400336x&amp;key=10.1016%2Fj.bbamem.2010.12.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=8&amp;doi=10.1021%2Fjm400336x&amp;key=21185259" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=32&amp;doi=10.1021%2Fjm400336x&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjvFSrsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&pages=1290-1308&author=C.+E.+M%C3%BCllerauthor=K.+A.+Jacobson&title=Recent+developments+in+adenosine+receptor+ligands+and+their+potential+as+novel+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10bR"><div class="casContent"><span class="casTitleNuber">10b</span><div class="casTitle"><span class="NLM_cas:atitle">Recent developments in adenosine receptor ligands and their potential as novel drugs</span></div><div class="casAuthors">Mueller, Christa E.; Jacobson, Kenneth A.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Biomembranes</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">1808</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1290-1308</span>CODEN:
                <span class="NLM_cas:coden">BBBMBS</span>;
        ISSN:<span class="NLM_cas:issn">0005-2736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Medicinal chem. approaches have been applied to all four of the adenosine receptor (AR) subtypes (A1, A2A, A2B, and A3) to create selective agonists and antagonists for each.  The most recent class of selective AR ligands to be reported is the class of A2BAR agonists.  The availability of these selective ligands has facilitated research on therapeutic applications of modulating the ARs and in some cases has provided clin. candidates.  Prodrug approaches have been developed which improve the bioavailability of the drugs, reduce side-effects, and/or may lead to site-selective effects.  The A2A agonist regadenoson (Lexiscan), a diagnostic drug for myocardial perfusion imaging, is the first selective AR agonist to be approved.  Other selective agonists and antagonists are or were undergoing clin. trials for a broad range of indications, including capadenoson and tecadenoson (A1 agonists) for atrial fibrillation, or paroxysmal supraventricular tachycardia, resp., apadenoson and binodenoson (A2A agonists) for myocardial perfusion imaging, preladenant (A2A antagonist) for the treatment of Parkinson's disease, and CF101 and CF102 (A3 agonists) for inflammatory diseases and cancer, resp.  This article is part of a Special Issue entitled: "Adenosine Receptors".</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoY8Cuch7XkT7Vg90H21EOLACvtfcHk0lg-MmvBhBL58A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjvFSrsr8%253D&md5=f143d2424c178c0a75e956ffb6b8320a</span></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=10.1016%2Fj.bbamem.2010.12.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbamem.2010.12.017%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26aulast%3DJacobson%26aufirst%3DK.%2BA.%26atitle%3DRecent%2520developments%2520in%2520adenosine%2520receptor%2520ligands%2520and%2520their%2520potential%2520as%2520novel%2520drugs%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Biomembr%252C%26date%3D2011%26spage%3D1290%26epage%3D1308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit10c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Baraldi, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tabrizi, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bovero, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avitabile, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Preti, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fruttarolo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romagnoli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varani, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borea, P. A.</span><span> </span><span class="NLM_article-title">Recent developments in the field of A<sub>2A</sub> and A<sub>3</sub> adenosine receptor antagonists</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">367</span><span class="NLM_x">–</span> <span class="NLM_lpage">382</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=16&amp;doi=10.1021%2Fjm400336x&amp;key=10.1016%2FS0223-5234%2803%2900042-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=8&amp;doi=10.1021%2Fjm400336x&amp;key=12750024" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=32&amp;doi=10.1021%2Fjm400336x&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjs1Clt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2003&pages=367-382&author=P.+G.+Baraldiauthor=M.+A.+Tabriziauthor=A.+Boveroauthor=B.+Avitabileauthor=D.+Pretiauthor=F.+Fruttaroloauthor=R.+Romagnoliauthor=K.+Varaniauthor=P.+A.+Borea&title=Recent+developments+in+the+field+of+A2A+and+A3+adenosine+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10cR"><div class="casContent"><span class="casTitleNuber">10c</span><div class="casTitle"><span class="NLM_cas:atitle">Recent developments in the field of A2A and A3 adenosine receptor antagonists</span></div><div class="casAuthors">Baraldi, Pier Giovanni; Tabrizi, Mojgan Aghazadeh; Bovero, Andrea; Avitabile, Barbara; Preti, Delia; Fruttarolo, Francesca; Romagnoli, Romeo; Varani, Katia; Borea, Pier Andrea</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">367-382</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Editions Scientifiques et Medicales Elsevier</span>)
        </div><div class="casAbstract">A review.  In the last years adenosine receptors have been extensively studied, and mainly at present the importance of A2A and A3 adenosine receptors is understood.  A2A selective adenosine receptors antagonists are promising new drugs for the treatment of Parkinson's disease, while A3 selective adenosine receptors antagonists have been postulated as novel anti-inflammatory and antiallergic agents; recent studies also indicated a possible employment of these derivs. as antitumor agents.  Lately different classes of compds. have been identified as potent A2A and A3 antagonists.  In this article we report the past and present efforts which led to development of more potent and selective A2A and A3 antagonists.  This research group has mainly worked on the pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine nucleus both as A2A and A3 antagonists, aiming to improve the affinity, selectivity and the hydrophilic profile.  In fact, several compds. endowed with high affinity and selectivity vs. A2A adenosine receptors or A3 adenosine receptors were synthesized. .</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrK30f4qobDTLVg90H21EOLACvtfcHk0lg-MmvBhBL58A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjs1Clt7c%253D&md5=59b296f9c26aa02f88a5141431434783</span></div><a href="/servlet/linkout?suffix=cit10c&amp;dbid=16384&amp;doi=10.1016%2FS0223-5234%2803%2900042-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0223-5234%252803%252900042-4%26sid%3Dliteratum%253Aachs%26aulast%3DBaraldi%26aufirst%3DP.%2BG.%26aulast%3DTabrizi%26aufirst%3DM.%2BA.%26aulast%3DBovero%26aufirst%3DA.%26aulast%3DAvitabile%26aufirst%3DB.%26aulast%3DPreti%26aufirst%3DD.%26aulast%3DFruttarolo%26aufirst%3DF.%26aulast%3DRomagnoli%26aufirst%3DR.%26aulast%3DVarani%26aufirst%3DK.%26aulast%3DBorea%26aufirst%3DP.%2BA.%26atitle%3DRecent%2520developments%2520in%2520the%2520field%2520of%2520A2A%2520and%2520A3%2520adenosine%2520receptor%2520antagonists%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2003%26volume%3D38%26spage%3D367%26epage%3D382" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit10d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Baraldi, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tabrizi, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gessi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borea, P. A.</span><span> </span><span class="NLM_article-title">Adenosine receptor antagonists: translating medicinal chemistry and pharmacology into clinical utility</span> <span class="citation_source-journal">Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">238</span><span class="NLM_x">–</span> <span class="NLM_lpage">263</span></span><div class="citationLinks">[<a href="/doi/10.1021/cr0682195" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10d&amp;dbid=32&amp;doi=10.1021%2Fjm400336x&amp;key=1%3ACAS%3A528%3ADC%252BD1cXis1OisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2008&pages=238-263&author=P.+G.+Baraldiauthor=M.+A.+Tabriziauthor=S.+Gessiauthor=P.+A.+Borea&title=Adenosine+receptor+antagonists%3A+translating+medicinal+chemistry+and+pharmacology+into+clinical+utility"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10dR"><div class="casContent"><span class="casTitleNuber">10d</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine Receptor Antagonists: Translating Medicinal Chemistry and Pharmacology into Clinical Utility</span></div><div class="casAuthors">Baraldi, Pier Giovanni; Tabrizi, Mojgan Aghazadeh; Gessi, Stefania; Borea, Pier Andrea</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">238-263</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  This review discusses the chem. and pharmacol. of adenosine A1, A2A, A2B and A3 receptor antagonists and their therapeutic potential in clin. developments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOXhQGKqAVLbVg90H21EOLACvtfcHk0lg15nl2GTk4kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXis1OisQ%253D%253D&md5=1ae9e978507a1bbe7ab7aea0bdb33bb8</span></div><a href="/servlet/linkout?suffix=cit10d&amp;dbid=16384&amp;doi=10.1021%2Fcr0682195&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr0682195%26sid%3Dliteratum%253Aachs%26aulast%3DBaraldi%26aufirst%3DP.%2BG.%26aulast%3DTabrizi%26aufirst%3DM.%2BA.%26aulast%3DGessi%26aufirst%3DS.%26aulast%3DBorea%26aufirst%3DP.%2BA.%26atitle%3DAdenosine%2520receptor%2520antagonists%253A%2520translating%2520medicinal%2520chemistry%2520and%2520pharmacology%2520into%2520clinical%2520utility%26jtitle%3DChem.%2520Rev.%26date%3D2008%26volume%3D108%26spage%3D238%26epage%3D263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Salamone, J. D.</span><span> </span><span class="NLM_article-title">Preladenant, a novel adenosine A<sub>2A</sub> receptor antagonist for the potential treatment of parkinsonism and other disorders</span> <span class="citation_source-journal">IDrugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">723</span><span class="NLM_x">–</span> <span class="NLM_lpage">731</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=8&amp;doi=10.1021%2Fjm400336x&amp;key=20878595" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=32&amp;doi=10.1021%2Fjm400336x&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlGjurfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2010&pages=723-731&author=J.+D.+Salamone&title=Preladenant%2C+a+novel+adenosine+A2A+receptor+antagonist+for+the+potential+treatment+of+parkinsonism+and+other+disorders"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11aR"><div class="casContent"><span class="casTitleNuber">11a</span><div class="casTitle"><span class="NLM_cas:atitle">Preladenant, a novel adenosine A2A receptor antagonist for the potential treatment of parkinsonism and other disorders</span></div><div class="casAuthors">Salamone, John D.</div><div class="citationInfo"><span class="NLM_cas:title">IDrugs</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">723-731</span>CODEN:
                <span class="NLM_cas:coden">IDRUFN</span>;
        ISSN:<span class="NLM_cas:issn">2040-3410</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  Adenosine A2A receptor antagonists exert antiparkinsonian effects in animal models and several drugs in this class are currently being assessed in clin. trials.  Preladenant (SCH-420814) is an adenosine A2A receptor antagonist with a high affinity and very high selectivity for adenosine A2A receptors, which is being developed by Merck & Co Inc (following its acquisition of Schering-Plough Corp) for the potential treatment of Parkinson's disease.  Preclin. studies in rodent and primate models of parkinsonism demonstrated that preladenant can reverse the motor impairments induced by dopamine depletion or antagonism.  Phase I and II clin. trials indicated that preladenant was well tolerated.  Moreover, preladenant met its major endpoints by reducing OFF time and increasing ON time in L-DOPA-treated patients with Parkinson's disease, without worsening dyskinesias.  Therefore, preladenant may have considerable utility for the treatment of Parkinson's disease, as well as the parkinsonian side effects of dopamine D2 receptor antagonists.  As research has suggested that adenosine A2A receptor antagonists are active in animal models of effort-based decision making, it is possible that preladenant could also be useful for treating energy-related symptoms, such as fatigue, psychomotor retardation and anergia in patients with parkinsonism or depression.  At the time of publication, phase III clin. trials were recruiting patients with Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJUD1bt1Mgv7Vg90H21EOLACvtfcHk0lg15nl2GTk4kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlGjurfO&md5=1ba49b3deaf5804f04cdfaa5f5a97ccf</span></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSalamone%26aufirst%3DJ.%2BD.%26atitle%3DPreladenant%252C%2520a%2520novel%2520adenosine%2520A2A%2520receptor%2520antagonist%2520for%2520the%2520potential%2520treatment%2520of%2520parkinsonism%2520and%2520other%2520disorders%26jtitle%3DIDrugs%26date%3D2010%26volume%3D13%26spage%3D723%26epage%3D731" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit11b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Cristalli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Volpini, R.</span><span> </span><span class="NLM_article-title">Recent developments in adenosine A<sub>2A</sub> receptor ligands</span> <span class="citation_source-journal">Handb. Exp. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">193</span><span class="NLM_x">, </span> <span class="NLM_fpage">59</span><span class="NLM_x">–</span> <span class="NLM_lpage">98</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=16&amp;doi=10.1021%2Fjm400336x&amp;key=10.1007%2F978-3-540-89615-9_3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=8&amp;doi=10.1021%2Fjm400336x&amp;key=19639279" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=32&amp;doi=10.1021%2Fjm400336x&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1Sktr7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=193&publication_year=2009&pages=59-98&author=G.+Cristalliauthor=C.+E.+M%C3%BCllerauthor=R.+Volpini&title=Recent+developments+in+adenosine+A2A+receptor+ligands"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11bR"><div class="casContent"><span class="casTitleNuber">11b</span><div class="casTitle"><span class="NLM_cas:atitle">Recent developments in adenosine A2A receptor ligands</span></div><div class="casAuthors">Cristalli, Gloria; Muller, Christa E.; Volpini, Rosaria</div><div class="citationInfo"><span class="NLM_cas:title">Handbook of Experimental Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">193</span>
        (<span class="NLM_cas:issue">Adenosine Receptors in Health and Disease</span>),
    <span class="NLM_cas:pages">59-98</span>CODEN:
                <span class="NLM_cas:coden">HEPHD2</span>;
        ISSN:<span class="NLM_cas:issn">0171-2004</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">A review.  The development of potent and selective agonists and antagonists of adenosine receptors (ARs) has been a target of medicinal chem. research for several decades, and recently the US Food and Drug Administration has approved Lexiscan, an adenosine deriv. substituted at the 2 position, for use as a pharmacol. stress agent in radionuclide myocardial perfusion imaging.  Currently, some other adenosine A2A receptor (A2AAR) agonists and antagonists are undergoing preclin. testing and clin. trials.  While agonists are potent antiinflammatory agents also showing hypotensive effects, antagonists are being developed for the treatment of Parkinson's disease.  However, since there are still major problems in this field, including side effects, low brain penetration (for the targeting of CNS diseases), short half-life, or lack of in vivo effects, the design and development of new AR ligands is a hot research topic.  This review presents an update on the medicinal chem. of A2AAR agonists and antagonists, and stresses the strong need for more selective ligands at the human A2AAR subtype, in particular in the case of agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZlneM0HaH4rVg90H21EOLACvtfcHk0lg15nl2GTk4kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1Sktr7E&md5=95c3e8fde30c9094d81cea882987ae64</span></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=10.1007%2F978-3-540-89615-9_3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-3-540-89615-9_3%26sid%3Dliteratum%253Aachs%26aulast%3DCristalli%26aufirst%3DG.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26aulast%3DVolpini%26aufirst%3DR.%26atitle%3DRecent%2520developments%2520in%2520adenosine%2520A2A%2520receptor%2520ligands%26jtitle%3DHandb.%2520Exp.%2520Pharmacol.%26date%3D2009%26volume%3D193%26spage%3D59%26epage%3D98" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Black, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koller, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gusnard, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bandak, S. I.</span><span> </span><span class="NLM_article-title">Quantification of indirect pathway inhibition by the adenosine A<sub>2A</sub> antagonist SYN115 in Parkinson disease</span> <span class="citation_source-journal">J. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">16284</span><span class="NLM_x">–</span> <span class="NLM_lpage">16292</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm400336x&amp;key=10.1523%2FJNEUROSCI.2590-10.2010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm400336x&amp;key=21123574" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm400336x&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1SlurjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2010&pages=16284-16292&author=K.+J.+Blackauthor=J.+M.+Kollerauthor=M.+C.+Campbellauthor=D.+A.+Gusnardauthor=S.+I.+Bandak&title=Quantification+of+indirect+pathway+inhibition+by+the+adenosine+A2A+antagonist+SYN115+in+Parkinson+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Quantification of indirect pathway inhibition by the adenosine A2a antagonist SYN115 in Parkinson disease</span></div><div class="casAuthors">Black, Kevin J.; Koller, Jonathan M.; Campbell, Meghan C.; Gusnard, Debra A.; Bandak, Stephen I.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">16284-16292</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Adenosine A2a receptor antagonists reduce symptom severity in Parkinson disease (PD) and animal models.  Rodent studies support the hypothesis that A2a antagonists produce this benefit by reducing the inhibitory output of the basal ganglia indirect pathway.  One way to test this hypothesis in humans is to quantify regional pharmacodynamic responses with cerebral blood flow (CBF) imaging.  That approach has also been proposed as a tool to accelerate pharmaceutical dose finding, but has not yet been applied in humans to drugs in development.  We successfully addressed both these aims with a perfusion magnetic resonance imaging (MRI) study of the novel adenosine A2a antagonist SYN115.  During a randomized, double-blind, placebo-controlled, crossover study in 21 PD patients on levodopa but no agonists, we acquired pulsed arterial spin labeling MRI at the end of each treatment period.  SYN115 produced a highly significant decrease in thalamic CBF, consistent with reduced pallidothalamic inhibition via the indirect pathway.  Similar decreases occurred in cortical regions whose activity decreases with increased alertness and externally focused attention, consistent with decreased self-reported sleepiness on SYN115.  Remarkably, we also derived quant. pharmacodynamic parameters from the CBF responses to SYN115.  These results suggested that the doses tested were on the low end of the ED range, consistent with clin. data reported sep.  We conclude that (1) SYN115 enters the brain and exerts dose-dependent regional effects, (2) the most prominent of these effects is consistent with deactivation of the indirect pathway as predicted by preclin. studies; and (3) perfusion MRI can provide rapid, quant., clin. relevant dose-finding information for pharmaceutical development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfZ_zdnYoIKrVg90H21EOLACvtfcHk0lj9BgyMMcledA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1SlurjE&md5=bae1faff5214462b8110b93ac5ec00da</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.2590-10.2010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.2590-10.2010%26sid%3Dliteratum%253Aachs%26aulast%3DBlack%26aufirst%3DK.%2BJ.%26aulast%3DKoller%26aufirst%3DJ.%2BM.%26aulast%3DCampbell%26aufirst%3DM.%2BC.%26aulast%3DGusnard%26aufirst%3DD.%2BA.%26aulast%3DBandak%26aufirst%3DS.%2BI.%26atitle%3DQuantification%2520of%2520indirect%2520pathway%2520inhibition%2520by%2520the%2520adenosine%2520A2A%2520antagonist%2520SYN115%2520in%2520Parkinson%2520disease%26jtitle%3DJ.%2520Neurosci.%26date%3D2010%26volume%3D30%26spage%3D16284%26epage%3D16292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Gütschow, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlenk, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gäb, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paskaleva, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alnouri, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scolari, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iqbal, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, C. E.</span><span> </span><span class="NLM_article-title">Benzothiazinones: A novel class of adenosine receptor antagonists structurally unrelated to xanthine and adenine derivatives</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">3331</span><span class="NLM_x">–</span> <span class="NLM_lpage">3341</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm300029s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=3331-3341&author=M.+G%C3%BCtschowauthor=M.+Schlenkauthor=J.+G%C3%A4bauthor=M.+Paskalevaauthor=M.+W.+Alnouriauthor=S.+W.+Scolariauthor=J.+Iqbalauthor=C.+E.+M%C3%BCller&title=Benzothiazinones%3A+A+novel+class+of+adenosine+receptor+antagonists+structurally+unrelated+to+xanthine+and+adenine+derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fjm300029s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300029s%26sid%3Dliteratum%253Aachs%26aulast%3DG%25C3%25BCtschow%26aufirst%3DM.%26aulast%3DSchlenk%26aufirst%3DM.%26aulast%3DG%25C3%25A4b%26aufirst%3DJ.%26aulast%3DPaskaleva%26aufirst%3DM.%26aulast%3DAlnouri%26aufirst%3DM.%2BW.%26aulast%3DScolari%26aufirst%3DS.%2BW.%26aulast%3DIqbal%26aufirst%3DJ.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26atitle%3DBenzothiazinones%253A%2520A%2520novel%2520class%2520of%2520adenosine%2520receptor%2520antagonists%2520structurally%2520unrelated%2520to%2520xanthine%2520and%2520adenine%2520derivatives%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D3331%26epage%3D3341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Carlsson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Z. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Irwin, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shoichet, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, K. A.</span><span> </span><span class="NLM_article-title">Structure-based discovery of A<sub>2A</sub> adenosine receptor ligands</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">3748</span><span class="NLM_x">–</span> <span class="NLM_lpage">3755</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm100240h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=32&amp;doi=10.1021%2Fjm400336x&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkvFaqsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=3748-3755&author=J.+Carlssonauthor=L.+Yooauthor=Z.+G.+Gaoauthor=J.+J.+Irwinauthor=B.+K.+Shoichetauthor=K.+A.+Jacobson&title=Structure-based+discovery+of+A2A+adenosine+receptor+ligands"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14aR"><div class="casContent"><span class="casTitleNuber">14a</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Discovery of A2A Adenosine Receptor Ligands</span></div><div class="casAuthors">Carlsson, Jens; Yoo, Lena; Gao, Zhan-Guo; Irwin, John J.; Shoichet, Brian K.; Jacobson, Kenneth A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3748-3755</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The recent detn. of X-ray structures of pharmacol. relevant GPCRs has made these targets accessible to structure-based ligand discovery.  Here we explore whether novel chemotypes may be discovered for the A2A adenosine receptor, based on complementarity to its recently detd. structure.  The A2A adenosine receptor signals in the periphery and the CNS, with agonists explored as anti-inflammatory drugs and antagonists explored for neurodegenerative diseases.  We used mol. docking to screen a 1.4 million compd. database against the X-ray structure computationally and tested 20 high-ranking, previously unknown mols. exptl.  Of these 35% showed substantial activity with affinities between 200 nM and 9 μM.  For the most potent of these new inhibitors, over 50-fold specificity was obsd. for the A2A vs. the related A1 and A3 subtypes.  These high hit rates and affinities at least partly reflect the bias of com. libraries toward GPCR-like chemotypes, an issue that we attempt to investigate quant.  Despite this bias, many of the most potent new ligands were novel, dissimilar from known ligands, providing new lead structures for modulation of this medically important target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzvS6-9T9bd7Vg90H21EOLACvtfcHk0lj9BgyMMcledA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkvFaqsL8%253D&md5=c36c941d52d2cec06387d79c4c423d46</span></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=10.1021%2Fjm100240h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100240h%26sid%3Dliteratum%253Aachs%26aulast%3DCarlsson%26aufirst%3DJ.%26aulast%3DYoo%26aufirst%3DL.%26aulast%3DGao%26aufirst%3DZ.%2BG.%26aulast%3DIrwin%26aufirst%3DJ.%2BJ.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26aulast%3DJacobson%26aufirst%3DK.%2BA.%26atitle%3DStructure-based%2520discovery%2520of%2520A2A%2520adenosine%2520receptor%2520ligands%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D3748%26epage%3D3755" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit14b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">van der Horst, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Pijl, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulder-Krieger, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ijzerman, A. P.</span><span> </span><span class="NLM_article-title">Substructure-based virtual screening for adenosine A<sub>2A</sub> receptor ligands</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">2302</span><span class="NLM_x">–</span> <span class="NLM_lpage">2311</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=2302-2311&author=E.+van+der+Horstauthor=R.+van+der+Pijlauthor=T.+Mulder-Kriegerauthor=A.+Benderauthor=A.+P.+Ijzerman&title=Substructure-based+virtual+screening+for+adenosine+A2A+receptor+ligands"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2Bder%2BHorst%26aufirst%3DE.%26aulast%3Dvan%2Bder%2BPijl%26aufirst%3DR.%26aulast%3DMulder-Krieger%26aufirst%3DT.%26aulast%3DBender%26aufirst%3DA.%26aulast%3DIjzerman%26aufirst%3DA.%2BP.%26atitle%3DSubstructure-based%2520virtual%2520screening%2520for%2520adenosine%2520A2A%2520receptor%2520ligands%26jtitle%3DChemMedChem%26date%3D2011%26volume%3D6%26spage%3D2302%26epage%3D2311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Pisani, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muncipinto, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miscioscia, T. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicolotti, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonetti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Catto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caccia, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salvati, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soto-Otero, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendez-Alvarez, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Passeleu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carotti, A.</span><span> </span><span class="NLM_article-title">Discovery of a novel class of potent coumarin monoamine oxidase B inhibitors: development and biopharmacological profiling of 7-[(3-chlorobenzyl)oxy]-4-[(methylamino)methyl]-2<i>H</i>-chromen-2-one methanesulfonate (NW-1772) as a highly potent, selective, reversible, and orally active monoamine oxidase B inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">6685</span><span class="NLM_x">–</span> <span class="NLM_lpage">6706</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm9010127" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=6685-6706&author=L.+Pisaniauthor=G.+Muncipintoauthor=T.+F.+Misciosciaauthor=O.+Nicolottiauthor=F.+Leonettiauthor=M.+Cattoauthor=C.+Cacciaauthor=P.+Salvatiauthor=R.+Soto-Oteroauthor=E.+Mendez-Alvarezauthor=C.+Passeleuauthor=A.+Carotti&title=Discovery+of+a+novel+class+of+potent+coumarin+monoamine+oxidase+B+inhibitors%3A+development+and+biopharmacological+profiling+of+7-%5B%283-chlorobenzyl%29oxy%5D-4-%5B%28methylamino%29methyl%5D-2H-chromen-2-one+methanesulfonate+%28NW-1772%29+as+a+highly+potent%2C+selective%2C+reversible%2C+and+orally+active+monoamine+oxidase+B+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15a&amp;dbid=16384&amp;doi=10.1021%2Fjm9010127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9010127%26sid%3Dliteratum%253Aachs%26aulast%3DPisani%26aufirst%3DL.%26aulast%3DMuncipinto%26aufirst%3DG.%26aulast%3DMiscioscia%26aufirst%3DT.%2BF.%26aulast%3DNicolotti%26aufirst%3DO.%26aulast%3DLeonetti%26aufirst%3DF.%26aulast%3DCatto%26aufirst%3DM.%26aulast%3DCaccia%26aufirst%3DC.%26aulast%3DSalvati%26aufirst%3DP.%26aulast%3DSoto-Otero%26aufirst%3DR.%26aulast%3DMendez-Alvarez%26aufirst%3DE.%26aulast%3DPasseleu%26aufirst%3DC.%26aulast%3DCarotti%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520a%2520novel%2520class%2520of%2520potent%2520coumarin%2520monoamine%2520oxidase%2520B%2520inhibitors%253A%2520development%2520and%2520biopharmacological%2520profiling%2520of%25207-%255B%25283-chlorobenzyl%2529oxy%255D-4-%255B%2528methylamino%2529methyl%255D-2H-chromen-2-one%2520methanesulfonate%2520%2528NW-1772%2529%2520as%2520a%2520highly%2520potent%252C%2520selective%252C%2520reversible%252C%2520and%2520orally%2520active%2520monoamine%2520oxidase%2520B%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D6685%26epage%3D6706" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit15b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Maccioni, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alcaro, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cirilli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vigo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cardia, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanna, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meleddu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yanez, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costa, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matyus, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Distinto, S.</span><span> </span><span class="NLM_article-title">3-Acetyl-2,5-diaryl-2,3-dihydro-1,3,4-oxadiazoles: a new scaffold for the selective inhibition of monoamine oxidase B</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">6394</span><span class="NLM_x">–</span> <span class="NLM_lpage">6398</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm2002876" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6394-6398&author=E.+Maccioniauthor=S.+Alcaroauthor=R.+Cirilliauthor=S.+Vigoauthor=M.+C.+Cardiaauthor=M.+L.+Sannaauthor=R.+Meledduauthor=M.+Yanezauthor=G.+Costaauthor=L.+Casuauthor=P.+Matyusauthor=S.+Distinto&title=3-Acetyl-2%2C5-diaryl-2%2C3-dihydro-1%2C3%2C4-oxadiazoles%3A+a+new+scaffold+for+the+selective+inhibition+of+monoamine+oxidase+B"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15b&amp;dbid=16384&amp;doi=10.1021%2Fjm2002876&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2002876%26sid%3Dliteratum%253Aachs%26aulast%3DMaccioni%26aufirst%3DE.%26aulast%3DAlcaro%26aufirst%3DS.%26aulast%3DCirilli%26aufirst%3DR.%26aulast%3DVigo%26aufirst%3DS.%26aulast%3DCardia%26aufirst%3DM.%2BC.%26aulast%3DSanna%26aufirst%3DM.%2BL.%26aulast%3DMeleddu%26aufirst%3DR.%26aulast%3DYanez%26aufirst%3DM.%26aulast%3DCosta%26aufirst%3DG.%26aulast%3DCasu%26aufirst%3DL.%26aulast%3DMatyus%26aufirst%3DP.%26aulast%3DDistinto%26aufirst%3DS.%26atitle%3D3-Acetyl-2%252C5-diaryl-2%252C3-dihydro-1%252C3%252C4-oxadiazoles%253A%2520a%2520new%2520scaffold%2520for%2520the%2520selective%2520inhibition%2520of%2520monoamine%2520oxidase%2520B%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6394%26epage%3D6398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit15c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Gaspar, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silva, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yáñez, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vina, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orallo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ortuso, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uriarte, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alcaro, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borges, F.</span><span> </span><span class="NLM_article-title">Chromone, a privileged scaffold for the development of monoamine oxidase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">5165</span><span class="NLM_x">–</span> <span class="NLM_lpage">5173</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm2004267" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15c&amp;dbid=32&amp;doi=10.1021%2Fjm400336x&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotlaisb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=5165-5173&author=A.+Gasparauthor=T.+Silvaauthor=M.+Y%C3%A1%C3%B1ezauthor=D.+Vinaauthor=F.+Oralloauthor=F.+Ortusoauthor=E.+Uriarteauthor=S.+Alcaroauthor=F.+Borges&title=Chromone%2C+a+privileged+scaffold+for+the+development+of+monoamine+oxidase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15cR"><div class="casContent"><span class="casTitleNuber">15c</span><div class="casTitle"><span class="NLM_cas:atitle">Chromone, a privileged scaffold for the development of monoamine oxidase inhibitors</span></div><div class="casAuthors">Gaspar, Alexandra; Silva, Tiago; Yanez, Matilde; Vina, Dolores; Orallo, Franscisco; Ortuso, Francesco; Uriarte, Eugenio; Alcaro, Stefano; Borges, Fernanda</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5165-5173</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Two series of novel chromone derivs. I and II ( R = Ph, 4-OH-C6H4, 3-OH-4-MeO-C6H3, 3,4-(OH)2-C6H3, 3,4-(MeO)2-C6H3, 4-Cl-C6H4, 4-OCF3-C6H4, 4-CF3-C6H4, 4-NO2-C6H4, cyclohexyl, nPr) were synthesized and investigated for their ability to inhibit the activity of monoamine oxidase.  The SAR data indicate that chromone derivs. with substituents in position 3 of γ-pyrone nucleus act preferably as MAO-B inhibitors, with IC50 values in the nanomolar to micromolar range.  Almost all chromone 3-carboxamides display selectivity toward MAO-B.  Identical substitutions on position 2 of γ-pyrone nucleus result in complete loss of activity in both isoforms (chromones I except R = 4-OH-C6H4 and 3,4-(OH)2-C6H3).  Notably, chromone II(R = 4-Cl-C6H4) exhibits an MAO-B IC50 of 63 nM, greater than 1000-fold selectivity over MAO-A, and behaves as a quasi-reversible inhibitor.  Docking expts. onto the MAO binding of the most active compd. highlight different interaction patterns among the isoforms A and B.  The differential anal. of the solvation effects among the chromone isomers gave addnl. insight about the superior outline of the 3-substituted chromone derivs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKKLGzqjz4yLVg90H21EOLACvtfcHk0lh5CuQi0xNS5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotlaisb0%253D&md5=27e7bd37930e26f28fb5b624b2360457</span></div><a href="/servlet/linkout?suffix=cit15c&amp;dbid=16384&amp;doi=10.1021%2Fjm2004267&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2004267%26sid%3Dliteratum%253Aachs%26aulast%3DGaspar%26aufirst%3DA.%26aulast%3DSilva%26aufirst%3DT.%26aulast%3DY%25C3%25A1%25C3%25B1ez%26aufirst%3DM.%26aulast%3DVina%26aufirst%3DD.%26aulast%3DOrallo%26aufirst%3DF.%26aulast%3DOrtuso%26aufirst%3DF.%26aulast%3DUriarte%26aufirst%3DE.%26aulast%3DAlcaro%26aufirst%3DS.%26aulast%3DBorges%26aufirst%3DF.%26atitle%3DChromone%252C%2520a%2520privileged%2520scaffold%2520for%2520the%2520development%2520of%2520monoamine%2520oxidase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D5165%26epage%3D5173" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Riederer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lachenmayer, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laux, G.</span><span> </span><span class="NLM_article-title">Clinical applications of MAO-inhibitors</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">2033</span><span class="NLM_x">–</span> <span class="NLM_lpage">2043</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=16&amp;doi=10.1021%2Fjm400336x&amp;key=10.2174%2F0929867043364775" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=8&amp;doi=10.1021%2Fjm400336x&amp;key=15279566" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=32&amp;doi=10.1021%2Fjm400336x&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlslWmu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2004&pages=2033-2043&author=P.+Riedererauthor=L.+Lachenmayerauthor=G.+Laux&title=Clinical+applications+of+MAO-inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16aR"><div class="casContent"><span class="casTitleNuber">16a</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical applications of MAO-Inhibitors</span></div><div class="casAuthors">Riederer, P.; Lachenmayer, L.; Laux, G.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2033-2043</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Monoamine oxidase inhibitors (MAO-I) have been useful in the treatment of both psychiatric and neurol. disorders over centuries.  Here the authors focus on the development of this drug treatment.  Focus is given on the use of irreversible MAO-I's as well as on reversible ones.  Benefit and side effects are reported for Parkinson's disease, Alzheimer's dementia, depression syndrome and panic disorders.  The preclin. and clin. effects of selegiline with regard to neuroprotection are highlighted and the conclusion is drawn that there is good evidence for a clin. neuroprotective capacity based on the assumption that the 50% recovery of MAO-B is obtained already after a 10 days withdrawal of selegiline.  There is also a focus on selegilines metab. to amphetamine and metamphetamine.  In order to avoid any such effects of metabolic compds. on the cardiovascular system Zydis Selegiline, a melt-tablet avoid of major metab. to amphetamine and metamphetamine is described in detail.  Developments in MAO-I research are discussed in detail as there are moclobemide, lacabemide, rasagiline.  Interactions of MAO-I' with tricyclics and serotonin selective reuptake inhibitors (SSRI's) are described as there is mentioning of interactions of MAO-I's with other compds. in general.  Tables and figures report on clin. studies and on pharmacol. properties of MAO-I's.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9Zf08abfhabVg90H21EOLACvtfcHk0lh5CuQi0xNS5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlslWmu7c%253D&md5=dabcabed0e363951ad40e258ddffa972</span></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=10.2174%2F0929867043364775&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867043364775%26sid%3Dliteratum%253Aachs%26aulast%3DRiederer%26aufirst%3DP.%26aulast%3DLachenmayer%26aufirst%3DL.%26aulast%3DLaux%26aufirst%3DG.%26atitle%3DClinical%2520applications%2520of%2520MAO-inhibitors%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2004%26volume%3D11%26spage%3D2033%26epage%3D2043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit16b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Youdim, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bakhle, Y. S.</span><span> </span><span class="NLM_article-title">Monoamine oxidase: isoforms and inhibitors in Parkinson’s disease and depressive illness</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">147</span><span class="NLM_x">, </span> <span class="NLM_fpage">S287</span><span class="NLM_x">–</span> <span class="NLM_lpage">S296</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=147&publication_year=2006&pages=S287-S296&author=M.+B.+Youdimauthor=Y.+S.+Bakhle&title=Monoamine+oxidase%3A+isoforms+and+inhibitors+in+Parkinson%E2%80%99s+disease+and+depressive+illness"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYoudim%26aufirst%3DM.%2BB.%26aulast%3DBakhle%26aufirst%3DY.%2BS.%26atitle%3DMonoamine%2520oxidase%253A%2520isoforms%2520and%2520inhibitors%2520in%2520Parkinson%25E2%2580%2599s%2520disease%2520and%2520depressive%2520illness%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2006%26volume%3D147%26spage%3DS287%26epage%3DS296" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Nicotra, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierucci, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parvez, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senatori, O.</span><span> </span><span class="NLM_article-title">Monoamine oxidase expression during development and aging</span> <span class="citation_source-journal">NeuroToxicology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">155</span><span class="NLM_x">–</span> <span class="NLM_lpage">165</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm400336x&amp;key=10.1016%2FS0161-813X%2803%2900095-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm400336x&amp;key=14697890" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm400336x&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhtVSjtLrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2004&pages=155-165&author=A.+Nicotraauthor=F.+Pierucciauthor=H.+Parvezauthor=O.+Senatori&title=Monoamine+oxidase+expression+during+development+and+aging"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Monoamine oxidase expression during development and aging</span></div><div class="casAuthors">Nicotra, Antonietta; Pierucci, Federica; Parvez, Hasan; Senatori, Ornella</div><div class="citationInfo"><span class="NLM_cas:title">Neurotoxicology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">155-165</span>CODEN:
                <span class="NLM_cas:coden">NRTXDN</span>;
        ISSN:<span class="NLM_cas:issn">0161-813X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A discussion and review on the authors' works.  Monoamine oxidase (MAO) isoenzymes play a major role in regulating the concn. of several bioactive amines, including serotonin and catecholamines.  Both in the nervous system and in peripheral organs, MAOs can potentially modulate all the processes involving these bioactive amines.  In the present article, we review some of the most significant articles published so far on changes in MAOs during development and aging.  The data available on development refer mainly to the mammal brain at fetal and post-fetal stages.  Very little work has been done on studying MAO ontogenesis during early development, i.e., at stages prior to organogenesis, and what has been done refers to non-mammal vertebrates such as fish, amphibians and birds.  MAO A and MAO B changes have been measured as values of enzymic activity, as amt. of protein or, more rarely, as amt. of mRNAs.  A knowledge of MAO developmental changes not only provides a basis for the investigation of factors regulating MAO expression, but can also contribute to a better understanding of the possible trophic and/or morphogenetic role of monoaminergic neurotransmitters in the developing brain.  Transgenic mice lacking MAO A and rodents treated with MAO inhibitors during gestation have been very useful in this second case.  The investigations of changes in MAO A and MAO B during aging in the literature refer mostly to humans, mice and rats.  Interest in studies on aging is stimulated, among other things, by the observation that age-related diseases leading to neurodegenerative phenomena could be accompanied by changes in MAO activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxv_AEJy1Nl7Vg90H21EOLACvtfcHk0lhk_pseOCvrxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhtVSjtLrO&md5=c89dd6fbfdda1ee597c77b27bcd54aba</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2FS0161-813X%2803%2900095-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0161-813X%252803%252900095-0%26sid%3Dliteratum%253Aachs%26aulast%3DNicotra%26aufirst%3DA.%26aulast%3DPierucci%26aufirst%3DF.%26aulast%3DParvez%26aufirst%3DH.%26aulast%3DSenatori%26aufirst%3DO.%26atitle%3DMonoamine%2520oxidase%2520expression%2520during%2520development%2520and%2520aging%26jtitle%3DNeuroToxicology%26date%3D2004%26volume%3D25%26spage%3D155%26epage%3D165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Sayre, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, M. A.</span><span> </span><span class="NLM_article-title">Oxidative stress and neurotoxicity</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">172</span><span class="NLM_x">–</span> <span class="NLM_lpage">188</span></span><div class="citationLinks">[<a href="/doi/10.1021/tx700210j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm400336x&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlygsr3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2008&pages=172-188&author=L.+M.+Sayreauthor=G.+Perryauthor=M.+A.+Smith&title=Oxidative+stress+and+neurotoxicity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Oxidative Stress and Neurotoxicity</span></div><div class="casAuthors">Sayre, Lawrence M.; Perry, George; Smith, Mark A.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">172-188</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  There is increasing awareness of the ubiquitous role of oxidative stress in neurodegenerative disease states.  A continuing challenge is to be able to distinguish between oxidative changes that occur early in the disease from those that are secondary manifestations of neuronal degeneration.  This perspective highlights the role of oxidative stress in Alzheimer's, Parkinson's, and Huntington's diseases, amyotrophic lateral sclerosis, and multiple sclerosis, neurodegenerative and neuroinflammatory disorders where there is evidence for a primary contribution of oxidative stress in neuronal death, as opposed to other diseases where oxidative stress more likely plays a secondary or by-stander role.  We begin with a brief review of the biochem. of oxidative stress as it relates to mechanisms that lead to cell death, and why the central nervous system is particularly susceptible to such mechanisms.  Following a review of oxidative stress involvement in individual disease states, some conclusions are provided as to what further research should hope to accomplish in the field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyOa0kfz_RVLVg90H21EOLACvtfcHk0lhk_pseOCvrxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlygsr3K&md5=800757a60a32641257fad2fe97fd20bd</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Ftx700210j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx700210j%26sid%3Dliteratum%253Aachs%26aulast%3DSayre%26aufirst%3DL.%2BM.%26aulast%3DPerry%26aufirst%3DG.%26aulast%3DSmith%26aufirst%3DM.%2BA.%26atitle%3DOxidative%2520stress%2520and%2520neurotoxicity%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2008%26volume%3D21%26spage%3D172%26epage%3D188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Pålhagen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinonen, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hägglund, J.</span><span> </span><span class="NLM_article-title">Selegiline slows the progression of the symptoms of Parkinson disease</span> <span class="citation_source-journal">Neurology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">1200</span><span class="NLM_x">–</span> <span class="NLM_lpage">1206</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=1200-1206&author=S.+P%C3%A5lhagenauthor=E.+Heinonenauthor=J.+H%C3%A4gglund&title=Selegiline+slows+the+progression+of+the+symptoms+of+Parkinson+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DP%25C3%25A5lhagen%26aufirst%3DS.%26aulast%3DHeinonen%26aufirst%3DE.%26aulast%3DH%25C3%25A4gglund%26aufirst%3DJ.%26atitle%3DSelegiline%2520slows%2520the%2520progression%2520of%2520the%2520symptoms%2520of%2520Parkinson%2520disease%26jtitle%3DNeurology%26date%3D2006%26volume%3D66%26spage%3D1200%26epage%3D1206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit19b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Parkinson study group.</span><span> </span><span class="NLM_article-title">A controlled, randomized, delayed-start study of rasagiline in early Parkinson’s disease</span> <span class="citation_source-journal">Arch. Neurol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">561</span><span class="NLM_x">–</span> <span class="NLM_lpage">566</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19b&amp;dbid=16&amp;doi=10.1021%2Fjm400336x&amp;key=10.1001%2Farchneur.61.4.561" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19b&amp;dbid=8&amp;doi=10.1021%2Fjm400336x&amp;key=15096406" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2004&pages=561-566&author=Parkinson+study+group.&title=A+controlled%2C+randomized%2C+delayed-start+study+of+rasagiline+in+early+Parkinson%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19b&amp;dbid=16384&amp;doi=10.1001%2Farchneur.61.4.561&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Farchneur.61.4.561%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DA%2520controlled%252C%2520randomized%252C%2520delayed-start%2520study%2520of%2520rasagiline%2520in%2520early%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DArch.%2520Neurol.%26date%3D2004%26volume%3D61%26spage%3D561%26epage%3D566" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Schapira, A. H. V.</span><span> </span><span class="NLM_article-title">Monoamine oxidase B inhibitors for the treatment of Parkinson’s disease: a review of symptomatic and potential disease-modifying effects</span> <span class="citation_source-journal">CNS Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">1061</span><span class="NLM_x">–</span> <span class="NLM_lpage">1071</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2011&pages=1061-1071&author=A.+H.+V.+Schapira&title=Monoamine+oxidase+B+inhibitors+for+the+treatment+of+Parkinson%E2%80%99s+disease%3A+a+review+of+symptomatic+and+potential+disease-modifying+effects"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchapira%26aufirst%3DA.%2BH.%2BV.%26atitle%3DMonoamine%2520oxidase%2520B%2520inhibitors%2520for%2520the%2520treatment%2520of%2520Parkinson%25E2%2580%2599s%2520disease%253A%2520a%2520review%2520of%2520symptomatic%2520and%2520potential%2520disease-modifying%2520effects%26jtitle%3DCNS%2520Drugs%26date%3D2011%26volume%3D25%26spage%3D1061%26epage%3D1071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit20b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Schapira, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stocchi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borgohain, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Onofrj, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhatt, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorenzana, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucini, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giuliani, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anand, R.</span><span> </span><span class="NLM_article-title">Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson’s disease</span> <span class="citation_source-journal">Eur. J. Neurol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">271</span><span class="NLM_x">–</span> <span class="NLM_lpage">280</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=16&amp;doi=10.1021%2Fjm400336x&amp;key=10.1111%2Fj.1468-1331.2012.03840.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=8&amp;doi=10.1021%2Fjm400336x&amp;key=22967035" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=32&amp;doi=10.1021%2Fjm400336x&amp;key=1%3ACAS%3A280%3ADC%252BC38bmtV2qsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=271-280&author=A.+H.+Schapiraauthor=F.+Stocchiauthor=R.+Borgohainauthor=M.+Onofrjauthor=M.+Bhattauthor=P.+Lorenzanaauthor=V.+Luciniauthor=R.+Giulianiauthor=R.+Anand&title=Long-term+efficacy+and+safety+of+safinamide+as+add-on+therapy+in+early+Parkinson%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20bR"><div class="casContent"><span class="casTitleNuber">20b</span><div class="casTitle"><span class="NLM_cas:atitle">Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson's disease</span></div><div class="casAuthors">Schapira A H V; Stocchi F; Borgohain R; Onofrj M; Bhatt M; Lorenzana P; Lucini V; Giuliani R; Anand R</div><div class="citationInfo"><span class="NLM_cas:title">European journal of neurology : the official journal of the European Federation of Neurological Societies</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">271-80</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND AND PURPOSE:  Safinamide is an α-aminoamide with both dopaminergic and non-dopaminergic mechanisms of action in Phase III clinical development as a once-daily add-on to dopamine agonist (DA) therapy for early Parkinson's disease (PD).  METHODS:  Study 017 was a 12-month, randomized, double-blind, placebo-controlled pre-planned extension study to the previously reported Study 015.  Patients received safinamide 100 or 200 mg/day or placebo added to a single DA in early PD.  The primary efficacy endpoint was the time from baseline (Study 015 randomization) to 'intervention', defined as increase in DA dose; addition of another DA, levodopa or other PD treatment; or discontinuation due to lack of efficacy.  Safinamide groups were pooled for the primary efficacy endpoint analysis; post hoc analyses were performed on each separate dose group.  RESULTS:  Of the 269 patients randomized in Study 015, 227 (84%) enrolled in Study 017 and 187/227 (82%) patients completed the extension study.  Median time to intervention was 559 and 466 days in the pooled safinamide and placebo groups, respectively (log-rank test; P = 0.3342).  In post hoc analyses, patients receiving safinamide 100 mg/day experienced a significantly lower rate of intervention compared with placebo (25% vs. 51%, respectively) and a delay in median time to intervention of 9 days (P < 0.05; 240- to 540-day analysis).  CONCLUSIONS:  The pooled data from the safinamide groups failed to reach statistical significance for the primary endpoint of median time from baseline to additional drug intervention.  Post hoc analyses indicate that safinamide 100 mg/day may be effective as add-on treatment to DA in PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTW8Q7CptAmznthwrmtH4OBfW6udTcc2ea2uHqMe2EqLbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38bmtV2qsw%253D%253D&md5=ae238c6d3d0f0952fc6993bd03615335</span></div><a href="/servlet/linkout?suffix=cit20b&amp;dbid=16384&amp;doi=10.1111%2Fj.1468-1331.2012.03840.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1468-1331.2012.03840.x%26sid%3Dliteratum%253Aachs%26aulast%3DSchapira%26aufirst%3DA.%2BH.%26aulast%3DStocchi%26aufirst%3DF.%26aulast%3DBorgohain%26aufirst%3DR.%26aulast%3DOnofrj%26aufirst%3DM.%26aulast%3DBhatt%26aufirst%3DM.%26aulast%3DLorenzana%26aufirst%3DP.%26aulast%3DLucini%26aufirst%3DV.%26aulast%3DGiuliani%26aufirst%3DR.%26aulast%3DAnand%26aufirst%3DR.%26atitle%3DLong-term%2520efficacy%2520and%2520safety%2520of%2520safinamide%2520as%2520add-on%2520therapy%2520in%2520early%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DEur.%2520J.%2520Neurol.%26date%3D2013%26volume%3D20%26spage%3D271%26epage%3D280" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Pisani, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Catto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonetti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicolotti, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stefanachi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campagna, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carotti, A.</span><span> </span><span class="NLM_article-title">Targeting monoamine oxidases with multipotent ligands: an emerging strategy in the search of new drugs against neurodegenerative diseases</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">4568</span><span class="NLM_x">–</span> <span class="NLM_lpage">4587</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=16&amp;doi=10.1021%2Fjm400336x&amp;key=10.2174%2F092986711797379302" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=8&amp;doi=10.1021%2Fjm400336x&amp;key=21864289" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=32&amp;doi=10.1021%2Fjm400336x&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlyitb7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=4568-4587&author=L.+Pisaniauthor=M.+Cattoauthor=F.+Leonettiauthor=O.+Nicolottiauthor=A.+Stefanachiauthor=F.+Campagnaauthor=A.+Carotti&title=Targeting+monoamine+oxidases+with+multipotent+ligands%3A+an+emerging+strategy+in+the+search+of+new+drugs+against+neurodegenerative+diseases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21aR"><div class="casContent"><span class="casTitleNuber">21a</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting monoamine oxidases with multipotent ligands: an emerging strategy in the search of new drugs against neurodegenerative diseases</span></div><div class="casAuthors">Pisani, L.; Catto, M.; Leonetti, F.; Nicolotti, O.; Stefanachi, A.; Campagna, F.; Carotti, A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">4568-4587</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The socioeconomic burden of multi-factorial pathologies, such as neurodegenerative diseases (NDs), is enormous worldwide.  Unfortunately, no proven disease-modifying therapy is available yet and in most cases (e.g., Alzheimer's and Parkinson's disease) the approved drugs exert only palliative and symptomatic effects.  Nowadays, an emerging strategy for the discovery of disease-modifying drugs is based on the multi-target directed ligand (MTDL) design, an innovative shift from the traditional approach one-drug-one-target to the more ambitious one-drug-more-targets goal.  Herein, we review the discovery strategy, the mechanism of action and the biopharmacol. evaluation of multipotent ligands exhibiting monoamine oxidase (MAO) inhibition as the core activity with a potential for the treatment of NDs.  In particular, MAO inhibitors exhibiting addnl. acetylcholinesterase (AChE) or nitric oxide synthase (NOS) inhibition, or ion chelation/antioxidant-radical scavenging/anti-inflammatory/A2A receptor antagonist/APP processing modulating activities have been thoroughly examd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4N8fMdFNcwrVg90H21EOLACvtfcHk0ljkH8vrx2gTuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlyitb7O&md5=2463da84a1da0142e353ff9d3a354fe6</span></div><a href="/servlet/linkout?suffix=cit21a&amp;dbid=16384&amp;doi=10.2174%2F092986711797379302&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986711797379302%26sid%3Dliteratum%253Aachs%26aulast%3DPisani%26aufirst%3DL.%26aulast%3DCatto%26aufirst%3DM.%26aulast%3DLeonetti%26aufirst%3DF.%26aulast%3DNicolotti%26aufirst%3DO.%26aulast%3DStefanachi%26aufirst%3DA.%26aulast%3DCampagna%26aufirst%3DF.%26aulast%3DCarotti%26aufirst%3DA.%26atitle%3DTargeting%2520monoamine%2520oxidases%2520with%2520multipotent%2520ligands%253A%2520an%2520emerging%2520strategy%2520in%2520the%2520search%2520of%2520new%2520drugs%2520against%2520neurodegenerative%2520diseases%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2011%26volume%3D18%26spage%3D4568%26epage%3D4587" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit21b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Morphy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rankovic, Z.</span><span> </span><span class="NLM_article-title">Designed multiple ligands. An emerging drug discovery paradigm</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">6523</span><span class="NLM_x">–</span> <span class="NLM_lpage">6543</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm058225d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=32&amp;doi=10.1021%2Fjm400336x&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6523-6543&author=R.+Morphyauthor=Z.+Rankovic&title=Designed+multiple+ligands.+An+emerging+drug+discovery+paradigm"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21bR"><div class="casContent"><span class="casTitleNuber">21b</span><div class="casTitle"><span class="NLM_cas:atitle">Designed Multiple Ligands.</span></div><div class="casAuthors">Morphy, Richard; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6523-6543</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The review discusses main areas in designed multiple ligands (DMLs) discovery that include 5HT transporter-based DMLs for depression, dopamine D2-receptor based DMLs for schizophrenia, histamine H1 receptor-based DMLs for allergies, DMLs targeting the angiotensin system for hypertension, nonsteroidal anti-inflammatory drugs, and PPAR-based DMLs for metabolic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgouWcjsiKgbVg90H21EOLACvtfcHk0ljJ81q3A-pi3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL&md5=00e3bf5a521fc91996ce95bb379a0b5c</span></div><a href="/servlet/linkout?suffix=cit21b&amp;dbid=16384&amp;doi=10.1021%2Fjm058225d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm058225d%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DDesigned%2520multiple%2520ligands.%2520An%2520emerging%2520drug%2520discovery%2520paradigm%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D6523%26epage%3D6543" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit21c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Patyar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prakash, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medhi, B.</span><span> </span><span class="NLM_article-title">Dual inhibition: a novel promising pharmacological approach for different disease conditions</span> <span class="citation_source-journal">J. Pharm. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">459</span><span class="NLM_x">–</span> <span class="NLM_lpage">471</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21c&amp;dbid=16&amp;doi=10.1021%2Fjm400336x&amp;key=10.1111%2Fj.2042-7158.2010.01236.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21c&amp;dbid=8&amp;doi=10.1021%2Fjm400336x&amp;key=21401597" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21c&amp;dbid=32&amp;doi=10.1021%2Fjm400336x&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktlantLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2011&pages=459-471&author=S.+Patyarauthor=A.+Prakashauthor=B.+Medhi&title=Dual+inhibition%3A+a+novel+promising+pharmacological+approach+for+different+disease+conditions"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21cR"><div class="casContent"><span class="casTitleNuber">21c</span><div class="casTitle"><span class="NLM_cas:atitle">Dual inhibition: a novel promising pharmacological approach for different disease conditions</span></div><div class="casAuthors">Patyar, Sazal; Prakash, Ajay; Medhi, Bikash</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacy and Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">459-471</span>CODEN:
                <span class="NLM_cas:coden">JPPMAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3573</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">A review.  To overcome the problems assocd. with polypharmacy, which include medication non compliance, adverse drug reactions, drug-drug interactions, and increased pill-burden, various strategies, such as sustained-release drugs and fixed-dose combination regimens (polypills), were developed.  Out of these, a novel and very much promising approach is the use of dual-action drugs.  Amongst the dual-action drugs, there is a class of compds. known as dual inhibitors, which possess the dual inhibitory activity.  The most common examples of dual inhibitors are rivastigmine, ladostigil, asenapine, phenserine, amitriptyline, clomipramine, doxepin, and desipramine.  This review article focuses on the conventional drugs used in different diseases which possess dual inhibition activity as well as those which are still in the preclin./clin. phase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoimW_BGkApX7Vg90H21EOLACvtfcHk0ljJ81q3A-pi3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktlantLs%253D&md5=5cae05a18a9246b765e400230e8ef62f</span></div><a href="/servlet/linkout?suffix=cit21c&amp;dbid=16384&amp;doi=10.1111%2Fj.2042-7158.2010.01236.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.2042-7158.2010.01236.x%26sid%3Dliteratum%253Aachs%26aulast%3DPatyar%26aufirst%3DS.%26aulast%3DPrakash%26aufirst%3DA.%26aulast%3DMedhi%26aufirst%3DB.%26atitle%3DDual%2520inhibition%253A%2520a%2520novel%2520promising%2520pharmacological%2520approach%2520for%2520different%2520disease%2520conditions%26jtitle%3DJ.%2520Pharm.%2520Pharmacol.%26date%3D2011%26volume%3D63%26spage%3D459%26epage%3D471" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit21d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Elsinghorst, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Härtig, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gündisch, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohr, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tränkle, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gütschow, M.</span><span> </span><span class="NLM_article-title">A hydrazide linker strategy for heterobivalent compounds as ortho- and allosteric ligands of acetylcholine-binding proteins</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">2731</span><span class="NLM_x">–</span> <span class="NLM_lpage">2748</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21d&amp;dbid=16&amp;doi=10.1021%2Fjm400336x&amp;key=10.2174%2F156802611798184427" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21d&amp;dbid=8&amp;doi=10.1021%2Fjm400336x&amp;key=22039876" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21d&amp;dbid=32&amp;doi=10.1021%2Fjm400336x&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1ehtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=2731-2748&author=P.+W.+Elsinghorstauthor=W.+H%C3%A4rtigauthor=D.+G%C3%BCndischauthor=K.+Mohrauthor=C.+Tr%C3%A4nkleauthor=M.+G%C3%BCtschow&title=A+hydrazide+linker+strategy+for+heterobivalent+compounds+as+ortho-+and+allosteric+ligands+of+acetylcholine-binding+proteins"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21dR"><div class="casContent"><span class="casTitleNuber">21d</span><div class="casTitle"><span class="NLM_cas:atitle">A hydrazide linker strategy for heterobivalent compounds as orthoand allosteric ligands of acetylcholine-binding proteins</span></div><div class="casAuthors">Elsinghorst, Paul W.; Haertig, Wolfgang; Guendisch, Daniela; Mohr, Klaus; Traenkle, Christian; Guetschow, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2731-2748</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The occurrence of orthosteric and allosteric binding sites is a characteristic common feature of several acetylcholine-binding proteins, like acetylcholinesterase or the nicotinic and muscarinic acetylcholine receptors.  These proteins are involved in a no. of neurol. disorders, such as Alzheimer's disease, and represent important therapeutic targets for the development of heterodimeric ligands addressing both of their binding sites.  Among the pharmacophores, which have been combined in such heterodimers, the tetrahydroacridine deriv. tacrine has attracted particular interest.  This review discusses the chem. behind the linker connection of tacrine to other pharmacophores and summarizes the types of linkers established to date.  Esp., the development of a hydrazide linker for tacrine-derived heterodimers is highlighted by applications in the inhibition of cholinesterases, the bivalent binding to nicotinic and muscarinic acetylcholine receptors, as well as the histochem. imaging of acetylcholinesterase and amyloid-β.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopf3BjJ8j7s7Vg90H21EOLACvtfcHk0ljJ81q3A-pi3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1ehtb8%253D&md5=4935799f17aff2b8cbd07f4a84281a5d</span></div><a href="/servlet/linkout?suffix=cit21d&amp;dbid=16384&amp;doi=10.2174%2F156802611798184427&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802611798184427%26sid%3Dliteratum%253Aachs%26aulast%3DElsinghorst%26aufirst%3DP.%2BW.%26aulast%3DH%25C3%25A4rtig%26aufirst%3DW.%26aulast%3DG%25C3%25BCndisch%26aufirst%3DD.%26aulast%3DMohr%26aufirst%3DK.%26aulast%3DTr%25C3%25A4nkle%26aufirst%3DC.%26aulast%3DG%25C3%25BCtschow%26aufirst%3DM.%26atitle%3DA%2520hydrazide%2520linker%2520strategy%2520for%2520heterobivalent%2520compounds%2520as%2520ortho-%2520and%2520allosteric%2520ligands%2520of%2520acetylcholine-binding%2520proteins%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2011%26volume%3D11%26spage%3D2731%26epage%3D2748" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit21e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Dunkel, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gelain, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barlocco, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haider, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gyires, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sperlágh, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magyar, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maccioni, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fadda, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mátyus, P.</span><span> </span><span class="NLM_article-title">Semicarbazide-sensitive amine oxidase/vascular adhesion protein 1: recent developments concerning substrates and inhibitors of a promising therapeutic target</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">1827</span><span class="NLM_x">–</span> <span class="NLM_lpage">1839</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21e&amp;dbid=16&amp;doi=10.1021%2Fjm400336x&amp;key=10.2174%2F092986708785133022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21e&amp;dbid=8&amp;doi=10.1021%2Fjm400336x&amp;key=18691041" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21e&amp;dbid=32&amp;doi=10.1021%2Fjm400336x&amp;key=1%3ACAS%3A528%3ADC%252BD1cXovFWnsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2008&pages=1827-1839&author=P.+Dunkelauthor=A.+Gelainauthor=D.+Barloccoauthor=N.+Haiderauthor=K.+Gyiresauthor=B.+Sperl%C3%A1ghauthor=K.+Magyarauthor=E.+Maccioniauthor=A.+Faddaauthor=P.+M%C3%A1tyus&title=Semicarbazide-sensitive+amine+oxidase%2Fvascular+adhesion+protein+1%3A+recent+developments+concerning+substrates+and+inhibitors+of+a+promising+therapeutic+target"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21eR"><div class="casContent"><span class="casTitleNuber">21e</span><div class="casTitle"><span class="NLM_cas:atitle">Semicarbazide-sensitive amine oxidase/vascular adhesion protein 1: recent developments concerning substrates and inhibitors of a promising therapeutic target</span></div><div class="casAuthors">Dunkel, P.; Gelain, A.; Barlocco, D.; Haider, N.; Gyires, K.; Sperlagh, B.; Magyar, K.; Maccioni, E.; Fadda, A.; Matyus, P.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1827-1839</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  SSAO/VAP-1 is not only involved in the metab. of biogenic and xenobiotic primary amines and in the prodn. of metabolites with cytotoxic effects or certain physiol. actions, but also plays a role, for example, as an adhesion mol., in leukocyte trafficking, in regulating glucose uptake and in adipocyte homeostasis.  Interest in the enzyme has been stimulated by the findings that the activities of the SSAOs are altered (mostly increased) in various human disorders, including diabetes, congestive heart failure, liver cirrhosis, Alzheimer's disease and several inflammatory diseases, although the underlying causes are often unknown.  On the basis of their insulin-mimicking effect, SSAO substrates are possibly capable of ameliorating metabolic changes in diabetes, while SSAO inhibitors (somewhat of a contradiction) are of potential benefit in preventing diabetes complications, atherosclerosis and oxidative stress contributing to several disorders or modulating inflammation, and hence may be of substantial therapeutic value.  Great efforts have been made to develop novel compds. which may lead to future drugs useful in therapy, based on their effects on SSAO/VAP-1, and some of the results relating to novel substrates and inhibitors are surveyed in the present review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5K-qNJjLyBLVg90H21EOLACvtfcHk0lgeRKlONka2vg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXovFWnsbs%253D&md5=2c770c22c9ef45837649373b1703cf8d</span></div><a href="/servlet/linkout?suffix=cit21e&amp;dbid=16384&amp;doi=10.2174%2F092986708785133022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986708785133022%26sid%3Dliteratum%253Aachs%26aulast%3DDunkel%26aufirst%3DP.%26aulast%3DGelain%26aufirst%3DA.%26aulast%3DBarlocco%26aufirst%3DD.%26aulast%3DHaider%26aufirst%3DN.%26aulast%3DGyires%26aufirst%3DK.%26aulast%3DSperl%25C3%25A1gh%26aufirst%3DB.%26aulast%3DMagyar%26aufirst%3DK.%26aulast%3DMaccioni%26aufirst%3DE.%26aulast%3DFadda%26aufirst%3DA.%26aulast%3DM%25C3%25A1tyus%26aufirst%3DP.%26atitle%3DSemicarbazide-sensitive%2520amine%2520oxidase%252Fvascular%2520adhesion%2520protein%25201%253A%2520recent%2520developments%2520concerning%2520substrates%2520and%2520inhibitors%2520of%2520a%2520promising%2520therapeutic%2520target%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2008%26volume%3D15%26spage%3D1827%26epage%3D1839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Weinreb, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amit, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bar-Am, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Youdim, M. B.</span><span> </span><span class="NLM_article-title">Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer’s disease treatment</span> <span class="citation_source-journal">Curr. Drug Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">483</span><span class="NLM_x">–</span> <span class="NLM_lpage">494</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=16&amp;doi=10.1021%2Fjm400336x&amp;key=10.2174%2F138945012799499794" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=8&amp;doi=10.1021%2Fjm400336x&amp;key=22280345" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=32&amp;doi=10.1021%2Fjm400336x&amp;key=1%3ACAS%3A528%3ADC%252BC38XkslCmurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=483-494&author=O.+Weinrebauthor=T.+Amitauthor=O.+Bar-Amauthor=M.+B.+Youdim&title=Ladostigil%3A+a+novel+multimodal+neuroprotective+drug+with+cholinesterase+and+brain-selective+monoamine+oxidase+inhibitory+activities+for+Alzheimer%E2%80%99s+disease+treatment"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22aR"><div class="casContent"><span class="casTitleNuber">22a</span><div class="casTitle"><span class="NLM_cas:atitle">Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment</span></div><div class="casAuthors">Weinreb, Orly; Amit, Tamar; Bar-Am, Orit; Youdim, Moussa B. H.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Targets</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">483-494</span>CODEN:
                <span class="NLM_cas:coden">CDTUAU</span>;
        ISSN:<span class="NLM_cas:issn">1389-4501</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Ladostigil [(N-propargyl-(3R) aminoindan-5yl)-Et Me carbamate] is a dual acetylcholine-butyrylcholineesterase and brain selective monoamine oxidase (MAO)-A and -B inhibitor in vivo (with little or no MAO inhibitory effect in the liver and small intestine), intended for the treatment of dementia co-morbid with extrapyramidal disorders and depression (presently in a Phase IIb clin. study).  This suggests that the drug should not cause a significant potentiation of the cardiovascular response to tyramine, thereby making it a potentially safer antidepressant than other irreversible MAO-A inhibitors.  Ladostigil was shown to antagonize scopolamine-induced impairment in spatial memory, indicating that it can cause significant increases in rat brain cholinergic activity.  Furthermore, ladostigil prevented gliosis and oxidative-nitrative stress and reduced the deficits in episodic and spatial memory induced by intracerebroventricular injection of streptozotocin in rats.  Ladostigil was demonstrated to possess potent anti-apoptotic and neuroprotective activities in vitro and in various neurodegenerative rat models, (e.g. hippocampal damage induced by global ischemia in gerbils and cerebral edema induced in mice by closed head injury).  These neuroprotective activities involve regulation of amyloid precursor protein processing; activation of protein kinase C and mitogen-activated protein kinase signaling pathways; inhibition of neuronal death markers; prevention of the fall in mitochondrial membrane potential and upregulation of neurotrophic factors and antioxidative activity.  Recent findings demonstrated that the major metabolite of ladostigil, hydroxy-1-(R)-aminoindan has also a neuroprotective activity and thus, may contribute to the overt activity of its parent compd.  This review will discuss the scientific evidence for the therapeutic potential use of ladostigil in Alzheimer's and Lewy Body diseases and the mol. signaling pathways that are considered to be involved in the biol. activities of the drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSPLqLnccsGLVg90H21EOLACvtfcHk0lgeRKlONka2vg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkslCmurY%253D&md5=2272d945e6eaf132035b6dfc43d2e569</span></div><a href="/servlet/linkout?suffix=cit22a&amp;dbid=16384&amp;doi=10.2174%2F138945012799499794&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138945012799499794%26sid%3Dliteratum%253Aachs%26aulast%3DWeinreb%26aufirst%3DO.%26aulast%3DAmit%26aufirst%3DT.%26aulast%3DBar-Am%26aufirst%3DO.%26aulast%3DYoudim%26aufirst%3DM.%2BB.%26atitle%3DLadostigil%253A%2520a%2520novel%2520multimodal%2520neuroprotective%2520drug%2520with%2520cholinesterase%2520and%2520brain-selective%2520monoamine%2520oxidase%2520inhibitory%2520activities%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%2520treatment%26jtitle%3DCurr.%2520Drug%2520Targets%26date%3D2012%26volume%3D13%26spage%3D483%26epage%3D494" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit22b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Youdim, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridkin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, H.</span><span> </span><span class="NLM_article-title">Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases</span> <span class="citation_source-journal">Mech. Ageing Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">126</span><span class="NLM_x">, </span> <span class="NLM_fpage">317</span><span class="NLM_x">–</span> <span class="NLM_lpage">326</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=16&amp;doi=10.1021%2Fjm400336x&amp;key=10.1016%2Fj.mad.2004.08.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=8&amp;doi=10.1021%2Fjm400336x&amp;key=15621213" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=32&amp;doi=10.1021%2Fjm400336x&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtFGhsbzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2005&pages=317-326&author=M.+B.+Youdimauthor=M.+Fridkinauthor=H.+Zheng&title=Bifunctional+drug+derivatives+of+MAO-B+inhibitor+rasagiline+and+iron+chelator+VK-28+as+a+more+effective+approach+to+treatment+of+brain+ageing+and+ageing+neurodegenerative+diseases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22bR"><div class="casContent"><span class="casTitleNuber">22b</span><div class="casTitle"><span class="NLM_cas:atitle">Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases</span></div><div class="casAuthors">Youdim, Moussa B. H.; Fridkin, Mati; Zheng, Hailin</div><div class="citationInfo"><span class="NLM_cas:title">Mechanisms of Ageing and Development</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">317-326</span>CODEN:
                <span class="NLM_cas:coden">MAGDA3</span>;
        ISSN:<span class="NLM_cas:issn">0047-6374</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Degeneration of nigrostriatal dopamine neurons and cholinergic cortical neurons are the main pathol. features of Parkinson's disease (PD) and for the cognitive deficit in dementia of the Alzheimer' type (AD) and in dementia with Lewy bodies (DLB), resp.  Many PD and DLB subjects have dementia and depression resulting from possible degeneration of cholinergic and noradrenergic and serotonergic neurons.  On the other hand, AD patients may also develop extrapyramidal features as well as depression.  In both PD and AD there is, resp., accumulation of iron within the melanin contg. dopamine neurons of pars compacta and with in the plaques and tangle.  It has been suggested that iron accumulation may contribute to the oxidative stress induced apoptosis reported in both diseases.  This may result from increased glia hydrogen peroxide producing monoamine oxidase (MAO) activity that can generate of reactive hydroxyl radical formed from interaction of iron and hydrogen peroxide.  We have therefore prepd. a series of novel bifunctional drugs from the neuroprotective-antiapoptotic antiparkinson monoamine oxidase B inhibitor, rasagiline, by introducing a carbamate cholinesterase (ChE) inhibitory moiety into it.  Ladostigil ((TV-3326, N-propargyl-3R-aminoindan-5yl)-Et methylcarbamate), has both ChE and MAO-AB inhibitory activity, as potential treatment of AD and DLB or PD subjects with dementia Being a brain selective MAO-AB inhibitor it has limited potentiation of the pressor response to oral tyramine and exhibits antidepressant activity similar to classical non-selective MAO inhibitor antidepressants by increasing brain serotonin and noradrenaline.  Ladostigil inhibits brain acetyl and butyrylcholinesterase in rats and antagonizes scopolamine-induced inhibition of spatial learning.  Ladostigil like MAO-B inhibitor it prevents MPTP Parkinsonism in mice model and retains the in vitro and in vivo neuroprotective activity of rasagiline.  Ladostigil, rasagiline and other propargylamines have been demonstrated to have neuroprotective activity in several in vitro and in vivo models, which have been shown be assocd. with propargylamines moiety, since propargylamines itself possess these properties.  The mechanism of neuroprotective activity has been attributed to the ability of propargylamines-inducing the antiapoptotic family proteins Bcl-2 and Bcl-xl, while decreasing Bad and Bax and preventing opening of mitochondrial permeability transition pore.  Iron accumulates in brain regions assocd. with neurodegenerative diseases of PD, AD, amyotrophic lateral sclerosis and Huntington disease.  It is thought to be involved in Fenton chem. oxidative stress obsd. in these diseases.  The neuroprotective activity of propargylamines led us to develop several novel bifunctional iron chelator from our prototype brain permeable iron chelators, VK-28, possessing propargylamine moiety (HLA-20, M30 and M30A) to iron out iron from the brain.  These compds. have been shown to have iron chelating and monoamine oxidase A and B selective brain inhibitory and neuroprotective-antiapoptotic actions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrI9NJwCsPUzLVg90H21EOLACvtfcHk0li-aHJthN115g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtFGhsbzN&md5=7c5bef9011b669fffccd501b07ed8455</span></div><a href="/servlet/linkout?suffix=cit22b&amp;dbid=16384&amp;doi=10.1016%2Fj.mad.2004.08.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mad.2004.08.023%26sid%3Dliteratum%253Aachs%26aulast%3DYoudim%26aufirst%3DM.%2BB.%26aulast%3DFridkin%26aufirst%3DM.%26aulast%3DZheng%26aufirst%3DH.%26atitle%3DBifunctional%2520drug%2520derivatives%2520of%2520MAO-B%2520inhibitor%2520rasagiline%2520and%2520iron%2520chelator%2520VK-28%2520as%2520a%2520more%2520effective%2520approach%2520to%2520treatment%2520of%2520brain%2520ageing%2520and%2520ageing%2520neurodegenerative%2520diseases%26jtitle%3DMech.%2520Ageing%2520Dev.%26date%3D2005%26volume%3D126%26spage%3D317%26epage%3D326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit22c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Samadi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de los Ríos, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolea, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chioua, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iriepa, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moraleda, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartolini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrisano, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gálvez, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valderas, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Unzeta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marco-Contelles, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Multipotent, M. A. O.</span><span> </span><span class="NLM_article-title">and cholinesterase inhibitors for the treatment of Alzheimer’s disease: synthesis, pharmacological analysis and molecular modeling of heterocyclic substituted alkyl and cycloalkyl propargyl amine</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">251</span><span class="NLM_x">–</span> <span class="NLM_lpage">262</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2012&pages=251-262&author=A.+Samadiauthor=C.+de+los+R%C3%ADosauthor=I.+Boleaauthor=M.+Chiouaauthor=I.+Iriepaauthor=I.+Moraledaauthor=M.+Bartoliniauthor=V.+Andrisanoauthor=E.+G%C3%A1lvezauthor=C.+Valderasauthor=M.+Unzetaauthor=J.+Marco-Contellesauthor=M.+A.+O.+Multipotent&title=and+cholinesterase+inhibitors+for+the+treatment+of+Alzheimer%E2%80%99s+disease%3A+synthesis%2C+pharmacological+analysis+and+molecular+modeling+of+heterocyclic+substituted+alkyl+and+cycloalkyl+propargyl+amine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSamadi%26aufirst%3DA.%26aulast%3Dde%2Blos%2BR%25C3%25ADos%26aufirst%3DC.%26aulast%3DBolea%26aufirst%3DI.%26aulast%3DChioua%26aufirst%3DM.%26aulast%3DIriepa%26aufirst%3DI.%26aulast%3DMoraleda%26aufirst%3DI.%26aulast%3DBartolini%26aufirst%3DM.%26aulast%3DAndrisano%26aufirst%3DV.%26aulast%3DG%25C3%25A1lvez%26aufirst%3DE.%26aulast%3DValderas%26aufirst%3DC.%26aulast%3DUnzeta%26aufirst%3DM.%26aulast%3DMarco-Contelles%26aufirst%3DJ.%26aulast%3DMultipotent%26aufirst%3DM.%2BA.%2BO.%26atitle%3Dand%2520cholinesterase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%253A%2520synthesis%252C%2520pharmacological%2520analysis%2520and%2520molecular%2520modeling%2520of%2520heterocyclic%2520substituted%2520alkyl%2520and%2520cycloalkyl%2520propargyl%2520amine%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2012%26volume%3D52%26spage%3D251%26epage%3D262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit22d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Bolea, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juárez-Jiménez, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Los Ríos, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chioua, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pouplana, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luque, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Unzeta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marco-Contelles, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samadi, A.</span><span> </span><span class="NLM_article-title">Synthesis, biological evaluation, and molecular modeling of donepezil and <i>N</i>-[(5-(benzyloxy)-1-methyl-1<i>H</i>-indol-2-yl)methyl]-<i>N</i>-methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer’s disease</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">8251</span><span class="NLM_x">–</span> <span class="NLM_lpage">8270</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm200853t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=8251-8270&author=I.+Boleaauthor=J.+Ju%C3%A1rez-Jim%C3%A9nezauthor=C.+de+Los+R%C3%ADosauthor=M.+Chiouaauthor=R.+Pouplanaauthor=F.+J.+Luqueauthor=M.+Unzetaauthor=J.+Marco-Contellesauthor=A.+Samadi&title=Synthesis%2C+biological+evaluation%2C+and+molecular+modeling+of+donepezil+and+N-%5B%285-%28benzyloxy%29-1-methyl-1H-indol-2-yl%29methyl%5D-N-methylprop-2-yn-1-amine+hybrids+as+new+multipotent+cholinesterase%2Fmonoamine+oxidase+inhibitors+for+the+treatment+of+Alzheimer%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22d&amp;dbid=16384&amp;doi=10.1021%2Fjm200853t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200853t%26sid%3Dliteratum%253Aachs%26aulast%3DBolea%26aufirst%3DI.%26aulast%3DJu%25C3%25A1rez-Jim%25C3%25A9nez%26aufirst%3DJ.%26aulast%3Dde%2BLos%2BR%25C3%25ADos%26aufirst%3DC.%26aulast%3DChioua%26aufirst%3DM.%26aulast%3DPouplana%26aufirst%3DR.%26aulast%3DLuque%26aufirst%3DF.%2BJ.%26aulast%3DUnzeta%26aufirst%3DM.%26aulast%3DMarco-Contelles%26aufirst%3DJ.%26aulast%3DSamadi%26aufirst%3DA.%26atitle%3DSynthesis%252C%2520biological%2520evaluation%252C%2520and%2520molecular%2520modeling%2520of%2520donepezil%2520and%2520N-%255B%25285-%2528benzyloxy%2529-1-methyl-1H-indol-2-yl%2529methyl%255D-N-methylprop-2-yn-1-amine%2520hybrids%2520as%2520new%2520multipotent%2520cholinesterase%252Fmonoamine%2520oxidase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D8251%26epage%3D8270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Chen, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steyn, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staal, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petzer, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van der Schyf, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castagnoli, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sonsalla, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castagnoli, N.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwarzschild, M. A.</span><span> </span><span class="NLM_article-title">8-(3-Chlorostyryl)caffeine may attenuate MPTP neurotoxicity through dual actions of monoamine oxidase inhibition and A<sub>2A</sub> receptor antagonism</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">277</span><span class="NLM_x">, </span> <span class="NLM_fpage">36040</span><span class="NLM_x">–</span> <span class="NLM_lpage">36044</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2002&pages=36040-36044&author=J.+F.+Chenauthor=S.+Steynauthor=R.+Staalauthor=J.+P.+Petzerauthor=K.+Xuauthor=C.+J.+Van+der+Schyfauthor=K.+Castagnoliauthor=P.+K.+Sonsallaauthor=N.+Castagnoliauthor=M.+A.+Schwarzschild&title=8-%283-Chlorostyryl%29caffeine+may+attenuate+MPTP+neurotoxicity+through+dual+actions+of+monoamine+oxidase+inhibition+and+A2A+receptor+antagonism"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%2BF.%26aulast%3DSteyn%26aufirst%3DS.%26aulast%3DStaal%26aufirst%3DR.%26aulast%3DPetzer%26aufirst%3DJ.%2BP.%26aulast%3DXu%26aufirst%3DK.%26aulast%3DVan%2Bder%2BSchyf%26aufirst%3DC.%2BJ.%26aulast%3DCastagnoli%26aufirst%3DK.%26aulast%3DSonsalla%26aufirst%3DP.%2BK.%26aulast%3DCastagnoli%26aufirst%3DN.%26aulast%3DSchwarzschild%26aufirst%3DM.%2BA.%26atitle%3D8-%25283-Chlorostyryl%2529caffeine%2520may%2520attenuate%2520MPTP%2520neurotoxicity%2520through%2520dual%2520actions%2520of%2520monoamine%2520oxidase%2520inhibition%2520and%2520A2A%2520receptor%2520antagonism%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2002%26volume%3D277%26spage%3D36040%26epage%3D36044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit23b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Aguiar, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macêdo, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vasconcelos, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliveira, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Sousa, F. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viana, G. S.</span><span> </span><span class="NLM_article-title">CSC, an adenosine A(2A) receptor antagonist and MAO B inhibitor, reverses behavior, monoamine neurotransmission, and amino acid alterations in the 6-OHDA-lesioned rats</span> <span class="citation_source-journal">Brain Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">1191</span><span class="NLM_x">, </span> <span class="NLM_fpage">192</span><span class="NLM_x">–</span> <span class="NLM_lpage">199</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23b&amp;dbid=16&amp;doi=10.1021%2Fjm400336x&amp;key=10.1016%2Fj.brainres.2007.11.051" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23b&amp;dbid=8&amp;doi=10.1021%2Fjm400336x&amp;key=18164694" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23b&amp;dbid=32&amp;doi=10.1021%2Fjm400336x&amp;key=1%3ACAS%3A528%3ADC%252BD1cXosFOhsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1191&publication_year=2008&pages=192-199&author=L.+M.+Aguiarauthor=D.+S.+Mac%C3%AAdoauthor=S.+M.+Vasconcelosauthor=A.+A.+Oliveiraauthor=F.+C.+de+Sousaauthor=G.+S.+Viana&title=CSC%2C+an+adenosine+A%282A%29+receptor+antagonist+and+MAO+B+inhibitor%2C+reverses+behavior%2C+monoamine+neurotransmission%2C+and+amino+acid+alterations+in+the+6-OHDA-lesioned+rats"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23bR"><div class="casContent"><span class="casTitleNuber">23b</span><div class="casTitle"><span class="NLM_cas:atitle">CSC, an adenosine A2A receptor antagonist and MAO B inhibitor, reverses behavior, monoamine neurotransmission, and amino acid alterations in the 6-OHDA-lesioned rats</span></div><div class="casAuthors">Aguiar, Lissiana M. V.; Macedo, Danielle S.; Vasconcelos, Silvania M. M.; Oliveira, Aline A.; de Sousa, F. Clea F.; Viana, Glauce S. B.</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">1191</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">192-199</span>CODEN:
                <span class="NLM_cas:coden">BRREAP</span>;
        ISSN:<span class="NLM_cas:issn">0006-8993</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The present work showed the effects of 8-(-3-chlorostyryl)-caffeine (CSC), an A2A receptors antagonist and MAO B inhibitor, on behavior and biochem. alterations in 6-OHDA-lesioned rats.  Male Wistar rats (280 g) were injected with CSC (1 and 5 mg/kg, i.p.) alone or combined with -DOPA (50 mg/kg + benserazide 12.5 mg/kg), starting 6 days after the striatal 6-OHDA lesions, and once daily for the next 7 days.  Fourteen days after the 6-OHDA lesion (and 24 h after CSC or vehicle), the no. of net body rotations/h (after the apomorphine challenge) was recorded and, at the next day, animals were sacrificed.  The ipsilateral striatum was used for HPLC measurements of monoamines and amino acids or for detn. of nitrite contents and lipid peroxidn.  Results showed that the increase in body rotation, induced by the 6-OHDA lesion, after the apomorphine challenge, was significantly and dose-dependently reversed by CSC.  Furthermore, the decreased striatal levels of DA and metabolites, in the 6-OHDA-lesioned rats, were reversed after CSC treatment, and these effects were potentiated after the combination with -DOPA.  Similar results were obsd. with NE, 5-HT and 5-HIAA.  While glutamate and GABA were increased in the 6-OHDA-lesioned group, CSC alone or mainly combined with -DOPA reversed these alterations.  In addn., the CSC treatment of 6-OHDA-lesioned rats reversed the increased nitrite formation and lipid peroxidn. induced by 6-OHDA.  In conclusion, CSC by means of its dual action as A2A antagonist and MAO-B inhibitor reversed behavior and biochem. alterations, obsd. in the 6-OHDA-lesioned rats, pointing out to its potential benefit for the treatment of PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQGeGo0gzm57Vg90H21EOLACvtfcHk0lgx-LNu7U-_Aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXosFOhsQ%253D%253D&md5=fa1a78f82d4872989baec9dd05737f6e</span></div><a href="/servlet/linkout?suffix=cit23b&amp;dbid=16384&amp;doi=10.1016%2Fj.brainres.2007.11.051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.brainres.2007.11.051%26sid%3Dliteratum%253Aachs%26aulast%3DAguiar%26aufirst%3DL.%2BM.%26aulast%3DMac%25C3%25AAdo%26aufirst%3DD.%2BS.%26aulast%3DVasconcelos%26aufirst%3DS.%2BM.%26aulast%3DOliveira%26aufirst%3DA.%2BA.%26aulast%3Dde%2BSousa%26aufirst%3DF.%2BC.%26aulast%3DViana%26aufirst%3DG.%2BS.%26atitle%3DCSC%252C%2520an%2520adenosine%2520A%25282A%2529%2520receptor%2520antagonist%2520and%2520MAO%2520B%2520inhibitor%252C%2520reverses%2520behavior%252C%2520monoamine%2520neurotransmission%252C%2520and%2520amino%2520acid%2520alterations%2520in%2520the%25206-OHDA-lesioned%2520rats%26jtitle%3DBrain%2520Res.%26date%3D2008%26volume%3D1191%26spage%3D192%26epage%3D199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit23c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Petzer, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castagnoli, N.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwarzschild, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van der Schyf, C. J.</span><span> </span><span class="NLM_article-title">Dual-target-directed drugs that block monoamine oxidase B and adenosine A<sub>2A</sub> receptors for Parkinson’s disease</span> <span class="citation_source-journal">Neurotherapeutics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">41</span><span class="NLM_x">–</span> <span class="NLM_lpage">151</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2009&pages=41-151&issue=1&author=J.+P.+Petzerauthor=N.+Castagnoliauthor=M.+A.+Schwarzschildauthor=J.+F.+Chenauthor=C.+J.+Van+der+Schyf&title=Dual-target-directed+drugs+that+block+monoamine+oxidase+B+and+adenosine+A2A+receptors+for+Parkinson%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPetzer%26aufirst%3DJ.%2BP.%26aulast%3DCastagnoli%26aufirst%3DN.%26aulast%3DSchwarzschild%26aufirst%3DM.%2BA.%26aulast%3DChen%26aufirst%3DJ.%2BF.%26aulast%3DVan%2Bder%2BSchyf%26aufirst%3DC.%2BJ.%26atitle%3DDual-target-directed%2520drugs%2520that%2520block%2520monoamine%2520oxidase%2520B%2520and%2520adenosine%2520A2A%2520receptors%2520for%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DNeurotherapeutics%26date%3D2009%26volume%3D6%26issue%3D1%26spage%3D41%26epage%3D151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Petzer, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steyn, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castagnoli, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwarzschild, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van der Schyf, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castagnoli, N.</span><span> </span><span class="NLM_article-title">Inhibition of monoamine oxidase B by selective adenosine A<sub>2A</sub> receptor antagonists</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1299</span><span class="NLM_x">–</span> <span class="NLM_lpage">1310</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2003&pages=1299-1310&author=J.+P.+Petzerauthor=S.+Steynauthor=K.+P.+Castagnoliauthor=J.+F.+Chenauthor=M.+A.+Schwarzschildauthor=C.+J.+Van+der+Schyfauthor=N.+Castagnoli&title=Inhibition+of+monoamine+oxidase+B+by+selective+adenosine+A2A+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPetzer%26aufirst%3DJ.%2BP.%26aulast%3DSteyn%26aufirst%3DS.%26aulast%3DCastagnoli%26aufirst%3DK.%2BP.%26aulast%3DChen%26aufirst%3DJ.%2BF.%26aulast%3DSchwarzschild%26aufirst%3DM.%2BA.%26aulast%3DVan%2Bder%2BSchyf%26aufirst%3DC.%2BJ.%26aulast%3DCastagnoli%26aufirst%3DN.%26atitle%3DInhibition%2520of%2520monoamine%2520oxidase%2520B%2520by%2520selective%2520adenosine%2520A2A%2520receptor%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2003%26volume%3D11%26spage%3D1299%26epage%3D1310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit24b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Pretorius, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castagnoli, N.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergh, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petzer, J. P.</span><span> </span><span class="NLM_article-title">Dual inhibition of monoamine oxidase B and antagonism of the adenosine A<sub>2A</sub> receptor by (<i>E</i>,<i>E</i>)-8-(4-phenylbutadien-1-yl)caffeine analogues</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">8676</span><span class="NLM_x">–</span> <span class="NLM_lpage">8684</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2008&pages=8676-8684&author=J.+Pretoriusauthor=S.+Malanauthor=N.+Castagnoliauthor=J.+J.+Berghauthor=J.+P.+Petzer&title=Dual+inhibition+of+monoamine+oxidase+B+and+antagonism+of+the+adenosine+A2A+receptor+by+%28E%2CE%29-8-%284-phenylbutadien-1-yl%29caffeine+analogues"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPretorius%26aufirst%3DJ.%26aulast%3DMalan%26aufirst%3DS.%26aulast%3DCastagnoli%26aufirst%3DN.%26aulast%3DBergh%26aufirst%3DJ.%2BJ.%26aulast%3DPetzer%26aufirst%3DJ.%2BP.%26atitle%3DDual%2520inhibition%2520of%2520monoamine%2520oxidase%2520B%2520and%2520antagonism%2520of%2520the%2520adenosine%2520A2A%2520receptor%2520by%2520%2528E%252CE%2529-8-%25284-phenylbutadien-1-yl%2529caffeine%2520analogues%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2008%26volume%3D16%26spage%3D8676%26epage%3D8684" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit24c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Rivara, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piersanti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartoccini, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diamantini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pala, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riccioni, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stasi, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cabri, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borsini, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mor, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarzia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minetti, P.</span><span> </span><span class="NLM_article-title">Synthesis of (<i>E</i>)-8-(3-chlorostyryl)caffeine analogues leading to 9-deazaxanthine derivatives as dual A<sub>2A</sub> antagonists/MAO-B inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">1247</span><span class="NLM_x">–</span> <span class="NLM_lpage">1261</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm301686s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=1247-1261&author=S.+Rivaraauthor=G.+Piersantiauthor=F.+Bartocciniauthor=G.+Diamantiniauthor=D.+Palaauthor=T.+Riccioniauthor=M.+A.+Stasiauthor=W.+Cabriauthor=F.+Borsiniauthor=M.+Morauthor=G.+Tarziaauthor=P.+Minetti&title=Synthesis+of+%28E%29-8-%283-chlorostyryl%29caffeine+analogues+leading+to+9-deazaxanthine+derivatives+as+dual+A2A+antagonists%2FMAO-B+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24c&amp;dbid=16384&amp;doi=10.1021%2Fjm301686s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301686s%26sid%3Dliteratum%253Aachs%26aulast%3DRivara%26aufirst%3DS.%26aulast%3DPiersanti%26aufirst%3DG.%26aulast%3DBartoccini%26aufirst%3DF.%26aulast%3DDiamantini%26aufirst%3DG.%26aulast%3DPala%26aufirst%3DD.%26aulast%3DRiccioni%26aufirst%3DT.%26aulast%3DStasi%26aufirst%3DM.%2BA.%26aulast%3DCabri%26aufirst%3DW.%26aulast%3DBorsini%26aufirst%3DF.%26aulast%3DMor%26aufirst%3DM.%26aulast%3DTarzia%26aufirst%3DG.%26aulast%3DMinetti%26aufirst%3DP.%26atitle%3DSynthesis%2520of%2520%2528E%2529-8-%25283-chlorostyryl%2529caffeine%2520analogues%2520leading%2520to%25209-deazaxanthine%2520derivatives%2520as%2520dual%2520A2A%2520antagonists%252FMAO-B%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D1247%26epage%3D1261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Müller, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thorand, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qurishi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diekmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padgett, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daly, J. W.</span><span> </span><span class="NLM_article-title">Imidazo[2,1-<i>i</i>]purin-5-ones and related tricyclic water-soluble purine derivatives: potent A<sub>2A</sub>- and A<sub>3</sub>-adenosine receptor antagonists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">3440</span><span class="NLM_x">–</span> <span class="NLM_lpage">3450</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm011093d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=3440-3450&author=C.+E.+M%C3%BCllerauthor=M.+Thorandauthor=R.+Qurishiauthor=M.+Diekmannauthor=K.+A.+Jacobsonauthor=W.+L.+Padgettauthor=J.+W.+Daly&title=Imidazo%5B2%2C1-i%5Dpurin-5-ones+and+related+tricyclic+water-soluble+purine+derivatives%3A+potent+A2A-+and+A3-adenosine+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm011093d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm011093d%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26aulast%3DThorand%26aufirst%3DM.%26aulast%3DQurishi%26aufirst%3DR.%26aulast%3DDiekmann%26aufirst%3DM.%26aulast%3DJacobson%26aufirst%3DK.%2BA.%26aulast%3DPadgett%26aufirst%3DW.%2BL.%26aulast%3DDaly%26aufirst%3DJ.%2BW.%26atitle%3DImidazo%255B2%252C1-i%255Dpurin-5-ones%2520and%2520related%2520tricyclic%2520water-soluble%2520purine%2520derivatives%253A%2520potent%2520A2A-%2520and%2520A3-adenosine%2520receptor%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D3440%26epage%3D3450" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Vollmann, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qurishi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hockemeyer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, C. E.</span><span> </span><span class="NLM_article-title">Synthesis and properties of a new water-soluble prodrug of the adenosine A<sub>2A</sub> receptor antagonist MSX-2</span> <span class="citation_source-journal">Molecules</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">348</span><span class="NLM_x">–</span> <span class="NLM_lpage">359</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2008&pages=348-359&author=K.+Vollmannauthor=R.+Qurishiauthor=J.+Hockemeyerauthor=C.+E.+M%C3%BCller&title=Synthesis+and+properties+of+a+new+water-soluble+prodrug+of+the+adenosine+A2A+receptor+antagonist+MSX-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVollmann%26aufirst%3DK.%26aulast%3DQurishi%26aufirst%3DR.%26aulast%3DHockemeyer%26aufirst%3DJ.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26atitle%3DSynthesis%2520and%2520properties%2520of%2520a%2520new%2520water-soluble%2520prodrug%2520of%2520the%2520adenosine%2520A2A%2520receptor%2520antagonist%2520MSX-2%26jtitle%3DMolecules%26date%3D2008%26volume%3D13%26spage%3D348%26epage%3D359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Hockemeyer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burbiel, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, C. E.</span><span> </span><span class="NLM_article-title">Multigram-scale syntheses, stability, and photoreactions of A<sub>2A</sub> adenosine receptor antagonists with 8-styrylxanthine structure: potential drugs for Parkinson’s disease</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">3308</span><span class="NLM_x">–</span> <span class="NLM_lpage">3318</span></span><div class="citationLinks">[<a href="/doi/10.1021/jo0358574" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2004&pages=3308-3318&author=J.+Hockemeyerauthor=J.+C.+Burbielauthor=C.+E.+M%C3%BCller&title=Multigram-scale+syntheses%2C+stability%2C+and+photoreactions+of+A2A+adenosine+receptor+antagonists+with+8-styrylxanthine+structure%3A+potential+drugs+for+Parkinson%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27a&amp;dbid=16384&amp;doi=10.1021%2Fjo0358574&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo0358574%26sid%3Dliteratum%253Aachs%26aulast%3DHockemeyer%26aufirst%3DJ.%26aulast%3DBurbiel%26aufirst%3DJ.%2BC.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26atitle%3DMultigram-scale%2520syntheses%252C%2520stability%252C%2520and%2520photoreactions%2520of%2520A2A%2520adenosine%2520receptor%2520antagonists%2520with%25208-styrylxanthine%2520structure%253A%2520potential%2520drugs%2520for%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2004%26volume%3D69%26spage%3D3308%26epage%3D3318" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit27b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Müller, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schobert, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hipp, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geis, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frobenius, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pawłowski, M.</span><span> </span><span class="NLM_article-title">Configurationally stable analogs of 8-styrylxanthines as A<sub>2A</sub>-adenosine receptor antagonists</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">709</span><span class="NLM_x">–</span> <span class="NLM_lpage">719</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1997&pages=709-719&author=C.+E.+M%C3%BCllerauthor=U.+Schobertauthor=J.+Hippauthor=U.+Geisauthor=W.+Frobeniusauthor=M.+Paw%C5%82owski&title=Configurationally+stable+analogs+of+8-styrylxanthines+as+A2A-adenosine+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26aulast%3DSchobert%26aufirst%3DU.%26aulast%3DHipp%26aufirst%3DJ.%26aulast%3DGeis%26aufirst%3DU.%26aulast%3DFrobenius%26aufirst%3DW.%26aulast%3DPaw%25C5%2582owski%26aufirst%3DM.%26atitle%3DConfigurationally%2520stable%2520analogs%2520of%25208-styrylxanthines%2520as%2520A2A-adenosine%2520receptor%2520antagonists%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D1997%26volume%3D32%26spage%3D709%26epage%3D719" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit27c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Nonaka, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimada, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nonaka, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koike, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aoki, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kase, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, F.</span><span> </span><span class="NLM_article-title">Photoisomerization of a potent and selective adenosine A<sub>2</sub> antagonist, (<i>E</i>)-1,3-dipropyl-8-(3,4-dimethoxystyryl)-7-methylxanthine</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">3731</span><span class="NLM_x">–</span> <span class="NLM_lpage">3733</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm00075a031" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1993&pages=3731-3733&author=Y.+Nonakaauthor=J.+Shimadaauthor=H.+Nonakaauthor=N.+Koikeauthor=N.+Aokiauthor=H.+Kobayashiauthor=H.+Kaseauthor=K.+Yamaguchiauthor=F.+Suzuki&title=Photoisomerization+of+a+potent+and+selective+adenosine+A2+antagonist%2C+%28E%29-1%2C3-dipropyl-8-%283%2C4-dimethoxystyryl%29-7-methylxanthine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27c&amp;dbid=16384&amp;doi=10.1021%2Fjm00075a031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00075a031%26sid%3Dliteratum%253Aachs%26aulast%3DNonaka%26aufirst%3DY.%26aulast%3DShimada%26aufirst%3DJ.%26aulast%3DNonaka%26aufirst%3DH.%26aulast%3DKoike%26aufirst%3DN.%26aulast%3DAoki%26aufirst%3DN.%26aulast%3DKobayashi%26aufirst%3DH.%26aulast%3DKase%26aufirst%3DH.%26aulast%3DYamaguchi%26aufirst%3DK.%26aulast%3DSuzuki%26aufirst%3DF.%26atitle%3DPhotoisomerization%2520of%2520a%2520potent%2520and%2520selective%2520adenosine%2520A2%2520antagonist%252C%2520%2528E%2529-1%252C3-dipropyl-8-%25283%252C4-dimethoxystyryl%2529-7-methylxanthine%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1993%26volume%3D36%26spage%3D3731%26epage%3D3733" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Leistner, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gütschow, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stach, J.</span><span> </span><span class="NLM_article-title">2-Amino-3,1-benzothiazin-4-ones: synthesis, Dimroth rearrangement to quinazolin-4(3<i>H</i>)-on-2(1<i>H</i>)-thiones, and MS/MS-fragmentation</span> <span class="citation_source-journal">Arch. Pharm. (Weinheim, Ger.)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">323</span><span class="NLM_x">, </span> <span class="NLM_fpage">857</span><span class="NLM_x">–</span> <span class="NLM_lpage">861</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Fjm400336x&amp;key=10.1002%2Fardp.19903231009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Fjm400336x&amp;key=1%3ACAS%3A528%3ADyaK3MXkt1Ohug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=323&publication_year=1990&pages=857-861&author=S.+Leistnerauthor=M.+G%C3%BCtschowauthor=J.+Stach&title=2-Amino-3%2C1-benzothiazin-4-ones%3A+synthesis%2C+Dimroth+rearrangement+to+quinazolin-4%283H%29-on-2%281H%29-thiones%2C+and+MS%2FMS-fragmentation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Polycyclic azines.  XXV.  2-amino-3,1-benzothiazin-4-ones:  synthesis, dimroth-rearrangement to quinazolin-4-(3H)-thiones, and MS/MS-fragmentation</span></div><div class="casAuthors">Leistner, Siegfried; Guetschow, Michael; Stach, Joachim</div><div class="citationInfo"><span class="NLM_cas:title">Archiv der Pharmazie (Weinheim, Germany)</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">323</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">857-61</span>CODEN:
                <span class="NLM_cas:coden">ARPMAS</span>;
        ISSN:<span class="NLM_cas:issn">0365-6233</span>.
    </div><div class="casAbstract">The intramol. cyclocondensation reaction of benzoylthiourea derivs., e.g. 4,2-RR1C6H3NHC(:S)NHCOPh (R = H, Me, Cl; R1 = CO2Me, CO2H, cyano) gave 2-amino-1,3-benzothiazin-4-ones I (same R).  Dimroth rearrangement of I gave quinazolin-2-thiones II (same R).  The cyclocondensation of 4,2-RR1C6H3NHC(:S)NHCOPh (R = H, Me, Cl; R1 = CO2Me, CO2H) gave 2-(benzoylamino)-1,3-benzothiazin-4-ones.  I (R = H) had antianaphylactic activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqS8r3YiDuw6rVg90H21EOLACvtfcHk0ljBXlP3zucfGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXkt1Ohug%253D%253D&md5=42d31c65137a42a990daee2256d866bc</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1002%2Fardp.19903231009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fardp.19903231009%26sid%3Dliteratum%253Aachs%26aulast%3DLeistner%26aufirst%3DS.%26aulast%3DG%25C3%25BCtschow%26aufirst%3DM.%26aulast%3DStach%26aufirst%3DJ.%26atitle%3D2-Amino-3%252C1-benzothiazin-4-ones%253A%2520synthesis%252C%2520Dimroth%2520rearrangement%2520to%2520quinazolin-4%25283H%2529-on-2%25281H%2529-thiones%252C%2520and%2520MS%252FMS-fragmentation%26jtitle%3DArch.%2520Pharm.%2520%2528Weinheim%252C%2520Ger.%2529%26date%3D1990%26volume%3D323%26spage%3D857%26epage%3D861" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Müller, C. E.; Hockemeyer, J.; Tzvetkov, N.; Burbiel, J.</span><span> </span><span class="NLM_article-title">Preparation of 8-ethynyl-xanthine derivatives as selective A<sub>2A</sub> receptor antagonists</span>, PCT Int. Appl., 2008077557, 03 Jul<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=C.+E.+M%C3%BCller&author=J.+Hockemeyer&author=N.+Tzvetkov&author=J.+Burbiel&title=Preparation+of+8-ethynyl-xanthine+derivatives+as+selective+A2A+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26atitle%3DPreparation%2520of%25208-ethynyl-xanthine%2520derivatives%2520as%2520selective%2520A2A%2520receptor%2520antagonists%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Travis, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sivakumar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollist, G. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borhan, B.</span><span> </span><span class="NLM_article-title">Facile oxidation of aldehydes to acids and esters with oxone</span> <span class="citation_source-journal">Org. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">1031</span><span class="NLM_x">–</span> <span class="NLM_lpage">1034</span></span><div class="citationLinks">[<a href="/doi/10.1021/ol0340078" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm400336x&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhvVygt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2003&pages=1031-1034&author=B.+R.+Travisauthor=M.+Sivakumarauthor=G.+O.+Hollistauthor=B.+Borhan&title=Facile+oxidation+of+aldehydes+to+acids+and+esters+with+oxone"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Facile Oxidation of Aldehydes to Acids and Esters with Oxone</span></div><div class="casAuthors">Travis, Benjamin R.; Sivakumar, Meenakshi; Hollist, G. Olatunji; Borhan, Babak</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1031-1034</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A highly efficient, mild, and simple protocol is presented for the oxidn. of aldehydes to carboxylic acids utilizing Oxone as the sole oxidant.  Direct conversion of aldehydes in alc. solvents to their corresponding ester products is also reported.  These reactions may prove to be valuable alternatives to traditional metal-mediated oxidns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-7dhAYUVfTbVg90H21EOLACvtfcHk0lhrAdSwqgfZww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhvVygt7c%253D&md5=0bf08019bd6f51b3d0e26d6c43954dd3</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fol0340078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol0340078%26sid%3Dliteratum%253Aachs%26aulast%3DTravis%26aufirst%3DB.%2BR.%26aulast%3DSivakumar%26aufirst%3DM.%26aulast%3DHollist%26aufirst%3DG.%2BO.%26aulast%3DBorhan%26aufirst%3DB.%26atitle%3DFacile%2520oxidation%2520of%2520aldehydes%2520to%2520acids%2520and%2520esters%2520with%2520oxone%26jtitle%3DOrg.%2520Lett.%26date%3D2003%26volume%3D5%26spage%3D1031%26epage%3D1034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Neumann, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gütschow, M.</span><span> </span><span class="NLM_article-title">3,1-Benzothiazin-4-ones and 3,1-benzoxazin-4-ones: highly different activities in chymotrypsin inactivation</span> <span class="citation_source-journal">Bioorg. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">72</span><span class="NLM_x">–</span> <span class="NLM_lpage">88</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Fjm400336x&amp;key=10.1006%2Fbioo.1995.1006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Fjm400336x&amp;key=1%3ACAS%3A528%3ADyaK2MXkvFemtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1995&pages=72-88&author=U.+Neumannauthor=M.+G%C3%BCtschow&title=3%2C1-Benzothiazin-4-ones+and+3%2C1-benzoxazin-4-ones%3A+highly+different+activities+in+chymotrypsin+inactivation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">3,1-Benzothiazin-4-ones and 3,1-benzoxazin-4-ones: highly different activities in chymotrypsin inactivation</span></div><div class="casAuthors">Neumann, U.; Guetschow, M.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">72-88</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    
            (<span class="NLM_cas:orgname">Academic</span>)
        </div><div class="casAbstract">3,1-Benzothiazin-4-ones are sulfur analogs of the potent serine protease inactivators of the 3,1-benzoxazin-4-one type, which acylate the serine residue within the active site of the enzymes.  A series of 2-amino-3,1-benzothiazinones was synthesized, but these compds. showed only very little inhibitory activity toward chymotrypsin, a model serine protease.  Detailed investigations revealed that benzothiazinones and benzoxazinones react with identical mechanisms, but benzothiazinones acylate chymotrypsin with much lower rate consts.  Investigations of nonenzymic hydrolysis showed the benzothiazinones to be intrinsically more stable than benzoxazinones.  It was concluded from spectroscopic results, that benzoxazinones are highly activated due to the absence of ester-like resonance.  2-Benzoylamino-4H-3,1-benzoxazin-4-one was a new, highly active chymotrypsin inactivator.  In contrast, benzothiazinones were resonance stabilized.  The contribution of a resonance structure with an exocyclic oxanion to the overall structure of the benzothiazinones and its nonproductive binding to the active site explained their low reactivity toward chymotrypsin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6cdfirR8I7rVg90H21EOLACvtfcHk0lhrAdSwqgfZww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXkvFemtro%253D&md5=0ae4729ed219892e56e23062ed9e43d5</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1006%2Fbioo.1995.1006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fbioo.1995.1006%26sid%3Dliteratum%253Aachs%26aulast%3DNeumann%26aufirst%3DU.%26aulast%3DG%25C3%25BCtschow%26aufirst%3DM.%26atitle%3D3%252C1-Benzothiazin-4-ones%2520and%25203%252C1-benzoxazin-4-ones%253A%2520highly%2520different%2520activities%2520in%2520chymotrypsin%2520inactivation%26jtitle%3DBioorg.%2520Chem.%26date%3D1995%26volume%3D23%26spage%3D72%26epage%3D88" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Scheiff, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yerande, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">El-Tayeb, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inamdar, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vasu, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sudarsanam, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, C. E.</span><span> </span><span class="NLM_article-title">2-Amino-5-benzoyl-4-phenylthiazoles: development of potent and selective adenosine A<sub>1</sub> receptor antagonists</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">2195</span><span class="NLM_x">–</span> <span class="NLM_lpage">2203</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2010&pages=2195-2203&author=A.+B.+Scheiffauthor=S.+G.+Yerandeauthor=A.+El-Tayebauthor=W.+Liauthor=G.+S.+Inamdarauthor=K.+K.+Vasuauthor=V.+Sudarsanamauthor=C.+E.+M%C3%BCller&title=2-Amino-5-benzoyl-4-phenylthiazoles%3A+development+of+potent+and+selective+adenosine+A1+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DScheiff%26aufirst%3DA.%2BB.%26aulast%3DYerande%26aufirst%3DS.%2BG.%26aulast%3DEl-Tayeb%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DInamdar%26aufirst%3DG.%2BS.%26aulast%3DVasu%26aufirst%3DK.%2BK.%26aulast%3DSudarsanam%26aufirst%3DV.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26atitle%3D2-Amino-5-benzoyl-4-phenylthiazoles%253A%2520development%2520of%2520potent%2520and%2520selective%2520adenosine%2520A1%2520receptor%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2010%26volume%3D18%26spage%3D2195%26epage%3D2203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Müller, C. E.; Jacobson, K. A.</span><span> </span><span class="NLM_article-title">Xanthines as Adenosine Receptor antagonists</span>. In  <span class="citation_source-book">Methylxanthines. Handbook of Experimental Pharmacology 200</span>, <span class="NLM_edition">1</span>st ed.; <span class="NLM_contrib-group">Fredholm, B. B.</span>, Ed.; <span class="NLM_publisher-name">Springer-Verlag</span>: <span class="NLM_publisher-loc">Berlin, Germany</span>,<span class="NLM_x"> </span><span class="NLM_year">2011</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">151</span><b>–</b> <span class="NLM_lpage">199</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&pages=151-199&author=C.+E.+M%C3%BCller&author=K.+A.+Jacobsonauthor=B.+B.+Fredholm&title=Methylxanthines.+Handbook+of+Experimental+Pharmacology+200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26atitle%3DXanthines%2520as%2520Adenosine%2520Receptor%2520antagonists%26btitle%3DMethylxanthines.%2520Handbook%2520of%2520Experimental%2520Pharmacology%2520200%26aulast%3DFredholm%26aufirst%3DB.%2BB.%26pub%3DSpringer-Verlag%26date%3D2011%26spage%3D151%26epage%3D199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Weiss, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benwell, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cliffe, I. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillespie, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knight, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lerpiniere, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Misra, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pratt, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Revell, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Upton, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dourish, C. T.</span><span> </span><span class="NLM_article-title">Discovery of nonxanthine adenosine A<sub>2A</sub> receptor antagonists for the treatment of Parkinson’s disease</span> <span class="citation_source-journal">Neurology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">101</span><span class="NLM_x">–</span> <span class="NLM_lpage">106</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2003&pages=101-106&author=S.+M.+Weissauthor=K.+Benwellauthor=I.+A.+Cliffeauthor=R.+J.+Gillespieauthor=A.+R.+Knightauthor=J.+Lerpiniereauthor=A.+Misraauthor=R.+M.+Prattauthor=D.+Revellauthor=R.+Uptonauthor=C.+T.+Dourish&title=Discovery+of+nonxanthine+adenosine+A2A+receptor+antagonists+for+the+treatment+of+Parkinson%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWeiss%26aufirst%3DS.%2BM.%26aulast%3DBenwell%26aufirst%3DK.%26aulast%3DCliffe%26aufirst%3DI.%2BA.%26aulast%3DGillespie%26aufirst%3DR.%2BJ.%26aulast%3DKnight%26aufirst%3DA.%2BR.%26aulast%3DLerpiniere%26aufirst%3DJ.%26aulast%3DMisra%26aufirst%3DA.%26aulast%3DPratt%26aufirst%3DR.%2BM.%26aulast%3DRevell%26aufirst%3DD.%26aulast%3DUpton%26aufirst%3DR.%26aulast%3DDourish%26aufirst%3DC.%2BT.%26atitle%3DDiscovery%2520of%2520nonxanthine%2520adenosine%2520A2A%2520receptor%2520antagonists%2520for%2520the%2520treatment%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DNeurology%26date%3D2003%26volume%3D61%26spage%3D101%26epage%3D106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Jacobson, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallo-Rodriguez, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melman, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maillard, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Bergen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Galen, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karton, Y.</span><span> </span><span class="NLM_article-title">Structure–activity relationships of 8-styrylxanthines as A<sub>2</sub>-selective adenosine antagonists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">1333</span><span class="NLM_x">–</span> <span class="NLM_lpage">1342</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm00062a005" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1993&pages=1333-1342&author=K.+A.+Jacobsonauthor=C.+Gallo-Rodriguezauthor=N.+Melmanauthor=B.+Fischerauthor=M.+Maillardauthor=A.+van+Bergenauthor=P.+J.+van+Galenauthor=Y.+Karton&title=Structure%E2%80%93activity+relationships+of+8-styrylxanthines+as+A2-selective+adenosine+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm00062a005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00062a005%26sid%3Dliteratum%253Aachs%26aulast%3DJacobson%26aufirst%3DK.%2BA.%26aulast%3DGallo-Rodriguez%26aufirst%3DC.%26aulast%3DMelman%26aufirst%3DN.%26aulast%3DFischer%26aufirst%3DB.%26aulast%3DMaillard%26aufirst%3DM.%26aulast%3Dvan%2BBergen%26aufirst%3DA.%26aulast%3Dvan%2BGalen%26aufirst%3DP.%2BJ.%26aulast%3DKarton%26aufirst%3DY.%26atitle%3DStructure%25E2%2580%2593activity%2520relationships%2520of%25208-styrylxanthines%2520as%2520A2-selective%2520adenosine%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1993%26volume%3D36%26spage%3D1333%26epage%3D1342" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Sterling, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herzig, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goren, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finkelstein, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lerner, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldenberg, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miskolczi, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molnar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rantal, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamas, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toth, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zagyva, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zekany, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finberg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavian, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gross, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Razin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krais, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chorev, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Youdim, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinstock, M.</span><span> </span><span class="NLM_article-title">Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer’s disease</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">5260</span><span class="NLM_x">–</span> <span class="NLM_lpage">5279</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm020120c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=5260-5279&author=J.+Sterlingauthor=Y.+Herzigauthor=T.+Gorenauthor=N.+Finkelsteinauthor=D.+Lernerauthor=W.+Goldenbergauthor=I.+Miskolcziauthor=S.+Molnarauthor=F.+Rantalauthor=T.+Tamasauthor=G.+Tothauthor=A.+Zagyvaauthor=A.+Zekanyauthor=J.+Finbergauthor=G.+Lavianauthor=A.+Grossauthor=R.+Friedmanauthor=M.+Razinauthor=W.+Huangauthor=B.+Kraisauthor=M.+Chorevauthor=M.+B.+Youdimauthor=M.+Weinstock&title=Novel+dual+inhibitors+of+AChE+and+MAO+derived+from+hydroxy+aminoindan+and+phenethylamine+as+potential+treatment+for+Alzheimer%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fjm020120c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020120c%26sid%3Dliteratum%253Aachs%26aulast%3DSterling%26aufirst%3DJ.%26aulast%3DHerzig%26aufirst%3DY.%26aulast%3DGoren%26aufirst%3DT.%26aulast%3DFinkelstein%26aufirst%3DN.%26aulast%3DLerner%26aufirst%3DD.%26aulast%3DGoldenberg%26aufirst%3DW.%26aulast%3DMiskolczi%26aufirst%3DI.%26aulast%3DMolnar%26aufirst%3DS.%26aulast%3DRantal%26aufirst%3DF.%26aulast%3DTamas%26aufirst%3DT.%26aulast%3DToth%26aufirst%3DG.%26aulast%3DZagyva%26aufirst%3DA.%26aulast%3DZekany%26aufirst%3DA.%26aulast%3DFinberg%26aufirst%3DJ.%26aulast%3DLavian%26aufirst%3DG.%26aulast%3DGross%26aufirst%3DA.%26aulast%3DFriedman%26aufirst%3DR.%26aulast%3DRazin%26aufirst%3DM.%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DKrais%26aufirst%3DB.%26aulast%3DChorev%26aufirst%3DM.%26aulast%3DYoudim%26aufirst%3DM.%2BB.%26aulast%3DWeinstock%26aufirst%3DM.%26atitle%3DNovel%2520dual%2520inhibitors%2520of%2520AChE%2520and%2520MAO%2520derived%2520from%2520hydroxy%2520aminoindan%2520and%2520phenethylamine%2520as%2520potential%2520treatment%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D5260%26epage%3D5279" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Chimenti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Secci, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolasco, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chimenti, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Granese, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carradori, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yáñez, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orallo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanna, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallinella, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cirilli, R.</span><span> </span><span class="NLM_article-title">Synthesis, stereochemical separation, and biological evaluation of selective inhibitors of human MAO-B: 1-(4-Arylthiazol-2-yl)-2-(3-methylcyclohexylidene)hydrazines</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">6516</span><span class="NLM_x">–</span> <span class="NLM_lpage">6520</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm100120s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=6516-6520&author=F.+Chimentiauthor=D.+Secciauthor=A.+Bolascoauthor=P.+Chimentiauthor=A.+Graneseauthor=S.+Carradoriauthor=M.+Y%C3%A1%C3%B1ezauthor=F.+Oralloauthor=M.+L.+Sannaauthor=B.+Gallinellaauthor=R.+Cirilli&title=Synthesis%2C+stereochemical+separation%2C+and+biological+evaluation+of+selective+inhibitors+of+human+MAO-B%3A+1-%284-Arylthiazol-2-yl%29-2-%283-methylcyclohexylidene%29hydrazines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fjm100120s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100120s%26sid%3Dliteratum%253Aachs%26aulast%3DChimenti%26aufirst%3DF.%26aulast%3DSecci%26aufirst%3DD.%26aulast%3DBolasco%26aufirst%3DA.%26aulast%3DChimenti%26aufirst%3DP.%26aulast%3DGranese%26aufirst%3DA.%26aulast%3DCarradori%26aufirst%3DS.%26aulast%3DY%25C3%25A1%25C3%25B1ez%26aufirst%3DM.%26aulast%3DOrallo%26aufirst%3DF.%26aulast%3DSanna%26aufirst%3DM.%2BL.%26aulast%3DGallinella%26aufirst%3DB.%26aulast%3DCirilli%26aufirst%3DR.%26atitle%3DSynthesis%252C%2520stereochemical%2520separation%252C%2520and%2520biological%2520evaluation%2520of%2520selective%2520inhibitors%2520of%2520human%2520MAO-B%253A%25201-%25284-Arylthiazol-2-yl%2529-2-%25283-methylcyclohexylidene%2529hydrazines%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D6516%26epage%3D6520" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Novaroli, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daina, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Favre, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bravo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carotti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonetti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Catto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carrupt, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reist, M.</span><span> </span><span class="NLM_article-title">Impact of species-dependent differences on screening, design, and development of MAO B inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">6264</span><span class="NLM_x">–</span> <span class="NLM_lpage">6272</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm060441e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=6264-6272&author=L.+Novaroliauthor=A.+Dainaauthor=E.+Favreauthor=J.+Bravoauthor=A.+Carottiauthor=F.+Leonettiauthor=M.+Cattoauthor=P.+A.+Carruptauthor=M.+Reist&title=Impact+of+species-dependent+differences+on+screening%2C+design%2C+and+development+of+MAO+B+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjm060441e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060441e%26sid%3Dliteratum%253Aachs%26aulast%3DNovaroli%26aufirst%3DL.%26aulast%3DDaina%26aufirst%3DA.%26aulast%3DFavre%26aufirst%3DE.%26aulast%3DBravo%26aufirst%3DJ.%26aulast%3DCarotti%26aufirst%3DA.%26aulast%3DLeonetti%26aufirst%3DF.%26aulast%3DCatto%26aufirst%3DM.%26aulast%3DCarrupt%26aufirst%3DP.%2BA.%26aulast%3DReist%26aufirst%3DM.%26atitle%3DImpact%2520of%2520species-dependent%2520differences%2520on%2520screening%252C%2520design%252C%2520and%2520development%2520of%2520MAO%2520B%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D6264%26epage%3D6272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Müller, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maurinsh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sauer, R.</span><span> </span><span class="NLM_article-title">Binding of [<sup>3</sup>H]MSX-2 (3-(3-hydroxypropyl)-7-methyl-8-(<i>m</i>-methoxystyryl)-1-propargylxanthine) to rat striatal membranes - a new, selective antagonist radioligand for A<sub>2A</sub> adenosine receptors</span> <span class="citation_source-journal">Eur. J. Pharm. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">259</span><span class="NLM_x">–</span> <span class="NLM_lpage">265</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Fjm400336x&amp;key=10.1016%2FS0928-0987%2800%2900064-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Fjm400336x&amp;key=10838015" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Fjm400336x&amp;key=1%3ACAS%3A528%3ADC%252BD3cXjs1Cgsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2000&pages=259-265&author=C.+E.+M%C3%BCllerauthor=J.+Maurinshauthor=R.+Sauer&title=Binding+of+%5B3H%5DMSX-2+%283-%283-hydroxypropyl%29-7-methyl-8-%28m-methoxystyryl%29-1-propargylxanthine%29+to+rat+striatal+membranes+-+a+new%2C+selective+antagonist+radioligand+for+A2A+adenosine+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Binding of [3H]MSX-2 (3-(3-hydroxypropyl)-7-methyl-8-(m-methoxystyryl)-1-propargylxanthine) to rat striatal membranes - a new, selective antagonist radioligand for A2A adenosine receptors</span></div><div class="casAuthors">Muller, C. E.; Maurinsh, J.; Sauer, R.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">259-265</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">The present study describes the prepn. and binding properties of a new, potent, and selective A2A adenosine receptor (AR) antagonist radioligand, [3H]3-(3-hydroxypropyl)-7-methyl-8-(m-methoxystyryl)-1-propargylxanthine ([3H]MSX-2).  [3H]MSX-2 binding to rat striatal membranes was saturable and reversible.  Satn. expts. showed that [3H]MSX-2 labeled a single class of binding sites with high affinity (Kd=8.0 nM) and limited capacity (Bmax=1.16 fmol·mg-1 of protein).  The presence of 100 μM GTP, or 10 mM magnesium chloride, resp., had no effect on [3H]MSX-2 binding.  AR agonists competed with the binding of 1 nM [3H]MSX-2 with the following order of potency: 5'-N-ethylcarboxamidoadenosine (NECA)°2-[4-(carboxyethyl)phenylethylamino]-5'-N-ethylcarboxamidoadenosine (CGS-21680)°2-chloroadenosine (2-CADO)°N6-cyclopentyladenosine (CPA).  AR antagonists showed the following order of potency: 8-(m-bromostyryl)-3,7-dimethyl-1-propargylxanthine (BS-DMPX)°1,3-dipropyl-8-cyclopentylxanthine (DPCPX)°(R)-5,6-dimethyl-7-(1-phenylethyl)-2-(4-pyridyl)-7H-pyrrolo[2,3-d]pyrimidine-4-amine (SH-128)°3,7-dimethyl-1-propargylxanthine (DMPX)°caffeine.  The Ki values for antagonists were in accordance with data from binding studies with the agonist radioligand [3H]CGS21680, while agonist affinities were 3-7-fold lower. [3H]MSX-2 is a highly selective A2A AR antagonist radioligand exhibiting a selectivity of at least two orders of magnitude vs. all other AR subtypes.  The new radioligand shows high specific radioactivity (85 Ci/mmol, 3150 GBq/mmol) and acceptable nonspecific binding at rat striatal membranes of 20-30%, at 1 nM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8VMEXXUj3RbVg90H21EOLACvtfcHk0liA91JZVWjC5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXjs1Cgsrs%253D&md5=012d1ae18ba96e8768e7652b25308998</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2FS0928-0987%2800%2900064-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0928-0987%252800%252900064-6%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26aulast%3DMaurinsh%26aufirst%3DJ.%26aulast%3DSauer%26aufirst%3DR.%26atitle%3DBinding%2520of%2520%255B3H%255DMSX-2%2520%25283-%25283-hydroxypropyl%2529-7-methyl-8-%2528m-methoxystyryl%2529-1-propargylxanthine%2529%2520to%2520rat%2520striatal%2520membranes%2520-%2520a%2520new%252C%2520selective%2520antagonist%2520radioligand%2520for%2520A2A%2520adenosine%2520receptors%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2000%26volume%3D10%26spage%3D259%26epage%3D265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Borrmann, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinz, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertarelli, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Florin, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheiff, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, C. E.</span><span> </span><span class="NLM_article-title">1-Alkyl-8-(piperazine-1-sulfonyl)-phenylxanthines: development and characterization of adenosine A<sub>2B</sub> receptor antagonists and a new radioligand with subnanomolar affinity and subtype specificity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">3994</span><span class="NLM_x">–</span> <span class="NLM_lpage">4006</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm900413e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=3994-4006&author=T.+Borrmannauthor=S.+Hinzauthor=D.+C.+Bertarelliauthor=W.+Liauthor=N.+C.+Florinauthor=A.+B.+Scheiffauthor=C.+E.+M%C3%BCller&title=1-Alkyl-8-%28piperazine-1-sulfonyl%29-phenylxanthines%3A+development+and+characterization+of+adenosine+A2B+receptor+antagonists+and+a+new+radioligand+with+subnanomolar+affinity+and+subtype+specificity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fjm900413e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900413e%26sid%3Dliteratum%253Aachs%26aulast%3DBorrmann%26aufirst%3DT.%26aulast%3DHinz%26aufirst%3DS.%26aulast%3DBertarelli%26aufirst%3DD.%2BC.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DFlorin%26aufirst%3DN.%2BC.%26aulast%3DScheiff%26aufirst%3DA.%2BB.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26atitle%3D1-Alkyl-8-%2528piperazine-1-sulfonyl%2529-phenylxanthines%253A%2520development%2520and%2520characterization%2520of%2520adenosine%2520A2B%2520receptor%2520antagonists%2520and%2520a%2520new%2520radioligand%2520with%2520subnanomolar%2520affinity%2520and%2520subtype%2520specificity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D3994%26epage%3D4006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Müller, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diekmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thorand, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ozola, V.</span><span> </span><span class="NLM_article-title">[<sup>3</sup>H]8-Ethyl-4-methyl-2-phenyl-(8R)-4,5,7,8-tetrahydro-1H-imidazo[2,1-<i>i</i>]-purin-5-one ([<sup>3</sup>H]PSB-11), a novel high-affinity antagonist radioligand for human A<sub>3</sub> adenosine receptors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">501</span><span class="NLM_x">–</span> <span class="NLM_lpage">503</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2002&pages=501-503&author=C.+E.+M%C3%BCllerauthor=M.+Diekmannauthor=M.+Thorandauthor=V.+Ozola&title=%5B3H%5D8-Ethyl-4-methyl-2-phenyl-%288R%29-4%2C5%2C7%2C8-tetrahydro-1H-imidazo%5B2%2C1-i%5D-purin-5-one+%28%5B3H%5DPSB-11%29%2C+a+novel+high-affinity+antagonist+radioligand+for+human+A3+adenosine+receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26aulast%3DDiekmann%26aufirst%3DM.%26aulast%3DThorand%26aufirst%3DM.%26aulast%3DOzola%26aufirst%3DV.%26atitle%3D%255B3H%255D8-Ethyl-4-methyl-2-phenyl-%25288R%2529-4%252C5%252C7%252C8-tetrahydro-1H-imidazo%255B2%252C1-i%255D-purin-5-one%2520%2528%255B3H%255DPSB-11%2529%252C%2520a%2520novel%2520high-affinity%2520antagonist%2520radioligand%2520for%2520human%2520A3%2520adenosine%2520receptors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2002%26volume%3D12%26spage%3D501%26epage%3D503" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Bulicz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertarelli, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumert, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fülle, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heber, D.</span><span> </span><span class="NLM_article-title">Synthesis and pharmacology of pyrido[2,3-<i>d</i>]-pyrimidinediones bearing polar substituents as adenosine receptor antagonists</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">2837</span><span class="NLM_x">–</span> <span class="NLM_lpage">2849</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2006&pages=2837-2849&author=J.+Buliczauthor=D.+C.+Bertarelliauthor=D.+Baumertauthor=F.+F%C3%BClleauthor=C.+E.+M%C3%BCllerauthor=D.+Heber&title=Synthesis+and+pharmacology+of+pyrido%5B2%2C3-d%5D-pyrimidinediones+bearing+polar+substituents+as+adenosine+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBulicz%26aufirst%3DJ.%26aulast%3DBertarelli%26aufirst%3DD.%2BC.%26aulast%3DBaumert%26aufirst%3DD.%26aulast%3DF%25C3%25BClle%26aufirst%3DF.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26aulast%3DHeber%26aufirst%3DD.%26atitle%3DSynthesis%2520and%2520pharmacology%2520of%2520pyrido%255B2%252C3-d%255D-pyrimidinediones%2520bearing%2520polar%2520substituents%2520as%2520adenosine%2520receptor%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2006%26volume%3D14%26spage%3D2837%26epage%3D2849" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Klotz, K. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lohse, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwabe, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cristalli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vittori, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grifantini, M.</span><span> </span><span class="NLM_article-title">2-Chloro-<i>N</i><sup>6</sup>-[<sup>3</sup>H]cyclopentyladenosine ([<sup>3</sup>H]CCPA) - a high affinity agonist radioligand for A<sub>1</sub> adenosine receptors</span> <span class="citation_source-journal">Naunyn-Schmiedeberg’s Arch. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">340</span><span class="NLM_x">, </span> <span class="NLM_fpage">679</span><span class="NLM_x">–</span> <span class="NLM_lpage">683</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Fjm400336x&amp;key=10.1007%2FBF00717744" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Fjm400336x&amp;key=2615857" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Fjm400336x&amp;key=1%3ACAS%3A528%3ADyaK3cXhtFGhsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=340&publication_year=1989&pages=679-683&author=K.+N.+Klotzauthor=M.+J.+Lohseauthor=U.+Schwabeauthor=G.+Cristalliauthor=S.+Vittoriauthor=M.+Grifantini&title=2-Chloro-N6-%5B3H%5Dcyclopentyladenosine+%28%5B3H%5DCCPA%29+-+a+high+affinity+agonist+radioligand+for+A1+adenosine+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">2-Chloro-N6-[3H]cyclopentyladenosine ([3H]CPPA) - a high affinity agonist radioligand for A1 adenosine receptors</span></div><div class="casAuthors">Klotz, Karl Norbert; Lohse, Martin J.; Schwabe, Ulrich; Cristalli, Gloria; Vittori, Sauro; Grifantini, Mario</div><div class="citationInfo"><span class="NLM_cas:title">Naunyn-Schmiedeberg's Archives of Pharmacology</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">340</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">679-83</span>CODEN:
                <span class="NLM_cas:coden">NSAPCC</span>;
        ISSN:<span class="NLM_cas:issn">0028-1298</span>.
    </div><div class="casAbstract">The tritiated analog of 2-chloro-N6-cyclopentyladenosine (CCPA) (I), an adenosine deriv. with subnanomolar affinity and a 10,000-fold selectivity for A1 adenosine receptors, has been examd. as a new agonist radioligand.  [3H]CCPA was prepd. with a specific radioactivity of 1.58 TBq/mmol (43 Ci/mmol) and bound in a reversible manner to A1 receptors from rat brain membranes with a high affinity KD value of 0.2 nmol/L.  In the presence of GTP, a KDvalue of 13 nmol/L was detd. for the low affinity state for agonist binding.  Competition of several adenosine receptor agonists and antagonists for [3H]CCPA binding to rat brain membranes confirmed binding to an A1 receptor.  Solubilized A1 receptors bound [3H]CCPA with similar affinity for the high affinity state.  At solubilized receptors a reduced assocn. rate was obsd. in the presence of MgCl2, as has been shown for the agonist [3H]N6-phenylisopropyladenosine ([3H]PIA).  [3H]CCPA was also used for detection of A1 receptors in rat cardiomyocyte membranes, a tissue with a very low receptor d.  Kd-Value of 0.4 nmol-L and a Bmax-value of 16 fmol-platelet membranes, no specific binding of [3H]CCPA was measured at concns. up to 400 nmol/L, indicating that A2 receptors did not bind [3H]CCPA.  Based on the subnanomolar affinity and the high selectivity for A1 receptors, [3H]CCPA proved to be a useful agonist radioligand for characterization of A1 adenosine receptors also in tissues with very low receptor d.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquP1vlbGByYrVg90H21EOLACvtfcHk0lioIlHw4y-9Jg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXhtFGhsL8%253D&md5=d44acdedb7aa0c3b3c6f7d79666ae139</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1007%2FBF00717744&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF00717744%26sid%3Dliteratum%253Aachs%26aulast%3DKlotz%26aufirst%3DK.%2BN.%26aulast%3DLohse%26aufirst%3DM.%2BJ.%26aulast%3DSchwabe%26aufirst%3DU.%26aulast%3DCristalli%26aufirst%3DG.%26aulast%3DVittori%26aufirst%3DS.%26aulast%3DGrifantini%26aufirst%3DM.%26atitle%3D2-Chloro-N6-%255B3H%255Dcyclopentyladenosine%2520%2528%255B3H%255DCCPA%2529%2520-%2520a%2520high%2520affinity%2520agonist%2520radioligand%2520for%2520A1%2520adenosine%2520receptors%26jtitle%3DNaunyn-Schmiedeberg%25E2%2580%2599s%2520Arch.%2520Pharmacol.%26date%3D1989%26volume%3D340%26spage%3D679%26epage%3D683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Yan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertarelli, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayallah, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klotz, K.. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, C. E.</span><span> </span><span class="NLM_article-title">A new synthesis of sulfonamides by aminolysis of pnitrophenylsulfonates yielding potent and selective adenosine A<sub>2B</sub> receptor antagonists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">4384</span><span class="NLM_x">–</span> <span class="NLM_lpage">4391</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm060277v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=4384-4391&author=L.+Yanauthor=D.+C.+Bertarelliauthor=A.+M.+Hayallahauthor=H.+Meyerauthor=K..+N.+Klotzauthor=C.+E.+M%C3%BCller&title=A+new+synthesis+of+sulfonamides+by+aminolysis+of+pnitrophenylsulfonates+yielding+potent+and+selective+adenosine+A2B+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Fjm060277v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060277v%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DL.%26aulast%3DBertarelli%26aufirst%3DD.%2BC.%26aulast%3DHayallah%26aufirst%3DA.%2BM.%26aulast%3DMeyer%26aufirst%3DH.%26aulast%3DKlotz%26aufirst%3DK..%2BN.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26atitle%3DA%2520new%2520synthesis%2520of%2520sulfonamides%2520by%2520aminolysis%2520of%2520pnitrophenylsulfonates%2520yielding%2520potent%2520and%2520selective%2520adenosine%2520A2B%2520receptor%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D4384%26epage%3D4391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Schumacher, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scholle, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holzl, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khudeir, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hess, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, C. E.</span><span> </span><span class="NLM_article-title">Lignans isolated from valerian: identification and characterization of a new olivil derivative with partial agonistic activity at A<sub>1</sub> adenosine receptors</span> <span class="citation_source-journal">J. Nat. Prod.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">1479</span><span class="NLM_x">–</span> <span class="NLM_lpage">1485</span></span><div class="citationLinks">[<a href="/doi/10.1021/np010464q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2002&pages=1479-1485&author=B.+Schumacherauthor=S.+Scholleauthor=J.+Holzlauthor=N.+Khudeirauthor=S.+Hessauthor=C.+E.+M%C3%BCller&title=Lignans+isolated+from+valerian%3A+identification+and+characterization+of+a+new+olivil+derivative+with+partial+agonistic+activity+at+A1+adenosine+receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fnp010464q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fnp010464q%26sid%3Dliteratum%253Aachs%26aulast%3DSchumacher%26aufirst%3DB.%26aulast%3DScholle%26aufirst%3DS.%26aulast%3DHolzl%26aufirst%3DJ.%26aulast%3DKhudeir%26aufirst%3DN.%26aulast%3DHess%26aufirst%3DS.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26atitle%3DLignans%2520isolated%2520from%2520valerian%253A%2520identification%2520and%2520characterization%2520of%2520a%2520new%2520olivil%2520derivative%2520with%2520partial%2520agonistic%2520activity%2520at%2520A1%2520adenosine%2520receptors%26jtitle%3DJ.%2520Nat.%2520Prod.%26date%3D2002%26volume%3D65%26spage%3D1479%26epage%3D1485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Schiedel, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinz, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thimm, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherbiny, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borrmann, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maass, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, C. E.</span><span> </span><span class="NLM_article-title">The four cysteine residues in the second extracellular loop of the human adenosine A<sub>2B</sub> receptor: role in ligand binding and receptor function</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">82</span><span class="NLM_x">, </span> <span class="NLM_fpage">389</span><span class="NLM_x">–</span> <span class="NLM_lpage">399</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2011&pages=389-399&author=A.+C.+Schiedelauthor=S.+Hinzauthor=D.+Thimmauthor=F.+Sherbinyauthor=T.+Borrmannauthor=A.+Maassauthor=C.+E.+M%C3%BCller&title=The+four+cysteine+residues+in+the+second+extracellular+loop+of+the+human+adenosine+A2B+receptor%3A+role+in+ligand+binding+and+receptor+function"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchiedel%26aufirst%3DA.%2BC.%26aulast%3DHinz%26aufirst%3DS.%26aulast%3DThimm%26aufirst%3DD.%26aulast%3DSherbiny%26aufirst%3DF.%26aulast%3DBorrmann%26aufirst%3DT.%26aulast%3DMaass%26aufirst%3DA.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26atitle%3DThe%2520four%2520cysteine%2520residues%2520in%2520the%2520second%2520extracellular%2520loop%2520of%2520the%2520human%2520adenosine%2520A2B%2520receptor%253A%2520role%2520in%2520ligand%2520binding%2520and%2520receptor%2520function%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2011%26volume%3D82%26spage%3D389%26epage%3D399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit46b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Nordstedt, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fredholm, B. B.</span><span> </span><span class="NLM_article-title">A modification of a protein-binding method for rapid quantification of cAMP in cell-culture supernatants and body fluid</span> <span class="citation_source-journal">Anal. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">189</span><span class="NLM_x">, </span> <span class="NLM_fpage">231</span><span class="NLM_x">–</span> <span class="NLM_lpage">234</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=189&publication_year=1990&pages=231-234&author=C.+Nordstedtauthor=B.+B.+Fredholm&title=A+modification+of+a+protein-binding+method+for+rapid+quantification+of+cAMP+in+cell-culture+supernatants+and+body+fluid"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNordstedt%26aufirst%3DC.%26aulast%3DFredholm%26aufirst%3DB.%2BB.%26atitle%3DA%2520modification%2520of%2520a%2520protein-binding%2520method%2520for%2520rapid%2520quantification%2520of%2520cAMP%2520in%2520cell-culture%2520supernatants%2520and%2520body%2520fluid%26jtitle%3DAnal.%2520Biochem.%26date%3D1990%26volume%3D189%26spage%3D231%26epage%3D234" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1a','cit1b'],'ref2':['cit2'],'ref3':['cit3a','cit3b','cit3c'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7a','cit7b'],'ref8':['cit8a','cit8b'],'ref9':['cit9a','cit9b'],'ref10':['cit10a','cit10b','cit10c','cit10d'],'ref11':['cit11a','cit11b'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14a','cit14b'],'ref15':['cit15a','cit15b','cit15c'],'ref16':['cit16a','cit16b'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19a','cit19b'],'ref20':['cit20a','cit20b'],'ref21':['cit21a','cit21b','cit21c','cit21d','cit21e'],'ref22':['cit22a','cit22b','cit22c','cit22d'],'ref23':['cit23a','cit23b','cit23c'],'ref24':['cit24a','cit24b','cit24c'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27a','cit27b','cit27c'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46a','cit46b']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 55 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Carina Lemke, Joscha Christmann, Jiafei Yin, José M. Alonso, Estefanía Serrano, Mourad Chioua, Lhassane Ismaili, María Angeles Martínez-Grau, Christopher D. Beadle, Tatiana Vetman, Florian M. Dato, Ulrike Bartz, Paul W. Elsinghorst, Markus Pietsch, Christa E. Müller, Isabel Iriepa, Timo Wille, José Marco-Contelles, <span class="NLM_string-name hlFld-ContribAuthor">Michael Gütschow</span>. </span><span class="cited-content_cbyCitation_article-title">Chromenones as Multineurotargeting Inhibitors of Human Enzymes. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2019,</strong> <em>4 </em>
                                    (26)
                                     , 22161-22168. <a href="https://doi.org/10.1021/acsomega.9b03409" title="DOI URL">https://doi.org/10.1021/acsomega.9b03409</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.9b03409&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.9b03409%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DChromenones%252Bas%252BMultineurotargeting%252BInhibitors%252Bof%252BHuman%252BEnzymes%26aulast%3DLemke%26aufirst%3DCarina%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D14102019%26date%3D21112019%26date%3D11122019%26volume%3D4%26issue%3D26%26spage%3D22161%26epage%3D22168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Mariama Jaiteh, Alexey Zeifman, Marcus Saarinen, Per Svenningsson, Jose Bréa, Maria Isabel Loza, <span class="NLM_string-name hlFld-ContribAuthor">Jens Carlsson</span>. </span><span class="cited-content_cbyCitation_article-title">Docking Screens for Dual Inhibitors of Disparate Drug Targets for Parkinson’s Disease. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (12)
                                     , 5269-5278. <a href="https://doi.org/10.1021/acs.jmedchem.8b00204" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00204</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00204&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00204%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDocking%252BScreens%252Bfor%252BDual%252BInhibitors%252Bof%252BDisparate%252BDrug%252BTargets%252Bfor%252BParkinson%2525E2%252580%252599s%252BDisease%26aulast%3DJaiteh%26aufirst%3DMariama%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D06022018%26date%3D15062018%26date%3D24052018%26volume%3D61%26issue%3D12%26spage%3D5269%26epage%3D5278" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Panagiotis Lagarias, Eleni Vrontaki, George Lambrinidis, Dimitrios Stamatis, Marino Convertino, Gabriella Ortore, Thomas Mavromoustakos, Karl-Norbert Klotz, <span class="NLM_string-name hlFld-ContribAuthor">Antonios Kolocouris</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Novel Adenosine Receptor Antagonists through a Combined Structure- and Ligand-Based Approach Followed by Molecular Dynamics Investigation of Ligand Binding Mode. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2018,</strong> <em>58 </em>
                                    (4)
                                     , 794-815. <a href="https://doi.org/10.1021/acs.jcim.7b00455" title="DOI URL">https://doi.org/10.1021/acs.jcim.7b00455</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.7b00455&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.7b00455%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DDiscovery%252Bof%252BNovel%252BAdenosine%252BReceptor%252BAntagonists%252Bthrough%252Ba%252BCombined%252BStructure-%252Band%252BLigand-Based%252BApproach%252BFollowed%252Bby%252BMolecular%252BDynamics%252BInvestigation%252Bof%252BLigand%252BBinding%252BMode%26aulast%3DLagarias%26aufirst%3DPanagiotis%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D29072017%26date%3D19032018%26date%3D27022018%26volume%3D58%26issue%3D4%26spage%3D794%26epage%3D815" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dominik  Dolles</span>, <span class="hlFld-ContribAuthor ">Matthias  Hoffmann</span>, <span class="hlFld-ContribAuthor ">Sandra  Gunesch</span>, <span class="hlFld-ContribAuthor ">Oliviero  Marinelli</span>, <span class="hlFld-ContribAuthor ">Jan  Möller</span>, <span class="hlFld-ContribAuthor ">Giorgio  Santoni</span>, <span class="hlFld-ContribAuthor ">Arnaud  Chatonnet</span>, <span class="hlFld-ContribAuthor ">Martin J.  Lohse</span>, <span class="hlFld-ContribAuthor ">Hans-Joachim  Wittmann</span>, <span class="hlFld-ContribAuthor ">Andrea  Strasser</span>, <span class="hlFld-ContribAuthor ">Massimo  Nabissi</span>, <span class="hlFld-ContribAuthor ">Tangui  Maurice</span>, and <span class="hlFld-ContribAuthor ">Michael  Decker</span>  . </span><span class="cited-content_cbyCitation_article-title">Structure–Activity Relationships and Computational Investigations into the Development of Potent and Balanced Dual-Acting Butyrylcholinesterase Inhibitors and Human Cannabinoid Receptor 2 Ligands with Pro-Cognitive in Vivo Profiles. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (4)
                                     , 1646-1663. <a href="https://doi.org/10.1021/acs.jmedchem.7b01760" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01760</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b01760%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure%2525E2%252580%252593Activity%252BRelationships%252Band%252BComputational%252BInvestigations%252Binto%252Bthe%252BDevelopment%252Bof%252BPotent%252Band%252BBalanced%252BDual-Acting%252BButyrylcholinesterase%252BInhibitors%252Band%252BHuman%252BCannabinoid%252BReceptor%252B2%252BLigands%252Bwith%252BPro-Cognitive%252Bin%252BVivo%252BProfiles%26aulast%3DDolles%26aufirst%3DDominik%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D29112017%26date%3D05022018%26date%3D22022018%26volume%3D61%26issue%3D4%26spage%3D1646%26epage%3D1663" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Simone  Carradori</span> and <span class="hlFld-ContribAuthor ">Romano  Silvestri</span>  . </span><span class="cited-content_cbyCitation_article-title">New Frontiers in Selective Human MAO-B Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (17)
                                     , 6717-6732. <a href="https://doi.org/10.1021/jm501690r" title="DOI URL">https://doi.org/10.1021/jm501690r</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm501690r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm501690r%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNew%252BFrontiers%252Bin%252BSelective%252BHuman%252BMAO-B%252BInhibitors%26aulast%3DCarradori%26aufirst%3DSimone%26date%3D2015%26date%3D2015%26date%3D2014%26date%3D31102014%26date%3D11052015%26date%3D10092015%26date%3D27042015%26volume%3D58%26issue%3D17%26spage%3D6717%26epage%3D6732" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Manuela  Jörg</span>, <span class="hlFld-ContribAuthor ">Lauren T.  May</span>, <span class="hlFld-ContribAuthor ">Frankie S.  Mak</span>, <span class="hlFld-ContribAuthor ">Kiew Ching K.  Lee</span>, <span class="hlFld-ContribAuthor ">Neil D.  Miller</span>, <span class="hlFld-ContribAuthor ">Peter J.  Scammells</span>, and <span class="hlFld-ContribAuthor ">Ben  Capuano</span>  . </span><span class="cited-content_cbyCitation_article-title">Synthesis and Pharmacological Evaluation of Dual Acting Ligands Targeting the Adenosine A2A and Dopamine D2 Receptors for the Potential Treatment of Parkinson’s Disease. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (2)
                                     , 718-738. <a href="https://doi.org/10.1021/jm501254d" title="DOI URL">https://doi.org/10.1021/jm501254d</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm501254d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm501254d%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252BPharmacological%252BEvaluation%252Bof%252BDual%252BActing%252BLigands%252BTargeting%252Bthe%252BAdenosine%252BA2A%252Band%252BDopamine%252BD2%252BReceptors%252Bfor%252Bthe%252BPotential%252BTreatment%252Bof%252BParkinson%2525E2%252580%252599s%252BDisease%26aulast%3DJ%25C3%25B6rg%26aufirst%3DManuela%26date%3D2015%26date%3D2014%26date%3D2014%26date%3D15082014%26date%3D24122014%26date%3D22012015%26date%3D09122014%26volume%3D58%26issue%3D2%26spage%3D718%26epage%3D738" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Oscar M.  Bautista-Aguilera</span>, <span class="hlFld-ContribAuthor ">Abdelouahid  Samadi</span>, <span class="hlFld-ContribAuthor ">Mourad  Chioua</span>, <span class="hlFld-ContribAuthor ">Katarina  Nikolic</span>, <span class="hlFld-ContribAuthor ">Slavica  Filipic</span>, <span class="hlFld-ContribAuthor ">Danica  Agbaba</span>, <span class="hlFld-ContribAuthor ">Elena  Soriano</span>, <span class="hlFld-ContribAuthor ">Lucía  de Andrés</span>, <span class="hlFld-ContribAuthor ">María Isabel  Rodríguez-Franco</span>, <span class="hlFld-ContribAuthor ">Stefano  Alcaro</span>, <span class="hlFld-ContribAuthor ">Rona R.  Ramsay</span>, <span class="hlFld-ContribAuthor ">Francesco  Ortuso</span>, <span class="hlFld-ContribAuthor ">Matilde  Yañez</span>, and <span class="hlFld-ContribAuthor ">José  Marco-Contelles</span>  . </span><span class="cited-content_cbyCitation_article-title">N-Methyl-N-((1-methyl-5-(3-(1-(2-methylbenzyl)piperidin-4-yl)propoxy)-1H-indol-2-yl)methyl)prop-2-yn-1-amine, a New Cholinesterase and Monoamine Oxidase Dual Inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>57 </em>
                                    (24)
                                     , 10455-10463. <a href="https://doi.org/10.1021/jm501501a" title="DOI URL">https://doi.org/10.1021/jm501501a</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm501501a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm501501a%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DN-Methyl-N-%252528%2525281-methyl-5-%2525283-%2525281-%2525282-methylbenzyl%252529piperidin-4-yl%252529propoxy%252529-1H-indol-2-yl%252529methyl%252529prop-2-yn-1-amine%25252C%252Ba%252BNew%252BCholinesterase%252Band%252BMonoamine%252BOxidase%252BDual%252BInhibitor%26aulast%3DBautista-Aguilera%26aufirst%3DOscar%2BM.%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D18092014%26date%3D08122014%26date%3D26122014%26date%3D24112014%26volume%3D57%26issue%3D24%26spage%3D10455%26epage%3D10463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nikolay T.  Tzvetkov</span>, <span class="hlFld-ContribAuthor ">Sonja  Hinz</span>, <span class="hlFld-ContribAuthor ">Petra  Küppers</span>, <span class="hlFld-ContribAuthor ">Marcus  Gastreich</span>, and <span class="hlFld-ContribAuthor ">Christa E.  Müller</span>  . </span><span class="cited-content_cbyCitation_article-title">Indazole- and Indole-5-carboxamides: Selective and Reversible Monoamine Oxidase B Inhibitors with Subnanomolar Potency. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>57 </em>
                                    (15)
                                     , 6679-6703. <a href="https://doi.org/10.1021/jm500729a" title="DOI URL">https://doi.org/10.1021/jm500729a</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm500729a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm500729a%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIndazole-%252Band%252BIndole-5-carboxamides%25253A%252BSelective%252Band%252BReversible%252BMonoamine%252BOxidase%252BB%252BInhibitors%252Bwith%252BSubnanomolar%252BPotency%26aulast%3DTzvetkov%26aufirst%3DNikolay%2BT.%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D10052014%26date%3D16072014%26date%3D14082014%26date%3D23062014%26volume%3D57%26issue%3D15%26spage%3D6679%26epage%3D6703" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Syeda  Uroos Qazi</span>, <span class="hlFld-ContribAuthor ">Asia  Naz</span>, <span class="hlFld-ContribAuthor ">Abdul  Hameed</span>, <span class="hlFld-ContribAuthor ">Faisal  Abdulrhman Osra</span>, <span class="hlFld-ContribAuthor ">Saquib  Jalil</span>, <span class="hlFld-ContribAuthor ">Jamshed  Iqbal</span>, <span class="hlFld-ContribAuthor ">Syed  Adnan Ali Shah</span>, <span class="hlFld-ContribAuthor ">Agha  Zeeshan Mirza</span>. </span><span class="cited-content_cbyCitation_article-title">Semicarbazones, thiosemicarbazone, thiazole and oxazole analogues as monoamine oxidase inhibitors: Synthesis, characterization, biological evaluation, molecular docking, and kinetic studies. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>464 </em>, 105209. <a href="https://doi.org/10.1016/j.bioorg.2021.105209" title="DOI URL">https://doi.org/10.1016/j.bioorg.2021.105209</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2021.105209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2021.105209%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DSemicarbazones%25252C%252Bthiosemicarbazone%25252C%252Bthiazole%252Band%252Boxazole%252Banalogues%252Bas%252Bmonoamine%252Boxidase%252Binhibitors%25253A%252BSynthesis%25252C%252Bcharacterization%25252C%252Bbiological%252Bevaluation%25252C%252Bmolecular%252Bdocking%25252C%252Band%252Bkinetic%252Bstudies%26aulast%3DUroos%2BQazi%26aufirst%3DSyeda%26date%3D2021%26volume%3D464%26spage%3D105209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Weichun  Wu</span>, <span class="hlFld-ContribAuthor ">Shenxi  Min</span>, <span class="hlFld-ContribAuthor ">Qin  Tong</span>, <span class="hlFld-ContribAuthor ">Junhao  Wang</span>, <span class="hlFld-ContribAuthor ">Jianghong  Hu</span>, <span class="hlFld-ContribAuthor ">Ashish  Dhamsaniya</span>, <span class="hlFld-ContribAuthor ">Anamik K.  Shah</span>, <span class="hlFld-ContribAuthor ">Vaibhav P.  Mehta</span>, <span class="hlFld-ContribAuthor ">Bin  Dong</span>, <span class="hlFld-ContribAuthor ">Bo  Song</span>. </span><span class="cited-content_cbyCitation_article-title">Highly sensitive and selective “turn-off” fluorescent probes based on coumarin for detection of Cu2+. </span><span class="cited-content_cbyCitation_journal-name">Colloid and Interface Science Communications</span><span> <strong>2021,</strong> <em>43 </em>, 100451. <a href="https://doi.org/10.1016/j.colcom.2021.100451" title="DOI URL">https://doi.org/10.1016/j.colcom.2021.100451</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.colcom.2021.100451&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.colcom.2021.100451%26sid%3Dliteratum%253Aachs%26jtitle%3DColloid%2520and%2520Interface%2520Science%2520Communications%26atitle%3DHighly%252Bsensitive%252Band%252Bselective%252B%2525E2%252580%25259Cturn-off%2525E2%252580%25259D%252Bfluorescent%252Bprobes%252Bbased%252Bon%252Bcoumarin%252Bfor%252Bdetection%252Bof%252BCu2%25252B%26aulast%3DWu%26aufirst%3DWeichun%26date%3D2021%26volume%3D43%26spage%3D100451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Saibabu  Polina</span>, <span class="hlFld-ContribAuthor ">V. P. Rama Kishore  Putta</span>, <span class="hlFld-ContribAuthor ">Raghuram  Gujjarappa</span>, <span class="hlFld-ContribAuthor ">Virender  Singh</span>, <span class="hlFld-ContribAuthor ">Prasad Pralhad  Pujar</span>, <span class="hlFld-ContribAuthor ">Chandi C.  Malakar</span>. </span><span class="cited-content_cbyCitation_article-title">P(III)‐Mediated Cascade C‐N/C‐S Bond Formation: A Protocol towards the Synthesis of
              N
              ,
              S
              ‐Heterocycles and Spiro Compounds. </span><span class="cited-content_cbyCitation_journal-name">Advanced Synthesis & Catalysis</span><span> <strong>2021,</strong> <em>363 </em>
                                    (2)
                                     , 431-445. <a href="https://doi.org/10.1002/adsc.202001149" title="DOI URL">https://doi.org/10.1002/adsc.202001149</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/adsc.202001149&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fadsc.202001149%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Synthesis%2520%2526%2520Catalysis%26atitle%3DP%252528III%252529%2525E2%252580%252590Mediated%252BCascade%252BC%2525E2%252580%252590N%25252FC%2525E2%252580%252590S%252BBond%252BFormation%25253A%252BA%252BProtocol%252Btowards%252Bthe%252BSynthesis%252Bof%252BN%252B%25252C%252BS%252B%2525E2%252580%252590Heterocycles%252Band%252BSpiro%252BCompounds%26aulast%3DPolina%26aufirst%3DSaibabu%26date%3D2021%26date%3D2020%26volume%3D363%26issue%3D2%26spage%3D431%26epage%3D445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Najoua  Sbei</span>, <span class="hlFld-ContribAuthor ">Alexander A.  Titov</span>, <span class="hlFld-ContribAuthor ">Subramani  Karthikeyan</span>, <span class="hlFld-ContribAuthor ">Leonid G.  Voskressensky</span>. </span><span class="cited-content_cbyCitation_article-title">Efficient synthesis of imino-1,3-thiazinan-4-one promoted by acetonitrile electrogenerated base and computational studies with CB1 and 11 βHSD1 molecules. </span><span class="cited-content_cbyCitation_journal-name">Research on Chemical Intermediates</span><span> <strong>2020,</strong> <em>46 </em>
                                    (12)
                                     , 5535-5545. <a href="https://doi.org/10.1007/s11164-020-04276-8" title="DOI URL">https://doi.org/10.1007/s11164-020-04276-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11164-020-04276-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11164-020-04276-8%26sid%3Dliteratum%253Aachs%26jtitle%3DResearch%2520on%2520Chemical%2520Intermediates%26atitle%3DEfficient%252Bsynthesis%252Bof%252Bimino-1%25252C3-thiazinan-4-one%252Bpromoted%252Bby%252Bacetonitrile%252Belectrogenerated%252Bbase%252Band%252Bcomputational%252Bstudies%252Bwith%252BCB1%252Band%252B11%252B%2525CE%2525B2HSD1%252Bmolecules%26aulast%3DSbei%26aufirst%3DNajoua%26date%3D2020%26date%3D2020%26volume%3D46%26issue%3D12%26spage%3D5535%26epage%3D5545" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vittorio  Canale</span>, <span class="hlFld-ContribAuthor ">Katarzyna  Grychowska</span>, <span class="hlFld-ContribAuthor ">Rafał  Kurczab</span>, <span class="hlFld-ContribAuthor ">Mateusz  Ryng</span>, <span class="hlFld-ContribAuthor ">Abdul Raheem  Keeri</span>, <span class="hlFld-ContribAuthor ">Grzegorz  Satała</span>, <span class="hlFld-ContribAuthor ">Agnieszka  Olejarz-Maciej</span>, <span class="hlFld-ContribAuthor ">Paulina  Koczurkiewicz</span>, <span class="hlFld-ContribAuthor ">Marcin  Drop</span>, <span class="hlFld-ContribAuthor ">Klaudia  Blicharz</span>, <span class="hlFld-ContribAuthor ">Kamil  Piska</span>, <span class="hlFld-ContribAuthor ">Elżbieta  Pękala</span>, <span class="hlFld-ContribAuthor ">Paulina  Janiszewska</span>, <span class="hlFld-ContribAuthor ">Martyna  Krawczyk</span>, <span class="hlFld-ContribAuthor ">Maria  Walczak</span>, <span class="hlFld-ContribAuthor ">Severine  Chaumont-Dubel</span>, <span class="hlFld-ContribAuthor ">Andrzej J.  Bojarski</span>, <span class="hlFld-ContribAuthor ">Philippe  Marin</span>, <span class="hlFld-ContribAuthor ">Piotr  Popik</span>, <span class="hlFld-ContribAuthor ">Paweł  Zajdel</span>. </span><span class="cited-content_cbyCitation_article-title">A dual-acting 5-HT6 receptor inverse agonist/MAO-B inhibitor displays glioprotective and pro-cognitive properties. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>208 </em>, 112765. <a href="https://doi.org/10.1016/j.ejmech.2020.112765" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112765</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112765&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112765%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DA%252Bdual-acting%252B5-HT6%252Breceptor%252Binverse%252Bagonist%25252FMAO-B%252Binhibitor%252Bdisplays%252Bglioprotective%252Band%252Bpro-cognitive%252Bproperties%26aulast%3DCanale%26aufirst%3DVittorio%26date%3D2020%26volume%3D208%26spage%3D112765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ting  Yang</span>, <span class="hlFld-ContribAuthor ">Xin  Sui</span>, <span class="hlFld-ContribAuthor ">Bing  Yu</span>, <span class="hlFld-ContribAuthor ">Youqing  Shen</span>, <span class="hlFld-ContribAuthor ">Hailin  Cong</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Advances in the Rational Drug Design Based on Multi-target Ligands. </span><span class="cited-content_cbyCitation_journal-name">Current Medicinal Chemistry</span><span> <strong>2020,</strong> <em>27 </em>
                                    (28)
                                     , 4720-4740. <a href="https://doi.org/10.2174/0929867327666200102120652" title="DOI URL">https://doi.org/10.2174/0929867327666200102120652</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/0929867327666200102120652&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F0929867327666200102120652%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Medicinal%2520Chemistry%26atitle%3DRecent%252BAdvances%252Bin%252Bthe%252BRational%252BDrug%252BDesign%252BBased%252Bon%252BMulti-target%252BLigands%26aulast%3DYang%26aufirst%3DTing%26date%3D2020%26volume%3D27%26issue%3D28%26spage%3D4720%26epage%3D4740" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michał  Załuski</span>, <span class="hlFld-ContribAuthor ">Jakub  Schabikowski</span>, <span class="hlFld-ContribAuthor ">Piotr  Jaśko</span>, <span class="hlFld-ContribAuthor ">Adrian  Bryła</span>, <span class="hlFld-ContribAuthor ">Agnieszka  Olejarz-Maciej</span>, <span class="hlFld-ContribAuthor ">Maria  Kaleta</span>, <span class="hlFld-ContribAuthor ">Monika  Głuch-Lutwin</span>, <span class="hlFld-ContribAuthor ">Andreas  Brockmann</span>, <span class="hlFld-ContribAuthor ">Sonja  Hinz</span>, <span class="hlFld-ContribAuthor ">Małgorzata  Zygmunt</span>, <span class="hlFld-ContribAuthor ">Kamil  Kuder</span>, <span class="hlFld-ContribAuthor ">Gniewomir  Latacz</span>, <span class="hlFld-ContribAuthor ">Christin  Vielmuth</span>, <span class="hlFld-ContribAuthor ">Christa E.  Müller</span>, <span class="hlFld-ContribAuthor ">Katarzyna  Kieć-Kononowicz</span>. </span><span class="cited-content_cbyCitation_article-title">8-Benzylaminoxanthine scaffold variations for selective ligands acting on adenosine A2A receptors. Design, synthesis and biological evaluation. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>101 </em>, 104033. <a href="https://doi.org/10.1016/j.bioorg.2020.104033" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.104033</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.104033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.104033%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3D8-Benzylaminoxanthine%252Bscaffold%252Bvariations%252Bfor%252Bselective%252Bligands%252Bacting%252Bon%252Badenosine%252BA2A%252Breceptors.%252BDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%26aulast%3DZa%25C5%2582uski%26aufirst%3DMicha%25C5%2582%26date%3D2020%26volume%3D101%26spage%3D104033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lan Phuong  Vu</span>, <span class="hlFld-ContribAuthor ">Michael  Gütschow</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and Biological Activities of 4H-3,1-Benzothiazin-4-Ones. </span><span class="cited-content_cbyCitation_journal-name">Chemistry of Heterocyclic Compounds</span><span> <strong>2020,</strong> <em>56 </em>
                                    (6)
                                     , 708-714. <a href="https://doi.org/10.1007/s10593-020-02719-z" title="DOI URL">https://doi.org/10.1007/s10593-020-02719-z</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10593-020-02719-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10593-020-02719-z%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520of%2520Heterocyclic%2520Compounds%26atitle%3DSynthesis%252Band%252BBiological%252BActivities%252Bof%252B4H-3%25252C1-Benzothiazin-4-Ones%26aulast%3DVu%26aufirst%3DLan%2BPhuong%26date%3D2020%26date%3D2020%26volume%3D56%26issue%3D6%26spage%3D708%26epage%3D714" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kamil J.  Kuder</span>, <span class="hlFld-ContribAuthor ">Michał  Załuski</span>, <span class="hlFld-ContribAuthor ">Jakub  Schabikowski</span>, <span class="hlFld-ContribAuthor ">Gniewomir  Latacz</span>, <span class="hlFld-ContribAuthor ">Agnieszka  Olejarz‐Maciej</span>, <span class="hlFld-ContribAuthor ">Piotr  Jaśko</span>, <span class="hlFld-ContribAuthor ">Agata  Doroz‐Płonka</span>, <span class="hlFld-ContribAuthor ">Andreas  Brockmann</span>, <span class="hlFld-ContribAuthor ">Christa E.  Müller</span>, <span class="hlFld-ContribAuthor ">Katarzyna  Kieć‐Kononowicz</span>. </span><span class="cited-content_cbyCitation_article-title">Novel, Dual Target‐Directed Annelated Xanthine Derivatives Acting on Adenosine Receptors and Monoamine Oxidase B. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2020,</strong> <em>15 </em>
                                    (9)
                                     , 772-786. <a href="https://doi.org/10.1002/cmdc.201900717" title="DOI URL">https://doi.org/10.1002/cmdc.201900717</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201900717&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201900717%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DNovel%25252C%252BDual%252BTarget%2525E2%252580%252590Directed%252BAnnelated%252BXanthine%252BDerivatives%252BActing%252Bon%252BAdenosine%252BReceptors%252Band%252BMonoamine%252BOxidase%252BB%26aulast%3DKuder%26aufirst%3DKamil%2BJ.%26date%3D2020%26date%3D2020%26volume%3D15%26issue%3D9%26spage%3D772%26epage%3D786" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daniel  Chavarria</span>, <span class="hlFld-ContribAuthor ">Carlos  Fernandes</span>, <span class="hlFld-ContribAuthor ">Vera  Silva</span>, <span class="hlFld-ContribAuthor ">Catia  Silva</span>, <span class="hlFld-ContribAuthor ">Eva  Gil-Martins</span>, <span class="hlFld-ContribAuthor ">Pedro  Soares</span>, <span class="hlFld-ContribAuthor ">Tiago  Silva</span>, <span class="hlFld-ContribAuthor ">Renata  Silva</span>, <span class="hlFld-ContribAuthor ">Fernando  Remião</span>, <span class="hlFld-ContribAuthor ">Paulo J.  Oliveira</span>, <span class="hlFld-ContribAuthor ">Fernanda  Borges</span>. </span><span class="cited-content_cbyCitation_article-title">Design of novel monoamine oxidase-B inhibitors based on piperine scaffold: Structure-activity-toxicity, drug-likeness and efflux transport studies. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>185 </em>, 111770. <a href="https://doi.org/10.1016/j.ejmech.2019.111770" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.111770</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.111770&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.111770%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Bof%252Bnovel%252Bmonoamine%252Boxidase-B%252Binhibitors%252Bbased%252Bon%252Bpiperine%252Bscaffold%25253A%252BStructure-activity-toxicity%25252C%252Bdrug-likeness%252Band%252Befflux%252Btransport%252Bstudies%26aulast%3DChavarria%26aufirst%3DDaniel%26date%3D2020%26volume%3D185%26spage%3D111770" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Siew L.  Cheong</span>, <span class="hlFld-ContribAuthor ">Stephanie  Federico</span>, <span class="hlFld-ContribAuthor ">Giampiero  Spalluto</span>, <span class="hlFld-ContribAuthor ">Karl-Norbert  Klotz</span>, <span class="hlFld-ContribAuthor ">Giorgia  Pastorin</span>. </span><span class="cited-content_cbyCitation_article-title">The current status of pharmacotherapy for the treatment of Parkinson’s disease: transition from single-target to multitarget therapy. </span><span class="cited-content_cbyCitation_journal-name">Drug Discovery Today</span><span> <strong>2019,</strong> <em>24 </em>
                                    (9)
                                     , 1769-1783. <a href="https://doi.org/10.1016/j.drudis.2019.05.003" title="DOI URL">https://doi.org/10.1016/j.drudis.2019.05.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.drudis.2019.05.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.drudis.2019.05.003%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520Today%26atitle%3DThe%252Bcurrent%252Bstatus%252Bof%252Bpharmacotherapy%252Bfor%252Bthe%252Btreatment%252Bof%252BParkinson%2525E2%252580%252599s%252Bdisease%25253A%252Btransition%252Bfrom%252Bsingle-target%252Bto%252Bmultitarget%252Btherapy%26aulast%3DCheong%26aufirst%3DSiew%2BL.%26date%3D2019%26volume%3D24%26issue%3D9%26spage%3D1769%26epage%3D1783" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pabitra Narayan  Samanta</span>, <span class="hlFld-ContribAuthor ">Supratik  Kar</span>, <span class="hlFld-ContribAuthor ">Jerzy  Leszczynski</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Advances of In-Silico Modeling of Potent Antagonists for the Adenosine Receptors. </span><span class="cited-content_cbyCitation_journal-name">Current Pharmaceutical Design</span><span> <strong>2019,</strong> <em>25 </em>
                                    (7)
                                     , 750-773. <a href="https://doi.org/10.2174/1381612825666190304123545" title="DOI URL">https://doi.org/10.2174/1381612825666190304123545</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1381612825666190304123545&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1381612825666190304123545%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Pharmaceutical%2520Design%26atitle%3DRecent%252BAdvances%252Bof%252BIn-Silico%252BModeling%252Bof%252BPotent%252BAntagonists%252Bfor%252Bthe%252BAdenosine%252BReceptors%26aulast%3DSamanta%26aufirst%3DPabitra%2BNarayan%26date%3D2019%26volume%3D25%26issue%3D7%26spage%3D750%26epage%3D773" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michał  Załuski</span>, <span class="hlFld-ContribAuthor ">Jakub  Schabikowski</span>, <span class="hlFld-ContribAuthor ">Miriam  Schlenk</span>, <span class="hlFld-ContribAuthor ">Agnieszka  Olejarz-Maciej</span>, <span class="hlFld-ContribAuthor ">Bartłomiej  Kubas</span>, <span class="hlFld-ContribAuthor ">Tadeusz  Karcz</span>, <span class="hlFld-ContribAuthor ">Kamil  Kuder</span>, <span class="hlFld-ContribAuthor ">Gniewomir  Latacz</span>, <span class="hlFld-ContribAuthor ">Małgorzata  Zygmunt</span>, <span class="hlFld-ContribAuthor ">David  Synak</span>, <span class="hlFld-ContribAuthor ">Sonja  Hinz</span>, <span class="hlFld-ContribAuthor ">Christa E.  Müller</span>, <span class="hlFld-ContribAuthor ">Katarzyna  Kieć-Kononowicz</span>. </span><span class="cited-content_cbyCitation_article-title">Novel multi-target directed ligands based on annelated xanthine scaffold with aromatic substituents acting on adenosine receptor and monoamine oxidase B. Synthesis, in vitro and in silico studies. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2019,</strong> <em>27 </em>
                                    (7)
                                     , 1195-1210. <a href="https://doi.org/10.1016/j.bmc.2019.02.004" title="DOI URL">https://doi.org/10.1016/j.bmc.2019.02.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2019.02.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2019.02.004%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DNovel%252Bmulti-target%252Bdirected%252Bligands%252Bbased%252Bon%252Bannelated%252Bxanthine%252Bscaffold%252Bwith%252Baromatic%252Bsubstituents%252Bacting%252Bon%252Badenosine%252Breceptor%252Band%252Bmonoamine%252Boxidase%252BB.%252BSynthesis%25252C%252Bin%252Bvitro%252Band%252Bin%252Bsilico%252Bstudies%26aulast%3DZa%25C5%2582uski%26aufirst%3DMicha%25C5%2582%26date%3D2019%26volume%3D27%26issue%3D7%26spage%3D1195%26epage%3D1210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ivanna Yu.  Danyliuk</span>, <span class="hlFld-ContribAuthor ">Ruslan I.  Vas’kevich</span>, <span class="hlFld-ContribAuthor ">Alla I.  Vas'kevich</span>, <span class="hlFld-ContribAuthor ">Eduard B.  Rusanov</span>, <span class="hlFld-ContribAuthor ">Mykhailo V.  Vovk</span>. </span><span class="cited-content_cbyCitation_article-title">Sulfanyl chloride induced heterocyclization of
              N
              -(pyrazolyl)styrylacetamides. </span><span class="cited-content_cbyCitation_journal-name">Phosphorus, Sulfur, and Silicon and the Related Elements</span><span> <strong>2019,</strong> <em>194 </em>
                                    (1-2)
                                     , 156-162. <a href="https://doi.org/10.1080/10426507.2018.1528257" title="DOI URL">https://doi.org/10.1080/10426507.2018.1528257</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/10426507.2018.1528257&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F10426507.2018.1528257%26sid%3Dliteratum%253Aachs%26jtitle%3DPhosphorus%252C%2520Sulfur%252C%2520and%2520Silicon%2520and%2520the%2520Related%2520Elements%26atitle%3DSulfanyl%252Bchloride%252Binduced%252Bheterocyclization%252Bof%252BN%252B-%252528pyrazolyl%252529styrylacetamides%26aulast%3DDanyliuk%26aufirst%3DIvanna%2BYu.%26date%3D2019%26date%3D2019%26volume%3D194%26issue%3D1-2%26spage%3D156%26epage%3D162" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rei  Saito</span>, <span class="hlFld-ContribAuthor ">Naohiro  Uemura</span>, <span class="hlFld-ContribAuthor ">Hiroki  Ishikawa</span>, <span class="hlFld-ContribAuthor ">Akina  Magara</span>, <span class="hlFld-ContribAuthor ">Yasushi  Yoshida</span>, <span class="hlFld-ContribAuthor ">Takashi  Mino</span>, <span class="hlFld-ContribAuthor ">Yoshio  Kasashima</span>, <span class="hlFld-ContribAuthor ">Masami  Sakamoto</span>. </span><span class="cited-content_cbyCitation_article-title">Umpolung cyclization reaction of
              N
              -cinnamoylthioureas in the presence of DBU. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2018,</strong> <em>16 </em>
                                    (42)
                                     , 7910-7919. <a href="https://doi.org/10.1039/C8OB02066C" title="DOI URL">https://doi.org/10.1039/C8OB02066C</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8OB02066C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8OB02066C%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DUmpolung%252Bcyclization%252Breaction%252Bof%252BN%252B-cinnamoylthioureas%252Bin%252Bthe%252Bpresence%252Bof%252BDBU%26aulast%3DSaito%26aufirst%3DRei%26date%3D2018%26date%3D2018%26volume%3D16%26issue%3D42%26spage%3D7910%26epage%3D7919" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pierre  Koch</span>, <span class="hlFld-ContribAuthor ">Andreas  Brunschweiger</span>, <span class="hlFld-ContribAuthor ">Vigneshwaran  Namasivayam</span>, <span class="hlFld-ContribAuthor ">Stefan  Ullrich</span>, <span class="hlFld-ContribAuthor ">Annalisa  Maruca</span>, <span class="hlFld-ContribAuthor ">Beatrice  Lazzaretto</span>, <span class="hlFld-ContribAuthor ">Petra  Küppers</span>, <span class="hlFld-ContribAuthor ">Sonja  Hinz</span>, <span class="hlFld-ContribAuthor ">Jörg  Hockemeyer</span>, <span class="hlFld-ContribAuthor ">Michael  Wiese</span>, <span class="hlFld-ContribAuthor ">Jag  Heer</span>, <span class="hlFld-ContribAuthor ">Stefano  Alcaro</span>, <span class="hlFld-ContribAuthor ">Katarzyna  Kiec-Kononowicz</span>, <span class="hlFld-ContribAuthor ">Christa E.  Müller</span>. </span><span class="cited-content_cbyCitation_article-title">Probing Substituents in the 1- and 3-Position: Tetrahydropyrazino-Annelated Water-Soluble Xanthine Derivatives as Multi-Target Drugs With Potent Adenosine Receptor Antagonistic Activity. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Chemistry</span><span> <strong>2018,</strong> <em>6 </em><a href="https://doi.org/10.3389/fchem.2018.00206" title="DOI URL">https://doi.org/10.3389/fchem.2018.00206</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fchem.2018.00206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffchem.2018.00206%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Chemistry%26atitle%3DProbing%252BSubstituents%252Bin%252Bthe%252B1-%252Band%252B3-Position%25253A%252BTetrahydropyrazino-Annelated%252BWater-Soluble%252BXanthine%252BDerivatives%252Bas%252BMulti-Target%252BDrugs%252BWith%252BPotent%252BAdenosine%252BReceptor%252BAntagonistic%252BActivity%26aulast%3DKoch%26aufirst%3DPierre%26date%3D2018%26date%3D2018%26volume%3D6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bhupinder  Kumar</span>, <span class="hlFld-ContribAuthor ">Mohit  Kumar</span>, <span class="hlFld-ContribAuthor ">Ashish Ranjan  Dwivedi</span>, <span class="hlFld-ContribAuthor ">Vinod  Kumar</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, Biological Evaluation and Molecular Modeling Studies of Propargyl-Containing 2,4,6-Trisubstituted Pyrimidine Derivatives as Potential Anti-Parkinson Agents. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2018,</strong> <em>13 </em>
                                    (7)
                                     , 705-712. <a href="https://doi.org/10.1002/cmdc.201700589" title="DOI URL">https://doi.org/10.1002/cmdc.201700589</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201700589&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201700589%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DSynthesis%25252C%252BBiological%252BEvaluation%252Band%252BMolecular%252BModeling%252BStudies%252Bof%252BPropargyl-Containing%252B2%25252C4%25252C6-Trisubstituted%252BPyrimidine%252BDerivatives%252Bas%252BPotential%252BAnti-Parkinson%252BAgents%26aulast%3DKumar%26aufirst%3DBhupinder%26date%3D2018%26date%3D2018%26volume%3D13%26issue%3D7%26spage%3D705%26epage%3D712" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Furqan Ahmad  Saddique</span>, <span class="hlFld-ContribAuthor ">Sumera  Zaib</span>, <span class="hlFld-ContribAuthor ">Saquib  Jalil</span>, <span class="hlFld-ContribAuthor ">Sana  Aslam</span>, <span class="hlFld-ContribAuthor ">Matloob  Ahmad</span>, <span class="hlFld-ContribAuthor ">Sadia  Sultan</span>, <span class="hlFld-ContribAuthor ">Humera  Naz</span>, <span class="hlFld-ContribAuthor ">Mazhar  Iqbal</span>, <span class="hlFld-ContribAuthor ">Jamshed  Iqbal</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, monoamine oxidase inhibition activity and molecular docking studies of novel 4-hydroxy-N′-[benzylidene or 1-phenylethylidene]-2-H/methyl/benzyl-1,2-benzothiazine-3-carbohydrazide 1,1-dioxides. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>143 </em>, 1373-1386. <a href="https://doi.org/10.1016/j.ejmech.2017.10.036" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.10.036</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.10.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.10.036%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%25252C%252Bmonoamine%252Boxidase%252Binhibition%252Bactivity%252Band%252Bmolecular%252Bdocking%252Bstudies%252Bof%252Bnovel%252B4-hydroxy-N%2525E2%252580%2525B2-%25255Bbenzylidene%252Bor%252B1-phenylethylidene%25255D-2-H%25252Fmethyl%25252Fbenzyl-1%25252C2-benzothiazine-3-carbohydrazide%252B1%25252C1-dioxides%26aulast%3DSaddique%26aufirst%3DFurqan%2BAhmad%26date%3D2018%26volume%3D143%26spage%3D1373%26epage%3D1386" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ben  Niu</span>, <span class="hlFld-ContribAuthor ">Bo  Jiang</span>, <span class="hlFld-ContribAuthor ">Liu-Zhu  Yu</span>, <span class="hlFld-ContribAuthor ">Min  Shi</span>. </span><span class="cited-content_cbyCitation_article-title">Base-promoted [3 + 3] cyclization of cyclopropenones and cyclopropenethiones with amides for the synthesis of 6
              H
              -1,3-oxazin-6-ones and 6
              H
              -1,3-thiazin-6-ones. </span><span class="cited-content_cbyCitation_journal-name">Organic Chemistry Frontiers</span><span> <strong>2018,</strong> <em>5 </em>
                                    (8)
                                     , 1267-1271. <a href="https://doi.org/10.1039/C8QO00091C" title="DOI URL">https://doi.org/10.1039/C8QO00091C</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8QO00091C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8QO00091C%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Chemistry%2520Frontiers%26atitle%3DBase-promoted%252B%25255B3%252B%25252B%252B3%25255D%252Bcyclization%252Bof%252Bcyclopropenones%252Band%252Bcyclopropenethiones%252Bwith%252Bamides%252Bfor%252Bthe%252Bsynthesis%252Bof%252B6%252BH%252B-1%25252C3-oxazin-6-ones%252Band%252B6%252BH%252B-1%25252C3-thiazin-6-ones%26aulast%3DNiu%26aufirst%3DBen%26date%3D2018%26date%3D2018%26volume%3D5%26issue%3D8%26spage%3D1267%26epage%3D1271" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhi-Wen  Zhou</span>, <span class="hlFld-ContribAuthor ">Feng-Cheng  Jia</span>, <span class="hlFld-ContribAuthor ">Cheng  Xu</span>, <span class="hlFld-ContribAuthor ">Shi-Fen  Jiang</span>, <span class="hlFld-ContribAuthor ">Yan-Dong  Wu</span>, <span class="hlFld-ContribAuthor ">An-Xin  Wu</span>. </span><span class="cited-content_cbyCitation_article-title">Temperature-Controlled Base-Promoted Cyclization for the Synthesis of 2-Amino-4
              H
              -benzo[
              d
              ][1,3]thiazin-4-ones and 2-Thioxo-4(3
              H
              )-quinazolinones. </span><span class="cited-content_cbyCitation_journal-name">Asian Journal of Organic Chemistry</span><span> <strong>2017,</strong> <em>6 </em>
                                    (12)
                                     , 1773-1777. <a href="https://doi.org/10.1002/ajoc.201700443" title="DOI URL">https://doi.org/10.1002/ajoc.201700443</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ajoc.201700443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fajoc.201700443%26sid%3Dliteratum%253Aachs%26jtitle%3DAsian%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DTemperature-Controlled%252BBase-Promoted%252BCyclization%252Bfor%252Bthe%252BSynthesis%252Bof%252B2-Amino-4%252BH%252B-benzo%25255B%252Bd%252B%25255D%25255B1%25252C3%25255Dthiazin-4-ones%252Band%252B2-Thioxo-4%2525283%252BH%252B%252529-quinazolinones%26aulast%3DZhou%26aufirst%3DZhi-Wen%26date%3D2017%26date%3D2017%26volume%3D6%26issue%3D12%26spage%3D1773%26epage%3D1777" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Syed Mobasher Ali  Abid</span>, <span class="hlFld-ContribAuthor ">Hafiza Amna  Younus</span>, <span class="hlFld-ContribAuthor ">Mariya  Al-Rashida</span>, <span class="hlFld-ContribAuthor ">Zunaira  Arshad</span>, <span class="hlFld-ContribAuthor ">Tooba  Maryum</span>, <span class="hlFld-ContribAuthor ">Mazhar Amjad  Gilani</span>, <span class="hlFld-ContribAuthor ">Abdulrahman I.  Alharthi</span>, <span class="hlFld-ContribAuthor ">Jamshed  Iqbal</span>. </span><span class="cited-content_cbyCitation_article-title">Sulfonyl hydrazones derived from 3-formylchromone as non-selective inhibitors of MAO-A and MAO-B: Synthesis, molecular modelling and in-silico ADME evaluation. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2017,</strong> <em>75 </em>, 291-302. <a href="https://doi.org/10.1016/j.bioorg.2017.10.001" title="DOI URL">https://doi.org/10.1016/j.bioorg.2017.10.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2017.10.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2017.10.001%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DSulfonyl%252Bhydrazones%252Bderived%252Bfrom%252B3-formylchromone%252Bas%252Bnon-selective%252Binhibitors%252Bof%252BMAO-A%252Band%252BMAO-B%25253A%252BSynthesis%25252C%252Bmolecular%252Bmodelling%252Band%252Bin-silico%252BADME%252Bevaluation%26aulast%3DAbid%26aufirst%3DSyed%2BMobasher%2BAli%26date%3D2017%26volume%3D75%26spage%3D291%26epage%3D302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Naeem  Abbas</span>, <span class="hlFld-ContribAuthor ">Sumera  Zaib</span>, <span class="hlFld-ContribAuthor ">Syeda Mahwish  Bakht</span>, <span class="hlFld-ContribAuthor ">Aliya  Ibrar</span>, <span class="hlFld-ContribAuthor ">Imtiaz  Khan</span>, <span class="hlFld-ContribAuthor ">Sadaf  Batool</span>, <span class="hlFld-ContribAuthor ">Aamer  Saeed</span>, <span class="hlFld-ContribAuthor ">Jamshed  Iqbal</span>. </span><span class="cited-content_cbyCitation_article-title">Symmetrical aryl linked bis-iminothiazolidinones as new chemical entities for the inhibition of monoamine oxidases: Synthesis, in vitro biological evaluation and molecular modelling analysis. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2017,</strong> <em>70 </em>, 17-26. <a href="https://doi.org/10.1016/j.bioorg.2016.11.004" title="DOI URL">https://doi.org/10.1016/j.bioorg.2016.11.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2016.11.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2016.11.004%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DSymmetrical%252Baryl%252Blinked%252Bbis-iminothiazolidinones%252Bas%252Bnew%252Bchemical%252Bentities%252Bfor%252Bthe%252Binhibition%252Bof%252Bmonoamine%252Boxidases%25253A%252BSynthesis%25252C%252Bin%252Bvitro%252Bbiological%252Bevaluation%252Band%252Bmolecular%252Bmodelling%252Banalysis%26aulast%3DAbbas%26aufirst%3DNaeem%26date%3D2017%26volume%3D70%26spage%3D17%26epage%3D26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dominik  Dolles</span>, <span class="hlFld-ContribAuthor ">Michael  Decker</span>. </span><span class="cited-content_cbyCitation_article-title">Dual-Acting Compounds Acting as Receptor Ligands and Enzyme Inhibitors. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 137-165. <a href="https://doi.org/10.1016/B978-0-08-101011-2.00005-2" title="DOI URL">https://doi.org/10.1016/B978-0-08-101011-2.00005-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-08-101011-2.00005-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-08-101011-2.00005-2%26sid%3Dliteratum%253Aachs%26atitle%3DDual-Acting%252BCompounds%252BActing%252Bas%252BReceptor%252BLigands%252Band%252BEnzyme%252BInhibitors%26aulast%3DDolles%26aufirst%3DDominik%26date%3D2017%26spage%3D137%26epage%3D165%26pub%3DElsevier%26atitle%3DDesign%252Bof%252BHybrid%252BMolecules%252Bfor%252BDrug%252BDevelopment%26date%3D2017%26volume%3D21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Syed Mobasher Ali  Abid</span>, <span class="hlFld-ContribAuthor ">Sana  Aslam</span>, <span class="hlFld-ContribAuthor ">Sumera  Zaib</span>, <span class="hlFld-ContribAuthor ">Syeda Mahwish  Bakht</span>, <span class="hlFld-ContribAuthor ">Matloob  Ahmad</span>, <span class="hlFld-ContribAuthor ">Muhammad Makshoof  Athar</span>, <span class="hlFld-ContribAuthor ">John M.  Gardiner</span>, <span class="hlFld-ContribAuthor ">Jamshed  Iqbal</span>. </span><span class="cited-content_cbyCitation_article-title">Pyrazolobenzothiazine-based carbothioamides as new structural leads for the inhibition of monoamine oxidases: design, synthesis, in vitro bioevaluation and molecular docking studies. </span><span class="cited-content_cbyCitation_journal-name">MedChemComm</span><span> <strong>2017,</strong> <em>8 </em>
                                    (2)
                                     , 452-464. <a href="https://doi.org/10.1039/C6MD00570E" title="DOI URL">https://doi.org/10.1039/C6MD00570E</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C6MD00570E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC6MD00570E%26sid%3Dliteratum%253Aachs%26jtitle%3DMedChemComm%26atitle%3DPyrazolobenzothiazine-based%252Bcarbothioamides%252Bas%252Bnew%252Bstructural%252Bleads%252Bfor%252Bthe%252Binhibition%252Bof%252Bmonoamine%252Boxidases%25253A%252Bdesign%25252C%252Bsynthesis%25252C%252Bin%252Bvitro%252Bbioevaluation%252Band%252Bmolecular%252Bdocking%252Bstudies%26aulast%3DAbid%26aufirst%3DSyed%2BMobasher%2BAli%26date%3D2017%26date%3D2017%26volume%3D8%26issue%3D2%26spage%3D452%26epage%3D464" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jidan  Liu</span>, <span class="hlFld-ContribAuthor ">Zixi  Xue</span>, <span class="hlFld-ContribAuthor ">Zhizhao  Zeng</span>, <span class="hlFld-ContribAuthor ">Yi-xin  Chen</span>, <span class="hlFld-ContribAuthor ">Guoshu  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Copper-Mediated Tandem C(
              sp
              2
              )-H Sulfenylation and Annulation of Arenes with 2-Mercaptoimidazoles: Regio- and Site-selective Access to Polycyclic Fused Imidazo[2,1-
              b
              ][1,3]thiazinones. </span><span class="cited-content_cbyCitation_journal-name">Advanced Synthesis & Catalysis</span><span> <strong>2016,</strong> <em>358 </em>
                                    (23)
                                     , 3694-3699. <a href="https://doi.org/10.1002/adsc.201600775" title="DOI URL">https://doi.org/10.1002/adsc.201600775</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/adsc.201600775&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fadsc.201600775%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Synthesis%2520%2526%2520Catalysis%26atitle%3DCopper-Mediated%252BTandem%252BC%252528%252Bsp%252B2%252B%252529-H%252BSulfenylation%252Band%252BAnnulation%252Bof%252BArenes%252Bwith%252B2-Mercaptoimidazoles%25253A%252BRegio-%252Band%252BSite-selective%252BAccess%252Bto%252BPolycyclic%252BFused%252BImidazo%25255B2%25252C1-%252Bb%252B%25255D%25255B1%25252C3%25255Dthiazinones%26aulast%3DLiu%26aufirst%3DJidan%26date%3D2016%26date%3D2016%26volume%3D358%26issue%3D23%26spage%3D3694%26epage%3D3699" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andreas  Brunschweiger</span>, <span class="hlFld-ContribAuthor ">Pierre  Koch</span>, <span class="hlFld-ContribAuthor ">Miriam  Schlenk</span>, <span class="hlFld-ContribAuthor ">Muhammad  Rafehi</span>, <span class="hlFld-ContribAuthor ">Hamid  Radjainia</span>, <span class="hlFld-ContribAuthor ">Petra  Küppers</span>, <span class="hlFld-ContribAuthor ">Sonja  Hinz</span>, <span class="hlFld-ContribAuthor ">Felipe  Pineda</span>, <span class="hlFld-ContribAuthor ">Michael  Wiese</span>, <span class="hlFld-ContribAuthor ">Jörg  Hockemeyer</span>, <span class="hlFld-ContribAuthor ">Jag  Heer</span>, <span class="hlFld-ContribAuthor ">Frédéric  Denonne</span>, <span class="hlFld-ContribAuthor ">Christa E.  Müller</span>. </span><span class="cited-content_cbyCitation_article-title">8-Substituted 1,3-dimethyltetrahydropyrazino[2,1- f ]purinediones: Water-soluble adenosine receptor antagonists and monoamine oxidase B inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2016,</strong> <em>24 </em>
                                    (21)
                                     , 5462-5480. <a href="https://doi.org/10.1016/j.bmc.2016.09.003" title="DOI URL">https://doi.org/10.1016/j.bmc.2016.09.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2016.09.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2016.09.003%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3D8-Substituted%252B1%25252C3-dimethyltetrahydropyrazino%25255B2%25252C1-%252Bf%252B%25255Dpurinediones%25253A%252BWater-soluble%252Badenosine%252Breceptor%252Bantagonists%252Band%252Bmonoamine%252Boxidase%252BB%252Binhibitors%26aulast%3DBrunschweiger%26aufirst%3DAndreas%26date%3D2016%26volume%3D24%26issue%3D21%26spage%3D5462%26epage%3D5480" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rona R.  Ramsay</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular aspects of monoamine oxidase B. </span><span class="cited-content_cbyCitation_journal-name">Progress in Neuro-Psychopharmacology and Biological Psychiatry</span><span> <strong>2016,</strong> <em>69 </em>, 81-89. <a href="https://doi.org/10.1016/j.pnpbp.2016.02.005" title="DOI URL">https://doi.org/10.1016/j.pnpbp.2016.02.005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.pnpbp.2016.02.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.pnpbp.2016.02.005%26sid%3Dliteratum%253Aachs%26jtitle%3DProgress%2520in%2520Neuro-Psychopharmacology%2520and%2520Biological%2520Psychiatry%26atitle%3DMolecular%252Baspects%252Bof%252Bmonoamine%252Boxidase%252BB%26aulast%3DRamsay%26aufirst%3DRona%2BR.%26date%3D2016%26volume%3D69%26spage%3D81%26epage%3D89" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dominik  Dolles</span>, <span class="hlFld-ContribAuthor ">Martin  Nimczick</span>, <span class="hlFld-ContribAuthor ">Matthias  Scheiner</span>, <span class="hlFld-ContribAuthor ">Jacqueline  Ramler</span>, <span class="hlFld-ContribAuthor ">Patricia  Stadtmüller</span>, <span class="hlFld-ContribAuthor ">Edgar  Sawatzky</span>, <span class="hlFld-ContribAuthor ">Antonios  Drakopoulos</span>, <span class="hlFld-ContribAuthor ">Christoph  Sotriffer</span>, <span class="hlFld-ContribAuthor ">Hans-Joachim  Wittmann</span>, <span class="hlFld-ContribAuthor ">Andrea  Strasser</span>, <span class="hlFld-ContribAuthor ">Michael  Decker</span>. </span><span class="cited-content_cbyCitation_article-title">Aminobenzimidazoles and Structural Isomers as Templates for Dual-Acting Butyrylcholinesterase Inhibitors and
              h
              CB
              2
              R Ligands To Combat Neurodegenerative Disorders. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2016,</strong> <em>11 </em>
                                    (12)
                                     , 1270-1283. <a href="https://doi.org/10.1002/cmdc.201500418" title="DOI URL">https://doi.org/10.1002/cmdc.201500418</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201500418&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201500418%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DAminobenzimidazoles%252Band%252BStructural%252BIsomers%252Bas%252BTemplates%252Bfor%252BDual-Acting%252BButyrylcholinesterase%252BInhibitors%252Band%252Bh%252BCB%252B2%252BR%252BLigands%252BTo%252BCombat%252BNeurodegenerative%252BDisorders%26aulast%3DDolles%26aufirst%3DDominik%26date%3D2016%26date%3D2015%26volume%3D11%26issue%3D12%26spage%3D1270%26epage%3D1283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gemma  Navarro</span>, <span class="hlFld-ContribAuthor ">Dasiel O.  Borroto-Escuela</span>, <span class="hlFld-ContribAuthor ">Kjell  Fuxe</span>, <span class="hlFld-ContribAuthor ">Rafael  Franco</span>. </span><span class="cited-content_cbyCitation_article-title">Purinergic signaling in Parkinson's disease. Relevance for treatment. </span><span class="cited-content_cbyCitation_journal-name">Neuropharmacology</span><span> <strong>2016,</strong> <em>104 </em>, 161-168. <a href="https://doi.org/10.1016/j.neuropharm.2015.07.024" title="DOI URL">https://doi.org/10.1016/j.neuropharm.2015.07.024</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.neuropharm.2015.07.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.neuropharm.2015.07.024%26sid%3Dliteratum%253Aachs%26jtitle%3DNeuropharmacology%26atitle%3DPurinergic%252Bsignaling%252Bin%252BParkinson%252527s%252Bdisease.%252BRelevance%252Bfor%252Btreatment%26aulast%3DNavarro%26aufirst%3DGemma%26date%3D2016%26volume%3D104%26spage%3D161%26epage%3D168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">S. S.  Bhayye</span>, <span class="hlFld-ContribAuthor ">K.  Roy</span>, <span class="hlFld-ContribAuthor ">A.  Saha</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmacophore generation, atom-based 3D-QSAR, HQSAR and activity cliff analyses of benzothiazine and deazaxanthine derivatives as dual A
              2A
              antagonists/MAO‑B inhibitors. </span><span class="cited-content_cbyCitation_journal-name">SAR and QSAR in Environmental Research</span><span> <strong>2016,</strong> <em>27 </em>
                                    (3)
                                     , 183-202. <a href="https://doi.org/10.1080/1062936X.2015.1136840" title="DOI URL">https://doi.org/10.1080/1062936X.2015.1136840</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/1062936X.2015.1136840&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F1062936X.2015.1136840%26sid%3Dliteratum%253Aachs%26jtitle%3DSAR%2520and%2520QSAR%2520in%2520Environmental%2520Research%26atitle%3DPharmacophore%252Bgeneration%25252C%252Batom-based%252B3D-QSAR%25252C%252BHQSAR%252Band%252Bactivity%252Bcliff%252Banalyses%252Bof%252Bbenzothiazine%252Band%252Bdeazaxanthine%252Bderivatives%252Bas%252Bdual%252BA%252B2A%252Bantagonists%25252FMAO%2525E2%252580%252591B%252Binhibitors%26aulast%3DBhayye%26aufirst%3DS.%2BS.%26date%3D2016%26date%3D2016%26volume%3D27%26issue%3D3%26spage%3D183%26epage%3D202" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Małgorzata  Juszczak</span>, <span class="hlFld-ContribAuthor ">Katarzyna  Walczak</span>, <span class="hlFld-ContribAuthor ">Joanna  Matysiak</span>, <span class="hlFld-ContribAuthor ">Marta K.  Lemieszek</span>, <span class="hlFld-ContribAuthor ">Ewa  Langner</span>, <span class="hlFld-ContribAuthor ">Monika M.  Karpińska</span>, <span class="hlFld-ContribAuthor ">Piotr  Pożarowski</span>, <span class="hlFld-ContribAuthor ">Andrzej  Niewiadomy</span>, <span class="hlFld-ContribAuthor ">Wojciech  Rzeski</span>. </span><span class="cited-content_cbyCitation_article-title">New derivative of 2-(2,4-dihydroxyphenyl)thieno-1,3-thiazin-4-one (BChTT) elicits antiproliferative effect via p38-mediated cell cycle arrest in cancer cells. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2016,</strong> <em>24 </em>
                                    (6)
                                     , 1356-1361. <a href="https://doi.org/10.1016/j.bmc.2016.02.009" title="DOI URL">https://doi.org/10.1016/j.bmc.2016.02.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2016.02.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2016.02.009%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DNew%252Bderivative%252Bof%252B2-%2525282%25252C4-dihydroxyphenyl%252529thieno-1%25252C3-thiazin-4-one%252B%252528BChTT%252529%252Belicits%252Bantiproliferative%252Beffect%252Bvia%252Bp38-mediated%252Bcell%252Bcycle%252Barrest%252Bin%252Bcancer%252Bcells%26aulast%3DJuszczak%26aufirst%3DMa%25C5%2582gorzata%26date%3D2016%26volume%3D24%26issue%3D6%26spage%3D1356%26epage%3D1361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Polya  Roydeva</span>, <span class="hlFld-ContribAuthor ">Anna-Madeleine  Beckmann</span>, <span class="hlFld-ContribAuthor ">Marit  Stirnberg</span>, <span class="hlFld-ContribAuthor ">Jožko  Cesar</span>, <span class="hlFld-ContribAuthor ">Danijel  Kikelj</span>, <span class="hlFld-ContribAuthor ">Janez  Ilaš</span>, <span class="hlFld-ContribAuthor ">Michael  Gütschow</span>. </span><span class="cited-content_cbyCitation_article-title">3,1-Benzothiazines, 1,4-Benzodioxines and 1,4-Benzoxazines as Inhibitors of Matriptase-2: Outcome of a Focused Screening Approach. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceuticals</span><span> <strong>2016,</strong> <em>9 </em>
                                    (1)
                                     , 2. <a href="https://doi.org/10.3390/ph9010002" title="DOI URL">https://doi.org/10.3390/ph9010002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ph9010002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fph9010002%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceuticals%26atitle%3D3%25252C1-Benzothiazines%25252C%252B1%25252C4-Benzodioxines%252Band%252B1%25252C4-Benzoxazines%252Bas%252BInhibitors%252Bof%252BMatriptase-2%25253A%252BOutcome%252Bof%252Ba%252BFocused%252BScreening%252BApproach%26aulast%3DRoydeva%26aufirst%3DPolya%26date%3D2016%26date%3D2016%26volume%3D9%26issue%3D1%26spage%3D2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">D.  Chavarria</span>, <span class="hlFld-ContribAuthor ">T.  Silva</span>, <span class="hlFld-ContribAuthor ">D.  Magalhães e Silva</span>, <span class="hlFld-ContribAuthor ">F.  Remião</span>, <span class="hlFld-ContribAuthor ">F.  Borges</span>. </span><span class="cited-content_cbyCitation_article-title">Lessons from black pepper: piperine and derivatives thereof. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2016,</strong> <em>26 </em>
                                    (2)
                                     , 245-264. <a href="https://doi.org/10.1517/13543776.2016.1118057" title="DOI URL">https://doi.org/10.1517/13543776.2016.1118057</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1517/13543776.2016.1118057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1517%2F13543776.2016.1118057%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DLessons%252Bfrom%252Bblack%252Bpepper%25253A%252Bpiperine%252Band%252Bderivatives%252Bthereof%26aulast%3DChavarria%26aufirst%3DD.%26date%3D2016%26date%3D2015%26volume%3D26%26issue%3D2%26spage%3D245%26epage%3D264" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christian  Steinebach</span>, <span class="hlFld-ContribAuthor ">Anna-Christina  Schulz-Fincke</span>, <span class="hlFld-ContribAuthor ">Gregor  Schnakenburg</span>, <span class="hlFld-ContribAuthor ">Michael  Gütschow</span>. </span><span class="cited-content_cbyCitation_article-title">In situ generation and trapping of thioimidates: an intermolecular tandem reaction to 4-acylimino-4H-3,1-benzothiazines. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2016,</strong> <em>6 </em>
                                    (19)
                                     , 15430-15440. <a href="https://doi.org/10.1039/C6RA00196C" title="DOI URL">https://doi.org/10.1039/C6RA00196C</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C6RA00196C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC6RA00196C%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DIn%252Bsitu%252Bgeneration%252Band%252Btrapping%252Bof%252Bthioimidates%25253A%252Ban%252Bintermolecular%252Btandem%252Breaction%252Bto%252B4-acylimino-4H-3%25252C1-benzothiazines%26aulast%3DSteinebach%26aufirst%3DChristian%26date%3D2016%26date%3D2016%26volume%3D6%26issue%3D19%26spage%3D15430%26epage%3D15440" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bhupinder  Kumar</span>, <span class="hlFld-ContribAuthor ">Sheetal  Sheetal</span>, <span class="hlFld-ContribAuthor ">Anil K.  Mantha</span>, <span class="hlFld-ContribAuthor ">Vinod  Kumar</span>. </span><span class="cited-content_cbyCitation_article-title">Recent developments on the structure–activity relationship studies of MAO inhibitors and their role in different neurological disorders. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2016,</strong> <em>6 </em>
                                    (48)
                                     , 42660-42683. <a href="https://doi.org/10.1039/C6RA00302H" title="DOI URL">https://doi.org/10.1039/C6RA00302H</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C6RA00302H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC6RA00302H%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DRecent%252Bdevelopments%252Bon%252Bthe%252Bstructure%2525E2%252580%252593activity%252Brelationship%252Bstudies%252Bof%252BMAO%252Binhibitors%252Band%252Btheir%252Brole%252Bin%252Bdifferent%252Bneurological%252Bdisorders%26aulast%3DKumar%26aufirst%3DBhupinder%26date%3D2016%26date%3D2016%26volume%3D6%26issue%3D48%26spage%3D42660%26epage%3D42683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Guozheng  Huang</span>, <span class="hlFld-ContribAuthor ">Martin  Nimczick</span>, <span class="hlFld-ContribAuthor ">Michael  Decker</span>. </span><span class="cited-content_cbyCitation_article-title">Rational Modification of the Biological Profile of GPCR Ligands through Combination with Other Biologically Active Moieties. </span><span class="cited-content_cbyCitation_journal-name">Archiv der Pharmazie</span><span> <strong>2015,</strong> <em>348 </em>
                                    (8)
                                     , 531-540. <a href="https://doi.org/10.1002/ardp.201500079" title="DOI URL">https://doi.org/10.1002/ardp.201500079</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ardp.201500079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fardp.201500079%26sid%3Dliteratum%253Aachs%26jtitle%3DArchiv%2520der%2520Pharmazie%26atitle%3DRational%252BModification%252Bof%252Bthe%252BBiological%252BProfile%252Bof%252BGPCR%252BLigands%252Bthrough%252BCombination%252Bwith%252BOther%252BBiologically%252BActive%252BMoieties%26aulast%3DHuang%26aufirst%3DGuozheng%26date%3D2015%26date%3D2015%26volume%3D348%26issue%3D8%26spage%3D531%26epage%3D540" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Delia  Preti</span>, <span class="hlFld-ContribAuthor ">Pier Giovanni  Baraldi</span>, <span class="hlFld-ContribAuthor ">Allan R.  Moorman</span>, <span class="hlFld-ContribAuthor ">Pier Andrea  Borea</span>, <span class="hlFld-ContribAuthor ">Katia  Varani</span>. </span><span class="cited-content_cbyCitation_article-title">History and Perspectives of A
              2A
              Adenosine Receptor Antagonists as Potential Therapeutic Agents. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2015,</strong> <em>35 </em>
                                    (4)
                                     , 790-848. <a href="https://doi.org/10.1002/med.21344" title="DOI URL">https://doi.org/10.1002/med.21344</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21344&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21344%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DHistory%252Band%252BPerspectives%252Bof%252BA%252B2A%252BAdenosine%252BReceptor%252BAntagonists%252Bas%252BPotential%252BTherapeutic%252BAgents%26aulast%3DPreti%26aufirst%3DDelia%26date%3D2015%26date%3D2015%26volume%3D35%26issue%3D4%26spage%3D790%26epage%3D848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mietha M.  Van der Walt</span>, <span class="hlFld-ContribAuthor ">Gisella  Terre’Blanche</span>, <span class="hlFld-ContribAuthor ">Anél  Petzer</span>, <span class="hlFld-ContribAuthor ">Jacobus P.  Petzer</span>. </span><span class="cited-content_cbyCitation_article-title">The adenosine receptor affinities and monoamine oxidase B inhibitory properties of sulfanylphthalimide analogues. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2015,</strong> <em>59 </em>, 117-123. <a href="https://doi.org/10.1016/j.bioorg.2015.02.005" title="DOI URL">https://doi.org/10.1016/j.bioorg.2015.02.005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2015.02.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2015.02.005%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DThe%252Badenosine%252Breceptor%252Baffinities%252Band%252Bmonoamine%252Boxidase%252BB%252Binhibitory%252Bproperties%252Bof%252Bsulfanylphthalimide%252Banalogues%26aulast%3DVan%2Bder%2BWalt%26aufirst%3DMietha%2BM.%26date%3D2015%26volume%3D59%26spage%3D117%26epage%3D123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Katarina  Nikolic</span>, <span class="hlFld-ContribAuthor ">Lazaros  Mavridis</span>, <span class="hlFld-ContribAuthor ">Oscar M.  Bautista-Aguilera</span>, <span class="hlFld-ContribAuthor ">José  Marco-Contelles</span>, <span class="hlFld-ContribAuthor ">Holger  Stark</span>, <span class="hlFld-ContribAuthor ">Maria  do Carmo Carreiras</span>, <span class="hlFld-ContribAuthor ">Ilaria  Rossi</span>, <span class="hlFld-ContribAuthor ">Paola  Massarelli</span>, <span class="hlFld-ContribAuthor ">Danica  Agbaba</span>, <span class="hlFld-ContribAuthor ">Rona R.  Ramsay</span>, <span class="hlFld-ContribAuthor ">John B. O.  Mitchell</span>. </span><span class="cited-content_cbyCitation_article-title">Predicting targets of compounds against neurological diseases using cheminformatic methodology. </span><span class="cited-content_cbyCitation_journal-name">Journal of Computer-Aided Molecular Design</span><span> <strong>2015,</strong> <em>29 </em>
                                    (2)
                                     , 183-198. <a href="https://doi.org/10.1007/s10822-014-9816-1" title="DOI URL">https://doi.org/10.1007/s10822-014-9816-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10822-014-9816-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10822-014-9816-1%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Computer-Aided%2520Molecular%2520Design%26atitle%3DPredicting%252Btargets%252Bof%252Bcompounds%252Bagainst%252Bneurological%252Bdiseases%252Busing%252Bcheminformatic%252Bmethodology%26aulast%3DNikolic%26aufirst%3DKatarina%26date%3D2015%26date%3D2014%26volume%3D29%26issue%3D2%26spage%3D183%26epage%3D198" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christa E.  Müller</span>. </span><span class="cited-content_cbyCitation_article-title">Adenosine A2A Receptor Antagonists in Drug Development. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2015,</strong>,, 39-56. <a href="https://doi.org/10.1007/978-3-319-20273-0_3" title="DOI URL">https://doi.org/10.1007/978-3-319-20273-0_3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-319-20273-0_3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-319-20273-0_3%26sid%3Dliteratum%253Aachs%26atitle%3DAdenosine%252BA2A%252BReceptor%252BAntagonists%252Bin%252BDrug%252BDevelopment%26aulast%3DM%25C3%25BCller%26aufirst%3DChrista%2BE.%26date%3D2015%26date%3D2015%26spage%3D39%26epage%3D56%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DThe%252BAdenosinergic%252BSystem%26aulast%3DMorelli%26aufirst%3DMicaela%26date%3D2015%26volume%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Imtiaz  Khan</span>, <span class="hlFld-ContribAuthor ">Syeda Mahwish  Bakht</span>, <span class="hlFld-ContribAuthor ">Aliya  Ibrar</span>, <span class="hlFld-ContribAuthor ">Saba  Abbas</span>, <span class="hlFld-ContribAuthor ">Shahid  Hameed</span>, <span class="hlFld-ContribAuthor ">Jonathan M.  White</span>, <span class="hlFld-ContribAuthor ">Usman Ali  Rana</span>, <span class="hlFld-ContribAuthor ">Sumera  Zaib</span>, <span class="hlFld-ContribAuthor ">Mohammad  Shahid</span>, <span class="hlFld-ContribAuthor ">Jamshed  Iqbal</span>. </span><span class="cited-content_cbyCitation_article-title">Exploration of a library of triazolothiadiazole and triazolothiadiazine compounds as a highly potent and selective family of cholinesterase and monoamine oxidase inhibitors: design, synthesis, X-ray diffraction analysis and molecular docking studies. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2015,</strong> <em>5 </em>
                                    (27)
                                     , 21249-21267. <a href="https://doi.org/10.1039/C5RA00906E" title="DOI URL">https://doi.org/10.1039/C5RA00906E</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C5RA00906E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC5RA00906E%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DExploration%252Bof%252Ba%252Blibrary%252Bof%252Btriazolothiadiazole%252Band%252Btriazolothiadiazine%252Bcompounds%252Bas%252Ba%252Bhighly%252Bpotent%252Band%252Bselective%252Bfamily%252Bof%252Bcholinesterase%252Band%252Bmonoamine%252Boxidase%252Binhibitors%25253A%252Bdesign%25252C%252Bsynthesis%25252C%252BX-ray%252Bdiffraction%252Banalysis%252Band%252Bmolecular%252Bdocking%252Bstudies%26aulast%3DKhan%26aufirst%3DImtiaz%26date%3D2015%26date%3D2015%26volume%3D5%26issue%3D27%26spage%3D21249%26epage%3D21267" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andreas  Brunschweiger</span>, <span class="hlFld-ContribAuthor ">Pierre  Koch</span>, <span class="hlFld-ContribAuthor ">Miriam  Schlenk</span>, <span class="hlFld-ContribAuthor ">Felipe  Pineda</span>, <span class="hlFld-ContribAuthor ">Petra  Küppers</span>, <span class="hlFld-ContribAuthor ">Sonja  Hinz</span>, <span class="hlFld-ContribAuthor ">Meryem  Köse</span>, <span class="hlFld-ContribAuthor ">Stefan  Ullrich</span>, <span class="hlFld-ContribAuthor ">Jörg  Hockemeyer</span>, <span class="hlFld-ContribAuthor ">Michael  Wiese</span>, <span class="hlFld-ContribAuthor ">Jag  Heer</span>, <span class="hlFld-ContribAuthor ">Christa E.  Müller</span>. </span><span class="cited-content_cbyCitation_article-title">8-Benzyltetrahydropyrazino[2,1-
              f
              ]purinediones: Water-Soluble Tricyclic Xanthine Derivatives as Multitarget Drugs for Neurodegenerative Diseases. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2014,</strong> <em>53 </em>, n/a-n/a. <a href="https://doi.org/10.1002/cmdc.201402082" title="DOI URL">https://doi.org/10.1002/cmdc.201402082</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201402082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201402082%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3D8-Benzyltetrahydropyrazino%25255B2%25252C1-%252Bf%252B%25255Dpurinediones%25253A%252BWater-Soluble%252BTricyclic%252BXanthine%252BDerivatives%252Bas%252BMultitarget%252BDrugs%252Bfor%252BNeurodegenerative%252BDiseases%26aulast%3DBrunschweiger%26aufirst%3DAndreas%26date%3D2014%26date%3D2014%26volume%3D53%26spage%3Dn%252Fa%26epage%3Dn%252Fa" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sana  Aslam</span>, <span class="hlFld-ContribAuthor ">Sumera  Zaib</span>, <span class="hlFld-ContribAuthor ">Matloob  Ahmad</span>, <span class="hlFld-ContribAuthor ">John M.  Gardiner</span>, <span class="hlFld-ContribAuthor ">Aqeel  Ahmad</span>, <span class="hlFld-ContribAuthor ">Abdul  Hameed</span>, <span class="hlFld-ContribAuthor ">Norbert  Furtmann</span>, <span class="hlFld-ContribAuthor ">Michael  Gütschow</span>, <span class="hlFld-ContribAuthor ">Jürgen  Bajorath</span>, <span class="hlFld-ContribAuthor ">Jamshed  Iqbal</span>. </span><span class="cited-content_cbyCitation_article-title">Novel structural hybrids of pyrazolobenzothiazines with benzimidazoles as cholinesterase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>78 </em>, 106-117. <a href="https://doi.org/10.1016/j.ejmech.2014.03.035" title="DOI URL">https://doi.org/10.1016/j.ejmech.2014.03.035</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2014.03.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2014.03.035%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNovel%252Bstructural%252Bhybrids%252Bof%252Bpyrazolobenzothiazines%252Bwith%252Bbenzimidazoles%252Bas%252Bcholinesterase%252Binhibitors%26aulast%3DAslam%26aufirst%3DSana%26date%3D2014%26volume%3D78%26spage%3D106%26epage%3D117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kazuhiro  Kobayashi</span>, <span class="hlFld-ContribAuthor ">Kazuya  Yamane</span>, <span class="hlFld-ContribAuthor ">Ippei  Nozawa</span>, <span class="hlFld-ContribAuthor ">Kosuke  Ezaki</span>. </span><span class="cited-content_cbyCitation_article-title">One-Pot Synthesis of
              N
              ,
              N
              -Disubstituted (
              Z
              )-4-(Halomethylidene)-4
              H
              -3,1-benzothiazin-2-amines from 2-(2,2-Dihaloethenyl)phenyl Isothiocyanates and Secondary Amines. </span><span class="cited-content_cbyCitation_journal-name">Helvetica Chimica Acta</span><span> <strong>2014,</strong> <em>97 </em>
                                    (3)
                                     , 315-320. <a href="https://doi.org/10.1002/hlca.201300357" title="DOI URL">https://doi.org/10.1002/hlca.201300357</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/hlca.201300357&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fhlca.201300357%26sid%3Dliteratum%253Aachs%26jtitle%3DHelvetica%2520Chimica%2520Acta%26atitle%3DOne-Pot%252BSynthesis%252Bof%252BN%252B%25252C%252BN%252B-Disubstituted%252B%252528%252BZ%252B%252529-4-%252528Halomethylidene%252529-4%252BH%252B-3%25252C1-benzothiazin-2-amines%252Bfrom%252B2-%2525282%25252C2-Dihaloethenyl%252529phenyl%252BIsothiocyanates%252Band%252BSecondary%252BAmines%26aulast%3DKobayashi%26aufirst%3DKazuhiro%26date%3D2014%26date%3D2014%26volume%3D97%26issue%3D3%26spage%3D315%26epage%3D320" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Matthias D.  Mertens</span>, <span class="hlFld-ContribAuthor ">Sonja  Hinz</span>, <span class="hlFld-ContribAuthor ">Christa E.  Müller</span>, <span class="hlFld-ContribAuthor ">Michael  Gütschow</span>. </span><span class="cited-content_cbyCitation_article-title">Alkynyl–coumarinyl ethers as MAO-B inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2014,</strong> <em>22 </em>
                                    (6)
                                     , 1916-1928. <a href="https://doi.org/10.1016/j.bmc.2014.01.046" title="DOI URL">https://doi.org/10.1016/j.bmc.2014.01.046</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2014.01.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2014.01.046%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DAlkynyl%2525E2%252580%252593coumarinyl%252Bethers%252Bas%252BMAO-B%252Binhibitors%26aulast%3DMertens%26aufirst%3DMatthias%2BD.%26date%3D2014%26volume%3D22%26issue%3D6%26spage%3D1916%26epage%3D1928" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Brian C.  Shook</span>. </span><span class="cited-content_cbyCitation_article-title">Adenosine A2A Receptor Antagonists. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2014,</strong>,, 1-42. <a href="https://doi.org/10.1007/7355_2014_67" title="DOI URL">https://doi.org/10.1007/7355_2014_67</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/7355_2014_67&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F7355_2014_67%26sid%3Dliteratum%253Aachs%26atitle%3DAdenosine%252BA2A%252BReceptor%252BAntagonists%26aulast%3DShook%26aufirst%3DBrian%2BC.%26date%3D2014%26date%3D2014%26spage%3D1%26epage%3D42%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DNovel%252BTherapeutic%252BApproaches%252Bto%252Bthe%252BTreatment%252Bof%252BParkinson%2525E2%252580%252599s%252BDisease%26aulast%3DHopkins%26aufirst%3DCorey%2BR.%26date%3D2016%26volume%3D18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pierre  Koch</span>, <span class="hlFld-ContribAuthor ">Rhalid  Akkari</span>, <span class="hlFld-ContribAuthor ">Andreas  Brunschweiger</span>, <span class="hlFld-ContribAuthor ">Thomas  Borrmann</span>, <span class="hlFld-ContribAuthor ">Miriam  Schlenk</span>, <span class="hlFld-ContribAuthor ">Petra  Küppers</span>, <span class="hlFld-ContribAuthor ">Meryem  Köse</span>, <span class="hlFld-ContribAuthor ">Hamid  Radjainia</span>, <span class="hlFld-ContribAuthor ">Jörg  Hockemeyer</span>, <span class="hlFld-ContribAuthor ">Anna  Drabczyńska</span>, <span class="hlFld-ContribAuthor ">Katarzyna  Kieć-Kononowicz</span>, <span class="hlFld-ContribAuthor ">Christa E.  Müller</span>. </span><span class="cited-content_cbyCitation_article-title">1,3-Dialkyl-substituted tetrahydropyrimido[1,2-f]purine-2,4-diones as multiple target drugs for the potential treatment of neurodegenerative diseases. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2013,</strong> <em>21 </em>
                                    (23)
                                     , 7435-7452. <a href="https://doi.org/10.1016/j.bmc.2013.09.044" title="DOI URL">https://doi.org/10.1016/j.bmc.2013.09.044</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2013.09.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2013.09.044%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3D1%25252C3-Dialkyl-substituted%252Btetrahydropyrimido%25255B1%25252C2-f%25255Dpurine-2%25252C4-diones%252Bas%252Bmultiple%252Btarget%252Bdrugs%252Bfor%252Bthe%252Bpotential%252Btreatment%252Bof%252Bneurodegenerative%252Bdiseases%26aulast%3DKoch%26aufirst%3DPierre%26date%3D2013%26volume%3D21%26issue%3D23%26spage%3D7435%26epage%3D7452" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400336x/production/images/medium/jm-2013-00336x_0014.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400336x/production/images/large/jm-2013-00336x_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400336x&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400336x/production/images/medium/jm-2013-00336x_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400336x/production/images/large/jm-2013-00336x_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of selected A<sub>2A</sub> adenosine receptor antagonists (<b>1</b>–<b>5</b>) and MAO-B inhibitors (<b>6</b>,<b>7</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400336x/production/images/large/jm-2013-00336x_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400336x&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400336x/production/images/medium/jm-2013-00336x_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400336x/production/images/large/jm-2013-00336x_0006.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of 2-Acylaminobenzothiazinones <b>8</b>–<b>24</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400336x/production/images/large/jm-2013-00336x_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400336x&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) benzoyl isothiocyanate, acetone, RT, 20 min; (ii) 1. concd H<sub>2</sub>SO<sub>4</sub>, 100 °C, 4 h; 2. NaHCO<sub>3</sub>; (iii) 1. carboxylic acids <b>40</b> or <b>41</b> (residues R correspond to those of compounds <b>8</b>–<b>24</b>), <i>N</i>-methylmorpholine, 2,4,6-trichlorobenzoyl chloride, THF, RT, 1 h; 2. <b>39</b>, pyridine, toluene, reflux, 2 h.</p></p></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400336x/production/images/medium/jm-2013-00336x_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400336x/production/images/large/jm-2013-00336x_0007.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Phenylbutenoic Acids <b>40</b> and Phenylbutyric Acids <b>41</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400336x/production/images/large/jm-2013-00336x_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400336x&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) PPh<sub>3</sub>, acetonitrile, reflux, 5 h; (ii) 1. aldehyde <b>43</b>, <i>tert</i>-BuOK, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C → RT, 12 h; (iii) Pd/C, H<sub>2</sub>, EtOH or THF, RT, 1–2 h.</p></p></figure><figure data-id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400336x/production/images/medium/jm-2013-00336x_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400336x/production/images/large/jm-2013-00336x_0008.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of 2-Acylaminobenzothiazinones <b>26</b>–<b>28</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400336x/production/images/large/jm-2013-00336x_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400336x&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) 1. 4-formylbenzoic acid, (COCl)<sub>2</sub>, DMF (cat), CH<sub>2</sub>Cl<sub>2</sub>, RT, 2 h; 2. pyridine, CH<sub>2</sub>Cl<sub>2</sub>, reflux, 2 h; (ii) oxone, DMF, RT, 12 h; (iii) 1. 1,1′-carbonyldiimidazole, DMF, RT, 1 h; 2. piperazine <b>45</b> (1.25 equiv), imidazole (1.0 equiv), HCl (2.0 equiv), DMF, RT, 2 h.</p></p></figure><figure data-id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400336x/production/images/medium/jm-2013-00336x_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400336x/production/images/large/jm-2013-00336x_0009.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of <i>N</i>-Methylated 2-Acylaminobenzothiazinone <b>29</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400336x/production/images/large/jm-2013-00336x_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400336x&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) 1. CH<sub>3</sub>I, THF, 0 °C; 2. NaH, RT, 24 h.</p></p></figure><figure data-id="sch5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400336x/production/images/medium/jm-2013-00336x_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400336x/production/images/large/jm-2013-00336x_0010.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Substituted 2-Acylaminobenzothiazinones <b>30</b>–<b>33</b> and 2-Acylaminothienothiazinone <b>34</b>–<b>36</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400336x/production/images/large/jm-2013-00336x_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400336x&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) benzoyl isothiocyanate, acetone, RT, 20 min; (ii) 1. concd H<sub>2</sub>SO<sub>4</sub>, 100 °C, 4 h; 2. NaHCO<sub>3</sub>; (iii) 1. 4-phenylbutyric acid, <i>N</i>-methylmorpholine, 2,4,6-trichlorobenzoyl chloride, THF, RT; 2. amine <b>48</b> or <b>49</b>, pyridine, toluene, reflux, 2 h.</p></p></figure><figure data-id="fig2" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400336x/production/images/medium/jm-2013-00336x_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400336x/production/images/large/jm-2013-00336x_0003.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. cAMP accumulation experiments in CHO cells stably transfected with the human A<sub>2A</sub>AR. The nonselective AR agonist NECA (0.1 and 1 μM) showed a concentration-dependent stimulation of cAMP formation. Benzothiazinone <b>17</b> did not show an effect by itself but inhibited NECA-induced cAMP accumulation. Graph bars represent results from three independent experiments ± SEM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400336x/production/images/large/jm-2013-00336x_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400336x&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400336x/production/images/medium/jm-2013-00336x_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400336x/production/images/large/jm-2013-00336x_0004.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Reactivation of MAO-B. Human MAO-B was treated under assay conditions with several inhibitors (each at the concentration that represents its IC<sub>80</sub> value) in the presence of the substrate <i>p</i>-tyramine. After 22 min, the substrate concentration was increased from 150 μM to 1 mM, and fluorescence was measured over a period of 5 h.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400336x/production/images/large/jm-2013-00336x_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400336x&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400336x/production/images/medium/jm-2013-00336x_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400336x/production/images/large/jm-2013-00336x_0005.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Lineweaver–Burk plot of the inhibition of human MAO-B in the presence of different concentrations of benzothiazinone <b>17</b> (0, 50, 100, and 300 nM) with <i>p</i>-tyramine (0.05, 0.1, 0.5, 1.0, 1.5, and 3.0 mM) as substrate. The reciprocal MAO-B activity was plotted against the reciprocal substrate concentration (<i>n</i> = 2).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-11/jm400336x/production/images/large/jm-2013-00336x_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400336x&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i76">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_75644" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_75644" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 46 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Samii, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nutt, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ransom, B. R.</span><span> </span><span class="NLM_article-title">Parkinson’s disease</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">363</span><span class="NLM_x">, </span> <span class="NLM_fpage">1783</span><span class="NLM_x">–</span> <span class="NLM_lpage">1793</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2004&pages=1783-1793&author=A.+Samiiauthor=J.+G.+Nuttauthor=B.+R.+Ransom&title=Parkinson%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSamii%26aufirst%3DA.%26aulast%3DNutt%26aufirst%3DJ.%2BG.%26aulast%3DRansom%26aufirst%3DB.%2BR.%26atitle%3DParkinson%25E2%2580%2599s%2520disease%26jtitle%3DLancet%26date%3D2004%26volume%3D363%26spage%3D1783%26epage%3D1793" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit1b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Schwarzschild, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agnati, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuxe, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morelli, M.</span><span> </span><span class="NLM_article-title">Targeting adenosine A<sub>2A</sub> receptors in Parkinson’s disease</span> <span class="citation_source-journal">Trends Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">647</span><span class="NLM_x">–</span> <span class="NLM_lpage">654</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2006&pages=647-654&author=M.+A.+Schwarzschildauthor=L.+Agnatiauthor=K.+Fuxeauthor=J.+F.+Chenauthor=M.+Morelli&title=Targeting+adenosine+A2A+receptors+in+Parkinson%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchwarzschild%26aufirst%3DM.%2BA.%26aulast%3DAgnati%26aufirst%3DL.%26aulast%3DFuxe%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DJ.%2BF.%26aulast%3DMorelli%26aufirst%3DM.%26atitle%3DTargeting%2520adenosine%2520A2A%2520receptors%2520in%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DTrends%2520Neurosci.%26date%3D2006%26volume%3D29%26spage%3D647%26epage%3D654" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Allain, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bentué-Ferre, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akwa, Y.</span><span> </span><span class="NLM_article-title">Disease-modifying drugs and Parkinson’s disease</span> <span class="citation_source-journal">Prog. Neurobiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">84</span><span class="NLM_x">, </span> <span class="NLM_fpage">25</span><span class="NLM_x">–</span> <span class="NLM_lpage">39</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm400336x&amp;key=10.1016%2Fj.pneurobio.2007.10.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm400336x&amp;key=18037225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm400336x&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVOrtb7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2008&pages=25-39&author=H.+Allainauthor=D.+Bentu%C3%A9-Ferreauthor=Y.+Akwa&title=Disease-modifying+drugs+and+Parkinson%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Disease-modifying drugs and Parkinson's disease</span></div><div class="casAuthors">Allain, Herve; Bentue-Ferrer, Daniele; Akwa, Yvette</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Neurobiology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25-39</span>CODEN:
                <span class="NLM_cas:coden">PGNBA5</span>;
        ISSN:<span class="NLM_cas:issn">0301-0082</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Symptomatic medications, L-Dopa and dopaminergic agents, remain the only clin. pertinent pharmacol. treatment proven effective and available for the large population of patients with Parkinson's disease.  The challenge for the pharmaceutical industry is to develop disease-modifying drugs which could arrest, delay or at least oppose the progression of the specific pathogenic processes underlying Parkinson's disease.  The purpose of this review, based on recent biol. and genetic data to be validated with appropriate animal models, was to re-examine the putative neuroprotective agents in Parkinson's disease and discuss the development of new strategies with the ultimate goal of demonstrating neurocytoprotective activity in this neurodegenerative disease.  Since guidelines for research on neurocytoprotective drugs remain to be written, innovation will be the key to success of future clin. trials.  It is reasonable to expect that future advances in our understanding of the pathogenic processes of Parkinson's disease will open the way to new perspectives for the treatment of other neurodegenerative diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOGvoX1QKb87Vg90H21EOLACvtfcHk0liP_voPwpVeDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVOrtb7J&md5=1a67583b9cc70135c2d988c45e205d65</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.pneurobio.2007.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pneurobio.2007.10.003%26sid%3Dliteratum%253Aachs%26aulast%3DAllain%26aufirst%3DH.%26aulast%3DBentu%25C3%25A9-Ferre%26aufirst%3DD.%26aulast%3DAkwa%26aufirst%3DY.%26atitle%3DDisease-modifying%2520drugs%2520and%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DProg.%2520Neurobiol.%26date%3D2008%26volume%3D84%26spage%3D25%26epage%3D39" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Rezak, M.</span><span> </span><span class="NLM_article-title">Current pharmacotherapeutic treatment options in Parkinson’s disease</span> <span class="citation_source-journal">Dis. Mon.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">214</span><span class="NLM_x">–</span> <span class="NLM_lpage">222</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=16&amp;doi=10.1021%2Fjm400336x&amp;key=10.1016%2Fj.disamonth.2007.05.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=8&amp;doi=10.1021%2Fjm400336x&amp;key=17586328" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=32&amp;doi=10.1021%2Fjm400336x&amp;key=1%3ACAS%3A280%3ADC%252BD2szntFCltg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2007&pages=214-222&author=M.+Rezak&title=Current+pharmacotherapeutic+treatment+options+in+Parkinson%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3aR"><div class="casContent"><span class="casTitleNuber">3a</span><div class="casTitle"><span class="NLM_cas:atitle">Current pharmacotherapeutic treatment options in Parkinson's disease</span></div><div class="casAuthors">Rezak Michael</div><div class="citationInfo"><span class="NLM_cas:title">Disease-a-month : DM</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">214-22</span>
        ISSN:<span class="NLM_cas:issn">0011-5029</span>.
    </div><div class="casAbstract">Treatment options for Parkinson's disease have greatly expanded in recent years.  Pharmacological treatments, such as levodopa, dopamine receptor agonists, anticholinergic medications, monoamine oxidase B inhibitors, and the catechol-O-methyl transferase inhibitors, remain the mainstay of therapeutic intervention and are reviewed.  Additionally, the traditional and new roles for amantadine are explained.  Despite the great efficacy of levodopa, "levodopa-sparing strategies" in early Parkinson's disease are emphasized in order to delay the development of difficult-to-manage motor fluctuations and dyskinesias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTqbhJIOrJpJaNc3HjJRoFAfW6udTcc2eb9tWHqqIyBNLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2szntFCltg%253D%253D&md5=ce5582e06be45302518167dfb257829b</span></div><a href="/servlet/linkout?suffix=cit3a&amp;dbid=16384&amp;doi=10.1016%2Fj.disamonth.2007.05.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.disamonth.2007.05.002%26sid%3Dliteratum%253Aachs%26aulast%3DRezak%26aufirst%3DM.%26atitle%3DCurrent%2520pharmacotherapeutic%2520treatment%2520options%2520in%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DDis.%2520Mon.%26date%3D2007%26volume%3D53%26spage%3D214%26epage%3D222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit3b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Lees, A.</span><span> </span><span class="NLM_article-title">Alternatives to levodopa in the initial treatment of early Parkinson’s disease</span> <span class="citation_source-journal">Drugs Aging</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">731</span><span class="NLM_x">–</span> <span class="NLM_lpage">740</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=16&amp;doi=10.1021%2Fjm400336x&amp;key=10.2165%2F00002512-200522090-00002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=8&amp;doi=10.1021%2Fjm400336x&amp;key=16156677" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=32&amp;doi=10.1021%2Fjm400336x&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFyhtbrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2005&pages=731-740&author=A.+Lees&title=Alternatives+to+levodopa+in+the+initial+treatment+of+early+Parkinson%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3bR"><div class="casContent"><span class="casTitleNuber">3b</span><div class="casTitle"><span class="NLM_cas:atitle">Alternatives to levodopa in the initial treatment of early parkinson's disease</span></div><div class="casAuthors">Lees, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Drugs & Aging</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">731-740</span>CODEN:
                <span class="NLM_cas:coden">DRAGE6</span>;
        ISSN:<span class="NLM_cas:issn">1170-229X</span>.
    
            (<span class="NLM_cas:orgname">Adis International Ltd.</span>)
        </div><div class="casAbstract">A review.  Parkinson's disease (PD) is primarily a disease of elderly patients.  This article reviews current knowledge and recent developments relating to drugs that can be used as alternatives to levodopa as initial treatment of PD.  Synthetic orally acting dopamine agonists have found increasing favor as an option for early PD in relatively young patients.  This strategy is based on evidence that this approach may delay the onset of motor fluctuations, at least during the first 5 years of treatment.  S.c. apomorphine infusions may attenuate motor fluctuations in late-stage disease, and transdermal rotigotine, a dopamine agonist in development, has also been shown to be efficacious.  The greater proclivity for dopamine agonists to cause psychotoxicity has, however, limited their routine use in the elderly.  Selective monoamine oxidase type B (MAO-B) inhibitors, used as monotherapy, delay the need for the introduction of levodopa by about 9 mo.  These agents appear to be less efficacious than dopamine agonists but are better tolerated.  Concern has been expressed about the potential of the MAO-B inhibitor selegiline (deprenyl) to induce cardiovascular adverse effects (orthostatic hypotension), either directly or through its amphetamine catabolites.  Rasagiline is a new MAO-B inhibitor that is not broken down to amphetamine derivs. and is indicated as both monotherapy in early PD and as adjunctive therapy in PD patients with motor fluctuations.  Two older classes of agents have undergone a resurgence of interest in recent years.  Amantadine, which enhances dopaminergic transmission and has antiglutamate activity, is occasionally used as monotherapy but has recently been widely used as an antidyskinetic agent in late-stage PD.  Anticholinergic drugs, such as benztropine (benzatropine) and orphenadrine also provide control of symptoms when used as monotherapy, but their psychotoxic, cognitive and autonomic adverse events make them inappropriate for the treatment of the elderly.  Effective therapy in PD should prevent disease progression and abolish motor and cognitive handicap.  Currently, none of the existing drugs meets all these needs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZoKtxp2djj7Vg90H21EOLACvtfcHk0lj3ESV3fvLSpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFyhtbrN&md5=df3ab7c50632db266f027b420323c413</span></div><a href="/servlet/linkout?suffix=cit3b&amp;dbid=16384&amp;doi=10.2165%2F00002512-200522090-00002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00002512-200522090-00002%26sid%3Dliteratum%253Aachs%26aulast%3DLees%26aufirst%3DA.%26atitle%3DAlternatives%2520to%2520levodopa%2520in%2520the%2520initial%2520treatment%2520of%2520early%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DDrugs%2520Aging%26date%3D2005%26volume%3D22%26spage%3D731%26epage%3D740" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit3c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Dunkel, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chai, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sperlágh, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huleatt, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mátyus, P.</span><span> </span><span class="NLM_article-title">Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer’s, Parkinson’s and Huntington’s diseases, and amyotrophic lateral sclerosis</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">1267</span><span class="NLM_x">–</span> <span class="NLM_lpage">1308</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2012&pages=1267-1308&author=P.+Dunkelauthor=C.+L.+Chaiauthor=B.+Sperl%C3%A1ghauthor=P.+B.+Huleattauthor=P.+M%C3%A1tyus&title=Clinical+utility+of+neuroprotective+agents+in+neurodegenerative+diseases%3A+current+status+of+drug+development+for+Alzheimer%E2%80%99s%2C+Parkinson%E2%80%99s+and+Huntington%E2%80%99s+diseases%2C+and+amyotrophic+lateral+sclerosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDunkel%26aufirst%3DP.%26aulast%3DChai%26aufirst%3DC.%2BL.%26aulast%3DSperl%25C3%25A1gh%26aufirst%3DB.%26aulast%3DHuleatt%26aufirst%3DP.%2BB.%26aulast%3DM%25C3%25A1tyus%26aufirst%3DP.%26atitle%3DClinical%2520utility%2520of%2520neuroprotective%2520agents%2520in%2520neurodegenerative%2520diseases%253A%2520current%2520status%2520of%2520drug%2520development%2520for%2520Alzheimer%25E2%2580%2599s%252C%2520Parkinson%25E2%2580%2599s%2520and%2520Huntington%25E2%2580%2599s%2520diseases%252C%2520and%2520amyotrophic%2520lateral%2520sclerosis%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2012%26volume%3D21%26spage%3D1267%26epage%3D1308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Armentero, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinna, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferré, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lanciego, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franco., R.</span><span> </span><span class="NLM_article-title">Past, present and future of A<sub>2A</sub> adenosine receptor antagonists in the therapy of Parkinson’s disease</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">132</span><span class="NLM_x">, </span> <span class="NLM_fpage">280</span><span class="NLM_x">–</span> <span class="NLM_lpage">299</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm400336x&amp;key=10.1016%2Fj.pharmthera.2011.07.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm400336x&amp;key=21810444" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm400336x&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtl2ntrzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2011&pages=280-299&author=M.+T.+Armenteroauthor=A.+Pinnaauthor=S.+Ferr%C3%A9author=J.+L.+Lanciegoauthor=C.+E.+M%C3%BCllerauthor=R.+Franco.&title=Past%2C+present+and+future+of+A2A+adenosine+receptor+antagonists+in+the+therapy+of+Parkinson%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Past, present and future of A2A adenosine receptor antagonists in the therapy of Parkinson's disease</span></div><div class="casAuthors">Armentero, Marie Therese; Pinna, Annalisa; Ferre, Sergi; Lanciego, Jose Luis; Mueller, Christa E.; Franco, Rafael</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">280-299</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Several selective antagonists for adenosine A2A receptors (A2AR) are currently under evaluation in clin. trials (phases I to III) to treat Parkinson's disease, and they will probably soon reach the market.  The usefulness of these antagonists has been deduced from studies demonstrating functional interactions between dopamine D2 and adenosine A2A receptors in the basal ganglia.  At present it is believed that A2AR antagonists can be used in combination with the dopamine precursor L-DOPA to minimize the motor symptoms of Parkinson's patients.  However, a considerable body of data indicates that in addn. to ameliorating motor symptoms, adenosine A2AR antagonists may also prevent neurodegeneration.  Despite these promising indications, one further issue must be considered in order to develop fully optimized antiparkinsonian drug therapy, namely the existence of (hetero)dimers/oligomers of G protein-coupled receptors, a topic that is currently the focus of intense debate within the scientific community.  Dopamine D2 receptors (D2Rs) expressed in the striatum are known to form heteromers with A2A adenosine receptors.  Thus, the development of heteromer-specific A2A receptor antagonists represents a promising strategy for the identification of more selective and safer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2pOYdmdfQMLVg90H21EOLACvtfcHk0ljlK_EiovmGZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtl2ntrzP&md5=39fa871338516f7574deb7845029e624</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2011.07.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2011.07.004%26sid%3Dliteratum%253Aachs%26aulast%3DArmentero%26aufirst%3DM.%2BT.%26aulast%3DPinna%26aufirst%3DA.%26aulast%3DFerr%25C3%25A9%26aufirst%3DS.%26aulast%3DLanciego%26aufirst%3DJ.%2BL.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26aulast%3DFranco.%26aufirst%3DR.%26atitle%3DPast%252C%2520present%2520and%2520future%2520of%2520A2A%2520adenosine%2520receptor%2520antagonists%2520in%2520the%2520therapy%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DPharmacol.%2520Ther.%26date%3D2011%26volume%3D132%26spage%3D280%26epage%3D299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Fredholm, B. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">IJzerman, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linden, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, C. E.</span><span> </span><span class="NLM_article-title">International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors–an update</span> <span class="citation_source-journal">Pharmacol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">34</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2011&pages=1-34&author=B.+B.+Fredholmauthor=A.+P.+IJzermanauthor=K.+A.+Jacobsonauthor=J.+Lindenauthor=C.+E.+M%C3%BCller&title=International+Union+of+Basic+and+Clinical+Pharmacology.+LXXXI.+Nomenclature+and+classification+of+adenosine+receptors%E2%80%93an+update"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFredholm%26aufirst%3DB.%2BB.%26aulast%3DIJzerman%26aufirst%3DA.%2BP.%26aulast%3DJacobson%26aufirst%3DK.%2BA.%26aulast%3DLinden%26aufirst%3DJ.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26atitle%3DInternational%2520Union%2520of%2520Basic%2520and%2520Clinical%2520Pharmacology.%2520LXXXI.%2520Nomenclature%2520and%2520classification%2520of%2520adenosine%2520receptors%25E2%2580%2593an%2520update%26jtitle%3DPharmacol.%2520Rev.%26date%3D2011%26volume%3D63%26spage%3D1%26epage%3D34" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Svenningsson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Moine, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisone, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fredholm, B. B.</span><span> </span><span class="NLM_article-title">Distribution, biochemistry and function of striatal adenosine A<sub>2A</sub> receptors</span> <span class="citation_source-journal">Prog. Neurobiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">355</span><span class="NLM_x">–</span> <span class="NLM_lpage">396</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm400336x&amp;key=10.1016%2FS0301-0082%2899%2900011-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm400336x&amp;key=10501634" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm400336x&amp;key=1%3ACAS%3A528%3ADyaK1MXmtlCgsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=1999&pages=355-396&author=P.+Svenningssonauthor=C.+Le+Moineauthor=G.+Fisoneauthor=B.+B.+Fredholm&title=Distribution%2C+biochemistry+and+function+of+striatal+adenosine+A2A+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Distribution, biochemistry and function of striatal adenosine A2A receptors</span></div><div class="casAuthors">Svenningsson, Per; Le Moine, Catherine; Fisone, Gilberto; Fredholm, Bertil B.</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Neurobiology (Oxford)</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">355-396</span>CODEN:
                <span class="NLM_cas:coden">PGNBA5</span>;
        ISSN:<span class="NLM_cas:issn">0301-0082</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review with >400 refs.  It is well known that the nucleoside adenosine exerts a modulatory influence in the central nervous system by activating G protein coupled receptors.  Adenosine A2A receptors, the subject of the present review, are predominantly expressed in striatum, the major area of the basal ganglia.  Activation of A2A receptors interferes with effects mediated by most of the principal neurotransmitters in striatum.  In particular, the inhibitory interactions between adenosine acting on A2A receptors and dopamine acting on D2 receptors have been well examd. and there is much evidence that A2A receptors may be a possible target for future development of drugs for treatment of Parkinson's disease, schizophrenia and affective disorders.  The authors' understanding of the role of striatal A2A receptors has increased dramatically over the last few years.  New selective antibodies, antagonist radioligands and optimized in situ hybridization protocols have provided detailed information on the distribution of A2A receptors in rodent as well as primate striatum.  Studies on the involvement of A2A receptors in the regulation of DARPP-32 and the expression of immediate early genes, such as nerve growth factor-induced clone A and c-fos, have pointed out an important role for these receptors in regulating striatopallidal neurotransmission.  Moreover, by using novel selective antagonists for A2A receptors and transgenic mice lacking functional A2A receptors, crucial information on the behavioral role of striatal A2A receptors has been provided, esp. concerning their involvement in the stimulatory action of caffeine and the anti-Parkinsonian properties of A2A receptor antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqANBDJTs7Mn7Vg90H21EOLACvtfcHk0ljlK_EiovmGZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmtlCgsbo%253D&md5=84888e21d742a721f43e0332a4d86be8</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2FS0301-0082%2899%2900011-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0301-0082%252899%252900011-8%26sid%3Dliteratum%253Aachs%26aulast%3DSvenningsson%26aufirst%3DP.%26aulast%3DLe%2BMoine%26aufirst%3DC.%26aulast%3DFisone%26aufirst%3DG.%26aulast%3DFredholm%26aufirst%3DB.%2BB.%26atitle%3DDistribution%252C%2520biochemistry%2520and%2520function%2520of%2520striatal%2520adenosine%2520A2A%2520receptors%26jtitle%3DProg.%2520Neurobiol.%26date%3D1999%26volume%3D59%26spage%3D355%26epage%3D396" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Ferré, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quiroz, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woods, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cunha, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Popoli, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciruela, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lluis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franco, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azdad, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiffmann, S. N.</span><span> </span><span class="NLM_article-title">An update on adenosine A<sub>2A</sub>-dopamine D<sub>2</sub> receptor interactions. Implications for the function of G-protein coupled receptors</span> <span class="citation_source-journal">Curr. Pharm. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">1468</span><span class="NLM_x">–</span> <span class="NLM_lpage">1474</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Fjm400336x&amp;key=10.2174%2F138161208784480108" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2009&pages=1468-1474&author=S.+Ferr%C3%A9author=C.+Quirozauthor=A.+S.+Woodsauthor=R.+Cunhaauthor=P.+Popoliauthor=F.+Ciruelaauthor=C.+Lluisauthor=R.+Francoauthor=K.+Azdadauthor=S.+N.+Schiffmann&title=An+update+on+adenosine+A2A-dopamine+D2+receptor+interactions.+Implications+for+the+function+of+G-protein+coupled+receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.2174%2F138161208784480108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161208784480108%26sid%3Dliteratum%253Aachs%26aulast%3DFerr%25C3%25A9%26aufirst%3DS.%26aulast%3DQuiroz%26aufirst%3DC.%26aulast%3DWoods%26aufirst%3DA.%2BS.%26aulast%3DCunha%26aufirst%3DR.%26aulast%3DPopoli%26aufirst%3DP.%26aulast%3DCiruela%26aufirst%3DF.%26aulast%3DLluis%26aufirst%3DC.%26aulast%3DFranco%26aufirst%3DR.%26aulast%3DAzdad%26aufirst%3DK.%26aulast%3DSchiffmann%26aufirst%3DS.%2BN.%26atitle%3DAn%2520update%2520on%2520adenosine%2520A2A-dopamine%2520D2%2520receptor%2520interactions.%2520Implications%2520for%2520the%2520function%2520of%2520G-protein%2520coupled%2520receptors%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2009%26volume%3D14%26spage%3D1468%26epage%3D1474" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit7b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ferré, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fredholm, B. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morelli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Popoli, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuxe, K.</span><span> </span><span class="NLM_article-title">Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia</span> <span class="citation_source-journal">Trends Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">482</span><span class="NLM_x">–</span> <span class="NLM_lpage">487</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=1997&pages=482-487&author=S.+Ferr%C3%A9author=B.+B.+Fredholmauthor=M.+Morelliauthor=P.+Popoliauthor=K.+Fuxe&title=Adenosine-dopamine+receptor-receptor+interactions+as+an+integrative+mechanism+in+the+basal+ganglia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFerr%25C3%25A9%26aufirst%3DS.%26aulast%3DFredholm%26aufirst%3DB.%2BB.%26aulast%3DMorelli%26aufirst%3DM.%26aulast%3DPopoli%26aufirst%3DP.%26aulast%3DFuxe%26aufirst%3DK.%26atitle%3DAdenosine-dopamine%2520receptor-receptor%2520interactions%2520as%2520an%2520integrative%2520mechanism%2520in%2520the%2520basal%2520ganglia%26jtitle%3DTrends%2520Neurosci.%26date%3D1997%26volume%3D20%26spage%3D482%26epage%3D487" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Ferré, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Navarro, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casadó, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortés, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mallol, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Canela, E. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lluís, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franco, R.</span><span> </span><span class="NLM_article-title">G protein-coupled receptor heteromers as new targets for drug development</span> <span class="citation_source-journal">Prog. Mol. Biol. Transl. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">91</span><span class="NLM_x">, </span> <span class="NLM_fpage">41</span><span class="NLM_x">–</span> <span class="NLM_lpage">52</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=16&amp;doi=10.1021%2Fjm400336x&amp;key=10.1016%2FS1877-1173%2810%2991002-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=32&amp;doi=10.1021%2Fjm400336x&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1Ols7nO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2010&pages=41-52&author=S.+Ferr%C3%A9author=G.+Navarroauthor=V.+Casad%C3%B3author=A.+Cort%C3%A9sauthor=J.+Mallolauthor=E.+I.+Canelaauthor=C.+Llu%C3%ADsauthor=R.+Franco&title=G+protein-coupled+receptor+heteromers+as+new+targets+for+drug+development"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8aR"><div class="casContent"><span class="casTitleNuber">8a</span><div class="casTitle"><span class="NLM_cas:atitle">G protein-coupled receptor heteromers as new targets for drug development</span></div><div class="casAuthors">Ferre, Sergi; Navarro, Gemma; Casado, Vicent; Cortes, Antoni; Mallol, Josefa; Canela, Enric I.; Lluis, Carme; Franco, Rafael</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Molecular Biology and Translational Science</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">Membrane Proteins as Drug Targets</span>),
    <span class="NLM_cas:pages">41-52</span>CODEN:
                <span class="NLM_cas:coden">PNARC5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review on G protein-coupled receptor (GPCR) heteromers as new targets for drug development.  Exptl. evidence shows that GPCR oligomerization, including homo- and heteromerization, is a general phenomenon.  The discovery of GPCR oligomers have been related to the parallel discovery and application of a variety of resonance energy transfer (RET) techniques, such as bioluminescence, fluorescence and sequential RET, time-resolved fluorescence RET, and fluorescence recovery after photobleaching microscopy.  However, RET techniques are difficult to implement in native tissues.  For receptor heteromers, indirect approaches, such as the detn. of a unique biochem. characteristic ('biochem. fingerprint'), permit their identification in native tissues and their use as targets for drug development.  Dopamine and opioid receptor heteromers are the focus of intense research which is related to the possible multiple applications of their putative ligands in pathol. conditions, including basal ganglia disorders, schizophrenia and drug addiction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZbglJJr6xMLVg90H21EOLACvtfcHk0lhqphkScClvOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1Ols7nO&md5=22f6b343826798aac91e23d4620cd97b</span></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=10.1016%2FS1877-1173%2810%2991002-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1877-1173%252810%252991002-8%26sid%3Dliteratum%253Aachs%26aulast%3DFerr%25C3%25A9%26aufirst%3DS.%26aulast%3DNavarro%26aufirst%3DG.%26aulast%3DCasad%25C3%25B3%26aufirst%3DV.%26aulast%3DCort%25C3%25A9s%26aufirst%3DA.%26aulast%3DMallol%26aufirst%3DJ.%26aulast%3DCanela%26aufirst%3DE.%2BI.%26aulast%3DLlu%25C3%25ADs%26aufirst%3DC.%26aulast%3DFranco%26aufirst%3DR.%26atitle%3DG%2520protein-coupled%2520receptor%2520heteromers%2520as%2520new%2520targets%2520for%2520drug%2520development%26jtitle%3DProg.%2520Mol.%2520Biol.%2520Transl.%2520Sci.%26date%3D2010%26volume%3D91%26spage%3D41%26epage%3D52" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit8b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Pollack, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fink, J. S.</span><span> </span><span class="NLM_article-title">Adenosine antagonists potentiate D<sub>2</sub> dopamine dependent activation of Fos in the striatopallidal pathway</span> <span class="citation_source-journal">Neuroscience</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">721</span><span class="NLM_x">–</span> <span class="NLM_lpage">728</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=1995&pages=721-728&author=A.+E.+Pollackauthor=J.+S.+Fink&title=Adenosine+antagonists+potentiate+D2+dopamine+dependent+activation+of+Fos+in+the+striatopallidal+pathway"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPollack%26aufirst%3DA.%2BE.%26aulast%3DFink%26aufirst%3DJ.%2BS.%26atitle%3DAdenosine%2520antagonists%2520potentiate%2520D2%2520dopamine%2520dependent%2520activation%2520of%2520Fos%2520in%2520the%2520striatopallidal%2520pathway%26jtitle%3DNeuroscience%26date%3D1995%26volume%3D68%26spage%3D721%26epage%3D728" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Lozano, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lang, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutchison, W. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dostrovsky, J. O.</span><span> </span><span class="NLM_article-title">New developments in understanding the etiology of Parkinson’s disease and in its treatment</span> <span class="citation_source-journal">Curr. Opin. Neurobiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">783</span><span class="NLM_x">–</span> <span class="NLM_lpage">790</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1998&pages=783-790&author=A.+M.+Lozanoauthor=A.+E.+Langauthor=W.+D.+Hutchisonauthor=J.+O.+Dostrovsky&title=New+developments+in+understanding+the+etiology+of+Parkinson%E2%80%99s+disease+and+in+its+treatment"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLozano%26aufirst%3DA.%2BM.%26aulast%3DLang%26aufirst%3DA.%2BE.%26aulast%3DHutchison%26aufirst%3DW.%2BD.%26aulast%3DDostrovsky%26aufirst%3DJ.%2BO.%26atitle%3DNew%2520developments%2520in%2520understanding%2520the%2520etiology%2520of%2520Parkinson%25E2%2580%2599s%2520disease%2520and%2520in%2520its%2520treatment%26jtitle%3DCurr.%2520Opin.%2520Neurobiol.%26date%3D1998%26volume%3D8%26spage%3D783%26epage%3D790" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Müller, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferré, S.</span><span> </span><span class="NLM_article-title">Blocking striatal adenosine A<sub>2A</sub> receptors: a new strategy for basal ganglia disorders</span> <span class="citation_source-journal">Recent Pat. CNS Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">21</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=1-21&author=C.+E.+M%C3%BCllerauthor=S.+Ferr%C3%A9&title=Blocking+striatal+adenosine+A2A+receptors%3A+a+new+strategy+for+basal+ganglia+disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26aulast%3DFerr%25C3%25A9%26aufirst%3DS.%26atitle%3DBlocking%2520striatal%2520adenosine%2520A2A%2520receptors%253A%2520a%2520new%2520strategy%2520for%2520basal%2520ganglia%2520disorders%26jtitle%3DRecent%2520Pat.%2520CNS%2520Drug%2520Discovery%26date%3D2007%26volume%3D2%26spage%3D1%26epage%3D21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Müller, C. E.</span><span> </span><span class="NLM_article-title">A<sub>2A</sub> Adenosine receptor antagonists – future drugs for Parkinson’s disease?</span> <span class="citation_source-journal">Drugs Future</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">1043</span><span class="NLM_x">–</span> <span class="NLM_lpage">1052</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=16&amp;doi=10.1021%2Fjm400336x&amp;key=10.1358%2Fdof.2000.025.10.858696" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=32&amp;doi=10.1021%2Fjm400336x&amp;key=1%3ACAS%3A528%3ADC%252BD3MXoslyq" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2000&pages=1043-1052&author=C.+E.+M%C3%BCller&title=A2A+Adenosine+receptor+antagonists+%E2%80%93+future+drugs+for+Parkinson%E2%80%99s+disease%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10aR"><div class="casContent"><span class="casTitleNuber">10a</span><div class="casTitle"><span class="NLM_cas:atitle">A2A adenosine receptor antagonists - future drugs for Parkinson's disease?</span></div><div class="casAuthors">Muller, Christa E.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of the Future</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1043-1052</span>CODEN:
                <span class="NLM_cas:coden">DRFUD4</span>;
        ISSN:<span class="NLM_cas:issn">0377-8282</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review with 101 refs.  Topics discussed include the adenosine receptors; A2A adenosine receptor antagonists; A2A antagonists as antiparkinsonian agents; and PET ligands for A2A receptors as diagnostics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1gOWi5c8MDLVg90H21EOLACvtfcHk0lgmYdLj-xd_3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXoslyq&md5=34c056a05c8a5dbd152c0d895684ca9f</span></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=10.1358%2Fdof.2000.025.10.858696&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdof.2000.025.10.858696%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26atitle%3DA2A%2520Adenosine%2520receptor%2520antagonists%2520%25E2%2580%2593%2520future%2520drugs%2520for%2520Parkinson%25E2%2580%2599s%2520disease%253F%26jtitle%3DDrugs%2520Future%26date%3D2000%26volume%3D25%26spage%3D1043%26epage%3D1052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit10b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Müller, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, K. A.</span><span> </span><span class="NLM_article-title">Recent developments in adenosine receptor ligands and their potential as novel drugs</span> <span class="citation_source-journal">Biochim. Biophys. Acta, Biomembr,</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_fpage">1290</span><span class="NLM_x">–</span> <span class="NLM_lpage">1308</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=16&amp;doi=10.1021%2Fjm400336x&amp;key=10.1016%2Fj.bbamem.2010.12.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=8&amp;doi=10.1021%2Fjm400336x&amp;key=21185259" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=32&amp;doi=10.1021%2Fjm400336x&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjvFSrsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&pages=1290-1308&author=C.+E.+M%C3%BCllerauthor=K.+A.+Jacobson&title=Recent+developments+in+adenosine+receptor+ligands+and+their+potential+as+novel+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10bR"><div class="casContent"><span class="casTitleNuber">10b</span><div class="casTitle"><span class="NLM_cas:atitle">Recent developments in adenosine receptor ligands and their potential as novel drugs</span></div><div class="casAuthors">Mueller, Christa E.; Jacobson, Kenneth A.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Biomembranes</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">1808</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1290-1308</span>CODEN:
                <span class="NLM_cas:coden">BBBMBS</span>;
        ISSN:<span class="NLM_cas:issn">0005-2736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Medicinal chem. approaches have been applied to all four of the adenosine receptor (AR) subtypes (A1, A2A, A2B, and A3) to create selective agonists and antagonists for each.  The most recent class of selective AR ligands to be reported is the class of A2BAR agonists.  The availability of these selective ligands has facilitated research on therapeutic applications of modulating the ARs and in some cases has provided clin. candidates.  Prodrug approaches have been developed which improve the bioavailability of the drugs, reduce side-effects, and/or may lead to site-selective effects.  The A2A agonist regadenoson (Lexiscan), a diagnostic drug for myocardial perfusion imaging, is the first selective AR agonist to be approved.  Other selective agonists and antagonists are or were undergoing clin. trials for a broad range of indications, including capadenoson and tecadenoson (A1 agonists) for atrial fibrillation, or paroxysmal supraventricular tachycardia, resp., apadenoson and binodenoson (A2A agonists) for myocardial perfusion imaging, preladenant (A2A antagonist) for the treatment of Parkinson's disease, and CF101 and CF102 (A3 agonists) for inflammatory diseases and cancer, resp.  This article is part of a Special Issue entitled: "Adenosine Receptors".</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoY8Cuch7XkT7Vg90H21EOLACvtfcHk0lgmYdLj-xd_3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjvFSrsr8%253D&md5=f143d2424c178c0a75e956ffb6b8320a</span></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=10.1016%2Fj.bbamem.2010.12.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbamem.2010.12.017%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26aulast%3DJacobson%26aufirst%3DK.%2BA.%26atitle%3DRecent%2520developments%2520in%2520adenosine%2520receptor%2520ligands%2520and%2520their%2520potential%2520as%2520novel%2520drugs%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Biomembr%252C%26date%3D2011%26spage%3D1290%26epage%3D1308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit10c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Baraldi, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tabrizi, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bovero, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avitabile, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Preti, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fruttarolo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romagnoli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varani, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borea, P. A.</span><span> </span><span class="NLM_article-title">Recent developments in the field of A<sub>2A</sub> and A<sub>3</sub> adenosine receptor antagonists</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">367</span><span class="NLM_x">–</span> <span class="NLM_lpage">382</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=16&amp;doi=10.1021%2Fjm400336x&amp;key=10.1016%2FS0223-5234%2803%2900042-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=8&amp;doi=10.1021%2Fjm400336x&amp;key=12750024" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=32&amp;doi=10.1021%2Fjm400336x&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjs1Clt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2003&pages=367-382&author=P.+G.+Baraldiauthor=M.+A.+Tabriziauthor=A.+Boveroauthor=B.+Avitabileauthor=D.+Pretiauthor=F.+Fruttaroloauthor=R.+Romagnoliauthor=K.+Varaniauthor=P.+A.+Borea&title=Recent+developments+in+the+field+of+A2A+and+A3+adenosine+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10cR"><div class="casContent"><span class="casTitleNuber">10c</span><div class="casTitle"><span class="NLM_cas:atitle">Recent developments in the field of A2A and A3 adenosine receptor antagonists</span></div><div class="casAuthors">Baraldi, Pier Giovanni; Tabrizi, Mojgan Aghazadeh; Bovero, Andrea; Avitabile, Barbara; Preti, Delia; Fruttarolo, Francesca; Romagnoli, Romeo; Varani, Katia; Borea, Pier Andrea</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">367-382</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Editions Scientifiques et Medicales Elsevier</span>)
        </div><div class="casAbstract">A review.  In the last years adenosine receptors have been extensively studied, and mainly at present the importance of A2A and A3 adenosine receptors is understood.  A2A selective adenosine receptors antagonists are promising new drugs for the treatment of Parkinson's disease, while A3 selective adenosine receptors antagonists have been postulated as novel anti-inflammatory and antiallergic agents; recent studies also indicated a possible employment of these derivs. as antitumor agents.  Lately different classes of compds. have been identified as potent A2A and A3 antagonists.  In this article we report the past and present efforts which led to development of more potent and selective A2A and A3 antagonists.  This research group has mainly worked on the pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine nucleus both as A2A and A3 antagonists, aiming to improve the affinity, selectivity and the hydrophilic profile.  In fact, several compds. endowed with high affinity and selectivity vs. A2A adenosine receptors or A3 adenosine receptors were synthesized. .</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrK30f4qobDTLVg90H21EOLACvtfcHk0ljHBJXsxPf5Wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjs1Clt7c%253D&md5=59b296f9c26aa02f88a5141431434783</span></div><a href="/servlet/linkout?suffix=cit10c&amp;dbid=16384&amp;doi=10.1016%2FS0223-5234%2803%2900042-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0223-5234%252803%252900042-4%26sid%3Dliteratum%253Aachs%26aulast%3DBaraldi%26aufirst%3DP.%2BG.%26aulast%3DTabrizi%26aufirst%3DM.%2BA.%26aulast%3DBovero%26aufirst%3DA.%26aulast%3DAvitabile%26aufirst%3DB.%26aulast%3DPreti%26aufirst%3DD.%26aulast%3DFruttarolo%26aufirst%3DF.%26aulast%3DRomagnoli%26aufirst%3DR.%26aulast%3DVarani%26aufirst%3DK.%26aulast%3DBorea%26aufirst%3DP.%2BA.%26atitle%3DRecent%2520developments%2520in%2520the%2520field%2520of%2520A2A%2520and%2520A3%2520adenosine%2520receptor%2520antagonists%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2003%26volume%3D38%26spage%3D367%26epage%3D382" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit10d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Baraldi, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tabrizi, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gessi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borea, P. A.</span><span> </span><span class="NLM_article-title">Adenosine receptor antagonists: translating medicinal chemistry and pharmacology into clinical utility</span> <span class="citation_source-journal">Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">238</span><span class="NLM_x">–</span> <span class="NLM_lpage">263</span></span><div class="citationLinks">[<a href="/doi/10.1021/cr0682195" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10d&amp;dbid=32&amp;doi=10.1021%2Fjm400336x&amp;key=1%3ACAS%3A528%3ADC%252BD1cXis1OisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2008&pages=238-263&author=P.+G.+Baraldiauthor=M.+A.+Tabriziauthor=S.+Gessiauthor=P.+A.+Borea&title=Adenosine+receptor+antagonists%3A+translating+medicinal+chemistry+and+pharmacology+into+clinical+utility"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10dR"><div class="casContent"><span class="casTitleNuber">10d</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine Receptor Antagonists: Translating Medicinal Chemistry and Pharmacology into Clinical Utility</span></div><div class="casAuthors">Baraldi, Pier Giovanni; Tabrizi, Mojgan Aghazadeh; Gessi, Stefania; Borea, Pier Andrea</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">238-263</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  This review discusses the chem. and pharmacol. of adenosine A1, A2A, A2B and A3 receptor antagonists and their therapeutic potential in clin. developments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOXhQGKqAVLbVg90H21EOLACvtfcHk0ljHBJXsxPf5Wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXis1OisQ%253D%253D&md5=1ae9e978507a1bbe7ab7aea0bdb33bb8</span></div><a href="/servlet/linkout?suffix=cit10d&amp;dbid=16384&amp;doi=10.1021%2Fcr0682195&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr0682195%26sid%3Dliteratum%253Aachs%26aulast%3DBaraldi%26aufirst%3DP.%2BG.%26aulast%3DTabrizi%26aufirst%3DM.%2BA.%26aulast%3DGessi%26aufirst%3DS.%26aulast%3DBorea%26aufirst%3DP.%2BA.%26atitle%3DAdenosine%2520receptor%2520antagonists%253A%2520translating%2520medicinal%2520chemistry%2520and%2520pharmacology%2520into%2520clinical%2520utility%26jtitle%3DChem.%2520Rev.%26date%3D2008%26volume%3D108%26spage%3D238%26epage%3D263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Salamone, J. D.</span><span> </span><span class="NLM_article-title">Preladenant, a novel adenosine A<sub>2A</sub> receptor antagonist for the potential treatment of parkinsonism and other disorders</span> <span class="citation_source-journal">IDrugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">723</span><span class="NLM_x">–</span> <span class="NLM_lpage">731</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=8&amp;doi=10.1021%2Fjm400336x&amp;key=20878595" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=32&amp;doi=10.1021%2Fjm400336x&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlGjurfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2010&pages=723-731&author=J.+D.+Salamone&title=Preladenant%2C+a+novel+adenosine+A2A+receptor+antagonist+for+the+potential+treatment+of+parkinsonism+and+other+disorders"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11aR"><div class="casContent"><span class="casTitleNuber">11a</span><div class="casTitle"><span class="NLM_cas:atitle">Preladenant, a novel adenosine A2A receptor antagonist for the potential treatment of parkinsonism and other disorders</span></div><div class="casAuthors">Salamone, John D.</div><div class="citationInfo"><span class="NLM_cas:title">IDrugs</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">723-731</span>CODEN:
                <span class="NLM_cas:coden">IDRUFN</span>;
        ISSN:<span class="NLM_cas:issn">2040-3410</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  Adenosine A2A receptor antagonists exert antiparkinsonian effects in animal models and several drugs in this class are currently being assessed in clin. trials.  Preladenant (SCH-420814) is an adenosine A2A receptor antagonist with a high affinity and very high selectivity for adenosine A2A receptors, which is being developed by Merck & Co Inc (following its acquisition of Schering-Plough Corp) for the potential treatment of Parkinson's disease.  Preclin. studies in rodent and primate models of parkinsonism demonstrated that preladenant can reverse the motor impairments induced by dopamine depletion or antagonism.  Phase I and II clin. trials indicated that preladenant was well tolerated.  Moreover, preladenant met its major endpoints by reducing OFF time and increasing ON time in L-DOPA-treated patients with Parkinson's disease, without worsening dyskinesias.  Therefore, preladenant may have considerable utility for the treatment of Parkinson's disease, as well as the parkinsonian side effects of dopamine D2 receptor antagonists.  As research has suggested that adenosine A2A receptor antagonists are active in animal models of effort-based decision making, it is possible that preladenant could also be useful for treating energy-related symptoms, such as fatigue, psychomotor retardation and anergia in patients with parkinsonism or depression.  At the time of publication, phase III clin. trials were recruiting patients with Parkinson's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJUD1bt1Mgv7Vg90H21EOLACvtfcHk0ljFk08OntuHfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlGjurfO&md5=1ba49b3deaf5804f04cdfaa5f5a97ccf</span></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSalamone%26aufirst%3DJ.%2BD.%26atitle%3DPreladenant%252C%2520a%2520novel%2520adenosine%2520A2A%2520receptor%2520antagonist%2520for%2520the%2520potential%2520treatment%2520of%2520parkinsonism%2520and%2520other%2520disorders%26jtitle%3DIDrugs%26date%3D2010%26volume%3D13%26spage%3D723%26epage%3D731" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit11b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Cristalli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Volpini, R.</span><span> </span><span class="NLM_article-title">Recent developments in adenosine A<sub>2A</sub> receptor ligands</span> <span class="citation_source-journal">Handb. Exp. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">193</span><span class="NLM_x">, </span> <span class="NLM_fpage">59</span><span class="NLM_x">–</span> <span class="NLM_lpage">98</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=16&amp;doi=10.1021%2Fjm400336x&amp;key=10.1007%2F978-3-540-89615-9_3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=8&amp;doi=10.1021%2Fjm400336x&amp;key=19639279" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=32&amp;doi=10.1021%2Fjm400336x&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1Sktr7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=193&publication_year=2009&pages=59-98&author=G.+Cristalliauthor=C.+E.+M%C3%BCllerauthor=R.+Volpini&title=Recent+developments+in+adenosine+A2A+receptor+ligands"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11bR"><div class="casContent"><span class="casTitleNuber">11b</span><div class="casTitle"><span class="NLM_cas:atitle">Recent developments in adenosine A2A receptor ligands</span></div><div class="casAuthors">Cristalli, Gloria; Muller, Christa E.; Volpini, Rosaria</div><div class="citationInfo"><span class="NLM_cas:title">Handbook of Experimental Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">193</span>
        (<span class="NLM_cas:issue">Adenosine Receptors in Health and Disease</span>),
    <span class="NLM_cas:pages">59-98</span>CODEN:
                <span class="NLM_cas:coden">HEPHD2</span>;
        ISSN:<span class="NLM_cas:issn">0171-2004</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">A review.  The development of potent and selective agonists and antagonists of adenosine receptors (ARs) has been a target of medicinal chem. research for several decades, and recently the US Food and Drug Administration has approved Lexiscan, an adenosine deriv. substituted at the 2 position, for use as a pharmacol. stress agent in radionuclide myocardial perfusion imaging.  Currently, some other adenosine A2A receptor (A2AAR) agonists and antagonists are undergoing preclin. testing and clin. trials.  While agonists are potent antiinflammatory agents also showing hypotensive effects, antagonists are being developed for the treatment of Parkinson's disease.  However, since there are still major problems in this field, including side effects, low brain penetration (for the targeting of CNS diseases), short half-life, or lack of in vivo effects, the design and development of new AR ligands is a hot research topic.  This review presents an update on the medicinal chem. of A2AAR agonists and antagonists, and stresses the strong need for more selective ligands at the human A2AAR subtype, in particular in the case of agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZlneM0HaH4rVg90H21EOLACvtfcHk0ljFk08OntuHfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1Sktr7E&md5=95c3e8fde30c9094d81cea882987ae64</span></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=10.1007%2F978-3-540-89615-9_3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-3-540-89615-9_3%26sid%3Dliteratum%253Aachs%26aulast%3DCristalli%26aufirst%3DG.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26aulast%3DVolpini%26aufirst%3DR.%26atitle%3DRecent%2520developments%2520in%2520adenosine%2520A2A%2520receptor%2520ligands%26jtitle%3DHandb.%2520Exp.%2520Pharmacol.%26date%3D2009%26volume%3D193%26spage%3D59%26epage%3D98" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Black, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koller, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gusnard, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bandak, S. I.</span><span> </span><span class="NLM_article-title">Quantification of indirect pathway inhibition by the adenosine A<sub>2A</sub> antagonist SYN115 in Parkinson disease</span> <span class="citation_source-journal">J. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">16284</span><span class="NLM_x">–</span> <span class="NLM_lpage">16292</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm400336x&amp;key=10.1523%2FJNEUROSCI.2590-10.2010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm400336x&amp;key=21123574" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm400336x&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1SlurjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2010&pages=16284-16292&author=K.+J.+Blackauthor=J.+M.+Kollerauthor=M.+C.+Campbellauthor=D.+A.+Gusnardauthor=S.+I.+Bandak&title=Quantification+of+indirect+pathway+inhibition+by+the+adenosine+A2A+antagonist+SYN115+in+Parkinson+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Quantification of indirect pathway inhibition by the adenosine A2a antagonist SYN115 in Parkinson disease</span></div><div class="casAuthors">Black, Kevin J.; Koller, Jonathan M.; Campbell, Meghan C.; Gusnard, Debra A.; Bandak, Stephen I.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">16284-16292</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Adenosine A2a receptor antagonists reduce symptom severity in Parkinson disease (PD) and animal models.  Rodent studies support the hypothesis that A2a antagonists produce this benefit by reducing the inhibitory output of the basal ganglia indirect pathway.  One way to test this hypothesis in humans is to quantify regional pharmacodynamic responses with cerebral blood flow (CBF) imaging.  That approach has also been proposed as a tool to accelerate pharmaceutical dose finding, but has not yet been applied in humans to drugs in development.  We successfully addressed both these aims with a perfusion magnetic resonance imaging (MRI) study of the novel adenosine A2a antagonist SYN115.  During a randomized, double-blind, placebo-controlled, crossover study in 21 PD patients on levodopa but no agonists, we acquired pulsed arterial spin labeling MRI at the end of each treatment period.  SYN115 produced a highly significant decrease in thalamic CBF, consistent with reduced pallidothalamic inhibition via the indirect pathway.  Similar decreases occurred in cortical regions whose activity decreases with increased alertness and externally focused attention, consistent with decreased self-reported sleepiness on SYN115.  Remarkably, we also derived quant. pharmacodynamic parameters from the CBF responses to SYN115.  These results suggested that the doses tested were on the low end of the ED range, consistent with clin. data reported sep.  We conclude that (1) SYN115 enters the brain and exerts dose-dependent regional effects, (2) the most prominent of these effects is consistent with deactivation of the indirect pathway as predicted by preclin. studies; and (3) perfusion MRI can provide rapid, quant., clin. relevant dose-finding information for pharmaceutical development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfZ_zdnYoIKrVg90H21EOLACvtfcHk0ljFk08OntuHfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1SlurjE&md5=bae1faff5214462b8110b93ac5ec00da</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.2590-10.2010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.2590-10.2010%26sid%3Dliteratum%253Aachs%26aulast%3DBlack%26aufirst%3DK.%2BJ.%26aulast%3DKoller%26aufirst%3DJ.%2BM.%26aulast%3DCampbell%26aufirst%3DM.%2BC.%26aulast%3DGusnard%26aufirst%3DD.%2BA.%26aulast%3DBandak%26aufirst%3DS.%2BI.%26atitle%3DQuantification%2520of%2520indirect%2520pathway%2520inhibition%2520by%2520the%2520adenosine%2520A2A%2520antagonist%2520SYN115%2520in%2520Parkinson%2520disease%26jtitle%3DJ.%2520Neurosci.%26date%3D2010%26volume%3D30%26spage%3D16284%26epage%3D16292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Gütschow, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlenk, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gäb, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paskaleva, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alnouri, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scolari, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iqbal, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, C. E.</span><span> </span><span class="NLM_article-title">Benzothiazinones: A novel class of adenosine receptor antagonists structurally unrelated to xanthine and adenine derivatives</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">3331</span><span class="NLM_x">–</span> <span class="NLM_lpage">3341</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm300029s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=3331-3341&author=M.+G%C3%BCtschowauthor=M.+Schlenkauthor=J.+G%C3%A4bauthor=M.+Paskalevaauthor=M.+W.+Alnouriauthor=S.+W.+Scolariauthor=J.+Iqbalauthor=C.+E.+M%C3%BCller&title=Benzothiazinones%3A+A+novel+class+of+adenosine+receptor+antagonists+structurally+unrelated+to+xanthine+and+adenine+derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fjm300029s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300029s%26sid%3Dliteratum%253Aachs%26aulast%3DG%25C3%25BCtschow%26aufirst%3DM.%26aulast%3DSchlenk%26aufirst%3DM.%26aulast%3DG%25C3%25A4b%26aufirst%3DJ.%26aulast%3DPaskaleva%26aufirst%3DM.%26aulast%3DAlnouri%26aufirst%3DM.%2BW.%26aulast%3DScolari%26aufirst%3DS.%2BW.%26aulast%3DIqbal%26aufirst%3DJ.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26atitle%3DBenzothiazinones%253A%2520A%2520novel%2520class%2520of%2520adenosine%2520receptor%2520antagonists%2520structurally%2520unrelated%2520to%2520xanthine%2520and%2520adenine%2520derivatives%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D3331%26epage%3D3341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Carlsson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Z. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Irwin, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shoichet, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, K. A.</span><span> </span><span class="NLM_article-title">Structure-based discovery of A<sub>2A</sub> adenosine receptor ligands</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">3748</span><span class="NLM_x">–</span> <span class="NLM_lpage">3755</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm100240h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=32&amp;doi=10.1021%2Fjm400336x&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkvFaqsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=3748-3755&author=J.+Carlssonauthor=L.+Yooauthor=Z.+G.+Gaoauthor=J.+J.+Irwinauthor=B.+K.+Shoichetauthor=K.+A.+Jacobson&title=Structure-based+discovery+of+A2A+adenosine+receptor+ligands"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14aR"><div class="casContent"><span class="casTitleNuber">14a</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Discovery of A2A Adenosine Receptor Ligands</span></div><div class="casAuthors">Carlsson, Jens; Yoo, Lena; Gao, Zhan-Guo; Irwin, John J.; Shoichet, Brian K.; Jacobson, Kenneth A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3748-3755</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The recent detn. of X-ray structures of pharmacol. relevant GPCRs has made these targets accessible to structure-based ligand discovery.  Here we explore whether novel chemotypes may be discovered for the A2A adenosine receptor, based on complementarity to its recently detd. structure.  The A2A adenosine receptor signals in the periphery and the CNS, with agonists explored as anti-inflammatory drugs and antagonists explored for neurodegenerative diseases.  We used mol. docking to screen a 1.4 million compd. database against the X-ray structure computationally and tested 20 high-ranking, previously unknown mols. exptl.  Of these 35% showed substantial activity with affinities between 200 nM and 9 μM.  For the most potent of these new inhibitors, over 50-fold specificity was obsd. for the A2A vs. the related A1 and A3 subtypes.  These high hit rates and affinities at least partly reflect the bias of com. libraries toward GPCR-like chemotypes, an issue that we attempt to investigate quant.  Despite this bias, many of the most potent new ligands were novel, dissimilar from known ligands, providing new lead structures for modulation of this medically important target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzvS6-9T9bd7Vg90H21EOLACvtfcHk0lg0-JyGff6uSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkvFaqsL8%253D&md5=c36c941d52d2cec06387d79c4c423d46</span></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=10.1021%2Fjm100240h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100240h%26sid%3Dliteratum%253Aachs%26aulast%3DCarlsson%26aufirst%3DJ.%26aulast%3DYoo%26aufirst%3DL.%26aulast%3DGao%26aufirst%3DZ.%2BG.%26aulast%3DIrwin%26aufirst%3DJ.%2BJ.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26aulast%3DJacobson%26aufirst%3DK.%2BA.%26atitle%3DStructure-based%2520discovery%2520of%2520A2A%2520adenosine%2520receptor%2520ligands%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D3748%26epage%3D3755" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit14b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">van der Horst, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Pijl, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulder-Krieger, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ijzerman, A. P.</span><span> </span><span class="NLM_article-title">Substructure-based virtual screening for adenosine A<sub>2A</sub> receptor ligands</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">2302</span><span class="NLM_x">–</span> <span class="NLM_lpage">2311</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=2302-2311&author=E.+van+der+Horstauthor=R.+van+der+Pijlauthor=T.+Mulder-Kriegerauthor=A.+Benderauthor=A.+P.+Ijzerman&title=Substructure-based+virtual+screening+for+adenosine+A2A+receptor+ligands"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2Bder%2BHorst%26aufirst%3DE.%26aulast%3Dvan%2Bder%2BPijl%26aufirst%3DR.%26aulast%3DMulder-Krieger%26aufirst%3DT.%26aulast%3DBender%26aufirst%3DA.%26aulast%3DIjzerman%26aufirst%3DA.%2BP.%26atitle%3DSubstructure-based%2520virtual%2520screening%2520for%2520adenosine%2520A2A%2520receptor%2520ligands%26jtitle%3DChemMedChem%26date%3D2011%26volume%3D6%26spage%3D2302%26epage%3D2311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Pisani, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muncipinto, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miscioscia, T. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicolotti, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonetti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Catto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caccia, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salvati, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soto-Otero, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendez-Alvarez, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Passeleu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carotti, A.</span><span> </span><span class="NLM_article-title">Discovery of a novel class of potent coumarin monoamine oxidase B inhibitors: development and biopharmacological profiling of 7-[(3-chlorobenzyl)oxy]-4-[(methylamino)methyl]-2<i>H</i>-chromen-2-one methanesulfonate (NW-1772) as a highly potent, selective, reversible, and orally active monoamine oxidase B inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">6685</span><span class="NLM_x">–</span> <span class="NLM_lpage">6706</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm9010127" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=6685-6706&author=L.+Pisaniauthor=G.+Muncipintoauthor=T.+F.+Misciosciaauthor=O.+Nicolottiauthor=F.+Leonettiauthor=M.+Cattoauthor=C.+Cacciaauthor=P.+Salvatiauthor=R.+Soto-Oteroauthor=E.+Mendez-Alvarezauthor=C.+Passeleuauthor=A.+Carotti&title=Discovery+of+a+novel+class+of+potent+coumarin+monoamine+oxidase+B+inhibitors%3A+development+and+biopharmacological+profiling+of+7-%5B%283-chlorobenzyl%29oxy%5D-4-%5B%28methylamino%29methyl%5D-2H-chromen-2-one+methanesulfonate+%28NW-1772%29+as+a+highly+potent%2C+selective%2C+reversible%2C+and+orally+active+monoamine+oxidase+B+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15a&amp;dbid=16384&amp;doi=10.1021%2Fjm9010127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9010127%26sid%3Dliteratum%253Aachs%26aulast%3DPisani%26aufirst%3DL.%26aulast%3DMuncipinto%26aufirst%3DG.%26aulast%3DMiscioscia%26aufirst%3DT.%2BF.%26aulast%3DNicolotti%26aufirst%3DO.%26aulast%3DLeonetti%26aufirst%3DF.%26aulast%3DCatto%26aufirst%3DM.%26aulast%3DCaccia%26aufirst%3DC.%26aulast%3DSalvati%26aufirst%3DP.%26aulast%3DSoto-Otero%26aufirst%3DR.%26aulast%3DMendez-Alvarez%26aufirst%3DE.%26aulast%3DPasseleu%26aufirst%3DC.%26aulast%3DCarotti%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520a%2520novel%2520class%2520of%2520potent%2520coumarin%2520monoamine%2520oxidase%2520B%2520inhibitors%253A%2520development%2520and%2520biopharmacological%2520profiling%2520of%25207-%255B%25283-chlorobenzyl%2529oxy%255D-4-%255B%2528methylamino%2529methyl%255D-2H-chromen-2-one%2520methanesulfonate%2520%2528NW-1772%2529%2520as%2520a%2520highly%2520potent%252C%2520selective%252C%2520reversible%252C%2520and%2520orally%2520active%2520monoamine%2520oxidase%2520B%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D6685%26epage%3D6706" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit15b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Maccioni, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alcaro, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cirilli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vigo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cardia, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanna, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meleddu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yanez, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costa, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matyus, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Distinto, S.</span><span> </span><span class="NLM_article-title">3-Acetyl-2,5-diaryl-2,3-dihydro-1,3,4-oxadiazoles: a new scaffold for the selective inhibition of monoamine oxidase B</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">6394</span><span class="NLM_x">–</span> <span class="NLM_lpage">6398</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm2002876" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6394-6398&author=E.+Maccioniauthor=S.+Alcaroauthor=R.+Cirilliauthor=S.+Vigoauthor=M.+C.+Cardiaauthor=M.+L.+Sannaauthor=R.+Meledduauthor=M.+Yanezauthor=G.+Costaauthor=L.+Casuauthor=P.+Matyusauthor=S.+Distinto&title=3-Acetyl-2%2C5-diaryl-2%2C3-dihydro-1%2C3%2C4-oxadiazoles%3A+a+new+scaffold+for+the+selective+inhibition+of+monoamine+oxidase+B"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15b&amp;dbid=16384&amp;doi=10.1021%2Fjm2002876&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2002876%26sid%3Dliteratum%253Aachs%26aulast%3DMaccioni%26aufirst%3DE.%26aulast%3DAlcaro%26aufirst%3DS.%26aulast%3DCirilli%26aufirst%3DR.%26aulast%3DVigo%26aufirst%3DS.%26aulast%3DCardia%26aufirst%3DM.%2BC.%26aulast%3DSanna%26aufirst%3DM.%2BL.%26aulast%3DMeleddu%26aufirst%3DR.%26aulast%3DYanez%26aufirst%3DM.%26aulast%3DCosta%26aufirst%3DG.%26aulast%3DCasu%26aufirst%3DL.%26aulast%3DMatyus%26aufirst%3DP.%26aulast%3DDistinto%26aufirst%3DS.%26atitle%3D3-Acetyl-2%252C5-diaryl-2%252C3-dihydro-1%252C3%252C4-oxadiazoles%253A%2520a%2520new%2520scaffold%2520for%2520the%2520selective%2520inhibition%2520of%2520monoamine%2520oxidase%2520B%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6394%26epage%3D6398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit15c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Gaspar, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silva, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yáñez, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vina, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orallo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ortuso, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uriarte, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alcaro, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borges, F.</span><span> </span><span class="NLM_article-title">Chromone, a privileged scaffold for the development of monoamine oxidase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">5165</span><span class="NLM_x">–</span> <span class="NLM_lpage">5173</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm2004267" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15c&amp;dbid=32&amp;doi=10.1021%2Fjm400336x&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotlaisb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=5165-5173&author=A.+Gasparauthor=T.+Silvaauthor=M.+Y%C3%A1%C3%B1ezauthor=D.+Vinaauthor=F.+Oralloauthor=F.+Ortusoauthor=E.+Uriarteauthor=S.+Alcaroauthor=F.+Borges&title=Chromone%2C+a+privileged+scaffold+for+the+development+of+monoamine+oxidase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15cR"><div class="casContent"><span class="casTitleNuber">15c</span><div class="casTitle"><span class="NLM_cas:atitle">Chromone, a privileged scaffold for the development of monoamine oxidase inhibitors</span></div><div class="casAuthors">Gaspar, Alexandra; Silva, Tiago; Yanez, Matilde; Vina, Dolores; Orallo, Franscisco; Ortuso, Francesco; Uriarte, Eugenio; Alcaro, Stefano; Borges, Fernanda</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5165-5173</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Two series of novel chromone derivs. I and II ( R = Ph, 4-OH-C6H4, 3-OH-4-MeO-C6H3, 3,4-(OH)2-C6H3, 3,4-(MeO)2-C6H3, 4-Cl-C6H4, 4-OCF3-C6H4, 4-CF3-C6H4, 4-NO2-C6H4, cyclohexyl, nPr) were synthesized and investigated for their ability to inhibit the activity of monoamine oxidase.  The SAR data indicate that chromone derivs. with substituents in position 3 of γ-pyrone nucleus act preferably as MAO-B inhibitors, with IC50 values in the nanomolar to micromolar range.  Almost all chromone 3-carboxamides display selectivity toward MAO-B.  Identical substitutions on position 2 of γ-pyrone nucleus result in complete loss of activity in both isoforms (chromones I except R = 4-OH-C6H4 and 3,4-(OH)2-C6H3).  Notably, chromone II(R = 4-Cl-C6H4) exhibits an MAO-B IC50 of 63 nM, greater than 1000-fold selectivity over MAO-A, and behaves as a quasi-reversible inhibitor.  Docking expts. onto the MAO binding of the most active compd. highlight different interaction patterns among the isoforms A and B.  The differential anal. of the solvation effects among the chromone isomers gave addnl. insight about the superior outline of the 3-substituted chromone derivs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKKLGzqjz4yLVg90H21EOLACvtfcHk0lgSTDZOixGKvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotlaisb0%253D&md5=27e7bd37930e26f28fb5b624b2360457</span></div><a href="/servlet/linkout?suffix=cit15c&amp;dbid=16384&amp;doi=10.1021%2Fjm2004267&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2004267%26sid%3Dliteratum%253Aachs%26aulast%3DGaspar%26aufirst%3DA.%26aulast%3DSilva%26aufirst%3DT.%26aulast%3DY%25C3%25A1%25C3%25B1ez%26aufirst%3DM.%26aulast%3DVina%26aufirst%3DD.%26aulast%3DOrallo%26aufirst%3DF.%26aulast%3DOrtuso%26aufirst%3DF.%26aulast%3DUriarte%26aufirst%3DE.%26aulast%3DAlcaro%26aufirst%3DS.%26aulast%3DBorges%26aufirst%3DF.%26atitle%3DChromone%252C%2520a%2520privileged%2520scaffold%2520for%2520the%2520development%2520of%2520monoamine%2520oxidase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D5165%26epage%3D5173" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Riederer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lachenmayer, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laux, G.</span><span> </span><span class="NLM_article-title">Clinical applications of MAO-inhibitors</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">2033</span><span class="NLM_x">–</span> <span class="NLM_lpage">2043</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=16&amp;doi=10.1021%2Fjm400336x&amp;key=10.2174%2F0929867043364775" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=8&amp;doi=10.1021%2Fjm400336x&amp;key=15279566" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=32&amp;doi=10.1021%2Fjm400336x&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlslWmu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2004&pages=2033-2043&author=P.+Riedererauthor=L.+Lachenmayerauthor=G.+Laux&title=Clinical+applications+of+MAO-inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16aR"><div class="casContent"><span class="casTitleNuber">16a</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical applications of MAO-Inhibitors</span></div><div class="casAuthors">Riederer, P.; Lachenmayer, L.; Laux, G.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2033-2043</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Monoamine oxidase inhibitors (MAO-I) have been useful in the treatment of both psychiatric and neurol. disorders over centuries.  Here the authors focus on the development of this drug treatment.  Focus is given on the use of irreversible MAO-I's as well as on reversible ones.  Benefit and side effects are reported for Parkinson's disease, Alzheimer's dementia, depression syndrome and panic disorders.  The preclin. and clin. effects of selegiline with regard to neuroprotection are highlighted and the conclusion is drawn that there is good evidence for a clin. neuroprotective capacity based on the assumption that the 50% recovery of MAO-B is obtained already after a 10 days withdrawal of selegiline.  There is also a focus on selegilines metab. to amphetamine and metamphetamine.  In order to avoid any such effects of metabolic compds. on the cardiovascular system Zydis Selegiline, a melt-tablet avoid of major metab. to amphetamine and metamphetamine is described in detail.  Developments in MAO-I research are discussed in detail as there are moclobemide, lacabemide, rasagiline.  Interactions of MAO-I' with tricyclics and serotonin selective reuptake inhibitors (SSRI's) are described as there is mentioning of interactions of MAO-I's with other compds. in general.  Tables and figures report on clin. studies and on pharmacol. properties of MAO-I's.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9Zf08abfhabVg90H21EOLACvtfcHk0ljsC2HbzWg1bQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlslWmu7c%253D&md5=dabcabed0e363951ad40e258ddffa972</span></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=10.2174%2F0929867043364775&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867043364775%26sid%3Dliteratum%253Aachs%26aulast%3DRiederer%26aufirst%3DP.%26aulast%3DLachenmayer%26aufirst%3DL.%26aulast%3DLaux%26aufirst%3DG.%26atitle%3DClinical%2520applications%2520of%2520MAO-inhibitors%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2004%26volume%3D11%26spage%3D2033%26epage%3D2043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit16b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Youdim, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bakhle, Y. S.</span><span> </span><span class="NLM_article-title">Monoamine oxidase: isoforms and inhibitors in Parkinson’s disease and depressive illness</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">147</span><span class="NLM_x">, </span> <span class="NLM_fpage">S287</span><span class="NLM_x">–</span> <span class="NLM_lpage">S296</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=147&publication_year=2006&pages=S287-S296&author=M.+B.+Youdimauthor=Y.+S.+Bakhle&title=Monoamine+oxidase%3A+isoforms+and+inhibitors+in+Parkinson%E2%80%99s+disease+and+depressive+illness"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYoudim%26aufirst%3DM.%2BB.%26aulast%3DBakhle%26aufirst%3DY.%2BS.%26atitle%3DMonoamine%2520oxidase%253A%2520isoforms%2520and%2520inhibitors%2520in%2520Parkinson%25E2%2580%2599s%2520disease%2520and%2520depressive%2520illness%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2006%26volume%3D147%26spage%3DS287%26epage%3DS296" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Nicotra, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierucci, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parvez, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senatori, O.</span><span> </span><span class="NLM_article-title">Monoamine oxidase expression during development and aging</span> <span class="citation_source-journal">NeuroToxicology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">155</span><span class="NLM_x">–</span> <span class="NLM_lpage">165</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm400336x&amp;key=10.1016%2FS0161-813X%2803%2900095-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm400336x&amp;key=14697890" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm400336x&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhtVSjtLrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2004&pages=155-165&author=A.+Nicotraauthor=F.+Pierucciauthor=H.+Parvezauthor=O.+Senatori&title=Monoamine+oxidase+expression+during+development+and+aging"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Monoamine oxidase expression during development and aging</span></div><div class="casAuthors">Nicotra, Antonietta; Pierucci, Federica; Parvez, Hasan; Senatori, Ornella</div><div class="citationInfo"><span class="NLM_cas:title">Neurotoxicology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">155-165</span>CODEN:
                <span class="NLM_cas:coden">NRTXDN</span>;
        ISSN:<span class="NLM_cas:issn">0161-813X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A discussion and review on the authors' works.  Monoamine oxidase (MAO) isoenzymes play a major role in regulating the concn. of several bioactive amines, including serotonin and catecholamines.  Both in the nervous system and in peripheral organs, MAOs can potentially modulate all the processes involving these bioactive amines.  In the present article, we review some of the most significant articles published so far on changes in MAOs during development and aging.  The data available on development refer mainly to the mammal brain at fetal and post-fetal stages.  Very little work has been done on studying MAO ontogenesis during early development, i.e., at stages prior to organogenesis, and what has been done refers to non-mammal vertebrates such as fish, amphibians and birds.  MAO A and MAO B changes have been measured as values of enzymic activity, as amt. of protein or, more rarely, as amt. of mRNAs.  A knowledge of MAO developmental changes not only provides a basis for the investigation of factors regulating MAO expression, but can also contribute to a better understanding of the possible trophic and/or morphogenetic role of monoaminergic neurotransmitters in the developing brain.  Transgenic mice lacking MAO A and rodents treated with MAO inhibitors during gestation have been very useful in this second case.  The investigations of changes in MAO A and MAO B during aging in the literature refer mostly to humans, mice and rats.  Interest in studies on aging is stimulated, among other things, by the observation that age-related diseases leading to neurodegenerative phenomena could be accompanied by changes in MAO activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxv_AEJy1Nl7Vg90H21EOLACvtfcHk0ljsC2HbzWg1bQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhtVSjtLrO&md5=c89dd6fbfdda1ee597c77b27bcd54aba</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2FS0161-813X%2803%2900095-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0161-813X%252803%252900095-0%26sid%3Dliteratum%253Aachs%26aulast%3DNicotra%26aufirst%3DA.%26aulast%3DPierucci%26aufirst%3DF.%26aulast%3DParvez%26aufirst%3DH.%26aulast%3DSenatori%26aufirst%3DO.%26atitle%3DMonoamine%2520oxidase%2520expression%2520during%2520development%2520and%2520aging%26jtitle%3DNeuroToxicology%26date%3D2004%26volume%3D25%26spage%3D155%26epage%3D165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Sayre, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, M. A.</span><span> </span><span class="NLM_article-title">Oxidative stress and neurotoxicity</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">172</span><span class="NLM_x">–</span> <span class="NLM_lpage">188</span></span><div class="citationLinks">[<a href="/doi/10.1021/tx700210j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm400336x&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlygsr3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2008&pages=172-188&author=L.+M.+Sayreauthor=G.+Perryauthor=M.+A.+Smith&title=Oxidative+stress+and+neurotoxicity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Oxidative Stress and Neurotoxicity</span></div><div class="casAuthors">Sayre, Lawrence M.; Perry, George; Smith, Mark A.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">172-188</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  There is increasing awareness of the ubiquitous role of oxidative stress in neurodegenerative disease states.  A continuing challenge is to be able to distinguish between oxidative changes that occur early in the disease from those that are secondary manifestations of neuronal degeneration.  This perspective highlights the role of oxidative stress in Alzheimer's, Parkinson's, and Huntington's diseases, amyotrophic lateral sclerosis, and multiple sclerosis, neurodegenerative and neuroinflammatory disorders where there is evidence for a primary contribution of oxidative stress in neuronal death, as opposed to other diseases where oxidative stress more likely plays a secondary or by-stander role.  We begin with a brief review of the biochem. of oxidative stress as it relates to mechanisms that lead to cell death, and why the central nervous system is particularly susceptible to such mechanisms.  Following a review of oxidative stress involvement in individual disease states, some conclusions are provided as to what further research should hope to accomplish in the field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyOa0kfz_RVLVg90H21EOLACvtfcHk0ljsC2HbzWg1bQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlygsr3K&md5=800757a60a32641257fad2fe97fd20bd</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Ftx700210j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx700210j%26sid%3Dliteratum%253Aachs%26aulast%3DSayre%26aufirst%3DL.%2BM.%26aulast%3DPerry%26aufirst%3DG.%26aulast%3DSmith%26aufirst%3DM.%2BA.%26atitle%3DOxidative%2520stress%2520and%2520neurotoxicity%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2008%26volume%3D21%26spage%3D172%26epage%3D188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Pålhagen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinonen, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hägglund, J.</span><span> </span><span class="NLM_article-title">Selegiline slows the progression of the symptoms of Parkinson disease</span> <span class="citation_source-journal">Neurology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">1200</span><span class="NLM_x">–</span> <span class="NLM_lpage">1206</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=1200-1206&author=S.+P%C3%A5lhagenauthor=E.+Heinonenauthor=J.+H%C3%A4gglund&title=Selegiline+slows+the+progression+of+the+symptoms+of+Parkinson+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DP%25C3%25A5lhagen%26aufirst%3DS.%26aulast%3DHeinonen%26aufirst%3DE.%26aulast%3DH%25C3%25A4gglund%26aufirst%3DJ.%26atitle%3DSelegiline%2520slows%2520the%2520progression%2520of%2520the%2520symptoms%2520of%2520Parkinson%2520disease%26jtitle%3DNeurology%26date%3D2006%26volume%3D66%26spage%3D1200%26epage%3D1206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit19b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Parkinson study group.</span><span> </span><span class="NLM_article-title">A controlled, randomized, delayed-start study of rasagiline in early Parkinson’s disease</span> <span class="citation_source-journal">Arch. Neurol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">561</span><span class="NLM_x">–</span> <span class="NLM_lpage">566</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19b&amp;dbid=16&amp;doi=10.1021%2Fjm400336x&amp;key=10.1001%2Farchneur.61.4.561" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19b&amp;dbid=8&amp;doi=10.1021%2Fjm400336x&amp;key=15096406" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2004&pages=561-566&author=Parkinson+study+group.&title=A+controlled%2C+randomized%2C+delayed-start+study+of+rasagiline+in+early+Parkinson%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19b&amp;dbid=16384&amp;doi=10.1001%2Farchneur.61.4.561&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Farchneur.61.4.561%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DA%2520controlled%252C%2520randomized%252C%2520delayed-start%2520study%2520of%2520rasagiline%2520in%2520early%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DArch.%2520Neurol.%26date%3D2004%26volume%3D61%26spage%3D561%26epage%3D566" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Schapira, A. H. V.</span><span> </span><span class="NLM_article-title">Monoamine oxidase B inhibitors for the treatment of Parkinson’s disease: a review of symptomatic and potential disease-modifying effects</span> <span class="citation_source-journal">CNS Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">1061</span><span class="NLM_x">–</span> <span class="NLM_lpage">1071</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2011&pages=1061-1071&author=A.+H.+V.+Schapira&title=Monoamine+oxidase+B+inhibitors+for+the+treatment+of+Parkinson%E2%80%99s+disease%3A+a+review+of+symptomatic+and+potential+disease-modifying+effects"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchapira%26aufirst%3DA.%2BH.%2BV.%26atitle%3DMonoamine%2520oxidase%2520B%2520inhibitors%2520for%2520the%2520treatment%2520of%2520Parkinson%25E2%2580%2599s%2520disease%253A%2520a%2520review%2520of%2520symptomatic%2520and%2520potential%2520disease-modifying%2520effects%26jtitle%3DCNS%2520Drugs%26date%3D2011%26volume%3D25%26spage%3D1061%26epage%3D1071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit20b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Schapira, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stocchi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borgohain, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Onofrj, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhatt, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorenzana, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucini, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giuliani, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anand, R.</span><span> </span><span class="NLM_article-title">Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson’s disease</span> <span class="citation_source-journal">Eur. J. Neurol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">271</span><span class="NLM_x">–</span> <span class="NLM_lpage">280</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=16&amp;doi=10.1021%2Fjm400336x&amp;key=10.1111%2Fj.1468-1331.2012.03840.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=8&amp;doi=10.1021%2Fjm400336x&amp;key=22967035" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=32&amp;doi=10.1021%2Fjm400336x&amp;key=1%3ACAS%3A280%3ADC%252BC38bmtV2qsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=271-280&author=A.+H.+Schapiraauthor=F.+Stocchiauthor=R.+Borgohainauthor=M.+Onofrjauthor=M.+Bhattauthor=P.+Lorenzanaauthor=V.+Luciniauthor=R.+Giulianiauthor=R.+Anand&title=Long-term+efficacy+and+safety+of+safinamide+as+add-on+therapy+in+early+Parkinson%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20bR"><div class="casContent"><span class="casTitleNuber">20b</span><div class="casTitle"><span class="NLM_cas:atitle">Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson's disease</span></div><div class="casAuthors">Schapira A H V; Stocchi F; Borgohain R; Onofrj M; Bhatt M; Lorenzana P; Lucini V; Giuliani R; Anand R</div><div class="citationInfo"><span class="NLM_cas:title">European journal of neurology : the official journal of the European Federation of Neurological Societies</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">271-80</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND AND PURPOSE:  Safinamide is an α-aminoamide with both dopaminergic and non-dopaminergic mechanisms of action in Phase III clinical development as a once-daily add-on to dopamine agonist (DA) therapy for early Parkinson's disease (PD).  METHODS:  Study 017 was a 12-month, randomized, double-blind, placebo-controlled pre-planned extension study to the previously reported Study 015.  Patients received safinamide 100 or 200 mg/day or placebo added to a single DA in early PD.  The primary efficacy endpoint was the time from baseline (Study 015 randomization) to 'intervention', defined as increase in DA dose; addition of another DA, levodopa or other PD treatment; or discontinuation due to lack of efficacy.  Safinamide groups were pooled for the primary efficacy endpoint analysis; post hoc analyses were performed on each separate dose group.  RESULTS:  Of the 269 patients randomized in Study 015, 227 (84%) enrolled in Study 017 and 187/227 (82%) patients completed the extension study.  Median time to intervention was 559 and 466 days in the pooled safinamide and placebo groups, respectively (log-rank test; P = 0.3342).  In post hoc analyses, patients receiving safinamide 100 mg/day experienced a significantly lower rate of intervention compared with placebo (25% vs. 51%, respectively) and a delay in median time to intervention of 9 days (P < 0.05; 240- to 540-day analysis).  CONCLUSIONS:  The pooled data from the safinamide groups failed to reach statistical significance for the primary endpoint of median time from baseline to additional drug intervention.  Post hoc analyses indicate that safinamide 100 mg/day may be effective as add-on treatment to DA in PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTW8Q7CptAmznthwrmtH4OBfW6udTcc2ebIYVronKubfLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38bmtV2qsw%253D%253D&md5=ae238c6d3d0f0952fc6993bd03615335</span></div><a href="/servlet/linkout?suffix=cit20b&amp;dbid=16384&amp;doi=10.1111%2Fj.1468-1331.2012.03840.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1468-1331.2012.03840.x%26sid%3Dliteratum%253Aachs%26aulast%3DSchapira%26aufirst%3DA.%2BH.%26aulast%3DStocchi%26aufirst%3DF.%26aulast%3DBorgohain%26aufirst%3DR.%26aulast%3DOnofrj%26aufirst%3DM.%26aulast%3DBhatt%26aufirst%3DM.%26aulast%3DLorenzana%26aufirst%3DP.%26aulast%3DLucini%26aufirst%3DV.%26aulast%3DGiuliani%26aufirst%3DR.%26aulast%3DAnand%26aufirst%3DR.%26atitle%3DLong-term%2520efficacy%2520and%2520safety%2520of%2520safinamide%2520as%2520add-on%2520therapy%2520in%2520early%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DEur.%2520J.%2520Neurol.%26date%3D2013%26volume%3D20%26spage%3D271%26epage%3D280" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Pisani, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Catto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonetti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicolotti, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stefanachi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campagna, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carotti, A.</span><span> </span><span class="NLM_article-title">Targeting monoamine oxidases with multipotent ligands: an emerging strategy in the search of new drugs against neurodegenerative diseases</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">4568</span><span class="NLM_x">–</span> <span class="NLM_lpage">4587</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=16&amp;doi=10.1021%2Fjm400336x&amp;key=10.2174%2F092986711797379302" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=8&amp;doi=10.1021%2Fjm400336x&amp;key=21864289" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=32&amp;doi=10.1021%2Fjm400336x&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlyitb7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=4568-4587&author=L.+Pisaniauthor=M.+Cattoauthor=F.+Leonettiauthor=O.+Nicolottiauthor=A.+Stefanachiauthor=F.+Campagnaauthor=A.+Carotti&title=Targeting+monoamine+oxidases+with+multipotent+ligands%3A+an+emerging+strategy+in+the+search+of+new+drugs+against+neurodegenerative+diseases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21aR"><div class="casContent"><span class="casTitleNuber">21a</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting monoamine oxidases with multipotent ligands: an emerging strategy in the search of new drugs against neurodegenerative diseases</span></div><div class="casAuthors">Pisani, L.; Catto, M.; Leonetti, F.; Nicolotti, O.; Stefanachi, A.; Campagna, F.; Carotti, A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">4568-4587</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The socioeconomic burden of multi-factorial pathologies, such as neurodegenerative diseases (NDs), is enormous worldwide.  Unfortunately, no proven disease-modifying therapy is available yet and in most cases (e.g., Alzheimer's and Parkinson's disease) the approved drugs exert only palliative and symptomatic effects.  Nowadays, an emerging strategy for the discovery of disease-modifying drugs is based on the multi-target directed ligand (MTDL) design, an innovative shift from the traditional approach one-drug-one-target to the more ambitious one-drug-more-targets goal.  Herein, we review the discovery strategy, the mechanism of action and the biopharmacol. evaluation of multipotent ligands exhibiting monoamine oxidase (MAO) inhibition as the core activity with a potential for the treatment of NDs.  In particular, MAO inhibitors exhibiting addnl. acetylcholinesterase (AChE) or nitric oxide synthase (NOS) inhibition, or ion chelation/antioxidant-radical scavenging/anti-inflammatory/A2A receptor antagonist/APP processing modulating activities have been thoroughly examd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4N8fMdFNcwrVg90H21EOLACvtfcHk0lhZiRgDpHyYXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlyitb7O&md5=2463da84a1da0142e353ff9d3a354fe6</span></div><a href="/servlet/linkout?suffix=cit21a&amp;dbid=16384&amp;doi=10.2174%2F092986711797379302&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986711797379302%26sid%3Dliteratum%253Aachs%26aulast%3DPisani%26aufirst%3DL.%26aulast%3DCatto%26aufirst%3DM.%26aulast%3DLeonetti%26aufirst%3DF.%26aulast%3DNicolotti%26aufirst%3DO.%26aulast%3DStefanachi%26aufirst%3DA.%26aulast%3DCampagna%26aufirst%3DF.%26aulast%3DCarotti%26aufirst%3DA.%26atitle%3DTargeting%2520monoamine%2520oxidases%2520with%2520multipotent%2520ligands%253A%2520an%2520emerging%2520strategy%2520in%2520the%2520search%2520of%2520new%2520drugs%2520against%2520neurodegenerative%2520diseases%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2011%26volume%3D18%26spage%3D4568%26epage%3D4587" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit21b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Morphy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rankovic, Z.</span><span> </span><span class="NLM_article-title">Designed multiple ligands. An emerging drug discovery paradigm</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">6523</span><span class="NLM_x">–</span> <span class="NLM_lpage">6543</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm058225d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=32&amp;doi=10.1021%2Fjm400336x&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6523-6543&author=R.+Morphyauthor=Z.+Rankovic&title=Designed+multiple+ligands.+An+emerging+drug+discovery+paradigm"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21bR"><div class="casContent"><span class="casTitleNuber">21b</span><div class="casTitle"><span class="NLM_cas:atitle">Designed Multiple Ligands.</span></div><div class="casAuthors">Morphy, Richard; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6523-6543</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The review discusses main areas in designed multiple ligands (DMLs) discovery that include 5HT transporter-based DMLs for depression, dopamine D2-receptor based DMLs for schizophrenia, histamine H1 receptor-based DMLs for allergies, DMLs targeting the angiotensin system for hypertension, nonsteroidal anti-inflammatory drugs, and PPAR-based DMLs for metabolic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgouWcjsiKgbVg90H21EOLACvtfcHk0lhZiRgDpHyYXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL&md5=00e3bf5a521fc91996ce95bb379a0b5c</span></div><a href="/servlet/linkout?suffix=cit21b&amp;dbid=16384&amp;doi=10.1021%2Fjm058225d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm058225d%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DDesigned%2520multiple%2520ligands.%2520An%2520emerging%2520drug%2520discovery%2520paradigm%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D6523%26epage%3D6543" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit21c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Patyar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prakash, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medhi, B.</span><span> </span><span class="NLM_article-title">Dual inhibition: a novel promising pharmacological approach for different disease conditions</span> <span class="citation_source-journal">J. Pharm. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">459</span><span class="NLM_x">–</span> <span class="NLM_lpage">471</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21c&amp;dbid=16&amp;doi=10.1021%2Fjm400336x&amp;key=10.1111%2Fj.2042-7158.2010.01236.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21c&amp;dbid=8&amp;doi=10.1021%2Fjm400336x&amp;key=21401597" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21c&amp;dbid=32&amp;doi=10.1021%2Fjm400336x&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktlantLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2011&pages=459-471&author=S.+Patyarauthor=A.+Prakashauthor=B.+Medhi&title=Dual+inhibition%3A+a+novel+promising+pharmacological+approach+for+different+disease+conditions"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21cR"><div class="casContent"><span class="casTitleNuber">21c</span><div class="casTitle"><span class="NLM_cas:atitle">Dual inhibition: a novel promising pharmacological approach for different disease conditions</span></div><div class="casAuthors">Patyar, Sazal; Prakash, Ajay; Medhi, Bikash</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacy and Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">459-471</span>CODEN:
                <span class="NLM_cas:coden">JPPMAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3573</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">A review.  To overcome the problems assocd. with polypharmacy, which include medication non compliance, adverse drug reactions, drug-drug interactions, and increased pill-burden, various strategies, such as sustained-release drugs and fixed-dose combination regimens (polypills), were developed.  Out of these, a novel and very much promising approach is the use of dual-action drugs.  Amongst the dual-action drugs, there is a class of compds. known as dual inhibitors, which possess the dual inhibitory activity.  The most common examples of dual inhibitors are rivastigmine, ladostigil, asenapine, phenserine, amitriptyline, clomipramine, doxepin, and desipramine.  This review article focuses on the conventional drugs used in different diseases which possess dual inhibition activity as well as those which are still in the preclin./clin. phase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoimW_BGkApX7Vg90H21EOLACvtfcHk0lhZiRgDpHyYXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktlantLs%253D&md5=5cae05a18a9246b765e400230e8ef62f</span></div><a href="/servlet/linkout?suffix=cit21c&amp;dbid=16384&amp;doi=10.1111%2Fj.2042-7158.2010.01236.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.2042-7158.2010.01236.x%26sid%3Dliteratum%253Aachs%26aulast%3DPatyar%26aufirst%3DS.%26aulast%3DPrakash%26aufirst%3DA.%26aulast%3DMedhi%26aufirst%3DB.%26atitle%3DDual%2520inhibition%253A%2520a%2520novel%2520promising%2520pharmacological%2520approach%2520for%2520different%2520disease%2520conditions%26jtitle%3DJ.%2520Pharm.%2520Pharmacol.%26date%3D2011%26volume%3D63%26spage%3D459%26epage%3D471" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit21d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Elsinghorst, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Härtig, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gündisch, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohr, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tränkle, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gütschow, M.</span><span> </span><span class="NLM_article-title">A hydrazide linker strategy for heterobivalent compounds as ortho- and allosteric ligands of acetylcholine-binding proteins</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">2731</span><span class="NLM_x">–</span> <span class="NLM_lpage">2748</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21d&amp;dbid=16&amp;doi=10.1021%2Fjm400336x&amp;key=10.2174%2F156802611798184427" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21d&amp;dbid=8&amp;doi=10.1021%2Fjm400336x&amp;key=22039876" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21d&amp;dbid=32&amp;doi=10.1021%2Fjm400336x&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1ehtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=2731-2748&author=P.+W.+Elsinghorstauthor=W.+H%C3%A4rtigauthor=D.+G%C3%BCndischauthor=K.+Mohrauthor=C.+Tr%C3%A4nkleauthor=M.+G%C3%BCtschow&title=A+hydrazide+linker+strategy+for+heterobivalent+compounds+as+ortho-+and+allosteric+ligands+of+acetylcholine-binding+proteins"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21dR"><div class="casContent"><span class="casTitleNuber">21d</span><div class="casTitle"><span class="NLM_cas:atitle">A hydrazide linker strategy for heterobivalent compounds as orthoand allosteric ligands of acetylcholine-binding proteins</span></div><div class="casAuthors">Elsinghorst, Paul W.; Haertig, Wolfgang; Guendisch, Daniela; Mohr, Klaus; Traenkle, Christian; Guetschow, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2731-2748</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The occurrence of orthosteric and allosteric binding sites is a characteristic common feature of several acetylcholine-binding proteins, like acetylcholinesterase or the nicotinic and muscarinic acetylcholine receptors.  These proteins are involved in a no. of neurol. disorders, such as Alzheimer's disease, and represent important therapeutic targets for the development of heterodimeric ligands addressing both of their binding sites.  Among the pharmacophores, which have been combined in such heterodimers, the tetrahydroacridine deriv. tacrine has attracted particular interest.  This review discusses the chem. behind the linker connection of tacrine to other pharmacophores and summarizes the types of linkers established to date.  Esp., the development of a hydrazide linker for tacrine-derived heterodimers is highlighted by applications in the inhibition of cholinesterases, the bivalent binding to nicotinic and muscarinic acetylcholine receptors, as well as the histochem. imaging of acetylcholinesterase and amyloid-β.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopf3BjJ8j7s7Vg90H21EOLACvtfcHk0lhKsPN0NIHeng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1ehtb8%253D&md5=4935799f17aff2b8cbd07f4a84281a5d</span></div><a href="/servlet/linkout?suffix=cit21d&amp;dbid=16384&amp;doi=10.2174%2F156802611798184427&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802611798184427%26sid%3Dliteratum%253Aachs%26aulast%3DElsinghorst%26aufirst%3DP.%2BW.%26aulast%3DH%25C3%25A4rtig%26aufirst%3DW.%26aulast%3DG%25C3%25BCndisch%26aufirst%3DD.%26aulast%3DMohr%26aufirst%3DK.%26aulast%3DTr%25C3%25A4nkle%26aufirst%3DC.%26aulast%3DG%25C3%25BCtschow%26aufirst%3DM.%26atitle%3DA%2520hydrazide%2520linker%2520strategy%2520for%2520heterobivalent%2520compounds%2520as%2520ortho-%2520and%2520allosteric%2520ligands%2520of%2520acetylcholine-binding%2520proteins%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2011%26volume%3D11%26spage%3D2731%26epage%3D2748" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit21e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Dunkel, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gelain, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barlocco, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haider, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gyires, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sperlágh, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magyar, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maccioni, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fadda, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mátyus, P.</span><span> </span><span class="NLM_article-title">Semicarbazide-sensitive amine oxidase/vascular adhesion protein 1: recent developments concerning substrates and inhibitors of a promising therapeutic target</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">1827</span><span class="NLM_x">–</span> <span class="NLM_lpage">1839</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21e&amp;dbid=16&amp;doi=10.1021%2Fjm400336x&amp;key=10.2174%2F092986708785133022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21e&amp;dbid=8&amp;doi=10.1021%2Fjm400336x&amp;key=18691041" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21e&amp;dbid=32&amp;doi=10.1021%2Fjm400336x&amp;key=1%3ACAS%3A528%3ADC%252BD1cXovFWnsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2008&pages=1827-1839&author=P.+Dunkelauthor=A.+Gelainauthor=D.+Barloccoauthor=N.+Haiderauthor=K.+Gyiresauthor=B.+Sperl%C3%A1ghauthor=K.+Magyarauthor=E.+Maccioniauthor=A.+Faddaauthor=P.+M%C3%A1tyus&title=Semicarbazide-sensitive+amine+oxidase%2Fvascular+adhesion+protein+1%3A+recent+developments+concerning+substrates+and+inhibitors+of+a+promising+therapeutic+target"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21eR"><div class="casContent"><span class="casTitleNuber">21e</span><div class="casTitle"><span class="NLM_cas:atitle">Semicarbazide-sensitive amine oxidase/vascular adhesion protein 1: recent developments concerning substrates and inhibitors of a promising therapeutic target</span></div><div class="casAuthors">Dunkel, P.; Gelain, A.; Barlocco, D.; Haider, N.; Gyires, K.; Sperlagh, B.; Magyar, K.; Maccioni, E.; Fadda, A.; Matyus, P.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1827-1839</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  SSAO/VAP-1 is not only involved in the metab. of biogenic and xenobiotic primary amines and in the prodn. of metabolites with cytotoxic effects or certain physiol. actions, but also plays a role, for example, as an adhesion mol., in leukocyte trafficking, in regulating glucose uptake and in adipocyte homeostasis.  Interest in the enzyme has been stimulated by the findings that the activities of the SSAOs are altered (mostly increased) in various human disorders, including diabetes, congestive heart failure, liver cirrhosis, Alzheimer's disease and several inflammatory diseases, although the underlying causes are often unknown.  On the basis of their insulin-mimicking effect, SSAO substrates are possibly capable of ameliorating metabolic changes in diabetes, while SSAO inhibitors (somewhat of a contradiction) are of potential benefit in preventing diabetes complications, atherosclerosis and oxidative stress contributing to several disorders or modulating inflammation, and hence may be of substantial therapeutic value.  Great efforts have been made to develop novel compds. which may lead to future drugs useful in therapy, based on their effects on SSAO/VAP-1, and some of the results relating to novel substrates and inhibitors are surveyed in the present review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5K-qNJjLyBLVg90H21EOLACvtfcHk0lhKsPN0NIHeng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXovFWnsbs%253D&md5=2c770c22c9ef45837649373b1703cf8d</span></div><a href="/servlet/linkout?suffix=cit21e&amp;dbid=16384&amp;doi=10.2174%2F092986708785133022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986708785133022%26sid%3Dliteratum%253Aachs%26aulast%3DDunkel%26aufirst%3DP.%26aulast%3DGelain%26aufirst%3DA.%26aulast%3DBarlocco%26aufirst%3DD.%26aulast%3DHaider%26aufirst%3DN.%26aulast%3DGyires%26aufirst%3DK.%26aulast%3DSperl%25C3%25A1gh%26aufirst%3DB.%26aulast%3DMagyar%26aufirst%3DK.%26aulast%3DMaccioni%26aufirst%3DE.%26aulast%3DFadda%26aufirst%3DA.%26aulast%3DM%25C3%25A1tyus%26aufirst%3DP.%26atitle%3DSemicarbazide-sensitive%2520amine%2520oxidase%252Fvascular%2520adhesion%2520protein%25201%253A%2520recent%2520developments%2520concerning%2520substrates%2520and%2520inhibitors%2520of%2520a%2520promising%2520therapeutic%2520target%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2008%26volume%3D15%26spage%3D1827%26epage%3D1839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Weinreb, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amit, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bar-Am, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Youdim, M. B.</span><span> </span><span class="NLM_article-title">Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer’s disease treatment</span> <span class="citation_source-journal">Curr. Drug Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">483</span><span class="NLM_x">–</span> <span class="NLM_lpage">494</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=16&amp;doi=10.1021%2Fjm400336x&amp;key=10.2174%2F138945012799499794" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=8&amp;doi=10.1021%2Fjm400336x&amp;key=22280345" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=32&amp;doi=10.1021%2Fjm400336x&amp;key=1%3ACAS%3A528%3ADC%252BC38XkslCmurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=483-494&author=O.+Weinrebauthor=T.+Amitauthor=O.+Bar-Amauthor=M.+B.+Youdim&title=Ladostigil%3A+a+novel+multimodal+neuroprotective+drug+with+cholinesterase+and+brain-selective+monoamine+oxidase+inhibitory+activities+for+Alzheimer%E2%80%99s+disease+treatment"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22aR"><div class="casContent"><span class="casTitleNuber">22a</span><div class="casTitle"><span class="NLM_cas:atitle">Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment</span></div><div class="casAuthors">Weinreb, Orly; Amit, Tamar; Bar-Am, Orit; Youdim, Moussa B. H.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Targets</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">483-494</span>CODEN:
                <span class="NLM_cas:coden">CDTUAU</span>;
        ISSN:<span class="NLM_cas:issn">1389-4501</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Ladostigil [(N-propargyl-(3R) aminoindan-5yl)-Et Me carbamate] is a dual acetylcholine-butyrylcholineesterase and brain selective monoamine oxidase (MAO)-A and -B inhibitor in vivo (with little or no MAO inhibitory effect in the liver and small intestine), intended for the treatment of dementia co-morbid with extrapyramidal disorders and depression (presently in a Phase IIb clin. study).  This suggests that the drug should not cause a significant potentiation of the cardiovascular response to tyramine, thereby making it a potentially safer antidepressant than other irreversible MAO-A inhibitors.  Ladostigil was shown to antagonize scopolamine-induced impairment in spatial memory, indicating that it can cause significant increases in rat brain cholinergic activity.  Furthermore, ladostigil prevented gliosis and oxidative-nitrative stress and reduced the deficits in episodic and spatial memory induced by intracerebroventricular injection of streptozotocin in rats.  Ladostigil was demonstrated to possess potent anti-apoptotic and neuroprotective activities in vitro and in various neurodegenerative rat models, (e.g. hippocampal damage induced by global ischemia in gerbils and cerebral edema induced in mice by closed head injury).  These neuroprotective activities involve regulation of amyloid precursor protein processing; activation of protein kinase C and mitogen-activated protein kinase signaling pathways; inhibition of neuronal death markers; prevention of the fall in mitochondrial membrane potential and upregulation of neurotrophic factors and antioxidative activity.  Recent findings demonstrated that the major metabolite of ladostigil, hydroxy-1-(R)-aminoindan has also a neuroprotective activity and thus, may contribute to the overt activity of its parent compd.  This review will discuss the scientific evidence for the therapeutic potential use of ladostigil in Alzheimer's and Lewy Body diseases and the mol. signaling pathways that are considered to be involved in the biol. activities of the drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSPLqLnccsGLVg90H21EOLACvtfcHk0liDn9BVVOgbuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkslCmurY%253D&md5=2272d945e6eaf132035b6dfc43d2e569</span></div><a href="/servlet/linkout?suffix=cit22a&amp;dbid=16384&amp;doi=10.2174%2F138945012799499794&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138945012799499794%26sid%3Dliteratum%253Aachs%26aulast%3DWeinreb%26aufirst%3DO.%26aulast%3DAmit%26aufirst%3DT.%26aulast%3DBar-Am%26aufirst%3DO.%26aulast%3DYoudim%26aufirst%3DM.%2BB.%26atitle%3DLadostigil%253A%2520a%2520novel%2520multimodal%2520neuroprotective%2520drug%2520with%2520cholinesterase%2520and%2520brain-selective%2520monoamine%2520oxidase%2520inhibitory%2520activities%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%2520treatment%26jtitle%3DCurr.%2520Drug%2520Targets%26date%3D2012%26volume%3D13%26spage%3D483%26epage%3D494" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit22b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Youdim, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridkin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, H.</span><span> </span><span class="NLM_article-title">Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases</span> <span class="citation_source-journal">Mech. Ageing Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">126</span><span class="NLM_x">, </span> <span class="NLM_fpage">317</span><span class="NLM_x">–</span> <span class="NLM_lpage">326</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=16&amp;doi=10.1021%2Fjm400336x&amp;key=10.1016%2Fj.mad.2004.08.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=8&amp;doi=10.1021%2Fjm400336x&amp;key=15621213" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=32&amp;doi=10.1021%2Fjm400336x&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtFGhsbzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2005&pages=317-326&author=M.+B.+Youdimauthor=M.+Fridkinauthor=H.+Zheng&title=Bifunctional+drug+derivatives+of+MAO-B+inhibitor+rasagiline+and+iron+chelator+VK-28+as+a+more+effective+approach+to+treatment+of+brain+ageing+and+ageing+neurodegenerative+diseases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22bR"><div class="casContent"><span class="casTitleNuber">22b</span><div class="casTitle"><span class="NLM_cas:atitle">Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases</span></div><div class="casAuthors">Youdim, Moussa B. H.; Fridkin, Mati; Zheng, Hailin</div><div class="citationInfo"><span class="NLM_cas:title">Mechanisms of Ageing and Development</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">317-326</span>CODEN:
                <span class="NLM_cas:coden">MAGDA3</span>;
        ISSN:<span class="NLM_cas:issn">0047-6374</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Degeneration of nigrostriatal dopamine neurons and cholinergic cortical neurons are the main pathol. features of Parkinson's disease (PD) and for the cognitive deficit in dementia of the Alzheimer' type (AD) and in dementia with Lewy bodies (DLB), resp.  Many PD and DLB subjects have dementia and depression resulting from possible degeneration of cholinergic and noradrenergic and serotonergic neurons.  On the other hand, AD patients may also develop extrapyramidal features as well as depression.  In both PD and AD there is, resp., accumulation of iron within the melanin contg. dopamine neurons of pars compacta and with in the plaques and tangle.  It has been suggested that iron accumulation may contribute to the oxidative stress induced apoptosis reported in both diseases.  This may result from increased glia hydrogen peroxide producing monoamine oxidase (MAO) activity that can generate of reactive hydroxyl radical formed from interaction of iron and hydrogen peroxide.  We have therefore prepd. a series of novel bifunctional drugs from the neuroprotective-antiapoptotic antiparkinson monoamine oxidase B inhibitor, rasagiline, by introducing a carbamate cholinesterase (ChE) inhibitory moiety into it.  Ladostigil ((TV-3326, N-propargyl-3R-aminoindan-5yl)-Et methylcarbamate), has both ChE and MAO-AB inhibitory activity, as potential treatment of AD and DLB or PD subjects with dementia Being a brain selective MAO-AB inhibitor it has limited potentiation of the pressor response to oral tyramine and exhibits antidepressant activity similar to classical non-selective MAO inhibitor antidepressants by increasing brain serotonin and noradrenaline.  Ladostigil inhibits brain acetyl and butyrylcholinesterase in rats and antagonizes scopolamine-induced inhibition of spatial learning.  Ladostigil like MAO-B inhibitor it prevents MPTP Parkinsonism in mice model and retains the in vitro and in vivo neuroprotective activity of rasagiline.  Ladostigil, rasagiline and other propargylamines have been demonstrated to have neuroprotective activity in several in vitro and in vivo models, which have been shown be assocd. with propargylamines moiety, since propargylamines itself possess these properties.  The mechanism of neuroprotective activity has been attributed to the ability of propargylamines-inducing the antiapoptotic family proteins Bcl-2 and Bcl-xl, while decreasing Bad and Bax and preventing opening of mitochondrial permeability transition pore.  Iron accumulates in brain regions assocd. with neurodegenerative diseases of PD, AD, amyotrophic lateral sclerosis and Huntington disease.  It is thought to be involved in Fenton chem. oxidative stress obsd. in these diseases.  The neuroprotective activity of propargylamines led us to develop several novel bifunctional iron chelator from our prototype brain permeable iron chelators, VK-28, possessing propargylamine moiety (HLA-20, M30 and M30A) to iron out iron from the brain.  These compds. have been shown to have iron chelating and monoamine oxidase A and B selective brain inhibitory and neuroprotective-antiapoptotic actions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrI9NJwCsPUzLVg90H21EOLACvtfcHk0liDn9BVVOgbuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtFGhsbzN&md5=7c5bef9011b669fffccd501b07ed8455</span></div><a href="/servlet/linkout?suffix=cit22b&amp;dbid=16384&amp;doi=10.1016%2Fj.mad.2004.08.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mad.2004.08.023%26sid%3Dliteratum%253Aachs%26aulast%3DYoudim%26aufirst%3DM.%2BB.%26aulast%3DFridkin%26aufirst%3DM.%26aulast%3DZheng%26aufirst%3DH.%26atitle%3DBifunctional%2520drug%2520derivatives%2520of%2520MAO-B%2520inhibitor%2520rasagiline%2520and%2520iron%2520chelator%2520VK-28%2520as%2520a%2520more%2520effective%2520approach%2520to%2520treatment%2520of%2520brain%2520ageing%2520and%2520ageing%2520neurodegenerative%2520diseases%26jtitle%3DMech.%2520Ageing%2520Dev.%26date%3D2005%26volume%3D126%26spage%3D317%26epage%3D326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit22c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Samadi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de los Ríos, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolea, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chioua, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iriepa, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moraleda, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartolini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrisano, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gálvez, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valderas, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Unzeta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marco-Contelles, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Multipotent, M. A. O.</span><span> </span><span class="NLM_article-title">and cholinesterase inhibitors for the treatment of Alzheimer’s disease: synthesis, pharmacological analysis and molecular modeling of heterocyclic substituted alkyl and cycloalkyl propargyl amine</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">251</span><span class="NLM_x">–</span> <span class="NLM_lpage">262</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2012&pages=251-262&author=A.+Samadiauthor=C.+de+los+R%C3%ADosauthor=I.+Boleaauthor=M.+Chiouaauthor=I.+Iriepaauthor=I.+Moraledaauthor=M.+Bartoliniauthor=V.+Andrisanoauthor=E.+G%C3%A1lvezauthor=C.+Valderasauthor=M.+Unzetaauthor=J.+Marco-Contellesauthor=M.+A.+O.+Multipotent&title=and+cholinesterase+inhibitors+for+the+treatment+of+Alzheimer%E2%80%99s+disease%3A+synthesis%2C+pharmacological+analysis+and+molecular+modeling+of+heterocyclic+substituted+alkyl+and+cycloalkyl+propargyl+amine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSamadi%26aufirst%3DA.%26aulast%3Dde%2Blos%2BR%25C3%25ADos%26aufirst%3DC.%26aulast%3DBolea%26aufirst%3DI.%26aulast%3DChioua%26aufirst%3DM.%26aulast%3DIriepa%26aufirst%3DI.%26aulast%3DMoraleda%26aufirst%3DI.%26aulast%3DBartolini%26aufirst%3DM.%26aulast%3DAndrisano%26aufirst%3DV.%26aulast%3DG%25C3%25A1lvez%26aufirst%3DE.%26aulast%3DValderas%26aufirst%3DC.%26aulast%3DUnzeta%26aufirst%3DM.%26aulast%3DMarco-Contelles%26aufirst%3DJ.%26aulast%3DMultipotent%26aufirst%3DM.%2BA.%2BO.%26atitle%3Dand%2520cholinesterase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%253A%2520synthesis%252C%2520pharmacological%2520analysis%2520and%2520molecular%2520modeling%2520of%2520heterocyclic%2520substituted%2520alkyl%2520and%2520cycloalkyl%2520propargyl%2520amine%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2012%26volume%3D52%26spage%3D251%26epage%3D262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit22d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Bolea, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juárez-Jiménez, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Los Ríos, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chioua, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pouplana, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luque, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Unzeta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marco-Contelles, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samadi, A.</span><span> </span><span class="NLM_article-title">Synthesis, biological evaluation, and molecular modeling of donepezil and <i>N</i>-[(5-(benzyloxy)-1-methyl-1<i>H</i>-indol-2-yl)methyl]-<i>N</i>-methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer’s disease</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">8251</span><span class="NLM_x">–</span> <span class="NLM_lpage">8270</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm200853t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=8251-8270&author=I.+Boleaauthor=J.+Ju%C3%A1rez-Jim%C3%A9nezauthor=C.+de+Los+R%C3%ADosauthor=M.+Chiouaauthor=R.+Pouplanaauthor=F.+J.+Luqueauthor=M.+Unzetaauthor=J.+Marco-Contellesauthor=A.+Samadi&title=Synthesis%2C+biological+evaluation%2C+and+molecular+modeling+of+donepezil+and+N-%5B%285-%28benzyloxy%29-1-methyl-1H-indol-2-yl%29methyl%5D-N-methylprop-2-yn-1-amine+hybrids+as+new+multipotent+cholinesterase%2Fmonoamine+oxidase+inhibitors+for+the+treatment+of+Alzheimer%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22d&amp;dbid=16384&amp;doi=10.1021%2Fjm200853t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200853t%26sid%3Dliteratum%253Aachs%26aulast%3DBolea%26aufirst%3DI.%26aulast%3DJu%25C3%25A1rez-Jim%25C3%25A9nez%26aufirst%3DJ.%26aulast%3Dde%2BLos%2BR%25C3%25ADos%26aufirst%3DC.%26aulast%3DChioua%26aufirst%3DM.%26aulast%3DPouplana%26aufirst%3DR.%26aulast%3DLuque%26aufirst%3DF.%2BJ.%26aulast%3DUnzeta%26aufirst%3DM.%26aulast%3DMarco-Contelles%26aufirst%3DJ.%26aulast%3DSamadi%26aufirst%3DA.%26atitle%3DSynthesis%252C%2520biological%2520evaluation%252C%2520and%2520molecular%2520modeling%2520of%2520donepezil%2520and%2520N-%255B%25285-%2528benzyloxy%2529-1-methyl-1H-indol-2-yl%2529methyl%255D-N-methylprop-2-yn-1-amine%2520hybrids%2520as%2520new%2520multipotent%2520cholinesterase%252Fmonoamine%2520oxidase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D8251%26epage%3D8270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Chen, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steyn, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staal, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petzer, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van der Schyf, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castagnoli, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sonsalla, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castagnoli, N.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwarzschild, M. A.</span><span> </span><span class="NLM_article-title">8-(3-Chlorostyryl)caffeine may attenuate MPTP neurotoxicity through dual actions of monoamine oxidase inhibition and A<sub>2A</sub> receptor antagonism</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">277</span><span class="NLM_x">, </span> <span class="NLM_fpage">36040</span><span class="NLM_x">–</span> <span class="NLM_lpage">36044</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2002&pages=36040-36044&author=J.+F.+Chenauthor=S.+Steynauthor=R.+Staalauthor=J.+P.+Petzerauthor=K.+Xuauthor=C.+J.+Van+der+Schyfauthor=K.+Castagnoliauthor=P.+K.+Sonsallaauthor=N.+Castagnoliauthor=M.+A.+Schwarzschild&title=8-%283-Chlorostyryl%29caffeine+may+attenuate+MPTP+neurotoxicity+through+dual+actions+of+monoamine+oxidase+inhibition+and+A2A+receptor+antagonism"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%2BF.%26aulast%3DSteyn%26aufirst%3DS.%26aulast%3DStaal%26aufirst%3DR.%26aulast%3DPetzer%26aufirst%3DJ.%2BP.%26aulast%3DXu%26aufirst%3DK.%26aulast%3DVan%2Bder%2BSchyf%26aufirst%3DC.%2BJ.%26aulast%3DCastagnoli%26aufirst%3DK.%26aulast%3DSonsalla%26aufirst%3DP.%2BK.%26aulast%3DCastagnoli%26aufirst%3DN.%26aulast%3DSchwarzschild%26aufirst%3DM.%2BA.%26atitle%3D8-%25283-Chlorostyryl%2529caffeine%2520may%2520attenuate%2520MPTP%2520neurotoxicity%2520through%2520dual%2520actions%2520of%2520monoamine%2520oxidase%2520inhibition%2520and%2520A2A%2520receptor%2520antagonism%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2002%26volume%3D277%26spage%3D36040%26epage%3D36044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit23b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Aguiar, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macêdo, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vasconcelos, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliveira, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Sousa, F. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viana, G. S.</span><span> </span><span class="NLM_article-title">CSC, an adenosine A(2A) receptor antagonist and MAO B inhibitor, reverses behavior, monoamine neurotransmission, and amino acid alterations in the 6-OHDA-lesioned rats</span> <span class="citation_source-journal">Brain Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">1191</span><span class="NLM_x">, </span> <span class="NLM_fpage">192</span><span class="NLM_x">–</span> <span class="NLM_lpage">199</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23b&amp;dbid=16&amp;doi=10.1021%2Fjm400336x&amp;key=10.1016%2Fj.brainres.2007.11.051" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23b&amp;dbid=8&amp;doi=10.1021%2Fjm400336x&amp;key=18164694" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23b&amp;dbid=32&amp;doi=10.1021%2Fjm400336x&amp;key=1%3ACAS%3A528%3ADC%252BD1cXosFOhsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1191&publication_year=2008&pages=192-199&author=L.+M.+Aguiarauthor=D.+S.+Mac%C3%AAdoauthor=S.+M.+Vasconcelosauthor=A.+A.+Oliveiraauthor=F.+C.+de+Sousaauthor=G.+S.+Viana&title=CSC%2C+an+adenosine+A%282A%29+receptor+antagonist+and+MAO+B+inhibitor%2C+reverses+behavior%2C+monoamine+neurotransmission%2C+and+amino+acid+alterations+in+the+6-OHDA-lesioned+rats"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23bR"><div class="casContent"><span class="casTitleNuber">23b</span><div class="casTitle"><span class="NLM_cas:atitle">CSC, an adenosine A2A receptor antagonist and MAO B inhibitor, reverses behavior, monoamine neurotransmission, and amino acid alterations in the 6-OHDA-lesioned rats</span></div><div class="casAuthors">Aguiar, Lissiana M. V.; Macedo, Danielle S.; Vasconcelos, Silvania M. M.; Oliveira, Aline A.; de Sousa, F. Clea F.; Viana, Glauce S. B.</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">1191</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">192-199</span>CODEN:
                <span class="NLM_cas:coden">BRREAP</span>;
        ISSN:<span class="NLM_cas:issn">0006-8993</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The present work showed the effects of 8-(-3-chlorostyryl)-caffeine (CSC), an A2A receptors antagonist and MAO B inhibitor, on behavior and biochem. alterations in 6-OHDA-lesioned rats.  Male Wistar rats (280 g) were injected with CSC (1 and 5 mg/kg, i.p.) alone or combined with -DOPA (50 mg/kg + benserazide 12.5 mg/kg), starting 6 days after the striatal 6-OHDA lesions, and once daily for the next 7 days.  Fourteen days after the 6-OHDA lesion (and 24 h after CSC or vehicle), the no. of net body rotations/h (after the apomorphine challenge) was recorded and, at the next day, animals were sacrificed.  The ipsilateral striatum was used for HPLC measurements of monoamines and amino acids or for detn. of nitrite contents and lipid peroxidn.  Results showed that the increase in body rotation, induced by the 6-OHDA lesion, after the apomorphine challenge, was significantly and dose-dependently reversed by CSC.  Furthermore, the decreased striatal levels of DA and metabolites, in the 6-OHDA-lesioned rats, were reversed after CSC treatment, and these effects were potentiated after the combination with -DOPA.  Similar results were obsd. with NE, 5-HT and 5-HIAA.  While glutamate and GABA were increased in the 6-OHDA-lesioned group, CSC alone or mainly combined with -DOPA reversed these alterations.  In addn., the CSC treatment of 6-OHDA-lesioned rats reversed the increased nitrite formation and lipid peroxidn. induced by 6-OHDA.  In conclusion, CSC by means of its dual action as A2A antagonist and MAO-B inhibitor reversed behavior and biochem. alterations, obsd. in the 6-OHDA-lesioned rats, pointing out to its potential benefit for the treatment of PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQGeGo0gzm57Vg90H21EOLACvtfcHk0liFQzTIxbBobA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXosFOhsQ%253D%253D&md5=fa1a78f82d4872989baec9dd05737f6e</span></div><a href="/servlet/linkout?suffix=cit23b&amp;dbid=16384&amp;doi=10.1016%2Fj.brainres.2007.11.051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.brainres.2007.11.051%26sid%3Dliteratum%253Aachs%26aulast%3DAguiar%26aufirst%3DL.%2BM.%26aulast%3DMac%25C3%25AAdo%26aufirst%3DD.%2BS.%26aulast%3DVasconcelos%26aufirst%3DS.%2BM.%26aulast%3DOliveira%26aufirst%3DA.%2BA.%26aulast%3Dde%2BSousa%26aufirst%3DF.%2BC.%26aulast%3DViana%26aufirst%3DG.%2BS.%26atitle%3DCSC%252C%2520an%2520adenosine%2520A%25282A%2529%2520receptor%2520antagonist%2520and%2520MAO%2520B%2520inhibitor%252C%2520reverses%2520behavior%252C%2520monoamine%2520neurotransmission%252C%2520and%2520amino%2520acid%2520alterations%2520in%2520the%25206-OHDA-lesioned%2520rats%26jtitle%3DBrain%2520Res.%26date%3D2008%26volume%3D1191%26spage%3D192%26epage%3D199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit23c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Petzer, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castagnoli, N.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwarzschild, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van der Schyf, C. J.</span><span> </span><span class="NLM_article-title">Dual-target-directed drugs that block monoamine oxidase B and adenosine A<sub>2A</sub> receptors for Parkinson’s disease</span> <span class="citation_source-journal">Neurotherapeutics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">41</span><span class="NLM_x">–</span> <span class="NLM_lpage">151</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2009&pages=41-151&issue=1&author=J.+P.+Petzerauthor=N.+Castagnoliauthor=M.+A.+Schwarzschildauthor=J.+F.+Chenauthor=C.+J.+Van+der+Schyf&title=Dual-target-directed+drugs+that+block+monoamine+oxidase+B+and+adenosine+A2A+receptors+for+Parkinson%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPetzer%26aufirst%3DJ.%2BP.%26aulast%3DCastagnoli%26aufirst%3DN.%26aulast%3DSchwarzschild%26aufirst%3DM.%2BA.%26aulast%3DChen%26aufirst%3DJ.%2BF.%26aulast%3DVan%2Bder%2BSchyf%26aufirst%3DC.%2BJ.%26atitle%3DDual-target-directed%2520drugs%2520that%2520block%2520monoamine%2520oxidase%2520B%2520and%2520adenosine%2520A2A%2520receptors%2520for%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DNeurotherapeutics%26date%3D2009%26volume%3D6%26issue%3D1%26spage%3D41%26epage%3D151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Petzer, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steyn, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castagnoli, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwarzschild, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van der Schyf, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castagnoli, N.</span><span> </span><span class="NLM_article-title">Inhibition of monoamine oxidase B by selective adenosine A<sub>2A</sub> receptor antagonists</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1299</span><span class="NLM_x">–</span> <span class="NLM_lpage">1310</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2003&pages=1299-1310&author=J.+P.+Petzerauthor=S.+Steynauthor=K.+P.+Castagnoliauthor=J.+F.+Chenauthor=M.+A.+Schwarzschildauthor=C.+J.+Van+der+Schyfauthor=N.+Castagnoli&title=Inhibition+of+monoamine+oxidase+B+by+selective+adenosine+A2A+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPetzer%26aufirst%3DJ.%2BP.%26aulast%3DSteyn%26aufirst%3DS.%26aulast%3DCastagnoli%26aufirst%3DK.%2BP.%26aulast%3DChen%26aufirst%3DJ.%2BF.%26aulast%3DSchwarzschild%26aufirst%3DM.%2BA.%26aulast%3DVan%2Bder%2BSchyf%26aufirst%3DC.%2BJ.%26aulast%3DCastagnoli%26aufirst%3DN.%26atitle%3DInhibition%2520of%2520monoamine%2520oxidase%2520B%2520by%2520selective%2520adenosine%2520A2A%2520receptor%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2003%26volume%3D11%26spage%3D1299%26epage%3D1310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit24b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Pretorius, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castagnoli, N.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergh, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petzer, J. P.</span><span> </span><span class="NLM_article-title">Dual inhibition of monoamine oxidase B and antagonism of the adenosine A<sub>2A</sub> receptor by (<i>E</i>,<i>E</i>)-8-(4-phenylbutadien-1-yl)caffeine analogues</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">8676</span><span class="NLM_x">–</span> <span class="NLM_lpage">8684</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2008&pages=8676-8684&author=J.+Pretoriusauthor=S.+Malanauthor=N.+Castagnoliauthor=J.+J.+Berghauthor=J.+P.+Petzer&title=Dual+inhibition+of+monoamine+oxidase+B+and+antagonism+of+the+adenosine+A2A+receptor+by+%28E%2CE%29-8-%284-phenylbutadien-1-yl%29caffeine+analogues"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPretorius%26aufirst%3DJ.%26aulast%3DMalan%26aufirst%3DS.%26aulast%3DCastagnoli%26aufirst%3DN.%26aulast%3DBergh%26aufirst%3DJ.%2BJ.%26aulast%3DPetzer%26aufirst%3DJ.%2BP.%26atitle%3DDual%2520inhibition%2520of%2520monoamine%2520oxidase%2520B%2520and%2520antagonism%2520of%2520the%2520adenosine%2520A2A%2520receptor%2520by%2520%2528E%252CE%2529-8-%25284-phenylbutadien-1-yl%2529caffeine%2520analogues%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2008%26volume%3D16%26spage%3D8676%26epage%3D8684" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit24c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Rivara, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piersanti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartoccini, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diamantini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pala, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riccioni, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stasi, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cabri, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borsini, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mor, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarzia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minetti, P.</span><span> </span><span class="NLM_article-title">Synthesis of (<i>E</i>)-8-(3-chlorostyryl)caffeine analogues leading to 9-deazaxanthine derivatives as dual A<sub>2A</sub> antagonists/MAO-B inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">1247</span><span class="NLM_x">–</span> <span class="NLM_lpage">1261</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm301686s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=1247-1261&author=S.+Rivaraauthor=G.+Piersantiauthor=F.+Bartocciniauthor=G.+Diamantiniauthor=D.+Palaauthor=T.+Riccioniauthor=M.+A.+Stasiauthor=W.+Cabriauthor=F.+Borsiniauthor=M.+Morauthor=G.+Tarziaauthor=P.+Minetti&title=Synthesis+of+%28E%29-8-%283-chlorostyryl%29caffeine+analogues+leading+to+9-deazaxanthine+derivatives+as+dual+A2A+antagonists%2FMAO-B+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24c&amp;dbid=16384&amp;doi=10.1021%2Fjm301686s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301686s%26sid%3Dliteratum%253Aachs%26aulast%3DRivara%26aufirst%3DS.%26aulast%3DPiersanti%26aufirst%3DG.%26aulast%3DBartoccini%26aufirst%3DF.%26aulast%3DDiamantini%26aufirst%3DG.%26aulast%3DPala%26aufirst%3DD.%26aulast%3DRiccioni%26aufirst%3DT.%26aulast%3DStasi%26aufirst%3DM.%2BA.%26aulast%3DCabri%26aufirst%3DW.%26aulast%3DBorsini%26aufirst%3DF.%26aulast%3DMor%26aufirst%3DM.%26aulast%3DTarzia%26aufirst%3DG.%26aulast%3DMinetti%26aufirst%3DP.%26atitle%3DSynthesis%2520of%2520%2528E%2529-8-%25283-chlorostyryl%2529caffeine%2520analogues%2520leading%2520to%25209-deazaxanthine%2520derivatives%2520as%2520dual%2520A2A%2520antagonists%252FMAO-B%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D1247%26epage%3D1261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Müller, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thorand, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qurishi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diekmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padgett, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daly, J. W.</span><span> </span><span class="NLM_article-title">Imidazo[2,1-<i>i</i>]purin-5-ones and related tricyclic water-soluble purine derivatives: potent A<sub>2A</sub>- and A<sub>3</sub>-adenosine receptor antagonists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">3440</span><span class="NLM_x">–</span> <span class="NLM_lpage">3450</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm011093d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=3440-3450&author=C.+E.+M%C3%BCllerauthor=M.+Thorandauthor=R.+Qurishiauthor=M.+Diekmannauthor=K.+A.+Jacobsonauthor=W.+L.+Padgettauthor=J.+W.+Daly&title=Imidazo%5B2%2C1-i%5Dpurin-5-ones+and+related+tricyclic+water-soluble+purine+derivatives%3A+potent+A2A-+and+A3-adenosine+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm011093d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm011093d%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26aulast%3DThorand%26aufirst%3DM.%26aulast%3DQurishi%26aufirst%3DR.%26aulast%3DDiekmann%26aufirst%3DM.%26aulast%3DJacobson%26aufirst%3DK.%2BA.%26aulast%3DPadgett%26aufirst%3DW.%2BL.%26aulast%3DDaly%26aufirst%3DJ.%2BW.%26atitle%3DImidazo%255B2%252C1-i%255Dpurin-5-ones%2520and%2520related%2520tricyclic%2520water-soluble%2520purine%2520derivatives%253A%2520potent%2520A2A-%2520and%2520A3-adenosine%2520receptor%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D3440%26epage%3D3450" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Vollmann, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qurishi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hockemeyer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, C. E.</span><span> </span><span class="NLM_article-title">Synthesis and properties of a new water-soluble prodrug of the adenosine A<sub>2A</sub> receptor antagonist MSX-2</span> <span class="citation_source-journal">Molecules</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">348</span><span class="NLM_x">–</span> <span class="NLM_lpage">359</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2008&pages=348-359&author=K.+Vollmannauthor=R.+Qurishiauthor=J.+Hockemeyerauthor=C.+E.+M%C3%BCller&title=Synthesis+and+properties+of+a+new+water-soluble+prodrug+of+the+adenosine+A2A+receptor+antagonist+MSX-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVollmann%26aufirst%3DK.%26aulast%3DQurishi%26aufirst%3DR.%26aulast%3DHockemeyer%26aufirst%3DJ.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26atitle%3DSynthesis%2520and%2520properties%2520of%2520a%2520new%2520water-soluble%2520prodrug%2520of%2520the%2520adenosine%2520A2A%2520receptor%2520antagonist%2520MSX-2%26jtitle%3DMolecules%26date%3D2008%26volume%3D13%26spage%3D348%26epage%3D359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Hockemeyer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burbiel, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, C. E.</span><span> </span><span class="NLM_article-title">Multigram-scale syntheses, stability, and photoreactions of A<sub>2A</sub> adenosine receptor antagonists with 8-styrylxanthine structure: potential drugs for Parkinson’s disease</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">3308</span><span class="NLM_x">–</span> <span class="NLM_lpage">3318</span></span><div class="citationLinks">[<a href="/doi/10.1021/jo0358574" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2004&pages=3308-3318&author=J.+Hockemeyerauthor=J.+C.+Burbielauthor=C.+E.+M%C3%BCller&title=Multigram-scale+syntheses%2C+stability%2C+and+photoreactions+of+A2A+adenosine+receptor+antagonists+with+8-styrylxanthine+structure%3A+potential+drugs+for+Parkinson%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27a&amp;dbid=16384&amp;doi=10.1021%2Fjo0358574&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo0358574%26sid%3Dliteratum%253Aachs%26aulast%3DHockemeyer%26aufirst%3DJ.%26aulast%3DBurbiel%26aufirst%3DJ.%2BC.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26atitle%3DMultigram-scale%2520syntheses%252C%2520stability%252C%2520and%2520photoreactions%2520of%2520A2A%2520adenosine%2520receptor%2520antagonists%2520with%25208-styrylxanthine%2520structure%253A%2520potential%2520drugs%2520for%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2004%26volume%3D69%26spage%3D3308%26epage%3D3318" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit27b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Müller, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schobert, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hipp, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geis, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frobenius, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pawłowski, M.</span><span> </span><span class="NLM_article-title">Configurationally stable analogs of 8-styrylxanthines as A<sub>2A</sub>-adenosine receptor antagonists</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">709</span><span class="NLM_x">–</span> <span class="NLM_lpage">719</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1997&pages=709-719&author=C.+E.+M%C3%BCllerauthor=U.+Schobertauthor=J.+Hippauthor=U.+Geisauthor=W.+Frobeniusauthor=M.+Paw%C5%82owski&title=Configurationally+stable+analogs+of+8-styrylxanthines+as+A2A-adenosine+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26aulast%3DSchobert%26aufirst%3DU.%26aulast%3DHipp%26aufirst%3DJ.%26aulast%3DGeis%26aufirst%3DU.%26aulast%3DFrobenius%26aufirst%3DW.%26aulast%3DPaw%25C5%2582owski%26aufirst%3DM.%26atitle%3DConfigurationally%2520stable%2520analogs%2520of%25208-styrylxanthines%2520as%2520A2A-adenosine%2520receptor%2520antagonists%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D1997%26volume%3D32%26spage%3D709%26epage%3D719" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit27c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Nonaka, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimada, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nonaka, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koike, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aoki, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kase, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, F.</span><span> </span><span class="NLM_article-title">Photoisomerization of a potent and selective adenosine A<sub>2</sub> antagonist, (<i>E</i>)-1,3-dipropyl-8-(3,4-dimethoxystyryl)-7-methylxanthine</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">3731</span><span class="NLM_x">–</span> <span class="NLM_lpage">3733</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm00075a031" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1993&pages=3731-3733&author=Y.+Nonakaauthor=J.+Shimadaauthor=H.+Nonakaauthor=N.+Koikeauthor=N.+Aokiauthor=H.+Kobayashiauthor=H.+Kaseauthor=K.+Yamaguchiauthor=F.+Suzuki&title=Photoisomerization+of+a+potent+and+selective+adenosine+A2+antagonist%2C+%28E%29-1%2C3-dipropyl-8-%283%2C4-dimethoxystyryl%29-7-methylxanthine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27c&amp;dbid=16384&amp;doi=10.1021%2Fjm00075a031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00075a031%26sid%3Dliteratum%253Aachs%26aulast%3DNonaka%26aufirst%3DY.%26aulast%3DShimada%26aufirst%3DJ.%26aulast%3DNonaka%26aufirst%3DH.%26aulast%3DKoike%26aufirst%3DN.%26aulast%3DAoki%26aufirst%3DN.%26aulast%3DKobayashi%26aufirst%3DH.%26aulast%3DKase%26aufirst%3DH.%26aulast%3DYamaguchi%26aufirst%3DK.%26aulast%3DSuzuki%26aufirst%3DF.%26atitle%3DPhotoisomerization%2520of%2520a%2520potent%2520and%2520selective%2520adenosine%2520A2%2520antagonist%252C%2520%2528E%2529-1%252C3-dipropyl-8-%25283%252C4-dimethoxystyryl%2529-7-methylxanthine%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1993%26volume%3D36%26spage%3D3731%26epage%3D3733" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Leistner, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gütschow, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stach, J.</span><span> </span><span class="NLM_article-title">2-Amino-3,1-benzothiazin-4-ones: synthesis, Dimroth rearrangement to quinazolin-4(3<i>H</i>)-on-2(1<i>H</i>)-thiones, and MS/MS-fragmentation</span> <span class="citation_source-journal">Arch. Pharm. (Weinheim, Ger.)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">323</span><span class="NLM_x">, </span> <span class="NLM_fpage">857</span><span class="NLM_x">–</span> <span class="NLM_lpage">861</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Fjm400336x&amp;key=10.1002%2Fardp.19903231009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Fjm400336x&amp;key=1%3ACAS%3A528%3ADyaK3MXkt1Ohug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=323&publication_year=1990&pages=857-861&author=S.+Leistnerauthor=M.+G%C3%BCtschowauthor=J.+Stach&title=2-Amino-3%2C1-benzothiazin-4-ones%3A+synthesis%2C+Dimroth+rearrangement+to+quinazolin-4%283H%29-on-2%281H%29-thiones%2C+and+MS%2FMS-fragmentation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Polycyclic azines.  XXV.  2-amino-3,1-benzothiazin-4-ones:  synthesis, dimroth-rearrangement to quinazolin-4-(3H)-thiones, and MS/MS-fragmentation</span></div><div class="casAuthors">Leistner, Siegfried; Guetschow, Michael; Stach, Joachim</div><div class="citationInfo"><span class="NLM_cas:title">Archiv der Pharmazie (Weinheim, Germany)</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">323</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">857-61</span>CODEN:
                <span class="NLM_cas:coden">ARPMAS</span>;
        ISSN:<span class="NLM_cas:issn">0365-6233</span>.
    </div><div class="casAbstract">The intramol. cyclocondensation reaction of benzoylthiourea derivs., e.g. 4,2-RR1C6H3NHC(:S)NHCOPh (R = H, Me, Cl; R1 = CO2Me, CO2H, cyano) gave 2-amino-1,3-benzothiazin-4-ones I (same R).  Dimroth rearrangement of I gave quinazolin-2-thiones II (same R).  The cyclocondensation of 4,2-RR1C6H3NHC(:S)NHCOPh (R = H, Me, Cl; R1 = CO2Me, CO2H) gave 2-(benzoylamino)-1,3-benzothiazin-4-ones.  I (R = H) had antianaphylactic activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqS8r3YiDuw6rVg90H21EOLACvtfcHk0lhlGWwE9BgPgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXkt1Ohug%253D%253D&md5=42d31c65137a42a990daee2256d866bc</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1002%2Fardp.19903231009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fardp.19903231009%26sid%3Dliteratum%253Aachs%26aulast%3DLeistner%26aufirst%3DS.%26aulast%3DG%25C3%25BCtschow%26aufirst%3DM.%26aulast%3DStach%26aufirst%3DJ.%26atitle%3D2-Amino-3%252C1-benzothiazin-4-ones%253A%2520synthesis%252C%2520Dimroth%2520rearrangement%2520to%2520quinazolin-4%25283H%2529-on-2%25281H%2529-thiones%252C%2520and%2520MS%252FMS-fragmentation%26jtitle%3DArch.%2520Pharm.%2520%2528Weinheim%252C%2520Ger.%2529%26date%3D1990%26volume%3D323%26spage%3D857%26epage%3D861" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Müller, C. E.; Hockemeyer, J.; Tzvetkov, N.; Burbiel, J.</span><span> </span><span class="NLM_article-title">Preparation of 8-ethynyl-xanthine derivatives as selective A<sub>2A</sub> receptor antagonists</span>, PCT Int. Appl., 2008077557, 03 Jul<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=C.+E.+M%C3%BCller&author=J.+Hockemeyer&author=N.+Tzvetkov&author=J.+Burbiel&title=Preparation+of+8-ethynyl-xanthine+derivatives+as+selective+A2A+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26atitle%3DPreparation%2520of%25208-ethynyl-xanthine%2520derivatives%2520as%2520selective%2520A2A%2520receptor%2520antagonists%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Travis, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sivakumar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollist, G. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borhan, B.</span><span> </span><span class="NLM_article-title">Facile oxidation of aldehydes to acids and esters with oxone</span> <span class="citation_source-journal">Org. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">1031</span><span class="NLM_x">–</span> <span class="NLM_lpage">1034</span></span><div class="citationLinks">[<a href="/doi/10.1021/ol0340078" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm400336x&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhvVygt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2003&pages=1031-1034&author=B.+R.+Travisauthor=M.+Sivakumarauthor=G.+O.+Hollistauthor=B.+Borhan&title=Facile+oxidation+of+aldehydes+to+acids+and+esters+with+oxone"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Facile Oxidation of Aldehydes to Acids and Esters with Oxone</span></div><div class="casAuthors">Travis, Benjamin R.; Sivakumar, Meenakshi; Hollist, G. Olatunji; Borhan, Babak</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1031-1034</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A highly efficient, mild, and simple protocol is presented for the oxidn. of aldehydes to carboxylic acids utilizing Oxone as the sole oxidant.  Direct conversion of aldehydes in alc. solvents to their corresponding ester products is also reported.  These reactions may prove to be valuable alternatives to traditional metal-mediated oxidns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-7dhAYUVfTbVg90H21EOLACvtfcHk0lhlGWwE9BgPgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhvVygt7c%253D&md5=0bf08019bd6f51b3d0e26d6c43954dd3</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fol0340078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol0340078%26sid%3Dliteratum%253Aachs%26aulast%3DTravis%26aufirst%3DB.%2BR.%26aulast%3DSivakumar%26aufirst%3DM.%26aulast%3DHollist%26aufirst%3DG.%2BO.%26aulast%3DBorhan%26aufirst%3DB.%26atitle%3DFacile%2520oxidation%2520of%2520aldehydes%2520to%2520acids%2520and%2520esters%2520with%2520oxone%26jtitle%3DOrg.%2520Lett.%26date%3D2003%26volume%3D5%26spage%3D1031%26epage%3D1034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Neumann, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gütschow, M.</span><span> </span><span class="NLM_article-title">3,1-Benzothiazin-4-ones and 3,1-benzoxazin-4-ones: highly different activities in chymotrypsin inactivation</span> <span class="citation_source-journal">Bioorg. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">72</span><span class="NLM_x">–</span> <span class="NLM_lpage">88</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Fjm400336x&amp;key=10.1006%2Fbioo.1995.1006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Fjm400336x&amp;key=1%3ACAS%3A528%3ADyaK2MXkvFemtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1995&pages=72-88&author=U.+Neumannauthor=M.+G%C3%BCtschow&title=3%2C1-Benzothiazin-4-ones+and+3%2C1-benzoxazin-4-ones%3A+highly+different+activities+in+chymotrypsin+inactivation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">3,1-Benzothiazin-4-ones and 3,1-benzoxazin-4-ones: highly different activities in chymotrypsin inactivation</span></div><div class="casAuthors">Neumann, U.; Guetschow, M.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">72-88</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    
            (<span class="NLM_cas:orgname">Academic</span>)
        </div><div class="casAbstract">3,1-Benzothiazin-4-ones are sulfur analogs of the potent serine protease inactivators of the 3,1-benzoxazin-4-one type, which acylate the serine residue within the active site of the enzymes.  A series of 2-amino-3,1-benzothiazinones was synthesized, but these compds. showed only very little inhibitory activity toward chymotrypsin, a model serine protease.  Detailed investigations revealed that benzothiazinones and benzoxazinones react with identical mechanisms, but benzothiazinones acylate chymotrypsin with much lower rate consts.  Investigations of nonenzymic hydrolysis showed the benzothiazinones to be intrinsically more stable than benzoxazinones.  It was concluded from spectroscopic results, that benzoxazinones are highly activated due to the absence of ester-like resonance.  2-Benzoylamino-4H-3,1-benzoxazin-4-one was a new, highly active chymotrypsin inactivator.  In contrast, benzothiazinones were resonance stabilized.  The contribution of a resonance structure with an exocyclic oxanion to the overall structure of the benzothiazinones and its nonproductive binding to the active site explained their low reactivity toward chymotrypsin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6cdfirR8I7rVg90H21EOLACvtfcHk0lj_RgQNx-BAdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXkvFemtro%253D&md5=0ae4729ed219892e56e23062ed9e43d5</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1006%2Fbioo.1995.1006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fbioo.1995.1006%26sid%3Dliteratum%253Aachs%26aulast%3DNeumann%26aufirst%3DU.%26aulast%3DG%25C3%25BCtschow%26aufirst%3DM.%26atitle%3D3%252C1-Benzothiazin-4-ones%2520and%25203%252C1-benzoxazin-4-ones%253A%2520highly%2520different%2520activities%2520in%2520chymotrypsin%2520inactivation%26jtitle%3DBioorg.%2520Chem.%26date%3D1995%26volume%3D23%26spage%3D72%26epage%3D88" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Scheiff, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yerande, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">El-Tayeb, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inamdar, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vasu, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sudarsanam, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, C. E.</span><span> </span><span class="NLM_article-title">2-Amino-5-benzoyl-4-phenylthiazoles: development of potent and selective adenosine A<sub>1</sub> receptor antagonists</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">2195</span><span class="NLM_x">–</span> <span class="NLM_lpage">2203</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2010&pages=2195-2203&author=A.+B.+Scheiffauthor=S.+G.+Yerandeauthor=A.+El-Tayebauthor=W.+Liauthor=G.+S.+Inamdarauthor=K.+K.+Vasuauthor=V.+Sudarsanamauthor=C.+E.+M%C3%BCller&title=2-Amino-5-benzoyl-4-phenylthiazoles%3A+development+of+potent+and+selective+adenosine+A1+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DScheiff%26aufirst%3DA.%2BB.%26aulast%3DYerande%26aufirst%3DS.%2BG.%26aulast%3DEl-Tayeb%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DInamdar%26aufirst%3DG.%2BS.%26aulast%3DVasu%26aufirst%3DK.%2BK.%26aulast%3DSudarsanam%26aufirst%3DV.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26atitle%3D2-Amino-5-benzoyl-4-phenylthiazoles%253A%2520development%2520of%2520potent%2520and%2520selective%2520adenosine%2520A1%2520receptor%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2010%26volume%3D18%26spage%3D2195%26epage%3D2203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Müller, C. E.; Jacobson, K. A.</span><span> </span><span class="NLM_article-title">Xanthines as Adenosine Receptor antagonists</span>. In  <span class="citation_source-book">Methylxanthines. Handbook of Experimental Pharmacology 200</span>, <span class="NLM_edition">1</span>st ed.; <span class="NLM_contrib-group">Fredholm, B. B.</span>, Ed.; <span class="NLM_publisher-name">Springer-Verlag</span>: <span class="NLM_publisher-loc">Berlin, Germany</span>,<span class="NLM_x"> </span><span class="NLM_year">2011</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">151</span><b>–</b> <span class="NLM_lpage">199</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&pages=151-199&author=C.+E.+M%C3%BCller&author=K.+A.+Jacobsonauthor=B.+B.+Fredholm&title=Methylxanthines.+Handbook+of+Experimental+Pharmacology+200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26atitle%3DXanthines%2520as%2520Adenosine%2520Receptor%2520antagonists%26btitle%3DMethylxanthines.%2520Handbook%2520of%2520Experimental%2520Pharmacology%2520200%26aulast%3DFredholm%26aufirst%3DB.%2BB.%26pub%3DSpringer-Verlag%26date%3D2011%26spage%3D151%26epage%3D199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Weiss, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benwell, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cliffe, I. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillespie, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knight, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lerpiniere, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Misra, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pratt, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Revell, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Upton, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dourish, C. T.</span><span> </span><span class="NLM_article-title">Discovery of nonxanthine adenosine A<sub>2A</sub> receptor antagonists for the treatment of Parkinson’s disease</span> <span class="citation_source-journal">Neurology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">101</span><span class="NLM_x">–</span> <span class="NLM_lpage">106</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2003&pages=101-106&author=S.+M.+Weissauthor=K.+Benwellauthor=I.+A.+Cliffeauthor=R.+J.+Gillespieauthor=A.+R.+Knightauthor=J.+Lerpiniereauthor=A.+Misraauthor=R.+M.+Prattauthor=D.+Revellauthor=R.+Uptonauthor=C.+T.+Dourish&title=Discovery+of+nonxanthine+adenosine+A2A+receptor+antagonists+for+the+treatment+of+Parkinson%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWeiss%26aufirst%3DS.%2BM.%26aulast%3DBenwell%26aufirst%3DK.%26aulast%3DCliffe%26aufirst%3DI.%2BA.%26aulast%3DGillespie%26aufirst%3DR.%2BJ.%26aulast%3DKnight%26aufirst%3DA.%2BR.%26aulast%3DLerpiniere%26aufirst%3DJ.%26aulast%3DMisra%26aufirst%3DA.%26aulast%3DPratt%26aufirst%3DR.%2BM.%26aulast%3DRevell%26aufirst%3DD.%26aulast%3DUpton%26aufirst%3DR.%26aulast%3DDourish%26aufirst%3DC.%2BT.%26atitle%3DDiscovery%2520of%2520nonxanthine%2520adenosine%2520A2A%2520receptor%2520antagonists%2520for%2520the%2520treatment%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DNeurology%26date%3D2003%26volume%3D61%26spage%3D101%26epage%3D106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Jacobson, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallo-Rodriguez, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melman, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maillard, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Bergen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Galen, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karton, Y.</span><span> </span><span class="NLM_article-title">Structure–activity relationships of 8-styrylxanthines as A<sub>2</sub>-selective adenosine antagonists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">1333</span><span class="NLM_x">–</span> <span class="NLM_lpage">1342</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm00062a005" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1993&pages=1333-1342&author=K.+A.+Jacobsonauthor=C.+Gallo-Rodriguezauthor=N.+Melmanauthor=B.+Fischerauthor=M.+Maillardauthor=A.+van+Bergenauthor=P.+J.+van+Galenauthor=Y.+Karton&title=Structure%E2%80%93activity+relationships+of+8-styrylxanthines+as+A2-selective+adenosine+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm00062a005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00062a005%26sid%3Dliteratum%253Aachs%26aulast%3DJacobson%26aufirst%3DK.%2BA.%26aulast%3DGallo-Rodriguez%26aufirst%3DC.%26aulast%3DMelman%26aufirst%3DN.%26aulast%3DFischer%26aufirst%3DB.%26aulast%3DMaillard%26aufirst%3DM.%26aulast%3Dvan%2BBergen%26aufirst%3DA.%26aulast%3Dvan%2BGalen%26aufirst%3DP.%2BJ.%26aulast%3DKarton%26aufirst%3DY.%26atitle%3DStructure%25E2%2580%2593activity%2520relationships%2520of%25208-styrylxanthines%2520as%2520A2-selective%2520adenosine%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1993%26volume%3D36%26spage%3D1333%26epage%3D1342" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Sterling, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herzig, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goren, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finkelstein, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lerner, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldenberg, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miskolczi, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molnar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rantal, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamas, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toth, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zagyva, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zekany, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finberg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavian, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gross, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Razin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krais, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chorev, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Youdim, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinstock, M.</span><span> </span><span class="NLM_article-title">Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer’s disease</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">5260</span><span class="NLM_x">–</span> <span class="NLM_lpage">5279</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm020120c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=5260-5279&author=J.+Sterlingauthor=Y.+Herzigauthor=T.+Gorenauthor=N.+Finkelsteinauthor=D.+Lernerauthor=W.+Goldenbergauthor=I.+Miskolcziauthor=S.+Molnarauthor=F.+Rantalauthor=T.+Tamasauthor=G.+Tothauthor=A.+Zagyvaauthor=A.+Zekanyauthor=J.+Finbergauthor=G.+Lavianauthor=A.+Grossauthor=R.+Friedmanauthor=M.+Razinauthor=W.+Huangauthor=B.+Kraisauthor=M.+Chorevauthor=M.+B.+Youdimauthor=M.+Weinstock&title=Novel+dual+inhibitors+of+AChE+and+MAO+derived+from+hydroxy+aminoindan+and+phenethylamine+as+potential+treatment+for+Alzheimer%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fjm020120c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020120c%26sid%3Dliteratum%253Aachs%26aulast%3DSterling%26aufirst%3DJ.%26aulast%3DHerzig%26aufirst%3DY.%26aulast%3DGoren%26aufirst%3DT.%26aulast%3DFinkelstein%26aufirst%3DN.%26aulast%3DLerner%26aufirst%3DD.%26aulast%3DGoldenberg%26aufirst%3DW.%26aulast%3DMiskolczi%26aufirst%3DI.%26aulast%3DMolnar%26aufirst%3DS.%26aulast%3DRantal%26aufirst%3DF.%26aulast%3DTamas%26aufirst%3DT.%26aulast%3DToth%26aufirst%3DG.%26aulast%3DZagyva%26aufirst%3DA.%26aulast%3DZekany%26aufirst%3DA.%26aulast%3DFinberg%26aufirst%3DJ.%26aulast%3DLavian%26aufirst%3DG.%26aulast%3DGross%26aufirst%3DA.%26aulast%3DFriedman%26aufirst%3DR.%26aulast%3DRazin%26aufirst%3DM.%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DKrais%26aufirst%3DB.%26aulast%3DChorev%26aufirst%3DM.%26aulast%3DYoudim%26aufirst%3DM.%2BB.%26aulast%3DWeinstock%26aufirst%3DM.%26atitle%3DNovel%2520dual%2520inhibitors%2520of%2520AChE%2520and%2520MAO%2520derived%2520from%2520hydroxy%2520aminoindan%2520and%2520phenethylamine%2520as%2520potential%2520treatment%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D5260%26epage%3D5279" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Chimenti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Secci, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolasco, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chimenti, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Granese, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carradori, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yáñez, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orallo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanna, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallinella, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cirilli, R.</span><span> </span><span class="NLM_article-title">Synthesis, stereochemical separation, and biological evaluation of selective inhibitors of human MAO-B: 1-(4-Arylthiazol-2-yl)-2-(3-methylcyclohexylidene)hydrazines</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">6516</span><span class="NLM_x">–</span> <span class="NLM_lpage">6520</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm100120s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=6516-6520&author=F.+Chimentiauthor=D.+Secciauthor=A.+Bolascoauthor=P.+Chimentiauthor=A.+Graneseauthor=S.+Carradoriauthor=M.+Y%C3%A1%C3%B1ezauthor=F.+Oralloauthor=M.+L.+Sannaauthor=B.+Gallinellaauthor=R.+Cirilli&title=Synthesis%2C+stereochemical+separation%2C+and+biological+evaluation+of+selective+inhibitors+of+human+MAO-B%3A+1-%284-Arylthiazol-2-yl%29-2-%283-methylcyclohexylidene%29hydrazines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fjm100120s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100120s%26sid%3Dliteratum%253Aachs%26aulast%3DChimenti%26aufirst%3DF.%26aulast%3DSecci%26aufirst%3DD.%26aulast%3DBolasco%26aufirst%3DA.%26aulast%3DChimenti%26aufirst%3DP.%26aulast%3DGranese%26aufirst%3DA.%26aulast%3DCarradori%26aufirst%3DS.%26aulast%3DY%25C3%25A1%25C3%25B1ez%26aufirst%3DM.%26aulast%3DOrallo%26aufirst%3DF.%26aulast%3DSanna%26aufirst%3DM.%2BL.%26aulast%3DGallinella%26aufirst%3DB.%26aulast%3DCirilli%26aufirst%3DR.%26atitle%3DSynthesis%252C%2520stereochemical%2520separation%252C%2520and%2520biological%2520evaluation%2520of%2520selective%2520inhibitors%2520of%2520human%2520MAO-B%253A%25201-%25284-Arylthiazol-2-yl%2529-2-%25283-methylcyclohexylidene%2529hydrazines%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D6516%26epage%3D6520" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Novaroli, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daina, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Favre, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bravo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carotti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonetti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Catto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carrupt, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reist, M.</span><span> </span><span class="NLM_article-title">Impact of species-dependent differences on screening, design, and development of MAO B inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">6264</span><span class="NLM_x">–</span> <span class="NLM_lpage">6272</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm060441e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=6264-6272&author=L.+Novaroliauthor=A.+Dainaauthor=E.+Favreauthor=J.+Bravoauthor=A.+Carottiauthor=F.+Leonettiauthor=M.+Cattoauthor=P.+A.+Carruptauthor=M.+Reist&title=Impact+of+species-dependent+differences+on+screening%2C+design%2C+and+development+of+MAO+B+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjm060441e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060441e%26sid%3Dliteratum%253Aachs%26aulast%3DNovaroli%26aufirst%3DL.%26aulast%3DDaina%26aufirst%3DA.%26aulast%3DFavre%26aufirst%3DE.%26aulast%3DBravo%26aufirst%3DJ.%26aulast%3DCarotti%26aufirst%3DA.%26aulast%3DLeonetti%26aufirst%3DF.%26aulast%3DCatto%26aufirst%3DM.%26aulast%3DCarrupt%26aufirst%3DP.%2BA.%26aulast%3DReist%26aufirst%3DM.%26atitle%3DImpact%2520of%2520species-dependent%2520differences%2520on%2520screening%252C%2520design%252C%2520and%2520development%2520of%2520MAO%2520B%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D6264%26epage%3D6272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Müller, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maurinsh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sauer, R.</span><span> </span><span class="NLM_article-title">Binding of [<sup>3</sup>H]MSX-2 (3-(3-hydroxypropyl)-7-methyl-8-(<i>m</i>-methoxystyryl)-1-propargylxanthine) to rat striatal membranes - a new, selective antagonist radioligand for A<sub>2A</sub> adenosine receptors</span> <span class="citation_source-journal">Eur. J. Pharm. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">259</span><span class="NLM_x">–</span> <span class="NLM_lpage">265</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Fjm400336x&amp;key=10.1016%2FS0928-0987%2800%2900064-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Fjm400336x&amp;key=10838015" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Fjm400336x&amp;key=1%3ACAS%3A528%3ADC%252BD3cXjs1Cgsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2000&pages=259-265&author=C.+E.+M%C3%BCllerauthor=J.+Maurinshauthor=R.+Sauer&title=Binding+of+%5B3H%5DMSX-2+%283-%283-hydroxypropyl%29-7-methyl-8-%28m-methoxystyryl%29-1-propargylxanthine%29+to+rat+striatal+membranes+-+a+new%2C+selective+antagonist+radioligand+for+A2A+adenosine+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Binding of [3H]MSX-2 (3-(3-hydroxypropyl)-7-methyl-8-(m-methoxystyryl)-1-propargylxanthine) to rat striatal membranes - a new, selective antagonist radioligand for A2A adenosine receptors</span></div><div class="casAuthors">Muller, C. E.; Maurinsh, J.; Sauer, R.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">259-265</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">The present study describes the prepn. and binding properties of a new, potent, and selective A2A adenosine receptor (AR) antagonist radioligand, [3H]3-(3-hydroxypropyl)-7-methyl-8-(m-methoxystyryl)-1-propargylxanthine ([3H]MSX-2).  [3H]MSX-2 binding to rat striatal membranes was saturable and reversible.  Satn. expts. showed that [3H]MSX-2 labeled a single class of binding sites with high affinity (Kd=8.0 nM) and limited capacity (Bmax=1.16 fmol·mg-1 of protein).  The presence of 100 μM GTP, or 10 mM magnesium chloride, resp., had no effect on [3H]MSX-2 binding.  AR agonists competed with the binding of 1 nM [3H]MSX-2 with the following order of potency: 5'-N-ethylcarboxamidoadenosine (NECA)°2-[4-(carboxyethyl)phenylethylamino]-5'-N-ethylcarboxamidoadenosine (CGS-21680)°2-chloroadenosine (2-CADO)°N6-cyclopentyladenosine (CPA).  AR antagonists showed the following order of potency: 8-(m-bromostyryl)-3,7-dimethyl-1-propargylxanthine (BS-DMPX)°1,3-dipropyl-8-cyclopentylxanthine (DPCPX)°(R)-5,6-dimethyl-7-(1-phenylethyl)-2-(4-pyridyl)-7H-pyrrolo[2,3-d]pyrimidine-4-amine (SH-128)°3,7-dimethyl-1-propargylxanthine (DMPX)°caffeine.  The Ki values for antagonists were in accordance with data from binding studies with the agonist radioligand [3H]CGS21680, while agonist affinities were 3-7-fold lower. [3H]MSX-2 is a highly selective A2A AR antagonist radioligand exhibiting a selectivity of at least two orders of magnitude vs. all other AR subtypes.  The new radioligand shows high specific radioactivity (85 Ci/mmol, 3150 GBq/mmol) and acceptable nonspecific binding at rat striatal membranes of 20-30%, at 1 nM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8VMEXXUj3RbVg90H21EOLACvtfcHk0liU04-HgCQaSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXjs1Cgsrs%253D&md5=012d1ae18ba96e8768e7652b25308998</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2FS0928-0987%2800%2900064-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0928-0987%252800%252900064-6%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26aulast%3DMaurinsh%26aufirst%3DJ.%26aulast%3DSauer%26aufirst%3DR.%26atitle%3DBinding%2520of%2520%255B3H%255DMSX-2%2520%25283-%25283-hydroxypropyl%2529-7-methyl-8-%2528m-methoxystyryl%2529-1-propargylxanthine%2529%2520to%2520rat%2520striatal%2520membranes%2520-%2520a%2520new%252C%2520selective%2520antagonist%2520radioligand%2520for%2520A2A%2520adenosine%2520receptors%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2000%26volume%3D10%26spage%3D259%26epage%3D265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Borrmann, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinz, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertarelli, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Florin, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheiff, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, C. E.</span><span> </span><span class="NLM_article-title">1-Alkyl-8-(piperazine-1-sulfonyl)-phenylxanthines: development and characterization of adenosine A<sub>2B</sub> receptor antagonists and a new radioligand with subnanomolar affinity and subtype specificity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">3994</span><span class="NLM_x">–</span> <span class="NLM_lpage">4006</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm900413e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=3994-4006&author=T.+Borrmannauthor=S.+Hinzauthor=D.+C.+Bertarelliauthor=W.+Liauthor=N.+C.+Florinauthor=A.+B.+Scheiffauthor=C.+E.+M%C3%BCller&title=1-Alkyl-8-%28piperazine-1-sulfonyl%29-phenylxanthines%3A+development+and+characterization+of+adenosine+A2B+receptor+antagonists+and+a+new+radioligand+with+subnanomolar+affinity+and+subtype+specificity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fjm900413e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900413e%26sid%3Dliteratum%253Aachs%26aulast%3DBorrmann%26aufirst%3DT.%26aulast%3DHinz%26aufirst%3DS.%26aulast%3DBertarelli%26aufirst%3DD.%2BC.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DFlorin%26aufirst%3DN.%2BC.%26aulast%3DScheiff%26aufirst%3DA.%2BB.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26atitle%3D1-Alkyl-8-%2528piperazine-1-sulfonyl%2529-phenylxanthines%253A%2520development%2520and%2520characterization%2520of%2520adenosine%2520A2B%2520receptor%2520antagonists%2520and%2520a%2520new%2520radioligand%2520with%2520subnanomolar%2520affinity%2520and%2520subtype%2520specificity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D3994%26epage%3D4006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Müller, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diekmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thorand, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ozola, V.</span><span> </span><span class="NLM_article-title">[<sup>3</sup>H]8-Ethyl-4-methyl-2-phenyl-(8R)-4,5,7,8-tetrahydro-1H-imidazo[2,1-<i>i</i>]-purin-5-one ([<sup>3</sup>H]PSB-11), a novel high-affinity antagonist radioligand for human A<sub>3</sub> adenosine receptors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">501</span><span class="NLM_x">–</span> <span class="NLM_lpage">503</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2002&pages=501-503&author=C.+E.+M%C3%BCllerauthor=M.+Diekmannauthor=M.+Thorandauthor=V.+Ozola&title=%5B3H%5D8-Ethyl-4-methyl-2-phenyl-%288R%29-4%2C5%2C7%2C8-tetrahydro-1H-imidazo%5B2%2C1-i%5D-purin-5-one+%28%5B3H%5DPSB-11%29%2C+a+novel+high-affinity+antagonist+radioligand+for+human+A3+adenosine+receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26aulast%3DDiekmann%26aufirst%3DM.%26aulast%3DThorand%26aufirst%3DM.%26aulast%3DOzola%26aufirst%3DV.%26atitle%3D%255B3H%255D8-Ethyl-4-methyl-2-phenyl-%25288R%2529-4%252C5%252C7%252C8-tetrahydro-1H-imidazo%255B2%252C1-i%255D-purin-5-one%2520%2528%255B3H%255DPSB-11%2529%252C%2520a%2520novel%2520high-affinity%2520antagonist%2520radioligand%2520for%2520human%2520A3%2520adenosine%2520receptors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2002%26volume%3D12%26spage%3D501%26epage%3D503" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Bulicz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertarelli, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumert, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fülle, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heber, D.</span><span> </span><span class="NLM_article-title">Synthesis and pharmacology of pyrido[2,3-<i>d</i>]-pyrimidinediones bearing polar substituents as adenosine receptor antagonists</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">2837</span><span class="NLM_x">–</span> <span class="NLM_lpage">2849</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2006&pages=2837-2849&author=J.+Buliczauthor=D.+C.+Bertarelliauthor=D.+Baumertauthor=F.+F%C3%BClleauthor=C.+E.+M%C3%BCllerauthor=D.+Heber&title=Synthesis+and+pharmacology+of+pyrido%5B2%2C3-d%5D-pyrimidinediones+bearing+polar+substituents+as+adenosine+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBulicz%26aufirst%3DJ.%26aulast%3DBertarelli%26aufirst%3DD.%2BC.%26aulast%3DBaumert%26aufirst%3DD.%26aulast%3DF%25C3%25BClle%26aufirst%3DF.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26aulast%3DHeber%26aufirst%3DD.%26atitle%3DSynthesis%2520and%2520pharmacology%2520of%2520pyrido%255B2%252C3-d%255D-pyrimidinediones%2520bearing%2520polar%2520substituents%2520as%2520adenosine%2520receptor%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2006%26volume%3D14%26spage%3D2837%26epage%3D2849" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Klotz, K. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lohse, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwabe, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cristalli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vittori, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grifantini, M.</span><span> </span><span class="NLM_article-title">2-Chloro-<i>N</i><sup>6</sup>-[<sup>3</sup>H]cyclopentyladenosine ([<sup>3</sup>H]CCPA) - a high affinity agonist radioligand for A<sub>1</sub> adenosine receptors</span> <span class="citation_source-journal">Naunyn-Schmiedeberg’s Arch. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">340</span><span class="NLM_x">, </span> <span class="NLM_fpage">679</span><span class="NLM_x">–</span> <span class="NLM_lpage">683</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Fjm400336x&amp;key=10.1007%2FBF00717744" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Fjm400336x&amp;key=2615857" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Fjm400336x&amp;key=1%3ACAS%3A528%3ADyaK3cXhtFGhsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=340&publication_year=1989&pages=679-683&author=K.+N.+Klotzauthor=M.+J.+Lohseauthor=U.+Schwabeauthor=G.+Cristalliauthor=S.+Vittoriauthor=M.+Grifantini&title=2-Chloro-N6-%5B3H%5Dcyclopentyladenosine+%28%5B3H%5DCCPA%29+-+a+high+affinity+agonist+radioligand+for+A1+adenosine+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">2-Chloro-N6-[3H]cyclopentyladenosine ([3H]CPPA) - a high affinity agonist radioligand for A1 adenosine receptors</span></div><div class="casAuthors">Klotz, Karl Norbert; Lohse, Martin J.; Schwabe, Ulrich; Cristalli, Gloria; Vittori, Sauro; Grifantini, Mario</div><div class="citationInfo"><span class="NLM_cas:title">Naunyn-Schmiedeberg's Archives of Pharmacology</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">340</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">679-83</span>CODEN:
                <span class="NLM_cas:coden">NSAPCC</span>;
        ISSN:<span class="NLM_cas:issn">0028-1298</span>.
    </div><div class="casAbstract">The tritiated analog of 2-chloro-N6-cyclopentyladenosine (CCPA) (I), an adenosine deriv. with subnanomolar affinity and a 10,000-fold selectivity for A1 adenosine receptors, has been examd. as a new agonist radioligand.  [3H]CCPA was prepd. with a specific radioactivity of 1.58 TBq/mmol (43 Ci/mmol) and bound in a reversible manner to A1 receptors from rat brain membranes with a high affinity KD value of 0.2 nmol/L.  In the presence of GTP, a KDvalue of 13 nmol/L was detd. for the low affinity state for agonist binding.  Competition of several adenosine receptor agonists and antagonists for [3H]CCPA binding to rat brain membranes confirmed binding to an A1 receptor.  Solubilized A1 receptors bound [3H]CCPA with similar affinity for the high affinity state.  At solubilized receptors a reduced assocn. rate was obsd. in the presence of MgCl2, as has been shown for the agonist [3H]N6-phenylisopropyladenosine ([3H]PIA).  [3H]CCPA was also used for detection of A1 receptors in rat cardiomyocyte membranes, a tissue with a very low receptor d.  Kd-Value of 0.4 nmol-L and a Bmax-value of 16 fmol-platelet membranes, no specific binding of [3H]CCPA was measured at concns. up to 400 nmol/L, indicating that A2 receptors did not bind [3H]CCPA.  Based on the subnanomolar affinity and the high selectivity for A1 receptors, [3H]CCPA proved to be a useful agonist radioligand for characterization of A1 adenosine receptors also in tissues with very low receptor d.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquP1vlbGByYrVg90H21EOLACvtfcHk0limeBGPzEobmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXhtFGhsL8%253D&md5=d44acdedb7aa0c3b3c6f7d79666ae139</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1007%2FBF00717744&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF00717744%26sid%3Dliteratum%253Aachs%26aulast%3DKlotz%26aufirst%3DK.%2BN.%26aulast%3DLohse%26aufirst%3DM.%2BJ.%26aulast%3DSchwabe%26aufirst%3DU.%26aulast%3DCristalli%26aufirst%3DG.%26aulast%3DVittori%26aufirst%3DS.%26aulast%3DGrifantini%26aufirst%3DM.%26atitle%3D2-Chloro-N6-%255B3H%255Dcyclopentyladenosine%2520%2528%255B3H%255DCCPA%2529%2520-%2520a%2520high%2520affinity%2520agonist%2520radioligand%2520for%2520A1%2520adenosine%2520receptors%26jtitle%3DNaunyn-Schmiedeberg%25E2%2580%2599s%2520Arch.%2520Pharmacol.%26date%3D1989%26volume%3D340%26spage%3D679%26epage%3D683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Yan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertarelli, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayallah, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klotz, K.. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, C. E.</span><span> </span><span class="NLM_article-title">A new synthesis of sulfonamides by aminolysis of pnitrophenylsulfonates yielding potent and selective adenosine A<sub>2B</sub> receptor antagonists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">4384</span><span class="NLM_x">–</span> <span class="NLM_lpage">4391</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm060277v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=4384-4391&author=L.+Yanauthor=D.+C.+Bertarelliauthor=A.+M.+Hayallahauthor=H.+Meyerauthor=K..+N.+Klotzauthor=C.+E.+M%C3%BCller&title=A+new+synthesis+of+sulfonamides+by+aminolysis+of+pnitrophenylsulfonates+yielding+potent+and+selective+adenosine+A2B+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Fjm060277v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060277v%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DL.%26aulast%3DBertarelli%26aufirst%3DD.%2BC.%26aulast%3DHayallah%26aufirst%3DA.%2BM.%26aulast%3DMeyer%26aufirst%3DH.%26aulast%3DKlotz%26aufirst%3DK..%2BN.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26atitle%3DA%2520new%2520synthesis%2520of%2520sulfonamides%2520by%2520aminolysis%2520of%2520pnitrophenylsulfonates%2520yielding%2520potent%2520and%2520selective%2520adenosine%2520A2B%2520receptor%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D4384%26epage%3D4391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Schumacher, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scholle, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holzl, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khudeir, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hess, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, C. E.</span><span> </span><span class="NLM_article-title">Lignans isolated from valerian: identification and characterization of a new olivil derivative with partial agonistic activity at A<sub>1</sub> adenosine receptors</span> <span class="citation_source-journal">J. Nat. Prod.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">1479</span><span class="NLM_x">–</span> <span class="NLM_lpage">1485</span></span><div class="citationLinks">[<a href="/doi/10.1021/np010464q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2002&pages=1479-1485&author=B.+Schumacherauthor=S.+Scholleauthor=J.+Holzlauthor=N.+Khudeirauthor=S.+Hessauthor=C.+E.+M%C3%BCller&title=Lignans+isolated+from+valerian%3A+identification+and+characterization+of+a+new+olivil+derivative+with+partial+agonistic+activity+at+A1+adenosine+receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fnp010464q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fnp010464q%26sid%3Dliteratum%253Aachs%26aulast%3DSchumacher%26aufirst%3DB.%26aulast%3DScholle%26aufirst%3DS.%26aulast%3DHolzl%26aufirst%3DJ.%26aulast%3DKhudeir%26aufirst%3DN.%26aulast%3DHess%26aufirst%3DS.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26atitle%3DLignans%2520isolated%2520from%2520valerian%253A%2520identification%2520and%2520characterization%2520of%2520a%2520new%2520olivil%2520derivative%2520with%2520partial%2520agonistic%2520activity%2520at%2520A1%2520adenosine%2520receptors%26jtitle%3DJ.%2520Nat.%2520Prod.%26date%3D2002%26volume%3D65%26spage%3D1479%26epage%3D1485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Schiedel, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinz, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thimm, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherbiny, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borrmann, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maass, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, C. E.</span><span> </span><span class="NLM_article-title">The four cysteine residues in the second extracellular loop of the human adenosine A<sub>2B</sub> receptor: role in ligand binding and receptor function</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">82</span><span class="NLM_x">, </span> <span class="NLM_fpage">389</span><span class="NLM_x">–</span> <span class="NLM_lpage">399</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2011&pages=389-399&author=A.+C.+Schiedelauthor=S.+Hinzauthor=D.+Thimmauthor=F.+Sherbinyauthor=T.+Borrmannauthor=A.+Maassauthor=C.+E.+M%C3%BCller&title=The+four+cysteine+residues+in+the+second+extracellular+loop+of+the+human+adenosine+A2B+receptor%3A+role+in+ligand+binding+and+receptor+function"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchiedel%26aufirst%3DA.%2BC.%26aulast%3DHinz%26aufirst%3DS.%26aulast%3DThimm%26aufirst%3DD.%26aulast%3DSherbiny%26aufirst%3DF.%26aulast%3DBorrmann%26aufirst%3DT.%26aulast%3DMaass%26aufirst%3DA.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%2BE.%26atitle%3DThe%2520four%2520cysteine%2520residues%2520in%2520the%2520second%2520extracellular%2520loop%2520of%2520the%2520human%2520adenosine%2520A2B%2520receptor%253A%2520role%2520in%2520ligand%2520binding%2520and%2520receptor%2520function%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2011%26volume%3D82%26spage%3D389%26epage%3D399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit46b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Nordstedt, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fredholm, B. B.</span><span> </span><span class="NLM_article-title">A modification of a protein-binding method for rapid quantification of cAMP in cell-culture supernatants and body fluid</span> <span class="citation_source-journal">Anal. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">189</span><span class="NLM_x">, </span> <span class="NLM_fpage">231</span><span class="NLM_x">–</span> <span class="NLM_lpage">234</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=189&publication_year=1990&pages=231-234&author=C.+Nordstedtauthor=B.+B.+Fredholm&title=A+modification+of+a+protein-binding+method+for+rapid+quantification+of+cAMP+in+cell-culture+supernatants+and+body+fluid"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNordstedt%26aufirst%3DC.%26aulast%3DFredholm%26aufirst%3DB.%2BB.%26atitle%3DA%2520modification%2520of%2520a%2520protein-binding%2520method%2520for%2520rapid%2520quantification%2520of%2520cAMP%2520in%2520cell-culture%2520supernatants%2520and%2520body%2520fluid%26jtitle%3DAnal.%2520Biochem.%26date%3D1990%26volume%3D189%26spage%3D231%26epage%3D234" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i72"><a href="/doi/suppl/10.1021/jm400336x">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_27674"></div></div></div></div></div><hr /></hr><p class="last">Plots of rat versus human p<i>K</i><sub>i</sub> (A<sub>1</sub> and A<sub>2A</sub>ARs) and rat versus human pIC<sub>50</sub> values (MAO-B), HPLC chromatograms, and <sup>1</sup>H NMR spectra of compounds <b>2</b> and <b>17</b>. This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm400336x/suppl_file/jm400336x_si_001.pdf">jm400336x_si_001.pdf (414.74 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm400336x&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Fjm400336x%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2013.56.issue-11%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm400336x" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                1MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67991c95c9043cd0","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
